session

session 

2 0 1 5 

tracker 

plus 

Pre-meeting Courses: Friday, November 6 – Saturday, November 7, 2015 

Scientific Sessions: Saturday, November 7 – Wednesday, November 11, 2015 

Exhibits: Sunday, November 8 – Tuesday, November 10, 2015 

2 015 ACR/ARHP ANNUAL MEETING

2 2015 ACR/ARHP Annual Meeting 


2 0 1 5 

tracker 

plus 

Use the Session Tracker Plus to record your CME/Hours of Participation as you go, 

then use the Session Tracker as a guide to apply for CME/Hours of Participation online at 

www.ACRannualmeeting.org to obtain a certificate for your records. 

EDUCATIONAL TRACKS 

Look for these icons to navigate the meeting by track: 

PRIMARY TRACKS 

BASIC SCIENCE BUSINESS/ADMINISTRATION CLINICAL SCIENCE CLINICAL PRACTICE 

SECONDARY TRACKS 

EdPM 

Pd PS Educators Pd PS PrM PrM FIT FITFellows-In-Training 

PM Ed Pd PS Pediatrics PrM FIT Practice Management Tech Med 

STATE CME DESIGNATIONS 

PM PS E ETHICS 

PM PAIN PS MANAGEMENT E PM PS PATIENT E SAFETY

2 0 1 5 


tracker 

plus 

3 

Accreditation Statement: The American College 

of Rheumatology is accredited by the Accreditation 

Council for Continuing Medical Education (ACCME) 

to provide continuing medical education for 

physicians. 

Designation Statement: The ACR designates this 

live educational activity for a maximum of 54.50 AMA 

PRA Category 1 Credits. Physicians should claim 

only the credit commensurate with the extent of 

their participation in the activity. 

International Physicians: International physicians 

who register as part of a group and require AMA 

PRA Category 1 Credit(s) must provide the following 

information to your tour leader: full name, mailing 

address, telephone and fax numbers and e-mail 

address. The information will be used to verify your 

meeting attendance. 

The American Medical Association has an 

agreement of mutual recognition of continuing 

medical education credit with the European Union 

of Medical Specialties. International physicians 

interested in converting AMA PRA Category 1 Credit 

to EACCME credit should contact the UEMS. 

Health Professionals: Participants may claim hours 

to receive a Certificate of Participation for an activity 

designated for AMA PRA Category 1 Credit(s). For 

non-CME sessions, attendees may also request a 

certificate of participation. 

How Do I Claim Credit? It is an AMA requirement 

that you claim only the EXACT amount of time spent 

in each educational session. This accurately reflects 

the extent of your participation in the activity. You 

may attend sessions for LESS than their entirety 

and claim partial credit to the nearest quarter 

hour. Note that you may NOT claim credit hours for 

attending two full sessions at a given time in their 

entirety. Therefore, if you inaccurately record your 

credit hours and exceed the meeting maximum of 

AMA/PRA Category 1 Credits, you will need to correct 

your claim in order to receive your certificate. 

Example: You attend half of a 1-hour session and half 

of another in the same time slot. You must report 

that you spent .5 hours in the first session and .5 

in the second session. If you attempt to claim full 

credit (1hr) for each of the two sessions, the claim 

system may over-calculate your CME credit and you 

may exceed the maximum number of credit hours 

allowed. In this case you would not be able to receive 

your certificate. 

How Do I Claim Credit for Poster Sessions? You 

may only be awarded CME credit for viewing 

posters during the 9:00 – 11:00 am time slot. It is an 

AMA requirement that poster presenters must be 

available to engage learners. You must therefore 

claim ONLY the credit commensurate with the 

extent for your participation in the activity during 

this time slot. You may claim partial credit. 

CLAIMING CME CREDIT 

You may claim your CME credit at the Technology 

Center, located on the North Building, Exhibit Level, 

in the lobby outside of Hall D, during or at the end 

of the meeting for all sessions attended. You may 

also claim your credit online during and after the 

meeting at ACRannualmeeting.org.

4 

2015 ACR/ARHP Annual Meeting 

IMPORTANT LOCATIONS 

ACR Office ................................................South – Mezzanine, 270; 

Telephone: (415) 978-3600 

Business Center ..........................................North – Exhibit Level, 

lobby outside of Hall D 

Career Connection ........................................Exhibit Hall: North – Hall D (Booth #920) 

Child Care ................................................Call for Location; 

Telephone: (858) 254-2563 

Coat/Baggage Check ......................................South Lobby 

Concierge Center .........................................North – Exhibit Level, 

lobby outside of Hall D 

Discovery Center .........................................Exhibit Hall: North – Hall D (Booth #920) 

Exhibit Hall ...............................................North – Hall D 

First Aid ..................................................North and South Buildings, Exhibit Level; 

and West Building, First Floor 

Foundation Booth ........................................Exhibit Hall: North – Hall D (Booth #920) 

Foundation Donors’ Lounge ...............................South – 105 

Hotel Reservations .......................................Registration: North Lobby 

Industry-Supported Symposia Information ................. South Lobby 

Innovation Theater . ......................................Exhibit Hall: North – Hall D 

Lost and Found ...........................................ACR Office: South – Mezzanine, 270 

Membership Booth .......................................Registration: North Lobby 

Newsroom ...............................................South – Mezzanine, 254; 

Telephone: (415) 978-3604 

Nursing Mothers’ Room ...................................South – 232 

Overflow Rooms ..........................................Various rooms in the South and West 

buildings will be announced as needed. 

Poster Hall ...............................................South – Halls B-C 

Prayer Room .............................................South – Mezzanine, 234 

Registration ..............................................North Lobby 

Restaurant Reservations ..................................South Lobby 

Ribbon Distribution .......................................Registration: North Lobby 

Shuttle Bus ...............................................Howard Street (Between North 

and South Buidlings)

2 0 1 5 


tracker 

plus 

5 

Simple Tasks .............................................Exhibit Hall: North – Hall D (Booth #920) 

Speaker Ready Room .....................................North – 120 

Technology Center ........................................North – Exhibit Level, lobby outside Hall D 

Visitor Information .......................................South Lobby 

Wheelchairs ..............................................Order through ScootAround, Inc.; 

Telephone: (888) 441-7575 

Special Needs 

If you require special arrangements, please contact the ACR Office (South – Mezzanine, 270); 

Telephone: (415) 978-3600. 

Emergency Contact Information 

Space is provided on the back of your badge to list names and telephone numbers of your emergency 

contacts. Please complete this information before inserting your badge in your badge holder. 

*All important locations are located in the three buildings of Moscone Center (North, South and West). 

Printing of this publication is supported by Amgen, Inc. 

Get On-Demand 

Rheumatology 

Education 

To learn more, go to 

acrannualmeeting.org/SessionSelect

6 


MEETING AT-A-GLANCE FRIDAY & SATURDAY, NOVEMBER 6 – 7, 2015 

FRIDAY, NOVEMBER 6, 2015 

TIME TITLE LOCATION 

P R E - M E E T I N G C O U R S E S 

PAGE 

NO. 

CME/HOURS OF 

PARTICIPATION 

7:45 am – 

4:30 pm 

9:00 am – 

5:00 pm 

1:00 pm – 

5:45 pm 

1:00 pm – 

6:00 pm 

ACR Musculoskeletal Ultrasound Course for 

Rheumatologists – Fundamentals – Day One of Two ..... West – 2010 45 

ACR Advanced Rheumatology Coding Course: Clinical 

Documentation Improvement .....................West – 2016 46 

ACR Basic Research Conference: Pathways of 

Inflammation and Resolution – Day One of Two ......... West – 3001 46 

ACR Clinical Research Conference: Improving Long Term 

Outcomes of Rheumatic Disease – Day One of Two ......West – 3007 47 

 

7.25 hrs. 

 

7 hrs. 

 

4.25 hrs. 

 

5 hrs. 

1:00 pm – 

6:00 pm 

ACR Maintenance of Certification (MOC) Annual 

Meeting Course .......................................South – Gateway 

Ballroom, 104 

47 

 

4.5 hrs. 

SATURDAY, NOVEMBER 7, 2015 


P R E - M E E T I N G C O U R S E S 

PAGE 

NO. 

CME/HOURS OF 

PARTICIPATION 

7:15 am – 

5:50 pm 

7:45 am – 

4:15 pm 

7:45 am – 

4:30 pm 

7:45 am – 

4:30 pm 

8:00 am – 

4:00 pm 

ACR Musculoskeletal Ultrasound for Rheumatologists – 

Fundamentals – Day Two of Two ........................ West – 2010 48 

ARHP Clinical Focus Course – Clinical Advances in 

Rheumatologic Diseases: A Case-based Approach ....... West – 2014 49 

ACR Basic Research Conference: Pathways of 

Inflammation and Resolution – Day Two of Two ......... West – 3001 50 

ACR Clinical Research Conference – ACR Clinical 

Research Conference: Improving Long Term Outcomes 

of Rheumatic Disease – Day Two of Two ................. West – 3007 51 

ACR Practice Management Pre-meeting Course: 

Transforming Theory Into Practice .................West – 2016 52 

 

9 hrs. 

 

7.75 hrs. 

 

7.5 hrs. 

 

6.75 hrs. 

 

6 hrs.

SATURDAY & SUNDAY, NOVEMBER 7 – 8, 2015 

2 0 1 5 


tracker 

plus 

MEETING AT-A-GLANCE 

7 


8:00 am – 

4:00 pm 

ACR Review Course ...................................South – Hall A 52 

6.5 hrs. 

PAGE 

NO. 

CME/HOURS OF 

PARTICIPATION 

9:00 am – 

4:00 pm 

4:30 pm – 

6:15 pm 

AAMC Medical Education Research Certificate (MERC) 

Workshop: Qualitative Data Collection and Analysis 

Methods .............................................West – 2004 53 

ACR/ARHP Opening Lecture and Awards 

Opening Lecture: Education at Scale: 

Beyond an Experiment PM Ed Pd PS 

.......................... 

PrM FIT 

South – Hall A 53 

 

0.75 hr. 

6:30 pm – 

8:00 pm 

Networking Event 

ACR/ARHP Opening Reception .............................. West – Second 

Floor Lobby 

54 

SUNDAY, NOVEMBER 8, 2015 


S C I E N T I F I C S E S S I O N S 

PAGE 

NO. 

CME/HOURS OF 

PARTICIPATION 

7:30 am – 

8:30 am 

ACR Sessions 

Rheumatology Research Foundation Philip Hench, MD 

Memorial Lecture: The Transition from Psoriasis to Arthritis – 

New Insights .......................................... West – First Floor 

54 

 

1 hr. 

The Interferonopathies ................................. West – 2022 

Year in Review ......................................... South – Hall A 

54 

54 

7:30 am – 

8:30 am 


ACR/ARHP Annual Meeting Orientation ......................South – 

Esplanade, 301 

54

8 


MEETING AT-A-GLANCE SUNDAY, NOVEMBER 8, 2015 


7:45 am – 

9:15 am 

7:45 am – 

9:45 am 

8:30 am – 

10:00 am 

ACR Meet the Professor Sessions 

001 – Ankylosing Spondylitis: 2015 Update ................ West – 3003 

002 – Antiphospholipid Syndrome ....................... West – 3005 

003 – Challenging Cases in Osteoporosis Management ..... West – 3007 

004 – Osteoporosis: Novel Treatments ................... West – 3009 

005 – Pregnancy and Rheumatic Diseases ................. West – 3011 

006 – Psoriatic Arthritis ................................. West – 3016 

007 – Rheumatoid Arthritis: Challenging Cases ............. West – 3018 

008 – Rheumatoid Arthritis: Outcome Measures in 

Clinical Practice – Moving from Measurements 

to Management .................................. West – 3020 

009 – Safety of Drugs Used to Treat Rheumatoid 

Arthritis ......................................... West – 3022 

010 – Systemic Sclerosis: Disease Staging and Subsetting 

in Clinical Practice ................................ West – 3024 

ACR/ARHP Workshops 

201 – Advanced Musculoskeletal Ultrasound ................. West – 3002 

202 – Clinical Anatomy and Physical Exam: Essential Tools 

in Upper Extremity Regional Pain Syndromes ........... West – 3008 

203 – How to Utilize Health Record Right to Maximize 

Meaningful Use .................................. West – 3006 

ACR Sessions 

Clots in Children: Where They Come From and 

What to Do With Them PM Ed Pd PS .............................. 

PrM FIT 

North – 132 

Coming to a Joint Near You: Chikungunya ................. South – Gateway 

Ballroom, 104 

Hot Topics in Osteoarthritis: Nutraceuticals, Narcotic 

Analgesics and Behavioral Interventions 

PM Ed Pd PS PrM PM FIT PS E . . . . . . . . South – Gateway 

Ballroom, 102 

Neutrophils in Inflammation ............................ West – 2001 

PAGE 

NO. 

54 

54 

55 

55 

55 

55 

55 

55 

55 

55 

55 

55 

55 

55 

56 

56 

56 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

 

2 hrs. 

 

1.5 hrs. 

9:00 am – 

10:00 am 

ACR Sessions 

Can We Replace Warfarin? An Update on the Direct Oral 

Anticoagulants ........................................ South – 


56 

 

1 hr. 

Legislative Update: Chat with Congress About 

Rheumatology Issues PM ............................... 

PS E 

West – 2018 

56


2 0 1 5 


tracker 

plus 


9 


9:00 am – 

10:00 am 

9:00 am – 

11:00 am 

ARHP Sessions 

ARHP Keynote Address: Cultural Humility for Rheumatology 

Health Professionals ...................................West – 2007 56 

ACR Poster Session A and Poster Tours 

(#1-895) ................................................. South – 

Poster Hall Morning Snack Break 

(8:30 – 10:00 am) 

Poster Presenters Available 

9:00 – 11:00 am 

Hall B-C 

(Poster Hall) 

PAGE 

NO. 

57 

CME/HOURS OF 

PARTICIPATION 

 

1 hr. 

 

2 hrs. 

10:00 am – 

5:00 pm 

Guided Poster Tours 

Check the annual meeting app for the most current poster tour titles. 

9:00 – 9:45 am 

301 - Fellows Only: How to Navigate the Poster Hall Tour 

302 - Epidemiology and Health Services Research Poster Tour 

303 - Rheumatoid Arthritis: Clinical Aspects Poster Tour 

304 - Rheumatoid Arthritis Treatment - Small Molecules, 

Biologics and Gene Therapy Poster Tour 

305 - Spondylarthropathies and Psoriatic Arthritis: Clinical 

Aspects and Treatment 

306 - Systemic Lupus Erythematosus: Clinical Aspects 

Poster Tour 

10:15 – 11:00 am 

307 - Health Services Research Poster Tour 

308 - Metabolic and Crystal Arthropathies Poster Tour 

309 - Miscellaneous Rheumatic and Inflammatory Diseases 

Poster Tour 




312 - Vasculitis Poster Tour 

Exhibits ................................................. North – Hall D 

Exhibit Hall Morning Snack Break 

(Exhibit Hall) 

(10:00 am) 

Exhibit Hall Afternoon Snack Break 

(2:30 pm) 

57

10 




PAGE 

NO. 

CME/HOURS OF 

PARTICIPATION 

10:30 am – 

11:15 am 

Exhibits 

Innovation Theater A ...................................... North – Hall D 


193 

10:30 am – 

12:30 pm 


204 – Beyond Musculoskeletal Ultrasound for 

Rheumatologists .................................... West – 3002 

205 – Clinical Anatomy and Physical Exam: Essential Tools in 

Lower Extremity Regional Pain Syndromes .............. West – 3008 

206 – Histopathology of Vasculitis ........................... West – 3006 

207 – Synovial Fluid Analysis and Crystal Identification ......... West – 3004 

57 

57 

58 

58 

 

2 hrs. 

11:00 am – 

Noon 

ACR Session 

Update in Antibody Testing: Clinical Significance of Antinuclear 

and Anti-Neutrophil Cytoplasmic Antibodies .............. West – 

First Floor 

58 

 

1 hr. 

11:00 am – 

Noon 

ARHP Sessions 

Immunology Boot Camp I: The Basics of Targeted 

Therapies ............................................. South – 


58 

 

1 hr. 

11:00 am – 

12:30 pm 

11:30 am – 

12:15 pm 

Navigating Insurance and Prior Authorization PM .......... 

PS E West – 2007 

Pediatric Research Methods ............................. West – 2009 

Peripheral Neuropathy in Rheumatic Disease: Etiology 

and Management 

PM Ed Pd PS PrM FIT PM ............................... 

PS E 

West – 2008 

ACR Plenary Session I: Discovery 2015 

(#896-900) ...............................................South – Hall A 58 

Exhibits 

Innovation Theater B ...................................... North – Hall D 


58 

58 

58 

193 

 

1.5 hrs.


2 0 1 5 


tracker 

plus 

11 



PAGE 

NO. 

CME/HOURS OF 

PARTICIPATION 

12:30 pm – 

1:15 pm 

Exhibits 



193 

12:30 pm – 

2:00 pm 

ACR Session 

CARE: MOC Sessions 2015 – Session 1 – Nonarticular and 

Regional Musculoskeletal Disorders ......................South – 


59 

 

1.5 hrs. 

12:30 pm – 

2:15 pm 


ARHP Discipline Round Tables: Networking Forum ............Marriott Marquis – 

Yerba Buena 8 

60 

12:45 pm – 

2:15 pm 

ACR Session 

ACR Knowledge Bowl: Preliminary Round 

.................South – Gateway 

Ballroom, 104 

60 

12:45 pm – 

2:15 pm 


011 – Adult Inflammatory Myopathy . . . . . . . . . . . . . . . . . . . . . . West – 3003 

012 – Ankylosing Spondylitis: Disease Modification ......... West – 3005 

013 – Non-surgical Treatments for Osteoarthritis .......... West – 3007 

014 – Pediatric Systemic Lupus Erythematosus PM Ed Pd PS ......... 

PrM FIT West – 3009 

015 – Pulmonary Manifestations of Rheumatic Disease ..... West – 3011 

016 – Reactive Arthritis: An Update ....................... West – 3016 

017 – Rheumatoid Arthritis: Biological Agents ............. West – 3018 

018 – Systemic Lupus Erythematosus: Lupus Nephritis ..... West – 3020 

019 – Vaccinations for Patients on Biologic Therapies ....... West – 3022 

020 – Vitamin D and Bone Health ........................ West – 3024 

61 

61 

61 

61 

61 

61 

61 

61 

61 

61 

 

1.5 hrs. 

1:00 pm – 

2:00 pm 

ACR Sessions 

Gender Differences in Pain Mechanisms .................. West – 2001 

Immunology Update on B Cell Biology .................... West – First Floor 

Medical Education: The Year in Review – Cultivating 

the Competent Clinician Educator PM Ed .................... 

Pd PS PrM FIT 

West – 2000 

Platelets as Immune Sensors and Effectors: 

New Biology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . West – 2004 

Vasculitis PM Ed Mimics 

Pd PS PrM FIT PM Ed Pd PS ................................ 

PrM FIT 

South – Hall A 

61 

61 

61 

62 

62 

 

1 hr.

12 




PAGE 

NO. 

CME/HOURS OF 

PARTICIPATION 

1:00 pm – 

2:00 pm 

Study Groups 

ACR Musculoskeletal Ultrasound Study Group ................ West – 2022 

63 

Antiphospholipid Syndrome Task Force Study Group .......... West – 3014 

63 

Biology in Rheumatology (Biological Therapy in 

Rheumatic Diseases from Structure to Clinical 

Applications) Study Group ................................. West – 2006 

63 

Geriatrics Rheumatology Special Interest Group Study Group ... West – 2007 

63 

High-Resolution Peripheral Quantitative Computed 

Tomography (HR-pQCT) Imaging in Arthritis and Other 

Autoimmunopathies Study Group .......................... West – 2008 

63 

Latin American Study Group ............................... West – 2018 

63 

Neuroendocrine Immunology Study Group .................. West – 2009 

63 

Sexuality and Intimacy in Rheumatic Diseases Study Group .... West – 2011 

63 

Veterans Affairs Rheumatology Study Group ................. West – 2016 

63 

1:15 pm – 

3:15 pm 


208 – Complementary and Alternative Therapies in 

Rheumatic Disease .................................. West – 3006 

63 

 

2 hrs. 

209 – Evaluation and Management of Shoulder Pain .......... West – 3002 

63 

210 – How to Apply Statistics to Your Research ............... West – 3004 

63 

211 – Joint Injections (Knee, Ankle, Shoulder and Wrist) ........ West – 3008 

64 

1:30 pm – 

2:15 pm 

Exhibits 



193 

2:30 pm – 

3:15 pm 

Exhibits 

Innovation Theater A ......................................North – Hall D 


193 

2:30 pm – 

4:00 pm 

ACR Sessions 

Novel Roles for the Inflammasome in the Pathogenesis 

of Autoimmune Diseases ............................... South – 


64 

 

1.5 hrs. 

Tech Tools for Rheumatologists ...................... West – 2000 

64 

The Great Debate: Long-term, Low-dose Corticosteroid Use 

in the Treatment of Rheumatoid Arthritis 

PM Ed Pd PS PrM PM Ed FIT Pd PS PM PrM PS FIT ... E 


64 

The Red, the White and the Blue: Digital Color Changes 

and the Rheumatologist ................................ West – First Floor 

64


2 0 1 5 


tracker 

plus 

13 



2:30 pm – 

4:00 pm 

ACR Concurrent Abstract Sessions 

(#901-906) Cytokines, Mediators, Cell-cell Adhesion, Cell 

Trafficking and Angiogenesis ............................ West – 2011 

(#907-912) Epidemiology and Public Health I: Rheumatoid 

Arthritis Comorbidities and Mortality ..................... West – 2001 

(#913-918) Fibromyalgia: Insights Into Diagnostic Criteria 

and Symptom Epidemiology PM ......................... 

PS E 

West – 2010 

(#919-924) Health Services Research I: Digital Health and 

Patient, Provider Factors in Rheumatic Disease ............ North – 132 

(#925-930) Imaging of Rheumatic Diseases I: Ultrasound .... West – 2022 

(#931-936) Innate Immunity and Rheumatic Disease ....... West – 2018 

(#937-942) Miscellaneous Rheumatic and Inflammatory 

Diseases .............................................. West – 3001 

(#943-948) Muscle Biology, Myositis and Myopathies I ...... South – 


(#949-954) Osteoarthritis – Clinical Aspects: Treatments 

and Epidemiology ...................................... South – 


(#955-960) Pediatric Rheumatology – Clinical and 

Therapeutic Aspects I: Juvenile Idiopathic Arthritis PM Ed Pd PS ...... PrM FITSouth – Gateway 

Ballroom, 102 

(#961-966) Rheumatoid Arthritis – Human Etiology 

and Pathogenesis I ..................................... North – 130 

(#967-972) Rheumatoid Arthritis-Small Molecules, Biologics 

and Gene Therapy I: Biologics ........................... South – Gateway 

Ballroom, 104 

(#973-978) Spondylarthropathies and Psoriatic Arthritis – 

Clinical Aspects and Treatment: Treatment of Ankylosing 

Spondylitis ............................................ South – 


(#979-984) Spondylarthropathies Psoriatic Arthritis – 

Pathogenesis, Etiology .................................. West – 2014 

(#985-990) Systemic Lupus Erythematosus – Clinical 

Aspects and Treatment I: Epidemiology and Prognosis ...... South – 


(#991-996) T Cell Biology and Targets in Autoimmune 

Disease I .............................................. West – 2016 

PAGE 

NO. 

65 

65 

66 

67 

68 

68 

69 

70 

71 

72 

74 

75 

76 

77 

78 

79 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs.

14 




2:30 pm – 

4:00 pm 

ARHP Sessions 

How to Manage Difficult Conversations in Your 

Practice ........................................... West – 2008 

Patient Advocacy: Patient and Professional 

Perspectives PM ....................................... 

PS E 

West – 2007 

Practicalities of Pain Management 

PM PS E PM PS E 

............. West – 2009 

PAGE 

NO. 

80 

80 

80 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

2:30 pm – 

4:00 pm 

3:30 pm – 

4:15 pm 

4:00 pm – 

6:00 pm 

Psychoneuroimmunology: The Brain-Behavior Connection .. West – 2006 

ARHP Concurrent Abstract Session 

(#997-1002) ARHP: Exemplary Abstracts .................. West – 2004 81 

Exhibits 

Innovation Theater B ......................................North – Hall D 

(Exhibit Hall 


212 – Dermatopathology of Rheumatic Diseases .............. West – 3004 

81 

193 

82 

 

1.5 hrs. 

 

2 hrs. 

213 – Magnetic Resonance Imaging (MRI) in the Diagnosis and 

Management of Spondylarthritis: A Clinician’s Guide ..... West – 3008 

82 

214 – Musculoskeletal Ultrasound .......................... West – 3002 

82 

4:30 pm – 

6:00 pm 

ACR Sessions 

Biosimilars in Rheumatology ............................ West – First Floor 

82 

 

1.5 hrs. 

Function of Non-coding RNA ............................ South – 


82 

Thieves’ Market: Show Me Your Best Cases ................ South – Gateway 

Ballroom, 104 

What Immunodeficiencies Can Teach Us About 

Autoimmunity and the Appropriate Care of 

Immunosuppressed Patients PM Ed Pd PS ........................ 

PrM FIT 

South – 


82 

83


2 0 1 5 


tracker 

plus 

15 



4:30 pm – 

6:00 pm 


(#1003-1008) Osteoarthritis – Clinical Aspects I: Imaging 

and Epidemiology ...................................... South – 


(#1009-1014) Education PM Ed ............................. 

Pd PS PrM FIT 

West – 2011 

(#1015-1020) Pain: Basic Aspects PM ........................ 

PS E 

North – 132 

(#1021-1026) Pediatric Rheumatology – Pathogenesis 

and Genetic PM Ed Pd PS ....................................... 

PrM FIT 

West – 2014 

(#1027-1032) Quality Measures and Quality of Care ........ West – 2016 

(#1033-1038) Rheumatoid Arthritis – Animal Models I ...... South – 


(#1039-1044) Rheumatoid Arthritis – Clinical Aspects I – 

Treatment Advances and Strategies ...................... South – Hall A 

(#1045-1050) Rheumatoid Arthritis-Small Molecules, Biologics 

and Gene Therapy II: Small Molecular Targeted Therapies .... South – Gateway 

Ballroom, 102 

(#1051-1056) Sjögren’s Syndrome I: Basic Insights .......... West – 2010 

(#1057-1062) Spondylarthropathies and Psoriatic Arthritis 

– Clinical Aspects and Treatment: Clinical Aspects and 

CoMorbidities ......................................... West – 2018 


Aspects and Treatment II: Patient-Reported Measures, 

Outcomes and Reporting ............................... South – 


(#1069-1074) Systemic Lupus Erythematosus – Human 

Etiology and Pathogenesis: Genetics, Gene Expression, 

and Epigenetics ........................................ North – 130 

(#1075-1080) Systemic Sclerosis, Fibrosing Syndromes, 

and Raynaud’s – Clinical Aspects and Therapeutics I ........ West – 2001 

(#1081-1086) Vasculitis I ................................ West – 2022 

PAGE 

NO. 

83 

84 

85 

86 

87 

87 

88 

89 

90 

92 

93 

94 

95 

96 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs.

16 




4:30 pm – 

6:00 pm 


021 – Antiphospholipid Syndrome .......................... West – 3003 

022 – Controversies in Sjögren’s Syndrome ................... West – 3005 

023 – Fibromyalgia 2015: Update on Management PM ......... 


024 – Hereditary Angioedema Update ....................... West – 3009 

025 – Hypermobility ...................................... West – 3011 

026 – Imaging of Crystal Arthritis ............................ West – 3016 

027 – Inflammatory Eye Disease/Uveitis ..................... West – 3018 

028 – Pain: Evaluation and Treatment of Back Pain PM ........ 


029 – Pediatric Rheumatology for Adult Rheumatologists PM 

... West – 3022 

Ed Pd PS PrM FIT 

PAGE 

NO. 

98 

98 

98 

98 

98 

98 

98 

98 

98 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

4:30 pm – 

6:00 pm 

4:30 pm – 

6:00 pm 

030 – Systemic Lupus Erythematosus: Novel Treatments ....... West – 3024 

ACR/ARHP Combined Abstract Session 

(#1087-1092) ACR/ARHP Combined Abstract Session: 

Rehabilitation .........................................West – 2004 98 

ARHP Sessions 

Emotional Distress: Tips to Help Your Patients ............. West – 2007 

98 

99 

 

1.5 hrs. 

 

1.5 hrs. 

Exercise After Total Knee Arthroplasty: Progressive 

Resistance PM PS ......................................... 

E 

West – 2008 

Pediatric Lupus Transitional Care: An Interactive 

Experience PM Ed Pd PS ........................................ 

PrM FIT 

West – 2009 

99 

99 

4:30 pm – 

6:00 pm 

6:30 – 

9:30 pm 

Vaccinations: Update and Controversies .................. West – 2006 


Annual Meeting Tweet-Up ...........................West – 2000 100 

Industry-Supported Symposia 

See Annual Meeting App for the full listing of symposia. 

99 

195

MONDAY, NOVEMBER 9, 2015 

2 0 1 5 


tracker 

plus 

17 




7:30 am – 

8:30 am 

7:30 am – 

8:30 am 

7:45 am – 

9:15 am 

ACR Sessions 

Clinicopathologic Conference (CPC) PM Ed Pd PS PrM PM PM FIT PS 

Ed Ed Pd Pd PS PrM PrM FIT FIT 

............ West – First Floor 

Maintenance Therapy in ANCA-associated Vasculitis: 

Evaluation and Treatment of Patients in Remission ......... South – Gateway 

Ballroom, 104 

Negative Regulation of Inflammation in Autoimmunity ..... South – 

Tips for Publishing Your Work in a Peer-Reviewed 


Medical PM Ed Journal Pd PS PrM FIT .................................... South – Gateway 

Ballroom, 102 

Wearable Biosensors to Advance Rheumatology ....... West – 2018 

ARHP Sessions 

Analysis and Interpretation of Meta-Analyses ............. West – 2007 

How Much and Who Said So? Evaluating Cost-of-Illness 

Studies ............................................... West – 2006 

Immunology Boot Camp II: Basic Mechanisms 

of Autoimmunity ...................................... West – 2001 

New Therapeutics on the Horizon ........................ West – 2004 


031 – Ankylosing Spondylitis: 2015 Update ................... West – 3003 

032 – Challenging Cases in Osteoporosis Management ........ West – 3005 

033 – Crystal: Diagnosis and Management of Gout PM . . PS . . . . . E. . West – 3007 

034 – Cutaneous Vasculitis ................................. West – 3009 

035 – Dermatological Manifestations of Rheumatic 

Diseases ........................................... West – 3011 

036 – Infections With Biologics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . West – 3016 

037 – Management of Difficult Raynaud’s and 

Digital Ischemia ..................................... West – 3018 

038 – Psoriatic Arthritis .................................... West – 3020 

039 – Safety of Drugs Used to Treat Rheumatoid Arthritis ...... West – 3022 

040 – Systemic Lupus Erythematosus: Novel Treatments 

(How to Treat Systemic Lupus Erythematosus) .......... West – 3024 

PAGE 

NO. 

100 

100 

100 

100 

100 

101 

101 

101 

101 

101 

101 

101 

101 

102 

102 

102 

102 

102 

102 

CME/HOURS OF 

PARTICIPATION 

 

1 hr. 

 

1 hr. 

 

1.5 hrs.

18 


MEETING AT-A-GLANCE MONDAY, NOVEMBER 9, 2015 


7:45 am – 

9:45 am 


215 – Advanced Musculoskeletal Ultrasound: Image 

Optimization and Pathology Recognition ............... West – 3002 

216 – Dermatopathology of Rheumatic Diseases .............. West – 3004 

217 – Joint Injections (Knee, Ankle, Shoulder and Wrist) ........ West – 3008 

PAGE 

NO. 

102 

102 

102 

CME/HOURS OF 

PARTICIPATION 

 

2 hrs. 

218 – Magnetic Resonance Imaging of Peripheral Joints 

in Rheumatology Practice ............................. West – 3006 

102 

8:30 am – 

10:00 am 

ACR Sessions 

Genetics and Epigenetics in Osteoarthritis: Update 2015 .... South – 


102 

 

1.5 hrs. 

Nuts and Bolts of Macrophage Activation Syndrome PM 

.... South – 



103 

RISE Registry: How Is It Impacting Patient Care? ..... West – 2022 

103 

9:00 am – 

10:00 am 

ACR Sessions 

Fatty Liver and the Rheumatology Patient ................. West – First Floor 

103 

 

1 hr. 

How to Make Learning More Effective: New Insights into 

the Science of Learning and Application to Teaching PM Ed .... Pd PS North PrM FIT 

– 132 

103 

9:00 am – 

10:00 am 

T Cell-based Treatments: The Next Generation 

of Immunotherapies ................................... West – 2000 

ARHP Session 

ARHP Distinguished Lecturer: Reclaim Life! Celebrating 50 

Years of Advances in Rheumatology Health Professional 

Practice PM ...........................................West PS E 

– 2004 103 

103 

 

1 hr.


2 0 1 5 


tracker 

plus 

19 



9:00 am – 

11:00 am 

ACR/ARHP Poster Session B and Poster Tours 

(#1093-1993)............................................. 

South – 


(8:30 – 10:00 am) 


9:00 – 11:00 am 



9:00 – 9:45 am 


314 - Genetics, Genomics and Proteomics Poster Tour 

315 - Imaging of Rheumatic Diseases Poster Tour 

316 - Osteoporosis and Metabolic Bone Disease – Clinical 

Aspects and Pathogenesis Poster Tours 


318 - Systemic Lupus Erythematosus: Human Etiology 

Poster Tour 

Hall B-C 

(Poster Hall) 

PAGE 

NO. 

103 

CME/HOURS OF 

PARTICIPATION 

 

2 hrs. 

10:00 am – 

5:00 pm 

10:15 – 11:00 am 

319 - Pediatric Rheumatology: Clinical Aspects Poster Tour 




Aspects and Treatment Poster Tour 

322 - Systemic Lupus Erythematosus: Animal Models 

323 - Systemic Lupus Erythematosus: Clinical Aspects 

Poster Tour 

324 - Vasculitis Poster Tour 

Exhibits ................................................. South – Hall D 



(10:00 am) 

Exhibit Hall Afternoon Snack Break 

(2:30 pm) 

104

20 




10:30 am – 

11:15 am 

10:30 am – 

12:30 pm 

11:00 am – 

Noon 

11:00 am – 

Noon 

11:00 am – 

12:30 pm 

11:00 am – 

12:30 pm 

11:30 am – 

12:15 pm 

Exhibits 

Innovation Theater A ......................................North – Hall D 



219 – Knee Braces, Foot Orthoses, and Shoe Gear for 

Managing Knee Osteoarthritis ......................... West – 3008 

220 – Musculoskeletal Ultrasound .......................... West – 3002 

221 – Renal Histopathology in Systemic Lupus 

Erythematosus and Vasculitis ......................... West – 3004 

222 – X-ray Challenges in Rheumatic Diseases ................ West – 3006 

ACR Sessions 

ACR Knowledge Bowl: Final Round ....................... South – Gateway 

Ballroom, 104 

Regulatory Dendritic Cells in Inflammation ................ South – 


What’s New in Localized Scleroderma: Viewpoints 

from a Dermatologist and Rheumatologist PM Ed Pd PS ............ 

PrM FIT 

North – 132 

ARHP Sessions 

ARHP Debate: Opioids for the Treatment of Chronic 

Non Cancer Pain… Use or Abuse? PM PS E PM PS ............. 

E 

West – 2006 

Getting Patients Back to Work: Resources for Clinicians ..... West – 2007 

Keep It Compliant: Tools for Researchers .............. West – 2009 

Psychosocial Components of Living with Psoriasis ......... West – 2008 

ACR Session 

All Things Arthroplasty: Outcomes and 

Complications PM PS E PM PS ..............................West E 

– First Floor 106 

ACR Plenary Session II: Discovery 2015 

(#1994-1999)............................................. South – Hall A 106 

Exhibits 

Innovation Theater B .....................................North – Hall D 


PAGE 

NO. 

193 

105 

105 

105 

105 

105 

105 

105 

105 

105 

106 

106 

193 

CME/HOURS OF 

PARTICIPATION 

 

2 hrs. 

 

1 hr. 

 

1 hr. 

 

1.5 hrs. 

 

1.5 hrs.


2 0 1 5 


tracker 

plus 

21 



Noon – 

2:00 pm 

12:30 pm – 

1:15 pm 

12:30 pm – 

2:00 pm 

12:45 pm – 

2:15 pm 

1:00 pm – 

2:00 pm 


ARHP Topic Round Tables: Networking Forum ................ Marriott Marquis – 

Yerba Buena 8 

Exhibits 



ACR Session 

CARE: MOC Sessions 2015 – Session 2 – Nonrheumatic and 

Systemic Diseases and Crystal-Induced Arthropathies ...... South – 

Esplanade, 304 107 


041 – Antiphospholipid Syndrome .......................... West – 3003 

042 – Biomechanical Interventions for Managing 

Orthoarthritis ....................................... West – 3005 

043 – Juvenile Dermatomyositis PM Ed Pd PS ......................... 

PrM FIT 

West – 3007 

044 – Myopathy: Issues in Diagnosis and Treatment ........... West – 3009 

045 – Osteoarthritis: Update 2015 .......................... West – 3011 

046 – Rheumatoid Arthritis: Biological Agents ................ West – 3016 

047 – Systemic Lupus Erythematosus: Central Nervous System ... West – 3018 

048 – Systemic Lupus Erythematosus: Lupus Nephritis ........ West – 3020 

049 – Vaccinations for Patients on Biologic Therapies .......... West – 3022 

050 – Vasculitis: Update ................................... West – 3024 

ACR Sessions 

An Hour Well Spent: Successful Stories of Members 

Enhancing Patient Care Through State Advocacy ....... West – 2000 

Current State of the Art in Spondyloarthritides (SpA): 

Tough Questions Your SpA Patients Might Ask You ......... West – First Floor 

Pathways of Innate Immune System Activation 

by Nucleic Acid ........................................ West – 2001 

Rheumatology Research Foundation Oscar S. Gluck, MD, 

Memorial Lecture: Close to the Bone: Schnurri-3 – 

A Novel Gene that Remodels the Skeleton ................. 

South – 


PAGE 

NO. 

107 

193 

108 

108 

108 

108 

108 

108 

108 

108 

108 

108 

108 

109 

109 

109 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

 

1.5 hrs. 

 

1 hr.

22 




1:00 pm – 

2:00 pm 

1:15 pm – 

3:15 pm 

1:30 pm – 

2:15 pm 

2:30 pm – 

3:15 pm 

2:30 pm – 

3:30 pm 

Study Groups 

Building Research Infrastructure in Spondylarthropathy – 

Focus on Trainees and Junior Investigators ................... West – 2011 

Capillaroscopy Study Group: Where Are We 

and Where Do We Want to Go? ............................. North – 132 

Giant Cell Arteritis Study Group ............................. West – 2004 

Hypermobility Study Group ................................ West – 2007 

Medication Adherence and Decision-Making in Lupus ......... West – 3014 

Myositis Study Group ..................................... West – 2018 

Osteoarthritis Study Group ................................ West – 2008 

Pediatric Rheumatology Imaging Study Group ................ West – 2009 

Reproductive Issues in Rheumatology Patients Study Group .... West – 2006 

Sjögren’s Syndrome Study Group ........................... West – 2014 

Wellbeing in Rheumatic Diseases Study Group ............... West – 2016 


223 – Joint Injection Techniques ............................ West – 3002 

224 – Muscle Involvement in Inflammatory Muscle Disease: 

How Muscle Biopsy Can Help ......................... West – 3006 

225 – Synovial Fluid Analysis and Crystal Identification ......... West – 3004 

226 – The Rheumatologic Musculoskeletal Screening 

Exam, With Emphasis on Objective Disease-specific 

Measurements ...................................... West – 3008 

Exhibits 

Innovation Theater B ...................................... South – Hall D 


Exhibits 



ACR Sessions 

Demonstrating the Value of Rheumatology Within 

Various Payment Models for Practice 

PM Ed Pd PS PrM FIT .............. West – 2000 

Immunology Update on Cytokine Signaling in 

Rheumatic Disease 

PM Ed Pd PS PrM FIT ................................. South – 


PAGE 

NO. 

109 

109 

109 

109 

109 

109 

109 

110 

110 

110 

110 

110 

110 

110 

110 

193 

193 

110 

110 

CME/HOURS OF 

PARTICIPATION 

 

2 hrs. 

 

1 hr.


2 0 1 5 


tracker 

plus 

23 



2:30 pm – 

4:00 pm 

ACR Sessions 

Curbside Consults: Ask the Professors .................... South – Hall A 

Evidence Based Assessment and Treatment Options 

for Interstitial Lung Disease in Patients with Systemic 

Sclerosis .............................................. South – Gateway 

Ballroom, 104 

TNF and Beyond: The TNF-TNFR Cytokine Superfamily From 

Bench to Bedside 

PM Ed Pd PS PrM FIT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . South – 


Where Is the Money?: Funding for Rheumatology Training 

and Research ......................................... North – 132 

PAGE 

NO. 

110 

111 

111 

111 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

2:30 pm – 

4:00 pm 


(#2000-2005) Antiphospholipid Syndrome: Recent Findings .. South – 300 

111 

 

1.5 hrs. 

(#2006-2011) Biology and Pathology of Bone and Joint: 

Osteoarthritis Pathogenesis ............................. West – 2014 

112 

(#2012-2017) Cytokines, Mediators, Cell-cell Adhesion, Cell 

Trafficking and Angiogenesis II .......................... South – 


(#2018-2023) Epidemiology and Public Health II: RA and 

Lifestyle Factors ....................................... West – 2010 

113 

114 

(#2024-2029) Imaging of Rheumatic Diseases II: MRI, 

PET and CT ............................................ West – 2018 

115 

(#2030-2035) Infection-related Rheumatic Disease ......... South – 


(#2036-2041) Miscellaneous Rheumatic and Inflammatory 

Diseases Oral Session II ................................. West – 2011 

116 

117 

(#2042-2047) Pediatric Rheumatology – Clinical and Therapeutic 

Aspects II: Pediatric Systemic Lupus Erythematosus PM Ed Pd PS ..... PrM South FIT – Gateway 

(#2048-2053) Rheumatoid Arthritis (RA) – Clinical Aspects II: 

Ballroom, 102 

Infection, Malignancy and Other Comorbidites in RA ....... South – 

(#2054-2059) Rheumatoid Arthritis – Small Molecules, 


Biologics and Gene Therapy III: Biosimilars ................ West – First Floor 

119 

120 

120 

(#2060-2065) Spondylarthropathies and Psoriatic Arthritis – 

Clinical Aspects and Treatment: Clinical Aspects ........... West – 2022 

122 


Aspects and Treatment III: Biomarkers ................... West – 2001 

123 

(#2072-2077) Systemic Lupus Erythematosus – Human 

Etiology and Pathogenesis: Modulators of Disease ......... North – 130 

124

24 




2:30 pm – 

4:00 pm 

2:30 pm – 

4:00 pm 

3:30 pm – 

4:15 pm 

4:00 pm – 

6:00 pm 

4:30 pm – 

5:30 pm 

4:30 pm – 

6:00 pm 

ARHP Sessions 

Evidence to Action: Translation of Rheumatology Research 

to Influence Programs, Policies, and Practice .............. West – 2007 

Integrating Support and Education Programs into Your 

Practice: Five Innovative Models PM Ed ...................... 

Pd PS PrM FIT 

West – 2009 

Pain in the Older Adult: An International Perspective on 

Improving Quality of Life PM ............................ 

PS E 

West – 2008 

Pregnancy and Infertility in Rheumatic Disease ............ West – 2006 


(#2078-2083) ARHP II: Lupus ...............................West – 2004 125 

Exhibits 




227 – Musculoskeletal Ultrasonography: Basic ................ West – 3002 

228 – Osteoporosis: Interpreting Dual Energy X-ray 

Absorptiometry and Clinical Risk Factors: The New 

Fracture Risk Assessment Algorithm ................... West – 3006 

229 – Physical Examination Skills for Improved Detection 

of Synovitis and Cervical Thoracolumbar Disorders ...... West – 3008 

ACR Sessions 

Fibrosis and New Therapeutic Approaches ................ South – Gateway 

Ballroom, 104 

Upper Extremity Arthritis: Epidemiology and Ergonomic 

Interventions PM PS ...................................... 

E 

West – 2009 

ACR Sessions 

Career Opportunities in Rheumatology: 

Making a PM EdChoice 

Pd PS PrM FIT ................................... West – 2001 

New ACR-EULAR Sjögren’s Syndrome Classification Criteria 

and Updates .......................................... South – 


Osteoimmunology: Cross-talk Between Bone and 

Immune PM Ed Cells Pd PS PrM FIT ...................................... South – 


Practice Without Walls .............................. West – 2000 

PAGE 

NO. 

125 

125 

125 

125 

193 

126 

126 

126 

127 

127 

127 

127 

127 

127 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

 

1.5 hrs. 

 

2 hrs. 

 

1 hr. 

 

1.5 hrs.


2 0 1 5 


tracker 

plus 

25 



4:30 pm – 

6:00 pm 


(#2084-2089) Biology and Pathology of Bone and Joint: 

Bone Remodeling ...................................... South – 


(#2090-2095) Epidemiology and Public Health III: Risk Factors, 

Treatment and Outcomes of Gout and Osteoarthritis ....... West – 2018 

(#2096-2101) Genetics, Genomics, and Proteomics ......... West – 2011 

(#2102-2107) Health Services Research II: Rheumatoid 

Arthritis Treatment and Healthcare Utilization ............. North – 130 

(#2108-2113) Metabolic and Crystal Arthropathies I: 

Therapeutics .......................................... West – 2010 

(#2114-2119) Orthopedics, Low Back Pain and 

Rehabilitation ......................................... South – 


(#2120-2125) Reproductive Issues in Rheumatic Disorders: 

Basic and Clinical Aspects ............................... West – 2014 

(#2126-2131) Rheumatoid Arthritis – Clinical Aspects III: 

Cardiovascular Disease and RA .......................... South – Gateway 

Ballroom, 102 

(#2132-2137) Rheumatoid Arthritis – Human Etiology and 

Pathogenesis II ........................................ North – 132 

(#2138-2143) Rheumatoid Arthritis – Small Molecules, Biologics 

and Gene Therapy IV: Safety of Targeted Therapies ........ South – Hall A 

(#2144-2149) Spondylarthropathies (SpA) and Psoriatic 

Arthritis (PsA) – Clinical Aspects and Treatment: Treatment 

of PsA and SpA ........................................ West – First Floor 

(#2150-2155) Systemic Sclerosis, Fibrosing Syndromes and 

Raynaud’s – Pathogenesis, Animal Models and Genetics I ... West – 3001 

(#2156-2161) Vasculitis II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . West – 2022 

PAGE 

NO. 

128 

128 

129 

130 

131 

132 

133 

134 

135 

136 

137 

138 

139 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs.

26 


MEETING AT-A-GLANCE MONDAY & TUESDAY, NOVEMBER 9 – 10, 2015 


4:30 pm – 

6:00 pm 

4:30 pm – 

6:00 pm 

4:30 pm – 

6:00 pm 

4:30 pm – 

6:00 pm 


051 – Adult Inflammatory Myopathy ....................... 

052 – Behçet’s Syndrome ................................ 

053 – Imaging of Crystal Arthritis .......................... 

054 – Pediatrics: Periodic Fevers in Children PM 

......... 

Ed Pd PS PM PrM PS FIT E 

055 – Polymyalgia Rheumatica ............................ 

056 – Rheumatology Practice 101: Starting Out in Practice 

for the Graduating Fellow ........................... 

057 – Systemic Lupus Erythematosus: Difficult to Treat 

Systemic Lupus Erythematosus ...................... 

West – 3003 

West – 3005 

West – 3007 

West – 3009 

West – 3011 

West – 3016 

West – 3018 

058 – Systemic Sclerosis: Disease Staging and Subsetting 

in Clinical Practice ................................. West – 3020 

059 – Vasculitis Mimics .................................. West – 3022 

060 – Vasculitis: Factors That Influence Disease Patterns ..... West – 3024 


(#2162-2167) ACR/ARHP Combined Abstract Session: 

Epidemiology and Pubic Health ........................ West – 2004 141 

ARHP Sessions 

Ethical Issues of the Consent Process PM PS E ............ West – 2006 

Men, Masculinity and Rheumatoid Arthritis .............. West – 2007 

Resilience: Functional and Neurobiological Influences PM ... PS West E – 2008 

141 

141 

141 

141 

141 

141 

141 

141 

141 

141 

142 

142 

142 


(#2168-2173) ARHP III: Epidemiology and Public Health ... West – 2016 143 

PAGE 

NO. 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

 

1.5 hrs. 

 

1.5 hrs. 

 

1.5 hrs. 

TUESDAY, NOVEMBER 10, 2015 

TIME TITLE LOCATION PAGE NO. 

CME/HOURS OF 

PARTICIPATION 

7:30 am – 

8:30 am 

ACR Sessions 

Pathophysiology Synovitis in Rheumatoid Arthritis ......... West – First Floor 

143 

 

1 hr. 

Rheumatology Research Foundation Paul Klemperer, MD 

Memorial Lecture: Old Dogs, New Tricks: Autoinflammatory 

Disease Reloaded ...................................... South – Gateway 

Ballroom, 104 

143


2 0 1 5 


tracker 

plus 

27 



7:30 am – 

8:30 am 

7:45 am – 

9:15 am 

7:45 am – 

9:45 am 

8:30 am – 

10:00 am 

ARHP Sessions 

Environmental Influences and Rheumatic Diseases ........ West – 2007 

Immunology Boot Camp III: Applying Principles 

of Immunology to Treatment Decisions ................... 

Sexual Issues in Rheumatology: Assessment and 

Intervention ........................................... 

What Do the Numbers Mean: Tools to Interpret 

Medical Literature ..................................... 


West – 2001 

West – 2008 

West – 2009 

061 – Behçet’s Syndrome .................................. West – 3003 

062 – Controversies in Sjögren’s Syndrome .................. West – 3005 

063 – Dermatological Manifestations of Rheumatic Diseases ... West – 3007 

064 – Infections with Biologics .............................. West – 3009 

065 – Pregnancy and Rheumatic Diseases. . . . . . . . . . . . . . . . . . . . West – 3011 

066 – Reactive Arthritis: An Update .......................... West – 3016 

067 – Rheumatoid Arthritis: Challenging Cases ............... West – 3018 

068 – Scleroderma Mimics ................................. West – 3020 

069 – Still’s Disease and Autoinflammatory Syndromes ........ West – 3022 

070 – Systemic Lupus Erythematosus: Central Nervous System .. West – 3024 


230 – Musculoskeletal Ultrasonography: Basic ............... West – 3002 

231 – Renal Histopathology in Systemic Lupus Erythematosus 

and Vasculitis ....................................... 

232 – Tai Chi, Yoga and Other Movement in Intervention 

in Disease .......................................... 

ACR Sessions 

Current Challenges in the Treatment of Systemic Lupus 

Erythematosus: Hope for the Future ..................... 

West – 3004 

West – 3008 


Novel Approaches for Intra-articular Arthritis Therapy ..... West – 2004 

PAGE 

NO. 

144 

144 

144 

144 

144 

144 

144 

144 

144 

144 

145 

145 

145 

145 

145 

145 

145 

145 

145 

CME/HOURS OF 

PARTICIPATION 

 

1 hr. 

 

1.5 hrs. 

 

2 hrs. 

 

1.5 hrs.

28 


MEETING AT-A-GLANCE TUESDAY, NOVEMBER 10, 2015 


9:00 am – 

10:00 am 

ACR Session 

Lipid Lowering in 2015: How Low Can You Go ................ South – Gateway 

Ballroom, 104 

Medial Education: The Tension Between Emerging Needs 

and Enduring Values PM Ed ................................ 

Pd PS PrM FIT 

West – 2000 

Pediatric Rheumatology Year in Review and Awards PM 

.... North – 132 


PAGE 

NO. 

146 

146 

146 

CME/HOURS OF 

PARTICIPATION 

 

1 hr. 

SESSION CANCELED – Public Medical Communication: An 

Essential Skill for 21st Century Health Professionals .... South – 


Rheumatology Research Foundation Memorial Lecture 

Honoring Dr. L. Emmerson Ward: Rheumatoid Arthritis (RA) 

Mechanisms and Predictors of Pre-clinical RA ............. West – First Floor 

146 

146 

9:00 am – 

10:00 am 

ARHP Sessions 

ARHP Daltroy Memorial Lecture: Arthritis Self-Management – 

Where We Have Been and Where We Are Going? 

PM 

....... 

PS EWest – 2008 

146 

 

1 hr. 

Less Scary Care for the Pediatric Patient PM 

............... West – 2007 


146 

Pharmacotherapy: What’s New in Rheumatology 

PM PS 

Ed Pd PrM FIT ....... 

West – 2011 

146 

What You Know About Your Patients’ Feet Could Make 

You a Superhero – Treat the Feet: Improve Foot Health 

in Rheumatology Patients PM PS ........................... 

E 

West – 2009 

147


2 0 1 5 


tracker 

plus 

29 



9:00 am – 

11:00 am 

ACR/ARHP Poster Session C and Poster Tours 

(#2174-3073)............................................. 

South – Hall B-C 

(Poster Hall) 


(8:30 – 10:00 am) 


9:00 – 11:00 am 



9:00 – 9:45 am 







329 - Systemic Lupus Erythematosus: Clinical Aspects Poster Tour 

330 - Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s- 

Clinical Aspects and Therapeutics Poster Tour 

PAGE 

NO. 

147 

CME/HOURS OF 

PARTICIPATION 

 

2 hrs. 

10:00 am – 

2:30 pm 

10:30 am – 

11:15 am 

10:15 – 11:00 am 

331 - Quality Measures, Quality of Care Poster Tour 

332 - NEW: Reproductive Issues in Rheumatic Disorders: Basic 

and Clinical Aspects Poster Tour 

333 - Rheumatology 360 Poster Tour 


335 - NEW: Rheumatology 360 Poster Tour (En Español) 



Exhibits ................................................. North – Hall D 



(10:00 am) 

Exhibits 



148 

194

30 




10:30 am – 

12:30 pm 

11:00 am – 

Noon 

11:00 am – 

12:30 pm 

11:00 am – 

12:30 pm 

11:30 am – 

12:15 am 

12:15 pm – 

1:00 pm 

12:30 pm – 

2:00 pm 


233 – Joint Injection Techniques ............................ West – 3002 

234 – Osteoporosis: Interpreting Dual Energy X-ray 

Absorptiometry and Clinical Risk Factors: 

The New Fracture Risk Assessment Algorithm ........... West – 3006 

235 – The Rheumatologic Musculoskeletal Screening 

Exam, with Emphasis on Objective Disease-specific 

Measurements ...................................... West – 3008 

ACR Sessions 

Controversies in Kawasaki Disease: Implications for 

Long-Term Outcomes PM Ed Pd PS ............................... 

PrM FIT 

North – 132 

Systemic Lupus Erythematosus 2015: Arthritis, Bone Loss, 

Pregnancy and Nephritis ................................ South – Gateway 

Ballroom, 104 

Using Twitter Effectively: Healthcare, Hashtags and 

Twitter Chats ...................................... South – 


ACR Session 

Prospects for Treating Rheumatic Diseases through 

Modification in the Microbiome .......................... South – 


ACR Plenary Session III: Discovery 2015 

(#3074-3079) ............................................. South – Hall A 149 

Exhibits 



Exhibits 



ACR Session 

CARE: MOC Sessions 2015 – Session 3 – Other Rheumatic 

and Connective Tissue Diseases ......................... South – 


PAGE 

NO. 

148 

148 

148 

148 

148 

148 

149 

194 

194 

150 

CME/HOURS OF 

PARTICIPATION 

 

2 hrs. 

 

1 hr. 

 

1.5 hrs. 

 

1.5 hrs. 

 

1.5 hrs.


2 0 1 5 


tracker 

plus 

31 



12:45 pm – 

2:15 pm 



072 – Immunodeficiency Syndromes ........................ West – 3005 

073 – Management of Patients with Hepatitis C and 

Rheumatic Diseases ................................. West – 3007 

074 – Myopathy: Issues in Diagnosis and Treatment ........... West – 3009 

075 – Osteoarthritis: Update 2015 .......................... West – 3011 

076 – Psoriatic Arthritis .................................... West – 3016 

077 – Pulmonary Manifestations of Rheumatic Disease ........ West – 3018 

078 – Spondylarthropathy: An Update ....................... West – 3020 

079 – Systemic Lupus Erythematosus: Novel Treatments – 

How to Treat Systemic Lupus Erythematosus ........... West – 3022 

080 – Vasculitis: Update ................................... West – 3024 

PAGE 

NO. 

150 

150 

150 

150 

151 

151 

151 

151 

151 

151 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

1:00 pm – 

2:00 pm 

ACR Sessions 

Advocacy Training: How-to From a U.S. Senator & 

the Age of Digital Advocacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . North – 132 

Immunology Update on Immunological Mechanisms 

in Sjögren’s 

PM Ed Pd PS PrM FIT ........................................ West – 2001 

Osteoporosis Update ................................... West – First Floor 

Pearls and Pitfalls in Fibromyalgia and Central Pain 

Syndromes 

PM Ed Pd PS PrM PM Ed FIT Pd PS . . PrM . . . . FIT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . South – 


Utilizing Big Data to Advance Rheumatology ........... South – 


151 

151 

151 

151 

151 

 

1 hr. 

1:00 pm – 

2:00 pm 

Study Groups 

Autonomic Neuroregulation of Rheumatoid Arthritis 

Study Group ............................................. West – 2016 

Extra-Articular Manifestations of Rheumatic Diseases 

Study Group ............................................. West – 2000 

Global Musculoskeletal Health Initiaitives Study Group ........ West – 2006 

Interstitial Lung Disease Study Group ....................... West – 2007 

Pediatric Rheumatologists Interested in Medical 

Education Study Group .................................... West – 2008 

Polymyalgia Rheumatica Study Group ....................... West – 2009 

The Challenges and Opportunities of Defining Axial 

Psoriatic Arthritis (axPsA) Study Group ...................... West – 2004 

Transparent Pain – Identifying Centralized Pain in the 

Rheumatology Patient Study Group ......................... West – 2011 

151 

152 

152 

152 

152 

152 

152 

152

32 




1:15 pm – 

3:15 pm 


236 – Advanced Musculoskeletal Ultrasound ................. 

West – 3002 

237 – Magnetic Resonance Imaging (MRI) in the Diagnosis and 

Management of Spondylarthritis: A Clinician’s Guide ..... West – 3008 

238 – MDHAQ/RAPID3 and RHEUMDOC: Quantitative, Standard, 

Scientific Summaries of Patient History and Physical 

Exam, Toward Better Clinical Decisions and Outcomes ... West – 3006 

PAGE 

NO. 

152 

152 

153 

CME/HOURS OF 

PARTICIPATION 

 

2 hrs. 

239 – Nailfold Capillarscopy ................................ West – 3004 

153 

1:30 pm – 

2:15 pm 

Exhibits 

Innovation Theater B ......................................North – Hall D 


194 

2:30 pm – 

3:00 pm 

ACR Session 

ACR Business Meeting .................................. South – 


153 

2:30 pm – 

4:00 pm 

ACR Session 

Current Topics in Myositis .............................. South – Gateway 

Ballroom, 104 

Gout Management in 2015: Nonpharmacological 

Treatments, Treat-to-Target Strategy and Emerging 

Therapies for PM Ed Gout Pd PS PrM FIT PM PS .......................... 

E 


153 

153 

 

1.5 hrs. 

Innovative Educators, Novel Techniques: A Rheumatology 

Research Foundation Special Session PM Ed ................. 

Pd PS PrM FIT North – 132 

153 

Next Generation Sequencing: A Novel Tool for 

Genomic Discovery .................................... South – 


Update on Safety Issues in the Treatment of Rheumatic 

Diseases: From the FDA and Beyond PM PS .............. 

E 

West – 2014 

154 

154


2 0 1 5 


tracker 

plus 

33 



2:30 pm – 

4:00 pm 


(#3080-3085) 2015 Rheumatology Research Foundation 

Edmond L. Dubois, MD Memorial Lectureship ............. South – 


(#3086-3091) Fibromyalgia: Clinical Issues ................ West – 2016 

(#3092-3097) Pediatric Rheumatology – Clinical 

and Therapeutic Aspects III: Miscellaneous Pediatric 

Rheumatic Diseases PM Ed Pd PS ................................ 

PrM FIT 

South – Gateway 

Ballroom, 102 

(#3098-3013) Rheumatoid Arthritis – Clinical Aspects IV: 

Biomarkers, Disease Progression and Treatment 

Response ............................................. West - First Floor 

(#3104-3109) Rheumatoid Arthritis – Human Etiology 

and Pathogenesis III .................................... West – 2011 

(#3110-3115) Rheumatoid Arthritis-Small Molecules, 

Biologics and Gene Therapy V: Immunogenecity ........... West – 2001 

(#3116-3121) Spondylarthropathies and Psoriatic Arthritis 

– Clinical Aspects and Treatment: Psoriatic Arthritis – 

Comorbidities ......................................... West – 2022 

(#3122-3127) Systemic Lupus Erythematosus – Clinical Aspects 

and Treatment V: Neuropsychiatric Lupus ................ West – 2000 

PAGE 

NO. 

154 

155 

155 

157 

158 

158 

161 

161 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

2:30 pm – 

4:00 pm 

(#3128-3133) Systemic Sclerosis, Fibrosing Syndromes and 

Raynaud’s – Pathogenesis, Animal Models and Genetics II ... South – 

163 



and Raynaud’s – Clinical Aspects and Therapeutics II ....... South – 

164 


(#3140-3145) Vasculitis III ............................... West – 2018 

165 


(#3146-3151) ACR/ARHP Combined Abstract Session: Pediatric 

Rheumatology PM Ed Pd PS .....................................West 

PrM FIT 

– 2004 166 

 

1.5 hrs.

34 




2:30 pm – 

4:00 pm 

ARHP Sessions 

Better Communication, Better Outcomes 

PM PS E 

.............. West – 2007 

Fall Prevention Interventions PM PS E 

.............................. West – 2009 

Make Self-Management a Reality PM ..................... 

PS E 

West – 2006 

PAGE 

NO. 

166 

167 

167 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

Manage Persistent Pain: An Interprofessional 

Approach PM ......................................... 

PS E 

West – 2008 

167 

3:00 pm – 

4:00 pm 

ACR Session 

ILAR Global Burdens of Rheumatic and Musculoskeletal 

Diseases in Different Regions of the World ................South – 


167 

 

1 hr. 

4:00 pm – 

6:00 pm 


240 – Histopathology of Rheumatic Lung Disease ............. West – 3006 

168 

 

2 hrs. 

241 – Systemic Sclerosis: How to Perform Skin Scores ......... West – 3008 

168 

4:30 pm – 

5:30 pm 

4:30 pm – 

6:00 pm 

242 – Ultrasound Injection Guidance ........................ West – 3002 

ARHP Sessions 

The Influence of Sleep on Health and Disease PM ..........West PS E – 2007 168 

ACR Sessions 

Disease Targeted Research: A Rheumatology Research 

Foundation Special Session ............................. West – 2011 

168 

168 

 

1.0 hrs. 

 

1.5 hrs. 

4:30 pm – 

6:00 pm 

Extra-articular Manifestations of Rheumatoid Arthritis ...... South – Hall A 

Novel Mechanisms in Myopathy ......................... South – Gateway 

Ballroom, 102 

ACR Late-Breaking Abstract Session ......................South – Gateway 

Ballroom, 104 

168 

169 

169 

1.5 hrs.


2 0 1 5 


tracker 

plus 

35 



4:30 pm – 

6:00 pm 


(#3152-3157) B Cell Biology and Targets in Autoimmune 

Disease: Novel B Cell roles in Rheumatoid Arthritis and 

Systemic Lupus Erythematosus .......................... West – 2014 

(#3158-3163) Epidemiology and Public Health IV: Risk 

Factors and Comorbidities for Systemic Lupus Erythematosus 

and Psoriatic Arthritis .................................. West – 2000 

(#3164-3169) Metabolic and Crystal Arthropathies II: 

Mechanisms and Associations ........................... North – 130 

(#3170-3175) Osteoporosis and Metabolic Bone Disease – 

Clinical Aspects and Pathogenesis I . . . . . . . . . . . . . . . . . . . . . . . South – 


(#3176-3181) Pediatric Rheumatology – Clinical and 

Therapeutic Aspects IV: Imaging and Novel Clinical 

Interventions PM Ed Pd PS ...................................... 

PrM FIT 

North – 132 

(#3182-3187) Rheumatoid Arthritis – Clinical Aspects V: 

Goal = Remission ...................................... West – 2001 

(#3188-3193) Rheumatoid Arthritis Animal Models II ....... South – 

(#3194-3199) Rheumatoid Arthritis-Small Molecules, 


Biologics and Gene Therapy VI: Strategies ................. South – 


(#3200-3205) Sjögren’s Syndrome II: Clinical Discoveries .... South – 

(#3206-3211) Spondylarthropathies and Psoriatic 


Arthritis – Clinical Aspects and Treatment: Clinical 

Aspects, Imaging and Biomarkers ........................ West – 2022 

(#3212-3217) Systemic Lupus Erythematosus – 

Animal Models ........................................ West – 2016 

(#3218-3223) Systemic Lupus Erythematosus – 

Clinical Aspects and Treatment VI: Novel Therapies ........ South – 


(#3224-3229) Vasculitis IV ............................... West – 2018 

PAGE 

NO. 

169 

170 

171 

172 

173 

174 

175 

176 

177 

178 

179 

179 

181 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs.

36 




4:30 pm – 

6:00 pm 



082 – Macrophage Activation Syndrome ..................... West – 3005 


Digital Ischemia ..................................... West – 3007 

084 – Pediatrics: Difficult to Treat Juvenile Idiopathic 

Arthritis PM Ed Pd PS ......................................... 

PrM FIT 

West – 3009 

085 – Pulmonary Hypertension in the Rheumatic Diseases ..... West – 3011 

086 – Rheumatoid Arthritis: Biological Agents ................ West – 3016 

087 – Systemic Lupus Erythematosus: Difficult to Treat 

Systemic Lupus Erythematosus. . . . . . . . . . . . . . . . . . . . . . . . West – 3018 

088 – Temporal Arteritis ................................... West – 3020 

089 – Vasculitis: Factors That Influence Disease Patterns ....... West – 3022 

PAGE 

NO. 

182 

182 

182 

182 

182 

182 

182 

182 

182 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

090 – What Is Not Central Nervous Angiitis: Making the 

Right Diagnosis ...................................... West – 3024 

182 

4:30 pm – 

6:00 pm 

ARHP Sessions 

Empowerment Through the Family-Centered 

Care Approach PM Ed Pd PS ..................................... 

PrM FIT 

West – 2006 

182 

 

1.5 hrs. 

Lesbian, Gay, Bisexual, Transgender and Queer: 

Conversations and Care PM Ed PM Pd PS PrM PS ......................... 

FIT E 

West – 2008 

183 

4:30 pm – 

6:00 pm 

6:30 – 

9:30 pm 

Telehealth: Opportunities and Pitfalls ................. West – 2009 


(#3230-3235) ARHP IV: Clinical Practice and Patient Care ....West – 2004 183 

Industry-Supported Symposia 


183 

196 

 

1.5 hrs

WEDNESDAY, NOVEMBER 11, 2015 

2 0 1 5 


tracker 

plus 

37 




7:30 am – 

8:30 am 

7:30 am – 

8:30 am 

9:00 am – 

10:00 am 

9:00 am – 

10:30 am 

9:00 am – 

10:30 am 

9:00 am – 

10:30 am 

ACR Sessions 

Immunology Update on Adaptive Immunity: 

Immune Regulation and Tolerance ....................... 

New Adult and Juvenile Myositis Response Criteria PM 

..... 


Rheumatology Roundup: Highlights from the 2015 

Annual Meeting ....................................... 

South – 



Ballroom, 104 


Use of Individual Cell and Cell Subset Transcriptomes 

as Biomarkers of Disease 

PM Ed Pd PS PrM PM Ed FIT Pd PS ........................ 

PrM FIT 


Ballroom, 102 

ARHP Session 

Modeling of Categorical Data ............................ South – 


ARHP Sessions 

Biosimilars: The Road Ahead ................................... 

Hematologic Manifestations of Rheumatologic Disease: 

Case Studies .......................................... 

ACR Sessions 

Chronic Nonbacterial Osteomyelitis (CNO): 

From the Bedside to the Bench PM Ed Pd PS ...................... 

PrM FIT 

Environmental Triggers of Autoantibodies and 

Autoimmunity ......................................... 

Racial Disparities in Rheumatic Diseases .................. 

T Follicular Cells and Their Mediators ..................... 

South – 


South – 


South – 


South – 



Ballroom, 104 

South – 


ACR Concurrent Abstract Session 

(#3236-3246) Rheumatoid Arthritis (RA) – Clinical Aspects VI: 

Death Be Not Proud – Mortality and Treatment Outcomes 

in RA (Includes 2014 Lee C. Howley, Sr. Prize for Arthritis 

Research Introductory Talk) .............................. South – Hall A 186 


(#3241-3246) ARHP V: Physical Activity .................... South – Hall A 187 

PAGE 

NO. 

184 

184 

184 

184 

184 

185 

185 

185 

185 

185 

185 

CME/HOURS OF 

PARTICIPATION 

 

1 hr. 

 

1 hr. 

 

1 hr. 

 

1.5 hrs. 

 

1.5 hrs. 

 

1.5 hrs.

38 


MEETING AT-A-GLANCE WEDNESDAY, NOVEMBER 11, 2015 


11:00 am – 

12:30 pm 

ACR Sessions 

Issues in Ultrasound PM Ed 2015 Pd PS PrM FIT ........................... 

South – 


PAGE 

NO. 

187 

CME/HOURS OF 

PARTICIPATION 

 

1.5 hrs. 

Novel T Cell Subsets .................................... 

South – 


188 

Reproductive Issues in Rheumatology .................... 


Ballroom, 104 

188 

11:00 am – 

12:30 pm 


(#3247-3252) Pain: Clinical Aspects PM ................... 

PS E 

(#3253-3258) Rheumatoid Arthritis – Clinical Aspects VII: 

Disease Activity and Updates in Measurement ............. 


Ballroom, 102 


188 

189 

 

1.5 hrs. 


and Raynaud’s – Clinical Aspects and Therapeutics III ....... 

South – 


190 

11:00 am – 

12:30 pm 

ARHP Session 

Bridging Research and Advocacy: The Osteoarthritis Action 

Alliance Update ........................................ South – 


191 

11:00 am – 

12:30 pm 

ARHP Abstract Session 

(#3244-3249) ARHP VI: Physical Function and Disability ..... South – 


191 

 

1.5 hrs. 

1:00 – 

4:00 pm 

Industry-Supported Post-Meeting Symposia 


197

The Moscone Convention Center 

2 0 1 5 


tracker 

plus 

39 

CONVENTION CENTER MAP 

Folsom Street 

Overhead View View 

Folsom Street 

South 

Building 

South 

Building 

South Lobby 

South Lobby 

Third Street 

Third Street 

Howard Street 

North Lobby 

North Lobby 

Fourth Street 

Howard Street 

Stairs 

Elevators 

North 

Building 

North 

Building 

Escalators 

Fourth Street 

West 

Building 

Mission Street 


San Francisco Marriott Marquis 

San Francisco Marriott Marquis 



Exhibit Level 

Rooms 100-135, Halls A-E 

Exhibit Level 

Rooms 100-135, Halls A-E 

Hall D 

Hall D 

North Building 

Esplanade Level 

Rooms 200-276 

Esplanade Level 

Rooms 200-276 

Hall E 

130-135 

Hall E 

130-135 

Side View 

Side View 

North 

Lobby 

110-125 North 

(Beyond) Lobby 

110-125 

(Beyond) 

Howard Howard Street Street 

Concourse 

Concourse 

Mezzanine Level 

South 

Lobby 

Rooms 300-310 


Rooms 300-310 

South Gateway Ballroom 

Lobby102-104 

Gateway Ballroom 

102-104 

Administration 

Esplanade Lobby 

Mezzanine 

Administration 200-276 

Esplanade Lobby 

Mezzanine 

200-276 

Esplanade Ballroom 300-310 

Esplanade Ballroom 300-310 

Halls ABC 100-106 

South Building 

Halls ABC 100-106 

Folsom Street 

Folsom Street 


South Building

40 


MAP CONVENTION CENTER 


3 

4 

North Building South Building 

234 236 238 

232 

226 

224 

256 

270 

East 

West 

1 ACR Office 

– Lost and Found 

2 Newsroom 

3 Nursing Mothers’ Room 

4 Prayer Room 

2 

1

Street Level and Esplanade Level 

2 0 1 5 


tracker 

plus 

41 


1 Coat and Baggage Check 

Industry-Supported 

Symposia Information 

Restaurant Reservations 

2 Registration 

– Membership Booth 

– Hotel Reservations 

– Ribbon Distribution 

3 Shuttle Buses 

1 

2 

3 

Third Street 

Folsom Street 

South Lobby 

South Driveway 

Howard Street 

North Driveway 

North Lobby 


Fourth Street 

South Building 

Mission Street

42 


MAP CONVENTION CENTER 

7 

Third Street 

North Building South Building 

6 5 4 

Folsom Street 

Hall A Hall B Hall C 

105 

Howard Street 

114 113 112 111 

122 121 120 

Hall E 

125 124 123 

Hall D 

2 

Fourth Street 

1 

Exhibit Level 

1 Exhibit Hall 

– Career Connection 

– Discovery Center 

– Foundation Booth 

– Innovation Theater 

– Simple Tasks 

2 Business Center 

Concierge Center 

– Technology Center 

3 First Aid 

4 Foundation Donors’ 

Lounge 

5 Poster Hall 

6 Session Room (General) 

– Opening Lecture and 

Awards 

– Plenary Sessions I, II, III 

– Rheumatology 

Roundup 

7 Speaker Ready Room 

3 

Mission Street

West Building 

Third Floor 

2 0 1 5 


tracker 

plus 

43 


1 Meet the Professor Rooms 

2 First-Aid 

3 Workshop Rooms 

4 Opening Reception 

3012 3010 3008 3006 

3011 3009 3007 

3024 

3022 

3020 

3004 3002 

3005 3003 

3018 3016 

3000 

3001 

3014 

Stairs 

Elevators 

Escalators 

Fourth Street 

3 

1 

Second Floor 

Howard Street 

Stairs 

2012 2010 2008 2006 

2004 

2002 

2000 

Elevators 

2011 2009 2007 

2024 

2022 

2020 

2005 

2003 

2018 2016 

2001 

2014 

Escalators 

Fourth Street 

4 

Howard Street 

2 

First Floor: Street Level 

Elevators 

Fourth Street 

Taxi Zone 

Escalators 

Stairs 

Howard Street

2015 ACR/ARHP Annual Meeting


2 0 1 5 


tracker 

plus 

PRE-MEETING COURSES – BY COURSE TITLE 

Pre-meeting courses require a separate registration fee. 

45 

P R E - M E E T I N G 

C O U R S E S 

9:15 – 9:30 am 

Morning Break 


ACR MUSCULOSKELETAL ULTRASOUND 

COURSE FOR RHEUMATOLOGISTS – 

FUNDAMENTALS – DAY ONE OF TWO 

7:45 am – 4:30 pm 

West – 2010 

7:00 – 7:45 am 

Continental Breakfast 

Course Director: Midori Jane Nishio, MD, RhMSUS 

Faculty: Rany Al Haj, MD; Catherine J. Bakewell, MD; 

Narandra Bethina, MD, RhMSUS; Jurgen Craig-Muller, 

MD, RhMSUS; Paul J. DeMarco, MD, RhMSUS; Amy M. 

Evangelisto, MD, RhMSUS; Jay B. Higgs, MD, RhMSUS; 

Gurjit S. Kaeley, MBBS, MRCP; Eugene Y. Kissin, MD, 

RhMSUS; Gary A. Kunkel, MD; Clara Lin, MD, RhMSUS; 

Daniel G. Malone, MD; Bethany A. Marston, MD; Midori 

Jane Nishio, MD, RhMSUS; Anthony M. Reginato, MD, 

PhD; Johannes Roth, MD; Jonathan Samuels, MD, 

RhMSUS; Ralf G. Thiele, MD, RhMSUS; Karina Marianne 

Torralba, MD, MMED, RhMSUS; Alicia Weeks, MD 

7:45 – 8:00 am 

Introduction 

Speaker: Midori Jane Nishio, MD, RhMSUS 

8:00 – 8:30 am 

Principles of Musculoskeletal Ultrasound 

for Rheumatologists 

Speaker: Jay B. Higgs, MD, RhMSUS 

8:30 – 9:15 am 

Introduction to Typical Sonographic Findings 

and Tissue Characteristics 

Speaker: Clara Lin, MD, RhMSUS 

9:30 – 11:45 am 

Hand and Wrist 

9:30 am 

Lecture: Standard Scans, Sonographic Anatomy 

and Basic Sonographic Pathology 

Eugene Y. Kissin, MD, RhMSUS 

10:00 am 

Live Demonstration: Hand and Wrist 


10:15 am 

Hands-on Scanning: The Hand and Wrist 

All Faculty 

11:45 am – 12:45 pm 

Boxed Lunch 

12:45 – 2:15 pm 

The Elbow 

12:45 pm 

Lecture: Standard Scans, Sonographic Anatomy 

and Basic Sonographic Pathology 

Amy M. Evangelisto, MD, RhMSUS 

1:15 pm 

Live Demonstration: Scanning of the Elbow 

Amy M. Evangelisto, MD, RhMSUS 

1:30 pm 

Hands-on Scanning: The Elbow 

All Faculty 

2:15 – 2:30 pm 

Afternoon Break 

2:30 – 4:30 pm 

The Shoulder 

2:30 pm 

Lecture: Standard Scans, Sonographic Anatomy and 

Basic Sonographic Pathology 

Gurjit S. Kaeley, MBBS, MRCP, RhMSUS 

ACRannualmeeting.org

46 




3:00 pm 

Live Demonstration: Scanning of the Shoulder 

Gurjit S. Kaeley, MBBS, MRCP, RhMSUS 

3:15 pm 

Hands-on Scanning: The Shoulder 

All Faculty 

ACR BASIC RESEARCH CONFERENCE: 

PATHWAYS OF INFLAMMATION AND 

RESOLUTION – DAY ONE OF TWO 

1:00 – 5:45 pm 

West – 3001 


4:30 – 5:30 pm 

Upper Extremity in Pediatrics 

Separate Registration Required 

4:30 pm 

Lecture: Pediatric Anatomy in Musculoskeletal 

Ultrasound 

Johannes Roth, MD 

5:00 pm 

Hands-on Scanning: Upper Extremity in Pediatrics 

Bethany A. Marston, MD; Clara Lin, MD, RhMSUS and 


ACR ADVANCED RHEUMATOLOGY 

CODING COURSE: CLINICAL 

DOCUMENTATION IMPROVEMENT 

9:00 am – 5:00 pm 

West – 2016 

8:00 – 9:00 am 


9:00 am – Noon 

The Fundamentals of Clinical Documentation 

Improvement 

Speaker: Melesia Tillman, CPC, CPC-I, CRHC, CHA 

Noon – 1:00 pm 

Boxed Lunch 

1:00 – 5:00 pm 

The Elements of E/M and DX Coding 

Speaker: Antanya Chung, CPC, CPC-I, CRHC, CCS-P 

1:00 – 3:45 pm 

Session I: Environmental Factors Set the Scene 

Moderator: Stephen P. Young, DDS 

1:00 pm 

Introduction 

Stephen P. Young, DDS 

1:15 pm 

Environmental Risk Factors for Inflammatory 

Rheumatic Diseases 

Deborah P.M. Symmons, MD 

1:45 pm 

Infectious Triggers 

John B. Harley, MD, PhD 

2:30 pm 

Keynote Lecture: The Intersection of Genes and 

Environment in Rheumatoid Arthritis 

V. Michael Holers, MD 

3:00 pm 

Question and Answer 

3:15 – 3:45 pm 


3:45 – 5:45 pm 

Session II: Neutrophils Light the Fire 

Moderator: Nora G. Singer, MD 

3:45 pm 

Neutrophils in Autoimmunity 

Mariana J. Kaplan, MD 

4:15 pm 

Neutrophil Extracellular Traps and Anti-citrullinated 

Protein Antibody 

Marko Radic, PhD 

For the most up-to-date meeting content, download the 2015 ACR/ARHP Annual Meeting app from the App Store or Google Play.


4:45 pm 

Neutrophil Extracellular Traps in Resolution of Gout 

Martin Herrmann, PhD 

5:15 pm 


5:30 pm 

Wrap-up 

ACR CLINICAL RESEARCH CONFERENCE: 

IMPROVING LONG TERM OUTCOMES 

OF RHEUMATIC DISEASE – DAY ONE OF 

TWO 

1:00 – 6:00 pm 

West – 3007 

1:00 – 3:30 pm 

Session I: Methodologies 

Moderator: Emily von Scheven, MD, MAS 

1:00 pm 

Introduction 

Christopher T. Ritchlin, MD, MPH 

1:15 pm 

Keynote Lecture: Introduction to Outcomes 

Maarten Boers, MD, PhD, MSc 

2:00 pm 

Measuring Outcomes Including Pitfalls and Barriers 

Vibeke Strand, MD 

2:30 pm 

Patient Based Data Sets (CORRONA; Practical 

Application of Methodology) 

Jeffrey D. Greenberg, MD, MPH 

3:00 pm 

Resources for Tracking Outcomes: Administrative 

Data 

Timothy Beukelman, MD, MSCE 

3:30 – 3:45 pm 


2 0 1 5 


tracker 

plus 

47 



3:45 pm 

Data for Tracking Outcomes: Imaging and Biomarker 

Data 

Christopher T. Ritchlin, MD, MPH 

4:15 pm 

Outcomes Research Using Electronic Medical Record 

Alexis Ogdie-Beatty, MD, MSCE 

4:45 pm 

Overview of Patient Report Outcomes: What Are They 

and How Do You Work With Them 

Esi M. Morgan DeWitt, MD, MSCE 

5:15 pm 

Patient-Reported Outcomes Measurement 

Information System (PROMIS) 

James P. Witter, MD, PhD 

5:45 pm 

Question and Answer and Wrap-up 

Christopher T. Ritchlin, MD, MPH and 

Emily von Scheven, MD, MAS 

ACR MAINTENANCE OF CERTIFICATION 

(MOC) ANNUAL MEETING COURSE 

1:00 – 6:00 pm 

South – Gateway Ballroom, 104 

Moderator: Carol A. Langford, MD, MHS 

1:00 pm 

Overview 

Carol A. Langford, MD, MHS 

1:10 – 2:40 pm 

Session I: Questions From 2015 Update 

Speaker: Carol A. Langford, MD, MHS 

2:40 – 3:00 pm 


3:00 – 4:30 pm 

Session II: Questions From 2015 Update 

Speaker: Juliet Aizer, MD, MPH 


48 




FRIDAY & SATURDAY, NOVEMBER 6, 7, 2015 

4:30 – 6:00 pm 

Session III: Questions From 2015 Update 

Speaker: Erika H. Noss, MD, PhD 

6:00 pm 

Wrap-up 

Carol A. Langford, MD, MHS 

8:00 am 

Live Demonstration: Scanning of the Hip 

Midori Jane Nishio, MD, RhMSUS 

8:15 am 

Hands-on Scanning: The Hip 

All Faculty 


9:00 – 9:15 am 

Morning Break 

ACR MUSCULOSKELETAL ULTRASOUND 

COURSE FOR RHEUMATOLOGISTS – 

FUNDAMENTALS – DAY TWO OF TWO 

7:15 am – 5:50 pm 

West – 2010 

6:45 – 7:15 am 


Course Director: Midori Jane Nishio, MD, RhMSUS 

Faculty: Rany Al Haj, MD; Catherine J. Bakewell, MD; 

Narandra Bethina, MD, RhMSUS; Jurgen Craig-Muller, 

MD, RhMSUS; Paul J. DeMarco, MD, RhMSUS; Amy M. 

Evangelisto, MD, RhMSUS; Jay B. Higgs, MD, RhMSUS; 

Gurjit S. Kaeley, MBBS, MRCP; Eugene Y. Kissin, MD, 

RhMSUS; Gary A. Kunkel, MD; Clara Lin, MD, RhMSUS; 

Daniel G. Malone, MD; Bethany A. Marston, MD; Midori 

Jane Nishio, MD, RhMSUS; Anthony M. Reginato, MD, 

PhD; Johannes Roth, MD; Jonathan Samuels, MD, 

RhMSUS; Ralf G. Thiele, MD, RhMSUS; Karina Marianne 

Torralba, MD, MMED, RhMSUS; Alicia Weeks, MD 

7:15 – 7:30 am 

Opening Remarks 

Speaker: Midori Jane Nishio, MD, RhMSUS 

7:30 – 9:00 am 

The Hip 

7:30 am 



Midori Jane Nishio, MD, RhMSUS 

9:15 – 11:45 am 

The Knee 

9:15 am 



Catherine J. Bakewell, MD 

9:45 am 

Live Demonstration: Scanning of the Knee 

Catherine J. Bakewell, MD 

10:00 am 

Hands-on Scanning: The Knee 

All Faculty 

11:15 am 

Billing, Coding and Report Generation 

Paul J. DeMarco, MD, RhMSUS 

11:45 am – 12:45 pm 

Boxed Lunch 

12:45 – 3:00 pm 

Foot and Ankle 

12:45 pm 



Ralf G. Thiele, MD, RhMSUS 

1:15 pm 

Live Demonstration: Scanning of Foot and Ankle 


1:30 pm 

Hands-on Scanning: Foot and Ankle 

All Faculty 



3:00 – 3:15 pm 


3:15 – 5:00 pm 

Ultrasound Needle Guidance 

3:15 pm 

Lecture: Evidence Base and Technique of Ultrasound 

Guidance of Procedures Guided Procedures 


3:45 pm 

Panel Discussion – Implementing Musculoskeletal 

Ultrasound in the Practice of Rheumatology 

Catherine Bakewell, MD; Paul J. DeMarco, MD, RhMSUS; 

Eugene Y. Kissin, MD, RhMSUS and Ralf G. Thiele, MD, 

RhMSUS 

4:15 pm 

Hands-on Scanning: Ultrasound in Procedure 

Guidance 

All Faculty 

5:00 – 5:50 pm 

Lower Extremity in Pediatrics 

Separate registration required. 

5:00 pm 

Lecture: Lower Extremity in Pediatrics 


5:20 pm 

Hands-on Scanning: Pediatrics 

Bethany A. Marston, MD, Clara Lin, MD, RhMSUS and 


ARHP CLINICAL FOCUS COURSE 

– CLINICAL ADVANCES IN 

RHEUMATOLOGIC DISEASES: A CASE- 

BASED APPROACH 

7:45 am – 4:15 pm 

West – 2014 

2 0 1 5 


tracker 

plus 

49 



7:00 – 7:45 am 


Moderator: Susan Richmond, MS, PA-C 

7:45 am 

Introduction 

Susan Richmond, MS, PA-C 

8:00 – 8:45 am 

What Is the Latest Breaking in Rheumatoid 

Arthritis? 

Speakers: Jessica F. Farrell, PharmD 

8:45 – 9:30 am 

What Is the Latest Breaking in Osteoarthritis? 

Speaker: Karen Huisinga, MN, ARNP, FNP 

9:30 – 10:15 am 

Latest and Greatest in Juvenile Idiopathic 

Arthritis 

Speaker: Peter Chira, MD, MS 

10:15 – 10:30 am 

Morning Break 

10:30 – 11:30 am 

Inter-professional Case Discussion: Rheumatoid 

Arthritis, Osteoarthritis and Juvenile Idiopathic 

Arthritis 

Speakers: Jessica F. Farrell, PharmD; Karen Huisinga, 

MN, ARNP, FNP and Peter Chira, MD, MS 

11:30 am – 12:30 pm 

Adult and Pediatric Systemic Lupus 

Erythematosus 

Speaker: David A. Isenberg, MD 

12:30 – 1:15 pm 

Boxed Lunch 

1:15 – 2:00 pm 

Inter-professional Case Discussion for Adult and 

Pediatric Systemic Lupus Erythematosus 

Speaker: David A. Isenberg, MD 


50 





2:00 – 3:00 pm 

Polymyositis and Dermatomyositis – Adult and 

Pediatric 

Speaker: Lisa G Rider, MD 

3:00 – 3:15 pm 


3:15 – 4:00 pm 

Inter-professional Case Discussion for Adult and 

Pediatric Polymyositis/Dermatomyositis 

Speaker: Lisa G Rider, MD 

4:00 pm 

Wrap-up 

Susan Richmond, MS, PA-C 

ACR BASIC RESEARCH CONFERENCE: 

PATHWAYS OF INFLAMMATION AND 

RESOLUTION – DAY TWO OF TWO 

7:45 am – 4:30 pm 

West – 3001 

7:00 – 7:45 am 


7:45 – 9:30 am 

Session III: Metabolism Supports and Extends 


7:45 am 

Introduction 

Nora G. Singer, MD 

8:00 am 

Dendritic Cells and Lipolysis 

Jeffrey Rathmell, PhD 

8:30 am 

Hypoxia in Inflammation 

Douglas J. Veale, MD 

9:00 am 

Metabolomics in Chronic and Acute Inflammation 

Stephen P. Young, DDS 

9:30 – 11:20 am 

Session IV: Lipids Set the Balance 


9:30 am 

η-3 Fatty Acids and Inflammation 

Leslie G. Cleland, MD 

10:00 – 10:20 am 

Morning Break 

10:20 am 

Pro-resolving Lipid Mediators 

Derek Gilroy, PhD 

10:50 am 

Prostaglandins in Innate and Acquired Immunity 

Karsten Gronert, PhD 

11:20 am – 2:20 pm 

Session V: Macrophages Respond, Sustain, 

and Resolve 


11:20 am 

Macrophage-fibroblast Interaction in the Synovium 

Lionel B. Ivashkiv, MD 

11:50 am 

Macrophage Subtypes in the Synovium 

Speaker: Ursula Fearon, PhD 

12:20 – 1:20 pm 

Boxed Lunch 

1:20 pm 

Tristetraprolin and Macrophage Resolution 

Andy Clark, BA, PhD 

1:50 pm 

Abstract Presentations 

2:20 – 4:30 pm 

Session VI: Resolution or Disease 




2:20 pm 

Toll-like Receptors, Mast Cells, and Anti-citrullinated 

Protein Antibodies 

René E. M. Toes, PhD 

2:50 – 3:05 pm 


3:05 pm 

Complement and Autoimmunity 

John Atkinson, MD 

3:35 pm 

The Role of Interferons in Lupus 

Mary K. Crow, MD 

4:05 pm 


4:15 pm 

Wrap-up 

Nora G. Singer, MD and Stephen P. Young, DDS 

ACR CLINICAL RESEARCH CONFERENCE: 

IMPROVING LONG TERM OUTCOMES 

OF RHEUMATIC DISEASE DAY TWO OF 

TWO 

7:45 am – 4:30 pm 

West – 3007 

7:00 – 7:45 am 


7:45 am – 1:45 pm 

Session II: Disease Oriented 

Moderator: Christopher T. Ritchlin, MD, MPH 

7:45 am 

Introduction 


8:00 am 

Vasculitis 

Peter A. Merkel, MD, MPH 

2 0 1 5 


tracker 

plus 

51 



8:30 am 

Inflammatory Arthritis 

Kaleb Michaud, PhD 

9:00 am 

Osteoarthritis 

David T. Felson, MD, MPH 

9:30 – 10:00 am 

Morning Break 

10:00 am 

Lupus 

Karen Costenbader, MD, MPH 

10:30 am 

Abstract Presentations 

11:00 am 

Pediatric Rheumatic Diseases 


11:30 – 12:30 am 

Boxed Lunch 

12:30 pm 

Transition From Pediatric to Adult Care 

Peter Chira, MD, MS 

1:00 pm 


1:45 – 4:30 pm 

Session III: Looking to the Future – Practical 

Applications 

Moderator: Alexis Ogdie-Beatty, MD, MSCE 

1:45 pm 

Measurement Versus Improvement in Long Term 

Outcomes 

Daniel H. Solomon, MD, MPH 

2:15 pm 

Application of Digital Technologies to Gather 

Patient Outcomes in the Office Setting 

Andrew Soll, MD 

2:45 pm 

Novel Technologies 

Jeffery R. Curtis, MD, MPH 


52 





3:15 pm 

How to Get Trained and Where to Get Funded in 

Outcomes Research 

Kenneth G. Saag, MD, MSc 

3:45 pm 

Panel Discussions 

4:15 pm 

Question and Answer and Wrap-up 

Christopher T. Ritchlin, MD, MPH and Emily von 

Scheven, MD, MAS 

ACR PRACTICE MANAGEMENT PRE- 

MEETING COURSE: TRANSFORMING 

THEORY INTO PRACTICE 

8:00 am – 4:00 pm 

West – 2016 

7:00 – 8:00 am 


Moderator: Nancy Ellis, MBA, MHA 

8:00 – 9:00 am 

Emerging Payment Models 

Speaker: Allison Brennan, MPP 

9:00 – 9:30 am 

Morning Break 

9:30 – 10:30 am 

Office of Inspector General Audits and 

Compliance 

Speaker: David Holtzman, JD 

10:30 – 11:30 am 

Optimizing Clinical Productivity and Revenue 

Cycle 

Speaker: Mark Painter 

11:30 am – 12:30 pm 

Boxed Lunch 

12:30 – 1:30 pm 

Practice Management 101 

Speaker: Nancy Ellis, MBA, MHA 

1:30 – 2:00 pm 


2:00 – 3:00 pm 

Understanding Resource-Based Relative Value 

Scale Impact on Practice 


3:00 – 4:00 pm 

Prevent Compliance Breaches 


ACR REVIEW COURSE 

8:00 am – 4:00 pm 


6:30 – 8:00 am 


Moderators: Simon M. Helfgott, MD and Peter Valen, 

MD 

8:00 – 8:45 am 

Central Nervous System Manifestations of 


Speakers: Julius Birnbaum, MD, MHS 

8:45 – 9:30 am 

Lupus Nephritis: a Proposition for the Mixed 

Martial Arts 

Speakers: Joan Merrill, MD 

9:30 – 10:15 am 

Metabolic Myopathies: A Hybrid Approach to 

Diagnosis and Management 

Speakers: Kenneth S. O’Rourke, MD 



10:15 – 10:45 am 

Morning Break 

10:45 – 11:30 am 

Extra-Pulmonary Manifestations of Sarcoidosis 

Speaker: Kristin Highland, MD 

11:30 am – 12:15 pm 

From Inflammasomes to Proteasomes: An 

Emerging Role for Cytokine Dysregulation 

Beyond IL-1 in Autoinflammation 

Speaker: Raphaela T. Goldbach-Mansky, MD, MHS 

12:15 – 1:15 pm 

Boxed Lunch 

1:15 – 2:00 pm 

Evolving Treatments for Amyloidosis 

Speaker: John Berk, MD 

2:00 – 2:45 pm 

An Overview of Behçet’s Disease in Children 

and Adolescents 

Speaker: Seza Ozen, MD 

2:45 – 3:15 pm 


3:15 – 4:00 pm 

A Rational Approach to Dermatology for the 

Rheumatologist 

Speaker: Joseph Merola, MD, MMSc 

AAMC MEDICAL EDUCATION RESEARCH 

CERTIFICATE (MERC) WORKSHOP: 

QUALITATIVE DATA COLLECTION AND 

ANALYSIS METHODS 

9:00 am – 4:00 pm 

West – 2004 

2 0 1 5 


tracker 

plus 

53 



8:00 – 9:00 am 


Moderator: Christopher E. Collins, MD 

9:00 am – 12:00 pm 

Introduction to Qualitative Data Collection 

Methods 

Speaker: Arianne Teherani, PhD 

12:00 – Noon 

Boxed Lunch 

1:00 – 4:00 pm 

Qualitative Analysis Methods in Medical 

Education 

Speaker: Arianne Teherani, PhD 

S C I E N T I F I C 

S E S S I O N S 

ACR/ARHP OPENING LECTURE AND 

AWARDS 

4:30 – 6:15 pm 


Moderators: E. William St.Clair, MD, ACR President and 

Kamala Nola, PharmD, MS, ARHP President 

4:30 pm 

ACR Presidential Address 

5:00 pm 

Recognition of 2015 ACR Masters 

Recognition of 2015 ACR Awards of Distinction 

Recipients 

Recognition of 2015 ARHP Merit Awards Recipients 

Recognition of 2015 ACR Distinguished Fellows 

Awards Recipients 

Recognition of 2015 Rheumatology Research 

Foundation Corporate Roundtable Donors 


54 


2015 SCIENTIFIC SESSIONS 

SATURDAY & SUNDAY, NOVEMBER 7, 8, 2015 

5:30 – 6:15 pm 

Opening Lecture and Awards: Education at 

Scale: Beyond An Experiment PM Ed Pd PS PrM FIT 

Speaker: Daphne Koller, PhD 

NETWORKING EVENT 

6:30 – 8:00 pm 

West – Second Floor Lobby 

ACR/ARHP Opening Reception 

Plan to socialize and network with your colleagues from 

around the world and enjoy the sounds of the 16-piece 

Mood Swing Orchestra. 

ACR SESSIONS 

7:30 – 8:30 am 


S C I E N T I F I C 

S E S S I O N S 

West – First Floor 

Rheumatology Research Foundation Philip 

Hench, MD Memorial Lecture: The Transition 

From Psoriasis to Arthritis- New Insights 

Moderator: Eric L. Matteson, MD 

Speaker: Christopher T. Ritchlin, MD, MPH 

West – 2022 

The Interferonopathies 

Moderator: Keith B. Elkon, MD 

Speakers Yanick Crow, BMedSci, MBBS, MRCP, PhD 


Year in Review 

Moderator: Richard F. Loeser, MD 

7:30 am 

The Year in Review: Basic Science Rheumatology 

Anne Davidson, MBBS 

8:00 am 

The Year in Review: Clinical Rheumatology 

Sterling West, MD 


7:30 – 8:30 am 

South – Esplanade, 301 

ACR/ARHP Annual Meeting Orientation 

First-time ACR/ARHP attendees are invited to join ACR 

Immediate Past President, Joseph Flood, MD and ARHP 

Immediate Past President Karen L. Smarr, PhD for an 

orientation to learn the “ins and outs” of the annual 

meeting. 

ACR MEET THE PROFESSOR SESSIONS 

7:45 – 9:15 am 

Admission to Meet the Professor sessions requires a 

separate registration and ticket. To verify which session you 

registered for, the registration code on your ticket needs 

to match the 3-digit code in front of the session title. If you 

are interested in participating in one of these sessions or 

exchanging your ticket, visit the ACR registration desk to 

check space availability. View the session overview and 

learning objectives online in the Annual Meeting App. 

Access and download the app at ACRannualmeeting.org. 

* Sessions denoted with an asterisk were sold out as of 

August 30. 

West – 3003 

*001 – Ankylosing Spondylitis: 2015 Update 

Speaker: Lianne S. Gensler, MD 

West – 3005 

002 – Antiphospholipid Syndrome 

Speaker: Alana B. Levine, MD 



2 0 1 5 


tracker 

plus 

55 


West – 3007 

*003 – Challenging Cases in Osteoporosis 

Management 

Speaker: Jeffrey Lisse, MD 

West – 3009 

004 – Osteoporosis: Novel Treatments 

Speaker: Linda Russell, MD 

West – 3011 

*005 – Pregnancy and Rheumatic Diseases 

Speaker: Jill P. Buyon, MD 

West – 3016 

006 – Psoriatic Arthritis 

Speaker: Dafna D. Gladman, MD 

West – 3018 

*007 – Rheumatoid Arthritis: Challenging Cases 

Speaker: Daniel E. Furst, MD 

West – 3020 

008 – Rheumatoid Arthritis: Outcome 

Measures in Clinical Practice – Moving from 

Measurements to Management 

Speaker: Eric Newman, MD 

West – 3022 


Arthritis 

Speaker: Jeffrey D. Greenberg, MD, MPH 

West – 3024 

*010 – Systemic Sclerosis: Disease Staging and 

Subsetting in Clinical Practice 

Speaker: Robyn T. Domsic, MD, MPH 

ACR/ARHP WORKSHOPS 

7:45 – 9:45 am 

Admission to Workshops requires a separate registration 

and ticket. To verify which session you registered for, the 

registration code on your ticket needs to match the 3-digit 

code in front of the session title. If you are interested 

in participating in one of these sessions or exchanging 

your ticket, visit the ACR registration desk to check space 

availability. View the session overview and learning 

objectives online in the Annual Meeting App. Access and 

download the app at ACRannualmeeting.org. 


August 30. 

West – 3002 

*201 – Advanced Musculoskeletal Ultrasound 

Speaker: Jay B. Higgs, MD and Catherine Bakewell, MD 

West – 3008 

202 – Clinical Anatomy and Physical Exam: 

Essential Tools in Upper Extremity Regional 

Pain Syndromes PM PS E 

Speaker: Robert A. Kalish, MD and Pablo Villasenor 

Ovies, MD 

West – 3006 

203 – How to Utilize Health Record Right to 

Maximize Meaningful Use 

Speaker: Salahuddin Kazi, MD 

ACR SESSIONS 

8:30 – 10:00 am 

North – 132 

Clots in Children: Where They Come From and 

What to Do With Them PM Ed Pd PS PrM FIT 

Moderators: Deborah M. Levy, MD, MS and Hermine I. 

Brunner, MD, MBA, MSC 

8:30 am 

Antiphospholipid Antibodies and Lupus 

Anticoagulants in Children 

Tadej Avcin, MD 


56 




9:00 am 

Diagnostic Imaging of Pediatric Cnetral Nervous 

System Vasculopathy 

Catherine M. Amlie-Lefond, MD 

9:30 am 

To Treat or Not to Treat 

Patti Massicotte, MD 


Coming to a Joint Near You: Chikungunya 

Moderator: Swamy Venuturupalli, MD 

8:30 am 

Immunopathogenic Mechanisms of Chikungunya 

Arthritis 

Kate Ryman, PhD 

9:15 am 

Clinical Manifestations and Treatment of 

Musculoskeletal Sequelae of Chikungunya 

Arvind Chopra, DNB, MD 


Hot Topics in Osteoarthritis: Nutraceuticals, 

Narcotic Analgesics and Behavioral 

Interventions 

PM Ed Pd PS PrM FIT PM PS E 

Moderators: Jasvinder A. Singh, MD, MPH and Joanne 

M. Jordan, MD, MPH 

8:30 am 

Chondroitin and Glucosamine: To Do or Not to Do? 

Timothy E. McAlindon, MD, MPH, MRCP 

9:00 am 

Beyond NSAIDS: Treatments Targeting Central Pain in 


Yvonne C. Lee, MD, MMSc 

9:30 am 

Are Behavioral Interventions Useful in Osteoarthritis? 

The Role of Biofeedback and Coping Skills 

Susan J. Bartlett, PhD 

West – 2001 

Neutrophils in Inflammation 

Moderators: Mariana J. Kaplan, MD and Peter C. 

Grayson, MD 

8:30 am 

Neutrophils in the Resolution of Inflammation 

Martin Herrmann, PhD 

9:00 am 

Update on Neutrophil Biology 

Paul Kubes, PhD 

9:30 am 

Neutrophils in Vasculitis 

Peter C. Grayson, MD 

ACR SESSIONS 

9:00 – 10:00 am 


Can We Replace Warfarin? An Update on the 

Direct Oral Anticoagulants 

Moderator: Kerry Stone, MD 

Speaker: Kenneth Friedman, MD 

West – 2018 

Legislative Update: Chat with Congress About 

Rheumatology Issues 

Moderator: William F. Harvey, MD, MSc 

Speaker: Member of Congress 

ARHP SESSIONS 

9:00 – 10:00 am 

West – 2007 

ARHP Keynote Address: Cultural Humility for 

Rheumatology Health Professionals 

Moderator: Hazel L. Breland, PhD, OTR/L 

Speaker: Vivian Chávez, DrPH 



2 0 1 5 


tracker 

plus 

57 


ACR POSTER SESSION A AND POSTER 

TOURS 

8:30 am – 4:00 pm 

Poster presenters will be available from 9:00 – 11:00 am 

(abstracts # 1-895). Poster tours will be held 9:00 – 9:45 am 

and 10:15 – 11:00 am. Morning snacks will be available at 

8:30 am. 

South – Halls B-C (Poster Hall) 


Guided poster tours allow scientific attendees to ask 

questions and gain insights from some of the bestknown 

rheumatology leaders. Tours are complimentary; 

however, registration is required and is limited to scientific 

attendees. If you pre-registered for a tour, you should have 

received a ticket with your meeting materials. Once you 

have your ticket, check in at the tour desk 15 minutes prior 

to the start of your tour to receive your headset. 

IMPORTANT: Your reservation will be held only until 

5 minutes prior to the start of the tour. After this time, 

your reservation is not guaranteed and may be released 

to standby attendees. If you did not pre-register, tickets 

may be available in the registration area (Exhibit Level: 

East Registration). Alternatively, you may go directly 

to the poster tour desk and wait for a standby ticket. 

Standby tickets will be assigned on a first-come, first 

served basis 5 minutes prior to the start of each tour. 

Each tour participant will receive a wireless headset which 

will be registered against the participants’ registration 

ID. Participants will be charged $50 if the headset is not 

returned within 15 minutes of the end of the tour. 

9:00 – 9:45 am 

Poster Tours # 301-306 

Check the annual meeting app for the most current poster 

tour titles. 

10:15 – 11:00 am 



tour titles. 

EXHIBITS 

10:00 am – 5:00 pm 

South – Hall D (Exhibit Hall) 

Join your colleagues in the Exhibit Hall for morning and 

afternoon refreshments at 10:00 am and 2:30 pm. 

Located in Hall E, Room 135 through the 

Exhibit Hall 

Innovation Theater A and B 

Non-CME accredited presentations have been planned and 

will be implemented in accordance with the requirements 

of the FDA and applicable standards of the PhRMA Code 

on Interactions with Healthcare Professionals. Innovation 

Theater A presentations will be held from 10:30 – 11:15 am, 

12:30 – 1:15 pm and 2:30 – 3:15 pm. Innovation Theater B 

presentations will be held from 11:30 am – 12:15 pm, 1:30 – 

2:15 pm and 3:30 – 4:15 pm. For a complete listing 

of Innovation Theater presentations, see page 193. 


10:30 am – 12:30 pm 










* Sessions denoted with an asterisk were sold out as 

of August 30. 

West – 3002 

204 – Beyond Musculoskeletal Ultrasound 


Speaker: Richard Hoppmann, MD 

West – 3008 

*205 – Clinical Anatomy and Physical Exam: 

Essential Tools in Lower Extremity Regional 

Pain Syndromes PM PS E 

Speakers: Robert A. Kalish, MD; Pablo Villasenor Ovies, 

MD 


58 




West – 2006 

206 – Histopathology of Vasculitis 

Speakers: Allen Burke, MD and Fabio Tavora, MD, PhD 

West – 3004 

207 – Synovial Fluid Analysis and Crystal 

Identification 

Speakers: Brian F. Mandell, MD, PhD; Lan Chen, MD, 

PhD and Gilda M. Clayburne, MLT 

ACR SESSION 

11:00 am – Noon 


Update in Antibody Testing: Clinical Significance 

of Antinuclear and Anti-Neutrophil Cytoplasmic 

Antibodies 

Moderators: Shawn Slack, MD and Shervin Assassi, MD, 

MS 

11:00 am 

The Clinical Significance of Antinuclear Antibodies 

Mark H. Wener, MD 

11:30 am 

Clinical Significance of Anti-Neutrophil Cytoplasmic 

Antibodies 

Ulrich Specks, MD 

ARHP SESSIONS 

11:00 am – Noon 


Immunology Boot Camp I: The Basics of 

Targeted Therapies 

Moderator: to be Determined 

Speaker: Troy R. Torgerson, MD, PhD 

West – 2007 

Navigating Insurance and Prior Authorization 

PM PS E 

Moderator: Lisa M. Kastanek, RN, CCRC 

Speaker: Larry Kemp, MS, MPA, FACHE 

West – 2009 

Pediatric Research Methods PM PS 

Moderator: Robert R. McLean, DSc, MPH 

Ed Pd PrM FIT 

11:00 am 

Overview of Data Sources and Methods to Conduct 

Studies of the Pediatric Rheumatic Diseases 

Timothy Beukelman, MD, MSCE 

11:30 am 

Important Considerations in Use of Patient Reported 

Outcomes as Endpoints in Registry-based Research 

Studies 

Esi Morgan-DeWitt, MD, MSCE 

West – 2008 

Peripheral Neuropathy in Rheumatic Disease: 

Etiology and Management 

PM Ed Pd PS PrM FIT PM PS E 

Moderator: Barbara A. Slusher, PA-C, MSW 

Speaker: Julius Birnbaum, MD, MHS 

ACR PLENARY SESSION 

11:00 am – 12:30 pm 


ACR Plenary Session I: Discovery 2015 

Moderators: E. William St.Clair, MD and Richard F. 

Loeser, MD 

11:00 am 

Rheumatology Research Foundation Corporate 

Roundtable Awards 

11:15 am 

896. Herpes Zoster and the Short Term Risk for 

Ischemic Stroke in Patients with Autoimmune 

Diseases 

Leonard H. Calabrese 1 , Fenglong Xie 2 , Huifeng 

Yun 2 , Kevin L. Winthrop 3 , John Baddley 4 , Cassandra 

Calabrese 1 and Jeffrey R. Curtis 2 , 1 Cleveland Clinic 

Foundation, Cleveland, OH, 2 University of Alabama 

at Birmingham, Birmingham, AL, 3 Oregon Health 

and Science University, Portland, OR, 4 University of 

Alabama, Birmingham, AL 



2 0 1 5 


tracker 

plus 

59 


11:30 am 

897. Intra-Articular Corticosteroids Are Safe and 

Have No Major Effect on Structural Progression of 

Synovitic Knee OA: A 2-Year Randomized Controlled 

Trial of 3-Monthly Triamcinolone Hexacetonide 

Jeffrey Driban 1 , Michael P. Lavalley 2 , Lori Lyn Price 1 , 

William F. Harvey 1 and Timothy E. McAlindon 1 , 1 Tufts 

Medical Center, Boston, MA, 2 Boston University, 

Boston, MA 

11:45 am 

898. A Randomized Double-Blind Study of 

Denosumab Compared with Zoledronic Acid 

in Postmenopausal Women with Osteoporosis 

Previously Treated with Oral Bisphosphonate 

PD Miller 1 , N Pannacciulli 2 , JP Brown 3 , E Czerwinski 4 , 

BS Nedergaard 5 , MA Bolognese 6 , J Malouf 7 , HG Bone 8 , 

JY Reginster 9 , A Singer 10 , C Wang 2 , RB Wagman 2 

and SR Cummings 11 , 1 Colorado Center for Bone 

Research, Lakewood, CO, 2 Amgen Inc., Thousand 

Oaks, CA, 3 Laval University and CHU de Québec (CHUL) 

Research Centre, Québec City, QC, 4 Krakow Medical 

Center, Krakow, Poland, 5 Center for Clinical and Basic 

Research, Aalborg, Denmark, 6 The Bethesda Health 

Research Center, Bethesda, MD, 7 Hospital de la Santa 

Creu i Sant Pau, Barcelona, Spain, 8 Michigan Bone and 

Mineral Clinic, Detroit, MI, 9 University of Liège, Liège, 

Belgium, 10 Georgetown University Medical Center, 

Washington, DC, 11 San Francisco Coordinating Center, 

CPMC Research Institute, San Francisco, CA 

12:00 pm 

899. HA20: A Novel Autoinflammatory Disease 

Caused By Haploinsufficiency of A20, Encoded By 

TNFAIP3 

Qing Zhou 1 , Hongying Wang 1 , Daniella M. Schwartz 2 , 

Monique Stoffels 3 , Yong Hwan Park 1 , Yuan Zhang 4 , 

Erkan Demirkaya 5 , Masaki Takeuchi 1 , Jonathan J. 

Lyons 4 , Xiaomin Yu 4 , Claudia Ouyang 2 , Amanda K. 

Ombrello 1 , Deborah L. Stone 1 , Patrycja Hoffmann 1 , 

Anne Jones 1 , Helen L. Leavis 6 , Annet van Royen- 

Kerkhof 6 , Ahmet Gül 7 , Seza Ozen 8 , Richard Siegel 9 , 

Massimo Gadina 10 , JaeJin Chae 1 , Ronald Laxer 11 , 

Daniel L. Kastner 1 and Ivona Aksentijevich 1 , 1 National 

Human Genome Research Institute, Bethesda, MD, 

2 

National Institute of Arthritis and Musculoskeletal 

and Skin Diseases, Bethesda, MD, 3 National Human 

Genome Research Institute, National Institutes of 

Health, Bethesda, MD, 4 National Institute of Allergy 

and Infectious Diseases, Bethesda, MD, 5 Gulhane 

Military Medical Academy, FMF Arthritis Vasculitis and 

Orphan disease Research Center (FAVOR),, Ankara, 

Turkey, 6 University Medical Center Utrecht, Utrecht, 

Netherlands, 7 Istanbul University, Istanbul Faculty 

of Medicine, Istanbul, Turkey, 8 Hacettepe University, 

Ankara, Turkey, Ankara, Turkey, 9 National Institute 

of Arthritis and Musculoskeletal and Skin Diseases, 

National Institutes of Health, Bethesda, MD, 10 NIAMS/ 

NIH, Bethesda, MD, 11 The Hospital for Sick Children, 

Toronto, ON 

12:15 pm 

900. A Multidimensional Immunomics Approach 

Annotates an Immunome Shaped By the 

Interplay Between the Periphery and the Skin 

Microenvironment in Systemic Sclerosis 

Hari Balaji Venkatanarayanan 1 , Andrea Low 2 , Raymond 

Ong Jr. 1 , Liyun Lai 1 , Juntao Li 3 , Chie Hwee Ang 1 , Suzan 

Saidin 1 , Camillus Chua 1 , Jing Yao Leong 3 , Agnieszka 

Maliszewska 3 , Lakshmi Ramakrishna 3 , Julian Thumboo 2 

and Salvatore Albani 3 , 1 Singapore Health Services Pte 

Ltd, Singapore, Singapore, 2 Singapore General Hospital, 

Singapore, Singapore, 3 Duke-National University 

of Singapore Graduate Medical School, Singapore, 

Singapore 

ACR SESSION 

12:30 – Noon 


CARE: MOC Sessions 2015 – Session 1 – 

Nonarticular and Regional Musculoskeletal 

Disorders 


Speaker: Geordie Lawry, MD 


60 





12:30 – 2:15 pm 

Marriott Marquis – Yerba Buena 8 

ARHP Discipline Round Tables: Networking 

Forum 

ARHP attendees are invited to this kickoff forum for the 

annual meeting. A box lunch will be provided for the first 

250 people. You will have an opportunity to meet and 

network with other health professionals. Discipline tables 

will be arranged to help facilitate connections. This session 

is not eligible for CME credit. 

ACR SESSION 

12:45 – 2:15 pm 


ACR Knowledge Bowl: Preliminary Round 

Moderator: Rebecca L. Manno, MD, MHS 

Competing Teams: 

Ann Arbor’s Anti-nuclear Option 

W. Joseph McCune, MD; Beth Wallace, MD; Viju Moses, 

MD, MBBS 

Boom Boom Rheum 

Vikas Majithia, MD, MPH; Teresa Crout, MD; Swathi 

Gonalaggadia, MD 

Chi-town Brain Fog 

Vladimir M. Liarski, MD; Mariam Siddiqui, MD; Heena A. 

Birbal Jain, MD 

GEAUX-ttron’s Papules 

Nirupa J. Patel, MD; Beau Boudreaux, MD; Alexander C. 

Hu, DO 

Men with Bones and Brains 

Canchi Balakrishnan, MBBS, MD; Parikshit Sagdeo, 

MBBS, MD; Taral Parikh, MBBS, MD 

Nebraska Rheum-ies 

Geoffrey M. Thiele, PhD; Melanie Rohr, MD; Priyanka 

Vashisht, MD 

“Oregon” Damage 

Pascale Schwab, MD; Rashmi Shah, MD; Jameel Youssef, 

MD 

Rock City Joints 

Alison Gizinski, MD, MS; Aaroop Haridas, MD; Sruthi 

Kanuru, MD 

Rogue Regulators 

Robert Quinet, MD; Magdalena Budziakowska, MD; Arif 

Shahzad, MD 

Ropes-a-Dopes 

Eli Miloslavsky, MD; Sara R. Schoenfeld, MD; Zachary 

Wallace, MD 

SKMC Joint Group 

Irena Khostanteen, MD; Amna Al Muhairi, MD; Manal 

Belooshi, MD 

Team Smallbany 

Prashant Kaushik, MB BS; Yamen Homsi, MD; Aung Aye, 

MD 

The Hawkeyes 

Namrata Singh, MD; Bharat Kumar, MD; Speaker to be 

Determined 

The Joint Commission 

Karina Marianne D. Torralba, MD; Michelle T. Ngo, DO; 

Sheila Lezcanom, MD 

Gulls of Galveston 

Vijaya Murthy, MD; Rajani Rudrangi, MD; Niharika Ganti, 

MD 

Joint Service 

Robert O’Brian, MD; Rachel C. Robbins, MD; Vanya D. 

Wagler, DO 



2 0 1 5 


tracker 

plus 

61 



12:45 – 2:15 pm 











August 30. 

West – 3003 

*011 – Adult Inflammatory Myopathy 

Speaker: Robert L. Wortmann, MD, MACR 

West – 3005 

*012 – Ankylosing Spondylitis: Disease 

Modification 

Speaker: Atul A. Deodhar, MD 

West – 3007 

013 – Non-surgical Treatments for 


Speaker: David T. Felson, MD, MPH 

West – 3009 

014 – Pediatric Systemic Lupus Erythematosus 

Speaker: Marisa S. Klein-Gitelman, MD, MPH 

West – 3011 

*015 – Pulmonary Manifestations of Rheumatic 

Disease 

Speaker: Aryeh Fischer, MD 

West – 3016 

016 – Reactive Arthritis: An Update 

Speaker: Siba Raychaudhuri, MD 

West – 3018 

*017 – Rheumatoid Arthritis: Biological Agents 

Speaker: Josef S. Smolen, MD 

West – 3020 

*018 – Systemic Lupus Erythematosus: Lupus 

Nephritis 

Speaker: Rosalind Ramsey-Goldman, MD, DrPH 

West – 3022 

*019 – Vaccinations for Patients on Biologic 

Therapies 

Speaker: Jeffery R. Curtis, MD, MPH 

West – 3024 

020 – Vitamin D and Bone Health 

Speaker: Chad Deal, MD 

ACR SESSIONS 

1:00 – 2:00 pm 

West – 2001 

Gender Differences in Pain Mechanisms 

Moderators: Anne-Marie Malfait, MD, PhD and Daniel J. 

Clauw, MD 

Speaker: Jon Levine, MD, PhD 


Immunology Update on B cell Biology 

Moderators: William Stohl, MD, PhD and Stamatis Nick 

Liossis, MD 

Speaker: Andrew C. Chan, MD PhD 

West – 2000 

Medical Education: The Year in Review 

Cultivating the Competent Clinician Educator 

PM Ed Pd PS PrM FIT 

Moderators: Jessica Berman, MD and Michael J. 

Battistone, MD 

Speaker: Marcy B. Bolster, MD 


62 




West – 2004 

Platelets as Immune Sensors and Effectors: 

New Biology 

Moderators: David M. Lee, MD, PhD and Ulf Müller- 

Ladner 

Speaker: Guy Zimmerman, MD 


Vasculitis Mimics PM PS PM 

Moderator: Irene Tan, MD 

Speaker: Philip Seo, MD 

STUDY GROUPS 

1:00 – 2:00 pm 

Ed Pd Ed PrM Pd PS FIT PrM FIT 

Take advantage of these unique social forums, designed 

to bring together small groups of attendees with common 

interest in a single disease, a group of related disorders 

or a specialized field of study. Study Groups are non-CME 

activities open to all attendees. 

West – 2022 

ACR Musculoskeletal Ultrasound Study Group 

Speakers: Anthony M. Reginato, MD, PhD; Ralf G. 

Thiele, MD, RhMSUS; Walter Grassi, MD and Nemanja 

Damjanov, MD, PhD 

West – 3014 

Antiphospholipid Syndrome Task Force Study 

Group 

1:00 pm 

2016 Antiphospholipid Syndrome Classification 

Criteria Task Force Update I: Current Efforts and 

Introduction to the Multi-criteria Decision Analysis 

Methods 

Medha Barbhaiya, MD, MPH and Karen H. 

Costenbader, MD, MPH 

1:15 pm 

2016 Antiphospholipid Syndrome (APS) Classification 

Criteria Task Force Update II: How Can Meta-analyses 

Help Us Develop New APS Classification Criteria? 

Stephane Zuily, MD, MPH, PhD and Denis Wahl, MD, 

PhD 

1:30 pm 

2016 Catastrophic Antiphospholipid Syndrome Task 

Force Update 

Ricard Cervera, MD, PhD 

1:40 pm 

2016 Pediatric Antiphospholipid Syndrome Task Force 

Update 

Barry Myones, MD 

1:50 pm 

Group Discussion (Members of the Antiphospholipid 

Syndrome (APS) Classification Criteria, Catastrophic 

Antiphospholipid Syndrome, and Pediatric APS Task 

Forces as well as the interested physician-scientists) 

All Faculty 

West – 2006 



Applications) Study Group 

1:00 pm 



Applications) Part One 

Nevine Mohannad Abbas, MD 

1:25 pm 



Applications) Part Two 

Ragaa Abdul Kader Mahmoud, MD 

West – 2007 

Geriatrics Rheumatology Special Interest Group 

Study Group 

Speakers: Una E. Makris, MD, Rebecca L. Manno, MD, 

MHS and Dvyano Mirsa, MD, MSC 

West – 2008 

High-Resolution Peripheral Quantitative 

Computed Tomography (HR-pQCT) Imaging in 

Arthritis and Other Autoimmunopathies Study 

Group 



2 0 1 5 


tracker 

plus 

63 


1:00 pm 

A Histology Study of Pathological and Physiological 

Bone Changes Correlated to HR-pQCT Imaging 

Ellen-Margrethe Hauge, PhD 

1:25 pm 

Assessment of Periarticular Bone Strength, 

Microarchitecture and Cortical Parameters in 

Rheumatoid Arthritis 

Stephanie Boutroy, PhD 

1:50 pm 

Introduction: Assessing Changes in Periarticular Bone 

in Arthritis with HR-pQCT Imaging 

Kathryn S. Stok, PhD 

2:15 pm 

Reliability of an Algorithm for Volumetric Bone 

Erosion Assessment Under Development for Clinical 

Studies 

Stephanie Finzel, MD 

West – 2018 

Latin American Study Group 

Speaker: Maria L. Massardo, MD 

West – 2009 

Neuroendocrine Immunology Study Group 

1:00 pm 

Possible Analogies Between Cholinergic Antiinflammatory 

Pathway in Experimental Models and 

Human Rheumatoid Arthritis 

Yaakov Levine, PhD 

1:25 pm 

Sympathetic Activation via Vagal Nerve Stimulation 

– Another Understanding of the Inflammation 

Triggered Autonomous Reflex 

Rainer Straub, MD 

1:50 pm 

The Interface Between Cholinergic Pathways and the 

Immune System – Relevance to Arthritis? 

John Hamilton, PhD, DSc 

West – 2011 

Sexuality and Intimacy in Rheumatic Diseases 

Study Group 

Speakers: Mary L. Jurisson, MD; Heather Howard, PhD, 

MPH and Leslie Barnard, PsyD 

West – 2016 

Veterans Affairs Rheumatology Study Group 

Speakers: Elizabeth Chang, MD and Mathilde H. Pioro, 

MD 


1:15 – 3:15 pm 











August 30. 

West – 3006 

208 – Complementary and Alternative 

Therapies in Rheumatic Disease 

Speaker: Donald M. Marcus, MD 

West – 3002 

*209 – Evaluation and Management of Shoulder 

Pain 

Speakers: Michael Battistone, MD and Andrea M. 

Barker, MPAS, PA-C 

West – 3004 

210 – How to Apply Statistics to Your Research 

Speakers: Dorothy D. Dunlop, PhD and Julia (Jungwha) 

Lee, PhD, MPH 


64 




West – 3008 

*211 – Joint Injections (Knee, Ankle, Shoulder 

and Wrist) 

Speakers: Jemima Albayda, MD and Pari Basharat, MD 

ACR SESSIONS 

2:30 – 4:00 pm 


Novel Roles for the Inflammasome in the 

Pathogenesis of Autoimmune Diseases 

Moderators: Mariana J. Kaplan, MD and Insoo Kang, MD 

2:30 pm 

Novel Aspects on Mechanisms and Function of 

Inflammasomes 

Jenny Ting, PhD 

3:00 pm 

Propagation of the Inflammasome Response 

Eicke Latz, MD PhD 

3:30 pm 

Role of the Inflammasome in Inflammatory Arthritis 

Mohamed Lamkanfi, PhD 

West – 2000 

Tech Tools for Rheumatologists 

Moderator: Jonathan S. Hausmann, MD 

2:30 pm 

Rheumatologist Tested Tech tools to Use in the Office 

Suleman Bhana, MD 

3:15 pm 

Introduction to Automation and Workflows to Save 

Time and Increase Office Productivity 

Paul Sufka, MD 


The Great Debate: Long-term, Low-dose 

Corticosteroids Use in the Treatment of 


PM Ed Pd PS PrM PM Ed FIT Pd PS PrM FIT 

Moderator: Daniel E. Furst, MD 

PM PS E 

2:30 pm 

Resolved: Continuous ,Low-dose Corticosteroids 

Should Comprise Part of the Management of 

Rheumatoid Arthritis (RA) During the Initial 6 Months 

of RA Therapy (PRO) 


2:50 pm 

Resolved: Continuous ,Low-dose Corticosteroids 

Should Comprise Part of the Management of 

Rheumatoid Arthritis (RA) During the Initial 6 Months 

of RA Therapy (CON) 

Eric M. Ruderman, MD 

3:10 pm 

Resolved: Continuous Corticosteroids Should Be 

a Component of the 12-36 Month Management of 

Rheumatoid Arthritis ( PRO) 


3:30 pm 

Resolved: Continuous Corticosteroids Should Be 

a Component of the 12-36 Month Management of 

Rheumatoid Arthritis (CON) 

Eric M. Ruderman, MD 


The Red, the White and the Blue: Digital Color 

Changes and the Rheumatologist 

Moderator: Tracy Frech, MD 

2:30 pm 

Erythromelalgia: Diagnosis and Management 

Christopher Denton, PhD 

3:00 pm 

Digital Ischemia: Differential Diagnosis and 

Management 

Robyn T. Domsic, MD, MPH 

3:30 pm 

Pathophysiology of Digital Perfusion 

Nicholas A Flavahan, PhD 



2 0 1 5 


tracker 

plus 

65 


ACR CONCURRENT ABSTRACT SESSIONS 

2:30 – 4:00 pm 

West – 2011 

Cytokines, Mediators, Cell-cell Adhesion, Cell 

Trafficking and Angiogenesis 

Moderators: George D. Kalliolias, MD, PhD and Stamatis 

Nick Liossis, MD 

2:30 pm 

901. Novel B Cell-Derived Peptide Regulation of 

Homeostatic T-Cell Trafficking Is Subverted in 


Helen McGettrick 1 , Myriam Chimen 1 , Ashley Martin 1 , 

Francesca Barone 2 , Andrew Filer 1 , Karim Raza 3 , 

Christopher Buckley 2 , Parth Narendran 1 and G. Ed 

Rainger 1 , 1 University of Birmingham, Birmingham, 

United Kingdom, 2 University of Birmingham, 

Rheumatology Research Group, Birmingham, United 

Kingdom, 3 University of Birmingham, Rheumatology 

Research Group, Institute of Inflammation and Ageing, 

United Kingdom, Birmingham, United Kingdom 

2:45 pm 

902. Inhibitor of DNA Binding 1 As a Fibroblast 

Derived Inflammatory Angiogenic Agonist in 


Gautam Edhayan 1 , Christine M. Ha 1 , Ray A. Ohara 1 , 

Takeo Isozaki 1 , M. Asif Amin 1 , Ali S. Arbab 2 , Phillip L. 

Campbell 1 , Rachel Morgan 1 , W. Alexander Stinson 1 , 

Sean C. Friday 1 , David A. Fox 1 and Jeffrey H. Ruth 1 , 

1 

Division of Rheumatology, University of Michigan 

Medical Center, Ann Arbor, MI, 2 Georgia Regents 

University, Augusta, GA 

3:00 pm 

903. CGEN-15001, a Novel B7-like Protein, Controls 

Inflammation in a Translational Rheumatoid 

Arthritis (RA) Assay and Induces Treg Driven Long- 

Term Remission in an Autoimmune Disease Model 

Iris Hecht 1 , Ashley Gilmour 2 , Clare Tange 2 , Donna 

McIntyre 2 , Joseph R. Podojil 3 , Kay McNamee 4 , Galit 

Rotman 1 , Eyal Neria 1 , Mariola Kurowska-Stolarska 2 , 

Richard O. Williams 4 , Stephen D. Miller 3 and Iain B. 

McInnes 2 , 1 Compugen Ltd., Tel Aviv, Israel, 2 University 

of Glasgow, Glasgow, United Kingdom, 3 Northwestern 

University, Chicago, IL, 4 University of Oxford, Oxford, 

United Kingdom 

3:15 pm 

904. Intracerebroventricular Tweak (TNF-like 

weak inducer of apoptosis) Induces Depressivelike 

Behavior and Cognitive Dysfunction in Non- 

Autoimmune Mice 

Jing Wen, Christopher Chen, Ariel Stock, Jessica 

Doerner, Maria Gulinello and Chaim Putterman, Albert 

Einstein College of Medicine, Bronx, NY 

3:30 pm 

905. Citrullinated Epithelial-Derived Neutrophil- 

Activating Peptide 78 (ENA-78/CXCL5) Induces 

Monocyte Migration Via JNK and NFκB Signaling 

Pathways 

Ray A. Ohara 1 , Nicholas Lepore 1 , W. Alexander Stinson 1 , 

Gautam Edhayan 1 , Phillip L. Campbell 1 , Sarah Arwani 1 , 

Rachel Morgan 1 , Jeffrey H. Ruth 1 , Alisa E. Koch 2 , David 

A. Fox 1 and M. Asif Amin 1 , 1 Division of Rheumatology, 

University of Michigan Medical Center, Ann Arbor, MI, 

2 

Eli Lilly and Company, Indianapolis, IN 

3:45 pm 

906. Distinct Expression of IL-36Î±, Î², Î³ and 

Their Antagonists IL-36Ra and IL-38 in Psoriasis, 

Rheumatoid Arthritis and Crohn’s Disease 

Marie-Astrid Boutet 1 , Géraldine Bart 2 , Jérôme Amiaud 1 , 

Bénédicte Brulin 1 , Céline Charrier 1 , Franck Morel 3 , 

Jean-Claude Lecron 3 , Malvyne Rolli-Derkinderen 4 , 

Arnaud Boureille 2 , Cem Gabay 5 , Gaby Palmer 5 , Benoit 

Le Goff 2 and Frédéric Blanchard 1 , 1 Inserm UMR 957, 

Nantes, France, 2 Nantes University Hospital, Nantes, 

France, 3 EA 4331, Poitiers, France, 4 Inserm UMR 913, 

Nantes, France, 5 Geneva University Hospital, Geneva, 

Switzerland 

West – 2001 

Epidemiology and Public Health I: RA 

Comorbidities and Mortality 

Moderators: Kaleb Michaud, PhD and Diane Lacaille, 

MD, MHSc 


66 




2:30 pm 

907. The Natural History of an Inception Cohort of 

Patients with Inflammatory Polyarthritis Followed 

for 20 Years: Disease Activity, Disability and 

Surgery 

James Gwinnutt 1 , Deborah P.M. Symmons 1 , Alex J 

Macgregor 2 , Jacqueline Chipping 2 , Tarnya Marshall 2 

and Suzanne M. Verstappen 1 , 1 ARC Epidemiology Unit, 

the University of Manchester, Manchester, United 

Kingdom, 2 Norfolk and Norwich University Hospital, 

Norwich, United Kingdom 

2:45 pm 

908. WITHDRAWN 

3:00 pm 

909. Smoking Behavior Changes after Rheumatoid 

Arthritis Diagnosis and Risk of Mortality during 36 

Years of Prospective Follow-up 

Jeffrey A. Sparks 1 , Uyen Sa D.T. Nguyen 2 , Shun-Chiao 

Chang 1 , Yuqing Zhang 2 , Hyon Choi 3 and Elizabeth W. 

Karlson 1 , 1 Brigham and Women’s Hospital, Harvard 

Medical School, Boston, MA, 2 Boston University School 

of Medicine, Boston, MA, 3 Massachusetts General 

Hospital, Harvard Medical School, Boston, MA 

3:15 pm 

910. Tumor Necrosis Factor-Alpha Inhibitor Use 

and the Risk of Incident Hypertension in Patients 

with Rheumatoid Arthritis: A Retrospective Cohort 

Study 

Rishi J. Desai 1 , Daniel H. Solomon 2 , Sebastian 

Schneeweiss 2 , Goodarz Danaei 3 , Katherine Liao 4 and 

Seoyoung C. Kim 2 , 1 Brigham & Women’s Hospital, 

Harvard Medical School, Boston, MA, 2 Brigham and 

Women’s Hospital, Boston, MA, 3 Harvard School of 

Public Health, Boston, MA, 4 Brigham & Women’s 

Hospital, Boston, MA 

3:30 pm 

911. Patients with Rheumatoid Arthritis Are at 

Increased Risk of Both Ischemic and Non-Ischemic 

Heart Failure 

Ängla Mantel 1 , Marie Holmqvist 1 , Daniel Andersson 2 , 

Lars Lund 2 and Johan Askling 3 , 1 Clinical Epidemiology 

Unit, Dept of Medicine, Karolinska Institutet, 

Stockholm, Sweden, 2 Cardiology Unit, Karolinska 

University Hospital, Stockholm, Sweden, 3 Clinical 

Epidemiology Unit, Department of Medicine, Karolinska 

Institutet, Stockholm, Sweden 

3:45 pm 

912. Secondary Preventive Pharmacotherapy and 

Longterm Outcomes Following Acute Coronary 

Events in Patients with Prevalent Rheumatoid 

Arthritis 

Ängla Mantel 1 , Marie Holmqvist 1 , Tomas Jernberg 2 , 

Solveig Wållberg-Jonsson 3 and Johan Askling 4 , 1 Clinical 

Epidemiology Unit, Dept of Medicine, Karolinska 

Institutet, Stockholm, Sweden, 2 Section of Cardiology, 

Department of medicine, Karolinska University 

Hospital, Stockholm, Sweden, 3 Institution of Public 

health and clinical medicine/ Rheumatology, University 

of Umeå, Umeå, Sweden, 4 Clinical Epidemiology 

Unit, Department of Medicine, Karolinska Institutet, 

Stockholm, Sweden 

West – 2010 

Fibromyalgia: Insights Into Diagnostic Criteria 

and Symptom Epidemiology 

Moderators: Richard Gracely, PhD and 

Robert S. Katz, MD 

2:30 pm 

913. A Comparison of Physician Based and Patient 

Based Criteria for the Diagnosis of Fibromyalgia 

Frederick Wolfe 1 , Mary-Ann Fitzcharles 2 , Don 

Goldenberg 3 , Winfried Häuser 4 , Robert S. Katz 5 , Philip 

J. Mease 6 , Anthony Russell 7 , Jon Russell 8 and Brian 

Walitt 9 , 1 National Data Bank, Wichita, KS, 2 MGH, 

Montreal, QC, 3 Newton-Wellesley Hospital, Newton, 

MA, 4 Technische Universität München, Munich, 

Germany, 5 Rush University Medical Center, Chicago, IL, 

6 

Swedish Medical Center and University of Washington, 

Seattle, WA, 7 University of Alberta, Edmonton, AB, 

8 

Fibromyalgia Research and Consulting, San Antonio, 

TX, 9 National Institute of Nursing Research, Bethesda, 

DC 

2:45 pm 

914. When Fibromyalgia Criteria Misclassify 

Frederick Wolfe 1 and Winfried Häuser 2 , 1 National Data 

Bank, Wichita, KS, 2 Technische Universität München, 

Munich, Germany 



2 0 1 5 


tracker 

plus 

67 


3:00 pm 

915. Defining Pain for Fibromyalgia Criteria: Multi- 

Site or Widespread? an Analysis of Data from Four 

UK Population-Based Studies 

Gary J. Macfarlane 1 , Linda E. Dean 1 , Robert Bennett 2 , 

Leslie J. Crofford 3 , Abimbola Ayorinde 1 , Elisa 

Fluess 1 , Daniel J. Clauw 4 , Mary-Ann Fitzcharles 5 , Don 

Goldenberg 6 , Eduardo Paiva 7 , Roland Staud 8 and Lesley 

Arnold 9 , 1 University of Aberdeen, Aberdeen, United 

Kingdom, 2 Oregon Health & Science Univ, Portland, 

OR, 3 Vanderbilt University, Nashville, TN, 4 University 

of Michigan, Ann Arbor, MI, 5 MGH, Montreal, QC, 

6 

Newton-Wellesley Hospital, Newton, MA, 7 Sociedade 

Brasileira de Reumatologia, São Paulo, Brazil, 

8 

University of Florida, Gainesville, FL, 9 University of 

Cincinnati, Cincinnati, OH 

3:15 pm 

916. Assessing Alternative Selection Criteria for 

Fibromyalgia Patients within a Multicenter Chronic 

Pain Claims Database 

Mark Gostine 1 , Fred Davis 1 , Bradley Roberts 2 , Rebecca 

Risko 2 , Joseph Cappelleri 3 , Michael Asmus 4 , Andrew 

Clair 5 and Alesia Sadosky 6 , 1 Michigan Pain Consultants, 

PC, Grand Rapids, MI, 2 ProCare Systems, Inc., Grand 

Rapids, MI, 3 Pfizer, Inc., Groton, CT, 4 Pfizer, Inc., 

Middleton, WI, 5 Pfizer Inc., New York, NY, 6 Pfizer Inc,, 

New York, NY 

3:30 pm 

917. Chronic Widespread Pain in Adolescents Is 

Highly Associated to Stress and Anxiety 

Stefan Bergman 1 , Ann Bremander 1 , Anna-Carin 

Bergman 2 and Sofia Brorsson 3 , 1 Department of 

Clinical Sciences, Lund, Section of Rheumatology, 

Lund University, Lund, Sweden, 2 Sannarpsgymnasiet, 

Halmstad, Sweden, 3 Dalarna University, Falun, Sweden 

3:45 pm 

918. Assessment of the Temporal Variation of the 

Fibromyalgia Patient Profile Between 2005 and 

2013: Do Guidelines Inform Clinical Care? 

Angeliki Karellis 1 , Emmanouil Rampakakis 2 , Peter A. 

Ste-Marie 3 , Yoram Shir 3 , John S. Sampalis 1 and Mary- 

Ann Fitzcharles 3 , 1 McGill University, Montreal, QC, 2 JSS 

Medical Research, St-Laurent, QC, 3 McGill University 

Health Centre, Montreal, QC 

North – 132 

Health Services Research I: Digital Health and 

Patient, Provider Factors in Rheumatic Disease 

Moderator: Charles G. Helmick 

2:30 pm 

919. Automated Case Identification of Lupus 

from an Electronic Health Record Using Novel 

Informatics Approaches 

Sara G. Murray 1 , Chris Tonner 1 , Ben J. Marafino 1 , Sarah 

Haserodt 2 , Gabriela Schmajuk 3 and Jinoos Yazdany 1 , 

1 

University of California, San Francisco, San Francisco, 

CA, 2 California Pacific Medical Center, San Francisco, 

CA, 3 San Francisco VA Medical Center, University of 

California, San Francisco, San Francisco, CA 

2:45 pm 

920. Patient Preferences for the Development of 

a Mobile Health (mHealth) Application (App) for 

Systemic Lupus Erythematosus (SLE) Patients: A 

Qualitative Study 

Alana B. Levine 1 , Adena Batterman 1 , Vivian P. Bykerk 1 , 

Aislinn Crank 1 , Su Jin Kim 2 , Juliette Kleinman 1 , Laura 

Leuenberger 1 , Laura Robbins 1 , Jillian A. Rose 1 , Jane E. 

Salmon 1 , Nadine Spring 1 , My-Lan Tran 3 and Roberta 

Horton 1 , 1 Hospital for Special Surgery, New York, NY, 

2 

Columbia University, New York, NY, 3 Hospital for 

Special Surgery, New York City, NY 

3:00 pm 

921. Poverty Associated with Increase in Damage in 

SLE over Two-Year Period 

Edward H. Yelin 1 , Laura Trupin 2 , Jinoos Yazdany 2 

and Stephanie Rush 2 , 1 University of California, San 

Francisco, San Francisco, CA, 2 UCSF, SF, CA 

3:15 pm 

922. Factors Associated with Performance on 

Quality Measures Pertaining to Assessment of 

Disease Activity in Juvenile Idiopathic Arthritis 

Lara H. Huber 1 , Murray H. Passo 1 , Kristen Morella 1 , 

Natasha M. Ruth 1 and Pediatric Rheumatology Care 

and Outcomes Improvement Network, 1 Medical 

University of South Carolina, Charleston, SC 


68 




3:30 pm 

923. Perceptions of Infectious Risk of 

Immunosuppressive Medications Among Treating 

Physicians 

Rebecca Sharim 1 , Leny Mathew 2 , Michael George 1 , 

Preethi Thomas 3 and Misha Rosenbach 1 , 1 Hospital 

of the University of Pennsylvania, Philadelphia, PA, 

2 

Children’s Hospital of Philadelphia, Philadelphia, 

PA, 3 Department of Rheumatology, Hospital of the 

University of Pennsylvania, Philadelphia, PA 

3:45 pm 

924. Patient and Provider Factors in Optimal Gout 

Management 

Brian W Coburn 1 , Kayli Bendlin 2 , Harlan Sayles 1 and Ted 

R. Mikuls 1 , 1 Omaha VA Medical Center and University of 

Nebraska Medical Center, Omaha, NE, 2 Veterans Affairs 

Nebraska-Western Iowa Health Care System, Omaha, 

NE 

West – 2022 

Imaging of Rheumatic Diseases I: Ultrasound 

Moderators: Jay B. Higgs, MD and Wolfgang A. Schmidt, 

MD 

2:30 pm 

925. Musculoskeletal Ultrasound (MSK-US): 

Innovation or Overutilization? 

Gurjit S. Kaeley, Dale Kraemer, Carmen Smotherman 

and Sunita Dodani, University of Florida College of 

Medicine, Jacksonville, Jacksonville, FL 

2:45 pm 

926. Development of an Ultrasound Joint 

Inflammation Score for Rheumatoid Arthritis 

through a Data-Driven Approach 

Anna-Birgitte Aga 1 , Elisabeth Lie 1 , Inge C Olsen 1 , Hilde 

Berner Hammer 1 , Till Uhlig 1 , Désirée van der Heijde 2 , 

Tore K. Kvien 1 , Espen A. Haavardsholm 1 and the ARCTIC 

study group, 1 Diakonhjemmet Hospital, Oslo, Norway, 

2 

Department of Rheumatology, Leiden University 

Medical Center, Leiden, the Netherlands, Leiden, 

Netherlands 

3:00 pm 

927. Ultrasound Assessment of Heel Entheses in 

Spondyloarthritis Patients: A Comparative Study 

with Radiography and Magnetic Resonance Imaging 

Rodrigo Aguila Maldonado 1 , Santiago Ruta 2 , Claudia 

Elizabeth Pena 1 , Maria Laura Valuntas 3 , Gisela Pendón 4 , 

Dora Pereira 4 and Mercedes Argentina García 5 , 1 HIGA 

San Martín La Plata, La Plata, Argentina, 2 Rheumatology 

Unit, Internal Medicine Service, Hospital Italiano de 

Buenos Aires, Buenos Aires, Argentina, 3 Servicio de 

Tomografía Computada y Resonancia Magnética, 

Sanatorio IPENSA, La Plata, Argentina, 4 Hospital 

Ricardo Gutierrez, La Plata, La Plata, Argentina, 5 HIGA 

San Martín, La Plata, Argentina 

3:15 pm 

928. The Value of Early Ultrasound-Detected 

Osteophytes in Hand Osteoarthritis: Predicting the 

Future 

Alexander Mathiessen 1 , Barbara Slatkowsky- 

Christensen 1 , Tore K. Kvien 1 , Ida K. Haugen 2 and Hilde 

Berner Hammer 1 , 1 Diakonhjemmet Hospital, Oslo, 

Norway, 2 Diakonhjemmet Hospital, Vinderen, Norway 

3:30 pm 

929. Diurnal Variation of Power Doppler in 

Metacarpophalangeal Joints of Patients with 


Marwin Gutierrez 1 , Emeline Minichiello 2 , Alarico 

Ariani 1 , Salima Challal 2 , Emilio Filippucci 1 , Marie- 

Christophe Boissier 3 , Walter Grassi 1 and Luca 

Semerano 3 , 1 Università Politecnica delle Marche, 

Jesi, Italy, 2 Assistance Publique – Hôpitaux de Paris 

(AP-HP) Groupe hospitalier Avicenne - Jean Verdier 

– René Muret, Bobigny, France, 3 Sorbonne Paris Cité - 

Université Paris 13, Bobigny, France 

3:45 pm 

930. Evaluation of Temporomandibular Joint 

Arthritis with Ultrasound in Juvenile Idiopathic 

Arthritis 

Edward J. Oberle 1 , James Nocton 2 and Arthur Meyers 3 , 

1 

Ohio State University, Columbus, OH, 2 Medical College 

of Wisconsin, Milwaukee, WI, 3 Children’s Hospital of 

Wisconsin, Milwaukee, WI 

West – 2018 

Innate Immunity and Rheumatic Disease 

Moderators: Robert Eisenberg, MD and Edward M. 

Behrens, M.D. 



2 0 1 5 


tracker 

plus 

69 


2:30 pm 

931. mTOR Complex 1 Signaling Is Required for the 

Steady-State in Vivo Development of Inflammatory 

Monocytes 

Pui Y. Lee 1 , David Sykes 2 , Sarah Ameri 3 , Allyn Morris 3 

and Peter A. Nigrovic 4 , 1 Boston Children’s Hospital, 

Boston, MA, 2 Massachusetts General Hospital, Boston, 

MA, 3 Brigham and Women’s Hospital, Boston, MA, 

4 

Department of Medicine, Division of Rheumatology, 

Immunology and Allergy, Brigham and Women’s 


2:45 pm 

932. IRF4-Dependent and IRF4-Independent 

Pathways Contribute to DC Dysfunction in Lupus 

Michela Manni 1 , Sanjay Gupta 1 , Briana G. Nixon 2 and 

Alessandra B. Pernis 3 , 1 Hospital for Special Surgery, 

New York, NY, 2 Weill Cornell Graduate School of 

Medical Sciences, New York, NY, 3 Hospital for Special 

Surgery, Weill Cornell Medical College, New York, NY 

3:00 pm 

933. DEK-Targeting DNA Aptamers As Novel 

Therapeutics for Inflammatory Arthritis 

Nirit Mor-Vaknin 1 , Anjan K. Saha 1 , Maureen Legendre 1 , 

Carmelo Carmona-Rivera 2 , M. Asif Amin 1 , Bradley 

J. Rabquer 3 , Marta J. Gonzalez-Hernandez 1 , Julie M. 

Jorns 1 , Srilakshmi Yalavarthi 1 , Smriti Mohan 1 , Dave Pai 4 , 

Kristine Angevine 5 , Barbara Adams 6 , Jason S. Knight 1 , 

Alisa E. Koch 7 , David Fox 7 , Dave Engelke 8 , Mariana J. 

Kaplan 2 and David Markovitz 1 , 1 University of Michigan, 

Ann Arbor, MI, 2 National Institutes of Health, Bethesda, 

MD, 3 Albion College, Ann Arbor, MI, 4 Scripps Research 

Institute, San Diego, CT, 5 Appistry, Inc, St. Louis, MO, 

6 

Univ of Michigan Hlth System, Ann Arbor, MI, 7 Division 

of Rheumatology, University of Michigan Medical 

Center, Ann Arbor, MI, 8 University Michigan, Ann Arbor, 

MI 

3:15 pm 

934. Platelet-Independent Role of Megakaryocytes 

in Antibody-Mediated Murine Arthritis 

Pierre Cunin 1 , Loka Penke 1 , Jonathan Thon 2 , Paul 

A. Monach 3 , Tatiana Jones 4 , Mary Chen 1 , Yoichiro 

Iwakura 5 , Jerry Ware 6 , Michael Gurish 1 , Joseph Italiano 2 , 

Eric Boilard 7 and Peter A. Nigrovic 8 , 1 Department of 

Medicine, Division of Rheumatology, Immunology 

and Allergy, Brigham and Women’s Hospital, Harvard 

Medical School, Boston, MA, 2 Department of Medicine, 

Hematology Division, Brigham and Women’s 

Hospital and Harvard Medical School, Boston, MA, 

3 

Boston University School of Medicine, Boston, MA, 

4 

Department of Clinical Laboratory and Nutritional 

Science, University of Massachusetts Lowell, Lowel, MA, 

5 

Center for Experimental Medicine, Institute of Medical 

Science, University of Tokyo, Tokyo, Japan, 6 Department 

of Physiology and Biophysics, University of Arkansas 

for Medical Sciences, Little Rock, AR, 7 Centre de 

Recherche en Rhumatologie et Immunologie, Centre 

de Recherche du Centre Hospitalier Universitaire de 

Québec, Faculté de Médecine de l’Université Laval, 

Quebec, QC, 8 Department of Medicine, Division of 

Immunology, Boston Children’s Hospital, Harvard 

Medical School, Boston, MA 

3:45 pm 

936. IL-1 Receptor Antagonist Maintains Intestinal 

Microbial Homeostasis to Prevent Overt Tolllike 

Receptor 4-Dependent Intestinal Th17 

Differentiation and Autoimmune Arthritis 

Rebecca Rogier 1 , Tom Ederveen 1 , Jos Boekhorst 2 , Harm 

Wopereis 3 , Johan Garssen 4 , Peter van der Kraan 5 , Sacha 

van Hijum 2 , Marije Koenders 2 , Wim van den Berg 2 and 

Shahla Abdollahi-Roodsaz 6 , 1 Rheumatology Research 

and Advanced Therapeutics, Radboud University 

Nijmegen Medical Center, Nijmegen, Netherlands, 

2 

Radboud university medical center, Nijmegen, 

Netherlands, 3 Danone Research, Wageningen, 

Netherlands, 4 Danone Nutricia Research, Utrecht, 

Netherlands, 5 Radboud University Nijmegen Medical 

Centre, Nijmegen, Netherlands, 6 NYU School of 

Medicine, New York, NY 

West – 2000 

Miscellaneous Rheumatic and Inflammatory 

Diseases I 

Moderators: Thomas Bardin, MD and Andy Abril, MD 

2:30 pm 

937. Safety and Efficacy of Canakinumab in Patients 

with CAPS: Interim Results from the Beta-Confident 

Registry 

Jasmin B. Kuemmerle-Deschner 1 , Hal M. Hoffman 2 , 

Philip N. Hawkins 3 , T. van der Poll 4 , Ulrich A. Walker 5 , 


70 




Antonio Speziale 6 and Hugh H. Tilson 7 , 1 University 

Hospital Tuebingen, Tuebingen, Germany, 2 University 

of California at San Deigo, La Jolla, CA, 3 University 

College London Medical School, London, United 

Kingdom, 4 University of Amsterdam, Amsterdam, 

Netherlands, 5 University Hospital, Basel, Basel, 

Switzerland, 6 Novartis Pharma AG, Basel, Switzerland, 

7 

University of North Carolina, Gillings School of Global 

Public Health, Chapel Hill, NC 

2:45 pm 

938. Long-Term Efficacy and Safety of Canakinumab 

in Patients with Active Recurrent or Chronic TNF 

Receptor-Associated Periodic Syndrome 

Marco Gattorno 1 , Marco Cattalini 2 , L. Obici 3 , Roberto 

Barcellona 4 , Antonio Speziale 5 , Yolandi Joubert 5 , Guido 

Junge 5 and Helen Lachmann 6 , 1 G. Gaslini Institute, 

Genova, Italy, 2 Pediatric Clinic, University of Brescia, 

Brescia, Italy, 3 Policlinico S. Matteo, Pavia, Italy, 

4 

Hospital of Sciacca, Sciacca, Italy, 5 Novartis Pharma 

AG, Basel, Switzerland, 6 University College London 

Medical School, London, United Kingdom 

3:00 pm 

939. Long-Term Efficacy and Safety of Canakinumab 

in Active Hyperimmunoglobulinemia D with 

Periodic Fever Syndrome 

Juan Ignacio Arostegui 1 , Jordi Anton 2 , Inmaculada 

Calvo-Penedes 3 , Angel Robles 4 , Antonio Speziale 5 , 

Yolandi Joubert 5 , Guido Junge 5 and Jordi Yagüe 6 , 

1 

Hospital Clínic, Barcelona, Spain, 2 Hospital Sant Joan 

de Déu, Barcelona, Spain, 3 Hospital de La Fe, Valencia, 

Spain, 4 Hospital La Paz, Madrid, Spain, 5 Novartis 

Pharma AG, Basel, Switzerland, 6 Hospital Clinic 

Barcelona, Barcelona, Spain 

3:15 pm 

940. NOD2-Associated Autoinflammatory Disease: 

Therapy and Outcomes 

Qingping Yao and Bo Shen, Cleveland Clinic, Cleveland, 

OH 

3:30 pm 

941. Relationship Between Colchine Plasma Level 

and Frequency of Familial Mediterranean Fever 

Attacks 

Fadime Canbolat 1 , Gulsen Ozen 2 , Selma Ozilhan 1 , 

Samet Gulturk 3 , Ayse Ozcetin 3 , Ali Ugur Unal 2 , Nevsun 

Inanc 2 , Pamir Atagunduz 2 , Haner Direskeneli 2 and 

Tuncel Ozden 1 , 1 Uskudar University Pharmacogenetic 

Laboratory, Istanbul, Turkey, 2 Marmara University 

Faculty of Medicine, Istanbul, Turkey, 3 Uskudar 

University, Istanbul, Turkey 

3:45 pm 

942. Update in the Management of Biologic 

Response Modifiers and Disease-Modifying 

Antirheumatic Drugs Following Coccidioidomycosis 

Usman Ajaz 1 , Neil M. Ampel 2 , Varun Bhalla 1 , Jeffrey R. 

Lisse 1 and Dominick Sudano 1 , 1 University of Arizona, 

Tucson, AZ, 2 Southern AZ VA Medical Center, Tucson, 

AZ 


Muscle Biology, Myositis and Myopathies I 

Moderators: Jeffrey A. Dvergsten, MD and Wael N. 

Jarjour, MD 

2:30 pm 

943. Development of an Internationally Agreed 

Minimal Dataset for Juvenile Dermatomyositis 

(JDM) for Clinical and Research Use 

Liza J. McCann 1 , Lucy R Wedderburn 2 , Clarissa 

Pilkington 3 , Adam M. Huber 4 , Angelo Ravelli 5 , 

Jamie Kirkham 6 , Paula Williamson 6 and Michael W. 

Beresford 7 , 1 Alder Hey Children’s NHS Foundation 

Trust, Liverpool, United Kingdom, 2 UCL Institute for 

Child Health, London, United Kingdom, 3 Department 

of Rheumatology, Great Ormond Street Hospital for 

Children NHS Trust, London, United Kingdom, 4 IWK 

Health Centre, Halifax, NS, 5 Pediatria-II, IRCCS G. Gaslini 

and University of Genova, Genova, Italy, 6 MRC North 

West Hub for Trials Methodology Research, Liverpool, 

United Kingdom, 7 Institute of Translational Medicine 

(Child Health), University of Liverpool, Liverpool, United 

Kingdom 

2:45 pm 

944. Activity of Type I and Type II Interferons 

in Dermatomyositis Skin Is Correlated with 

Characteristic Pathologic Features 

Hayley W. Leatham 1 , Kerri Rieger 1 , Lorinda Chung 2 , 

Shufeng Li 1 , Brandon W. Higgs 3 , Yihong Yao 3 , Kavita 

Sarin 1 and David Fiorentino 1 , 1 Stanford University, 

Stanford, CA, 2 Stanford University School of Medicine, 



2 0 1 5 


tracker 

plus 

71 


Stanford, CA, 3 MedImmune, LLC, Gaithersburg, MD 

3:00 pm 

945. Anti-Hmgcr Antibodies As Specific Marker for 

Immune Mediated Necrotizing Myopathies 

Lucile Musset 1 , Chelsea Bentow 2 , Marvin J. Fritzler 3 , Jiri 

Vencovsky 4 , Olivier Benveniste 5 , Ignacio Garcia de la 

Torre 6 , Franco Franceschini 7 , Katalin Danko 8 , Qinglin 

Peng 9 , Sophie Hue 10 , Olivier Boyer 11 , Nicola Bizzaro 12 , 

Yoshinao Muro 13 , Xavier Bossuyt 14 , Anna Ghirardello 15 

and Michael Mahler 2 , 1 Pitié-Salpêtrière University 

Hospital, Paris, France, 2 Inova Diagnostics, San Diego, 

CA, 3 University of Calgary, Calgary, AB, 4 Charles 

University, Prague, Czech Republic, 5 Department 

de Internal Medicine and Clinical Immunology, 

Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, 

6 

Hospital General de Occidente, Zapopan, Mexico, 

7 

Rheumatology and Clinical Immunology, Spedali Civili 

and University of Brescia, Brescia, Italy, 8 Co-Author, 

Debrecen, Hungary, 9 China-Japan Friendship Hospital, 

Beijing, China, 10 CHU Henri Mondor, APHP, Créteil, 

France, 11 INSERM, U905 & Normandy University, 

Institute for Research and Innovation in Biomedicine, 

Rouen University Hospital, Rouen, France, 12 San 

Antonio Hospital, Tolmezzo, Italy, 13 Nagoya University 

Graduate School of Medicine, Nagoya, Japan, 14 Catholic 

University of Leuven, Leuven, Belgium, 15 University of 

Padova, Padova, Italy 

3:15 pm 

946. Novel Tripartite Motif Proteins Linked 

to Membrane Integrity As Biomarkers of 

Dermatomyositis and Polymyositis 

Kevin McElhanon 1 , Jenna Alloush 1 , Nicholas A. Young 2 , 

Zarife Sahenk 3 , Rohit Aggarwal 4 , Chester V. Oddis 5 , 

Wael N. Jarjour 2 and Noah Weisleder 1 , 1 The Ohio 

State University College of Medicine, Columbus, OH, 

2 

The Ohio State University Wexner Medical Center, 

Columbus, OH, 3 Research Institute at Nationwide 

Children’s Hospital, Columbus, OH, 4 University of 

Pittsburgh Medical Center, Pittsburgh, PA, 5 University 

of Pittsburgh, Pittsburgh, PA 

3:30 pm 

947. Cohesin Complex Is a New Myositis 

Autoantigen 

Shin Tanaka 1 , S. John Calise 2 , Yurie Satoh 3 , Yoshiya 

Tanaka 4 , Monica Vazquez-Del Mercado 5 , Gabriel 

Medrano-Ramírez 6 , Eric S. Sobel 7 , Westley H. Reeves 7 , 

Edward K.L. Chan 7 and Minoru Satoh 8 , 1 University 

of Occupational and Environmental Health, Japan, 

Kitakyushu, Japan, 2 University of Florida, Miami, FL, 

3 

University of Occupational and Environmental Health, 

KItakyushu, Japan, 4 University of Occupational & 

Environmental Health, Kitakyusyu, Japan, 5 Hospital Civil 

Dr. Juan I. Menchaca, Guadalajara, Mexico, 6 Hospital 

General de Mexico, Secretaria de Salud, Mexico 

City, Mexico, 7 University of Florida, Gainesville, FL, 

8 

University of Occupational and Environmental Health, 

Kitakyushu, Japan 

3:45 pm 

948. Autoimmune Myopathies: Effects of 

Intravenous Immunoglobulin Therapy on Muscle 

Strength and Predictors of Response 

Arash Lahoutiharahdashti 1 , Iago Pinal-Fernandez 2 , 

Jemima Albayda 1 , Julie J. Paik 1 , Sonye K. Danoff 3 , 

Andrew L. Mammen 1 and Lisa Christopher-Stine 1 , 

1 

Johns Hopkins University School of Medicine, 

Baltimore, MD, 2 Vall D’Hebron University Hospital, 

Universitat Autònoma de Barcelona, Barcelona, Spain, 

3 

Johns Hopkins School of Medicine, Baltimore, MD 


Osteoarthritis – Clinical Aspects: Treatments 

and Epidemiology 

Moderators: Philip G. Conaghan, MD, PhD and Kelli D. 

Allen, PhD 

2:30 pm 

949. The Metabolic Syndrome, Its Elements 

and Knee Osteoarthritis: The Framingham 

Osteoarthritis (OA) Study 

Jingbo Niu 1 , Mary Clancy 2 , Piran Aliabadi 3 and David T. 

Felson 1 , 1 Boston University School of Medicine, Boston, 

MA, 2 BUSM, Boston, MA, 3 Brigham and Women’s 


2:45 pm 

950. In a Two-Year Double-Blind Randomized 

Controlled Multicenter Study, Chondroitin Sulfate 

Was Significantly Superior to Celecoxib at Reducing 

Cartilage Loss with Similar Efficacy at Reducing 

Disease Symptoms in Knee Osteoarthritis Patients 

Jean-Pierre Pelletier 1 , Jean Pierre Raynauld 2 , André 


72 




Beaulieu 3 , Louis Bessette 4 , Frédéric Morin 5 , Artur 

J Fernandes 6 , François Abram 7 , Marc Dorais 8 and 

Johanne Martel-Pelletier 9 , 1 Institut de recherche en 

rhumatologie de Montréal (IRRM), Montréal, QC, 

2 

Osteoarthritis Research Unit, CRCHUM, Montreal, 

Montreal, QC, 3 Centre de rhumatologie St-Louis, St. 

Louis, QC, 4 Groupe de Recherche en Rhumatologie 

et Maladies Osseuses, Quebec, Quebec, QC, 5 Centre 

de Recherche Musculo-squelettique, Trois-Rivières, 

Trois-Rivières, QC, 6 Centre de Recherche Musculosquelettique, 

Trois-Rivières, 6Rheumatology Division, 

Sherbrooke, Sherbrooke, QC, 7 Medical Imaging 

Research & Development, ArthroLab Inc, Montreal, QC, 

8 

StatSciences Inc., Montreal, Canada, Montreal, QC, 

9 

Osteoarthritis Research Unit, University of Montreal 

Hospital Research Centre (CRCHUM),, Montreal, QC 

3:00 pm 

951. Comparative Effectiveness of Tai Chi Versus 

Physical Therapy in Treating Knee Osteoarthritis: A 

Randomized, Single-Blind Trial 

Chenchen Wang 1 , Christopher Schmid 2 , Maura D. 

Iversen 3 , William F. Harvey 4 , Roger A. Fielding 5 , Jeffrey 

B. Driban 4 , Lori Lyn Price 4 , John B. Wong 4 , Kieran 

Reid 5 , Ramel Rones 6 and Timothy E. McAlindon 4 , 

1 

Tufts Medical Center, Bosotn, MA, 2 Brown University 

School of Public Health, Providence, RI, 3 Northeastern 

University,, Boston, MA, 4 Tufts Medical Center, Boston, 

MA, 5 Tufts University, Boston, MA, 6 Center for Mind– 

Body Therapies, Boston, MA 

3:15 pm 

952. Cost-Effectiveness of Opioids for the 

Treatment of Knee Osteoarthritis: Impact of 

Chronic Opioid Use on Total Knee Arthroplasty 

Outcomes 

Savannah R. Smith 1 , Jeffrey N. Katz 2 , Jamie E. Collins 2 

and Elena Losina 3 , 1 Brigham and Women’s Hospital, 

Boston, MA, 2 Brigham and Women’s Hospital and 

Harvard Medical School, Boston, MA, 3 Brigham and 

Women’s Hospital, BU School of Public Health and 

Harvard Medical School, Boston, MA 

3:30 pm 

953. Effectiveness of a Progressive Resistence 

Strength Programme on Hand Osteoarthritis: A 

Randomized Crontrolled Trial 

Michele V. Nery 1 , Anamaria Martinez 2 , Fabio 

Jennings 3 , Marcelo Souza 2 and Jamil Natour 2 , 

1 

Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 

2 

Federal University of Sao Paulo, Sao Paulo, Brazil, 

3 

Universidade Federal de São Paulo, Sao Paulo, Brazil 

3:45 pm 

954. The Relationship Between Osteoarthritis and 

Cardiovascular Disease: Results from a Population- 

Based Cohort 

Lauren King 1 , Tetyana Kendzerska 1 and Gillian Hawker 2 , 

1 

Department of Medicine, University of Toronto, 

Toronto, ON, 2 Women’s College Research Institute, 

Women’s College Hospital, University of Toronto, 

Toronto, ON 


Pediatric Rheumatology – Clinical and 

Therapeutic Aspects I: Juvenile Idiopathic 

Arthritis PM Ed Pd PS PrM FIT 

Moderators: Mara L Becker, MD, MSCE and Thomas 

Brent Graham, MD, MS 

2:30 pm 

955. Cancer Risk in 5,108 Patients with Juvenile 

Idiopathic Arthritis (JIA) 

Omid Zahedi Niaki 1 , Ann E. Clarke 2 , Rosalind Ramsey- 

Goldman 3 , Rae S.M. Yeung 4 , Kristen Hayward 5 , Kiem 

Oen 6 , Ciarán M. Duffy 7 , Alan M. Rosenberg 8 , Kathleen 

O’Neil 9 , Emily von Scheven 10 , Laura Schanberg 11 , Jeremy 

Labrecque 12 , Jennifer LF Lee 12 and Sasha Bernatsky 13 , 

1 

McGill University, Montreal, QC, 2 Montreal General 

Hospital, Montreal, QC, 3 Northwestern University 

Feinberg School of Medicine, Chicago, IL, 4 The Hospital 

for Sick Children, University of Toronto, Toronto, 

ON, 5 University of Washington & SCH, Seattle, WA, 

6 

University of Manitoba, The Children`s Hospital 

Foundation of Manitoba, Winnipeg, MB, 7 Children’s 

Hospital of Eastern Ontario and University of Ottawa, 

Ottawa, ON, 8 University of Saskatchewan, Saskatoon, 

SK, 9 RIley Hospital for Children, Indianapolis, IN, 10 Univ 

of California San Francisco, San Francisco, CA, 11 Duke 

Medical Center, Durham, NC, 12 McGill UHC/RVH, 

Montreal, QC, 13 McGill MUHC/RVH, Montreal, QC 

2:45 pm 

956. The Addition of One or More Biologics to 

Methotrexate in Children with Juvenile Idiopathic 



2 0 1 5 


tracker 

plus 

73 


Arthritis Increases the Incidence of Infections and 

Other Adverse Events 

Joost F. Swart 1 , Angela Pistorio 2 , Francesca Bovis 2 , 

Ekaterina Alexeeva 3 , Michael Hofer 4 , Susan Nielsen 5 , 

Jordi Anton 6 , Alessandro Consolaro 2 , Violeta Vladislava 

Panaviene 7 , Valda Stanevicha 8 , Maria Trachana 9 , 

Constantin Ailioaie 10 , Florence Uettwiller 11 , Fabrizio 

De Benedetti Sr. 12 , Elena Tsitsami 13 , Berit Flato 14 , 

Pavla Dolezalová 15 , Tamás Constantin 16 , Troels 

Herlin 17 , Sylvia Kamphuis 18 , Sujata Sawhney 19 , 

Despoina Maritsi 20 , Veronika Vargova 21 , Luca Villa 2 , 

Chiara Pallotti 2 , Angelo Ravelli 2 , Alberto Martini 22 , 

Nico Wulffraat 1 , Nicolino Ruperto 23 and on behalf of 

for PRINTO, 1 Wilhelmina Children’s Hospital/ UMC 

Utrecht, Utrecht, Netherlands, 2 Istituto Giannina 

Gaslini, Genoa, Italy, 3 Scientific Center of Children’s 

Health of RAMS, Moscow, Russia, 4 Unité Romande de 

Rhumatologie Pédiatrique, Hospitalier Universitaire 

Vaudois, Lausanne, Switzerland, 5 Juliane Marie Centret, 

Rigshospitalet, Copenhagen, Denmark, 6 Hospital Sant 

Joan de Déu, Barcelona, Spain, 7 Vilnius University, 

Vilnius, Lithuania, 8 Riga Stradins University, Riga, Latvia, 

9 

1st Department of Pediatrics, Aristotle University, 

Thessaloniki, Greece, 10 Private Medical Clinic, IASI, 

Romania, 11 Université Paris-Descartes, IMAGINE 

Institute, Hôpital Necker-Enfants Malades, Paris, 

France, 12 Ospedale Pediatrico Bambino Gesù, Roma, 

Italy, 13 Children Hospital Aghia Sophia, Athens, Greece, 

14 

Oslo University Hospital, Oslo, Norway, 15 General 

University Hospital in Prague, Prague, Czech Republic, 

16 

Semmelweis University, Budapest, Hungary, 17 Aarhus 

University Hospital, Aarhus N, Denmark, 18 Erasmus MC 

Sophia Children’s Hospital, Rotterdam, Netherlands, 

19 

Sir Ganga Ram Hospital, New Delhi, India, 20 Athens 

Medical School, university of Athens, Athens, Greece, 

21 

Šafarik University and Children Faculty Hospital in 

Košice, Kosice, Slovakia, 22 Istituto G. Gaslini, Pediatria II, 

PRINTO, and University of Genoa, Genoa, Italy, 23 Istituto 

G. Gaslini, Pediatria II, PRINTO, Genoa, Italy 

3:00 pm 

957. Double Blind Placebo Controlled Randomized 

Trial of Probiotics in Enthesitis-Related- 

Arthritis Category of JIA: Effect on Clinical and 

Immunological Parameters 

Anuj Shukla, Priyanka Gaur and Amita Aggarwal, Sanjay 

Gandhi Postgraduate Institute of Medical Sciences, 

Lucknow, India 

3:15 pm 

958. The Time Spent in Inactive Disease before 

MTX Withdrawal Is Relevant with Regard to the 

Recurrence of Active Disease in Juvenile Idiopathic 

Arthritis (JIA) Patients 

Jens Klotsche 1 , Gerd Ganser 2 , Ivan Foeldvari 3 , Hans 

Huppertz 4 , Rolf M. Kuester 5 , Angelika Thon 6 , Kirsten 

Minden 7 and Gerd Horneff 8 , 1 German Rheumatism 

Research Center, Berlin, Germany, 2 Sankt Josef Stift, 

Sendenhorst, Germany, 3 Hamburger Zentrum für 

Kinder-und Jugendrheumatologie, Hamburg, Germany, 

4 

Prof Hess Children’s Hospital, Bremen, Germany, 

5 

Asklepios Rheumazentrum Hamburg, Hamburg, 

Germany, 6 Kinderklinik der Medizinischen Hochschule 

Hannover, Hannover, Germany, 7 Children’s University 

Hospital Charite/German Rheumatism Research 

Centre Berlin, Berlin, Germany, 8 Asklepios Klinik Sankt 

Augustin GmbH, Sankt Augustin, Germany 

3:30 pm 

959. Results from the Childhood Arthritis and 

Rheumatology Research Alliance Systemic JIA 

Consensus Treatment Plans Pilot Study 

Yukiko Kimura 1 , Timothy Beukelman 2 , Esi Morgan- 

DeWitt 3 , Kelly L. Mieszkalski 4 , Thomas Brent Graham 5 , 

Maria F. Ibarra 6 , Norman Ilowite 7 , Marisa S. Klein- 

Gitelman 8 , Karen Onel 9 , Sampath Prahalad 10 , Marilynn 

G. Punaro 11 , Sarah Ringold 12 , Dana Toib 13 , Heather 

Van Mater 4 , Pamela F. Weiss 14 , Laura Schanberg 15 and 

the CARRA Registry Investigators, 1 Joseph M Sanzari 

Children’s Hospital, Hackensack University Medical 

Center, Hackensack, NJ, 2 University of Alabama at 

Birmingham, Birmingham, AL, 3 Cincinnati Children’s 

Hospital Medical Center, Cincinnati, OH, 4 Duke 

University Medical Center, Durham, NC, 5 Vanderbilt 

Children’s Hospital, Nashville, TN, 6 Children’s Mercy 

Hospital, Kansas City, MO, 7 Children’s Hospital 

at Montefiore, Bronx, NY, 8 Ann & Robert H. Lurie 

Children’s Hospital of Chicago, Chicago, IL, 9 Univ of 

Chicago, Chicago, IL, 10 Emory University, Atlanta, GA, 

11 

Texas Scottish Rite Hospital, Dallas, TX, 12 Seattle 

Children’s Hospital, Seattle, WA, 13 St. Christopher’s 

Hospital for Children, Philadelphia, PA, 14 Children’s 

Hospital of Philadelphia, Philadelphia, PA, 15 Duke 


74 




University, Durham, NC 

3:45 pm 

960. Efficacy of Canakinumab in Systemic Juvenile 

Idiopathic Arthritis Patients Previously Exposed to 

Biologics 

Hermine I. Brunner 1 , Nicolino Ruperto 2 , Pierre 

Quartier 3 , Tamas Constantin 2 , Yackov Berkun 2 , 

Inmaculada Calvo-Penedes 2 , Müferet Erguven 2 , 

Laurence Goffin 2 , Michael Hofer 2 , Tilmann Kallinich 2 , 

Sheila Oliveira 2 , Yosef Uziel 2 , Stefania Viola 4 , Kiran 

Nistala 2 , Carine Wouters 2 , Karolynn Leon 5 , Antonio 

Speziale 6 , Karine Lheritier 6 , Guido Junge 6 , Daniel Lovell 7 

and Alberto Martini 2 , 1 PRCSG, Cincinnati, OH, 2 PRINTO- 

Istituto Gaslini, Genova, Italy, 3 Necker-Enfant Malades 

Hospital, Paris, France, 4 Istituto G Gaslini, Pediatria II, 

Reumatologia, Genova, Italy, 5 Novartis Pharmaceuticals 

Corporation, East Hanover, NJ, 6 Novartis Pharma AG, 

Basel, Switzerland, 7 Cincinnati Children’s Hospital 

Medical Center, Cincinnati, OH 

North – 130 

Rheumatoid Arthritis – Human Etiology and 

Pathogenesis I 

Moderators: Jeremy Sokolove, MD and Miriam A. Shelef, 

MD, PhD 

2:30 pm 

961. Altered Th Cell Plasticity Favors Th17 Cells in 


Jan Leipe, Fausto Pirronello, Hendrik Schulze-Koops 

and Alla Skapenko, University of Munich, Munich, 

Germany 

2:45 pm 

962. Profiling at the Single-Cell Level Reveals 

Evidence for Antigen-Driven Oligoclonal Expansion 

of Citrullinated Vimentin-Specific CD4+ T Cells in 

Peripheral Blood of Rheumatoid Arthritis (RA) 

Patients 

Soi Cheng Law 1 , Hendrik Nel 1 , Jamie Rossjohn 2 , Hugh 

H Reid 3 , Nicole L La Gruta 4 and Ranjeny Thomas 1 , 

1 

The University of Queensland Diamantina Institute, 

Translational Research Institute, Princess Alexandra 

Hospital, Brisbane, Australia, 2 Institute of Infection and 

Immunity, Cardiff University, School of Medicine, Heath 

Park, Cardiff, England, 3 Department of Biochemistry 

and Molecular Biology, School of Biomedical Sciences, 

Monash University, Clayton, Melbourne, Australia, 

4 

Department of Microbiology & Immunology, Peter 

Doherty Institute for Infection and Immunity, University 

of Melbourne, Melbourne, Australia 

3:00 pm 

963. Ectopic Lymphoid Tissue in the Lung Is 

Associated with Serum Rheumatoid Arthritis- 

Related Autoantibodies Even in Absence of 

Clinically Apparent Rheumatoid Arthritis 

Lindsay E. Brown 1 , M. Kristen Demoruelle 1 , Mark C. 

Parish 2 , Marie L. Feser 1 , Peter B. Sachs 1 , David E. Heinz 1 , 

Carlyne D. Cool 1 and Kevin D. Deane 3 , 1 University of 

Colorado School of Medicine, Aurora, CO, 2 University 

of Colorado Anschutz Medical Campus, Aurora, CO, 3 U 

Colo Denver, Aurora, CO 

3:15 pm 

964. Neutrophil Extracellular Traps Are Not Only 

Targets for ACPA-Positive IgG from Rheumatoid 

Arthritis Patients but Also Directly Trigger Pro- and 

Anti-Inflammatory Effects Partly Mediated By the 

C1q Complement Protein 

Matthieu Ribon 1 , Sarra Seninet 1 , Katarzyna Matyja 1 , 

Mireille Sebbag 2 , Cyril Clavel 2 , Julie Mussard 1 , Guy 

Serre 2 , Marie-Christophe Boissier 3 and Patrice Decker 1 , 

1 

Inserm UMR 1125, Li2P, University of Paris 13, 

Sorbonne Paris Cité, Bobigny, France, 2 University of 

Toulouse, UMR 5165 CNRS-1056 Inserm, Toulouse, 

France, 3 Avicenne Hospital, AP-HP, Bobigny, France 

3:30 pm 

965. Crystal Structure of Porphyromonas Gingivalis 

peptidylarginine Deiminase: Implications for 

Autoimmunity in Rheumatoid Arthritis 

Anna B. Montgomery, Jolanta Kopec, Leela Shresha, 

Marie-Laetitia Thezenasc, Nicola A. Burgess-Brown, 

Roman Fischer, Wyatt W. Yue and Patrick J. Venables, 

University of Oxford, Oxford, United Kingdom 

3:45 pm 

966. In Rheumatoid Arthritis, Smoking Is Not 

Associated with Anti-Citrullinated Protein 

Antibodies per Se, but with the Concurrent 

Presence of Rheumatoid Factor, Anti-Citrullinated 

Protein Antibodies and Anti-Carbamylated Protein 

Antibodies 



2 0 1 5 


tracker 

plus 

75 


Tineke van Wesemael 1 , Ammar Muhammad 1 , Sofia 

ajeganova 2 , Jennifer Humphreys 3 , Deborah P.M. 

Symmons 4 , Alex J Macgregor 5 , Ingiäld Hafström 2 , 

Leendert Trouw 1 , Tom W.J. Huizinga 1 , Björn Svensson 6 , 

R E M Toes 1 , Suzanne M. Verstappen 7 and Diane 

van der Woude 1 , 1 Leiden University Medical Center, 

Leiden, Netherlands, 2 Department of Medicine 

Karolinska Institutet at Karolinska University Hospital 

Huddinge, Stockholm, Sweden, 3 Arthritis Research 

UK Epidemiology Unit,, Manchester, United Kingdom, 

4 

NIHR Manchester Musculoskeletal Biomedical 

Research Unit, Central Manchester University Hospitals 

NHS Foundation Trust, Manchester, United Kingdom, 

5 

Norfolk and Norwich University Hospital, Norwich, 

United Kingdom, 6 University of Lund, Lund, Sweden, 

7 

The University of Manchester, Manchester, United 

Kingdom 


Rheumatoid Arthritis-Small Molecules, Biologics 

and Gene Therapy I: Biologics 

Moderators: Mark C. Genovese, MD and Ernest H. Choy, 

MD 

2:30 pm 

967. Safety, Tolerability, and Pharmacodynamics 

of ABT-122, a Dual TNF- and IL-17-Targeted Dual 

Variable Domain (DVD)-Ig TM in Subjects with 


Roy M. Fleischmann 1 , Frank Wagner 2 , Alan J. Kivitz 3 , 

Heikki T. Mansikka 4 , Nasser Khan 4 , Jia Liu 4 , Jacob 

Gagnon 4 , Feng Hong 5 , Melanie Ruzek 4 and Robert J. 

Padley 4 , 1 University of Texas Southwestern Medical 

Center at Dallas, Dallas, TX, 2 Charité Research 

Organisation GmbH, Berlin, Germany, 3 Altoona Center 

for Clinical Research, Duncansville, PA, 4 AbbVie Inc., 

North Chicago, IL, 5 AbbVie Inc., Worcester, MA 

2:45 pm 

968. Certolizumab Pegol in Combination with 

Methotrexate in DMARD-Naïve Patients with 

Active, Severe, Progressive Rheumatoid Arthritis: 

Results from a Randomized, Double-Blind, 

Controlled Phase 3 Study 

Michael Weinblatt 1 , Clifton Bingham 2 , Gerd Burmester 3 , 

Vivian P. Bykerk 4 , Daniel E. Furst 5 , Xavier Mariette 6 , 

Désirée van der Heijde 7 , Daljit Tatla 8 , Catherine 

Arendt 9 , Irina Mountian 9 , Brenda VanLunen 8 and Paul 

Emery 10 , 1 Brigham and Women’s Hospital, Boston, 

MA, 2 Johns Hopkins University, Baltimore, MD, 

3 

Charité - Universitätsmedizin Berlin, Berlin, Germany, 

4 

Hospital for Special Surgery, New York, NY, 5 University 

of California, Los Angeles, David Geffen School of 

Medicine, Los Angeles, CA, 6 Université Paris-Sud, AP- 

HP, Hôpitaux Universitaires Paris-Sud, Paris, France, 

7 

University Hospital, Maastricht, Netherlands, 8 UCB 

Pharma, Raleigh, NC, 9 UCB Pharma, Brussels, Belgium, 

10 

Leeds Institute of Rheumatic and Musculoskeletal 

Medicine, University of Leeds, Leeds, United Kingdom 

3:00 pm 

969. Namilumab, an Anti-Granulocyte Macrophage- 

Colony Stimulating Factor (GM-CSF) Monoclonal 

Antibody: Results of the First Study in Patients with 

Mild-to-Moderate Rheumatoid Arthritis (RA) 

Tom W.J. Huizinga 1 , Anastas Batalov 2 , Rumen Stoilov 3 , 

Eric Lloyd 4 , Thomas Wagner 5 , Didier Saurigny 6 , Bernard 

Souberbielle 6 and Ehsanollah Esfandiari 6 , 1 Department 

of Rheumatology, Leiden University Medical Center, 

Leiden, Netherlands, 2 UMHAT Kaspela, Plovdiv, 

Bulgaria, 3 University Hospital (MHAT) St Ivan Rilski, 

Sofia, Bulgaria, 4 Takeda Pharmaceuticals, Deerfield, IL, 

5 

Takeda Pharmaceuticals, Zurich, Switzerland, 6 Takeda 

Pharmaceuticals, London, United Kingdom 

3:15 pm 

970. Efficacy and Safety of Sarilumab in 

Combination with Csdmards in Patients with 

Active Rheumatoid Arthritis Who Were Inadequate 

Responders or Intolerant of Antiâ€“TNF-Î± Therapy: 

Results from a Phase 3 Study 

Roy Fleischmann 1 , Geraldo Castelar-Pinheiro 2 , 

Jan Brzezicki 3 , Pawel Hrycaj 4 , Yong Lin 5 , Janet van 

Adelsberg 6 , Neil Graham 7 , Hubert van Hoogstraten 5 , 

Deborah Bauer 5 and Gerd Burmester 8 , 1 University 

of Texas Southwestern Medical Center, Dallas, TX, 

2 

Rio de Janeiro State University, Rio de Janeiro, Brazil, 

3 

Centrum Kliniczno-Badawcze, Elblag, Poland, 4 Poznan 

University of Medical Sciences, Poznan, Poland, 5 Sanofi, 

Bridgewater, NJ, 6 Regeneron Pharmaceutials, Inc., 

Tarrytown, NY, 7 Regeneron Pharmaceuticals, Inc., 

Tarrytown, NY, 8 Charité - Universitätsmedizin Berlin, 

Berlin, Germany 


76 




3:30 pm 

971. Safety and Tolerability of Subcutaneous 

Sarilumab Compared to Intravenous Tocilizumab in 

Patients with RA 

Paul Emery 1 , Juan Rondon 2 , Anju Garg 3 , Hubert van 

Hoogstraten 3 , Neil Graham 4 , Ming Liu 5 , Janie Parrino 6 , 

Alberto J. Spindler 7 and Nancy Liu 5 , 1 University of 

Leeds, Leeds, United Kingdom, 2 Elite Research Institute, 

Miami, FL, 3 Sanofi, Bridgewater, NJ, 4 Regeneron 

Pharmaceuticals, Inc., Tarrytown, NY, 5 Regeneron 

Pharmaceuticals, Tarrytown, NY, 6 Merck & Co., Inc., 

Whitehouse Station, NJ, 7 Hospital Padilla, Tucuman, 

Argentina 

3:45 pm 

972. A Phase 2b Study Evaluating the Efficacy 

and Safety of Subcutaneously Administered 

Tregalizumab in Subjects with Active Rheumatoid 

Arthritis (RA) Despite Treatment with 

Methotrexate (MTX) 

Ronald F. van Vollenhoven 1 , Edward C. Keystone 2 , 

Vibeke Strand 3 , Cesar Pacheco-Tena 4 , Jiri Vencovsky 5 , 

Frank Behrens 6 , Daniela Zipp 7 , Faiza Rharbaoui 7 , Ralf 

Wolter 7 , Rolf-Dietrich Tiemann 7 , Luise Knierim 7 , Rainer 

Schmeidl 7 , Xuefei Zhou 7 , Silke Aigner 7 , Benjamin 

Daelken 8 and Andrea Wartenberg-Demand 7 , 1 Unit 

for Clinical Therapy Research, Inflammatory Diseases 

(ClinTRID), The Karolinska Institute, Stockholm, 

Sweden, 2 Mount Sinai Hospital, University of Toronto, 

Toronto, ON, 3 Biopharmaceutical Consultant, Portola 

Valley, CA, 4 Universidad Autónoma de Chihuahua, 

Chihuahua, Mexico, 5 Institute of Rheumatology, 

Prague, Czech Republic, 6 Goethe University, Frankfurt, 

Germany, 7 Biotest AG, Dreieich, Germany, 8 Biotest 

Pharmaceuticals Corporation, Boca Raton, FL 


Spondylarthropathies and Psoriatic Arthritis – 

Clinical Aspects and Treatment: Treatment of 

Ankylosing Spondylitis 

Moderators: Christopher T. Ritchlin, MD, MPH and Philip 

J. Mease, MD 

2:30 pm 

973. The Effect of TNF Inhibitor Treatment on 

Occurrence of Anterior Uveitis in Ankylosing 

Spondylitis: Results from the Swedish Biologics 

Register 

Elisabeth Lie 1 , Ulf Lindström 2 , Tatiana Zverkova- 

Sandström 2 , Inge C Olsen 1 , Helena Forsblad-d’Elia 3 , 

Johan Askling 4 , Lars Erik Kristensen 5 and Lennart TH 

Jacobsson 2 , 1 Diakonhjemmet Hospital, Oslo, Norway, 

2 

Sahlgrenska Academy at University of Gothenburg, 

Gothenburg, Sweden, 3 Departments of Public Health 

and Clinical Medicine, Rheumatology, Umeå University, 

Umeå, Sweden, 4 Karolinska Institutet, Stockholm, 

Sweden, 5 Copenhagen University Hospital, Bispebjerg 

and Frederiksberg, Copenhagen, Denmark 

2:45 pm 

974. Secukinumab Significantly Improves Signs 

and Symptoms of Active Ankylosing Spondylitis: 

52-Week Results from a Randomized, Double- 

Blind, Placebo-Controlled Phase 3 Trial with 

Subcutaneous Loading and Maintenance Dosing 

Juergen Braun 1 , Atul A. Deodhar 2 , Joachim Sieper 3 , 

Maxime Dougados 4 , Brian Porter 5 , Mats Andersson 6 

and Hanno Richards 6 , 1 Rheumazentrum Ruhrgebiet, 

Herne, Germany, 2 Oregon Health & Science 

University, Portland, OR, 3 University Clinic Benjamin 

Franklin, Berlin, Germany, 4 Université Paris René 

Descartes and Hôpital Cochin, Paris, France, 5 Novartis 

Pharmaceuticals Corporation, East Hanover, NJ, 

6 

Novartis Pharma AG, Basel, Switzerland 

3:00 pm 

975. The Effect of TNF Inhibition on Radiographic 

Progression in Ankylosing Spondylitis: An 

Observational Cohort Study of 374 Patients 

Walter Maksymowych 1 , Yufei Zheng 2 , Stephanie 

Wichuk 1 , Sasha Bernatsky 3 , Praveena 

Chiowchanwisawakit 4 and Robert G Lambert 5 , 

1 

Medicine, University of Alberta, Edmonton, AB, 

2 

Alberta Institute of Health Economics, Edmonton, AB, 

3 

McGill MUHC/RVH, Montreal, QC, 4 Medicine, Siriraj 

Hospital, Mahidol University, Bangkok, Thailand, 

5 

Radiology, University of Alberta, Edmonton, AB 

3:15 pm 

976. The Reason of Discontinuation of a First TNF 

Inhibitor Affects Drug Retention of a Second Anti- 

TNF Agent in Axial Spondyloarthritis 

Adrian Ciurea 1 , Pascale Exer 2 , Ulrich Weber 3 , Giorgio 

Tamborrini 4 , Beate Steininger 1 , Rudolf O. Kissling 5 , Jürg 



2 0 1 5 


tracker 

plus 

77 


Bernhard 6 and Almut Scherer 7 , 1 University Hospital 

Zurich, Zurich, Switzerland, 2 Private rheumatology 

practice, Basel, Switzerland, 3 King Christian 10th 

Hospital for Rheumatic Diseases, Graasten, Denmark, 

4 

University Hospital, Zurich, Switzerland, 5 Balgrist 

University Hospital, Zurich, Switzerland, 6 Bürgerspital 

Solothurn, Solothurn, Switzerland, 7 SCQM Foundation, 

Zurich, Switzerland 

3:30 pm 

977. A Randomized, Double-Blind, Active- and 

Placebo-Controlled Phase 3 Study of Efficacy and 

Safety of Ixekizumab, Adalimumab, and Placebo 

Therapy in Patients Naïve to Biologic Disease 

Modifying Anti-Rheumatic Drugs with Active 

Psoriatic Arthritis 

Philip Mease 1 , Désirée van der Heijde 2 , Christopher T. 

Ritchlin 3 , Raquel Cuchacovich 4 , Catherine L. Shuler 4 , 

Chin H. Lee 4 , Suvajit Samanta 4 , Chen-Yen Lin 4 , Dafna 

D. Gladman 5 and Harald Vangerow 4 , 1 Swedish Medical 

Center and University of Washington, Seattle, WA, 

2 



Netherlands, 3 University of Rochester Medical Center, 

Rochester, NY, 4 Eli Lilly and Company, Indianapolis, IN, 

5 

University of Toronto, Toronto, ON 

3:45 pm 

978. Continuous Versus on Demand Treatment of 

Ankylosing Spondylitis with Diclofenac over 2 Years 

Does Not Prevent Radiographic Progression of the 

Spine: Results from a Randomized Prospective 

Multi-Center Trial 

Joachim Sieper 1 , Joachim Listing 2 , Denis Poddubnyy 1 , 

In-Ho Song 1 , Kay-Geert Hermann 1 , Johanna Callhoff 2 , 

Jürgen Braun 3 and Martin Rudwaleit 4 , 1 Charité 

Universitätsmedizin Berlin, Berlin, Germany, 2 German 

Rheumatism Research Centre, Berlin, Germany, 

3 

Rheumazentrum Ruhrgebiet, Herne, Germany, 

4 

Klinikum Bielefeld, Bielefeld, Germany 

West – 2014 

Spondylarthropathies Psoriatic Arthritis – 

Pathogenesis, Etiology 

Moderators: Dirk Elewaut, MD, PhD and Jose U. Scher, 

MD 

2:30 pm 

979. HLA Class I Genes As Susceptibility Markers 

of Psoriatic Arthritis in Patients with Psoriasis - a 

Meta-Analysis 

Lihi Eder 1 , Fatima Abji 1 , Cheryl Rosen 1 , Muhammad 

Haroon 2 , Vinod Chandran 1 , Rubén Queiro 3 , Shelley 

Bull 4 , Richard J. Cook 5 , Proton Rahman 6 , Robert 

Winchester 7 , Oliver FitzGerald 8 and Dafna D. Gladman 1 , 

1 

University of Toronto, Toronto Western Hospital, 

Toronto, ON, 2 Kerry General Hospital, Tralee, Ireland, 

3 

Hospital Universitario Central de Asturias, Oviedo, 

Spain, 4 Mount Sinai Hospital, Toronto, ON, 5 University 

of Waterloo, Waterloo, ON, 6 Memorial University of 

Newfoundland, St. John’s, NF, 7 Columbia University, 

New York, NY, 8 St Vincent’s University Hospital, Dublin, 

Ireland 

2:45 pm 

980. Association of Platelet Endothelial Cell 

Adhesion Molecule-1 and ß1 Integrin Gene 

Polymorphisms with Uveitis Development in 


Seung-Cheol Shim 1 , In-Seol Yoo 1 , Su-Jin Yoo 1 , Young 

Kim 1 , Mi-Kyoung Lim 2 , Dong-Hyuk Sheen 2 and Jinhyun 

Kim 1 , 1 Chungnam National University School of 

Medicine, Daejeon, South Korea, 2 Eulji University 

Hospital, Daejeon, South Korea 

3:00 pm 

981. Anti-IL-17A Treatment Blocks Inflammation, 

Destruction and New Bone Formation in 

Experimental Spondyloarthritis in HLA-B27 

Transgenic Rats 

Melissa van Tok 1 , Leonie van Duivenvoorde 1 , Ina 

Kramer 2 , Peter Ingold 2 , Joel Taurog 3 , Frank Kolbinger 2 

and Dominique Baeten 1 , 1 Amsterdam Rheumatology 

and Immunology Center, Amsterdam, Netherlands, 

2 

Novartis Institutes for Biomedical Research, Basel, 

Switzerland, 3 UT Southwestern Medical Center, Dallas, 

TX 

3:15 pm 

982. CD4+CD146+ T Cells: The Primed IL-17 Secreting 

Cells in the Pathogenesis of Psoriatic Arthritis 

Siba Raychaudhuri 1 and Smriti K. Raychaudhuri 2 , 

1 

Univ California Davis/VA Sacramento, Davis, CA, 2 VA 

Sacramento Medical Center, Davis, CA 


78 




3:30 pm 

983. ERAP1 Deficiency Protects HLA-B27 Transgenic 

Rats from Arthritis 

Tri M. Tran 1 , Sohee Hong 1 , Tejpal Gill 1 , Joshua Bennett 1 , 

Keith Sikora 1 and Robert A. Colbert 2 , 1 NIAMS/NIH, 

Bethesda, MD, 2 National Institute of Arthritis and 

Musculoskeletal and Skin Diseases, National Institutes 

of Health, Bethesda, MD 

3:45 pm 

984. Tofacitinib Inhibits Inflammation and New 

Bone Formation in Murine Spondyloarthritis but 

Does Not Adversely Inhibit Normal Human MSC 

Function 

Rik Lories 1 , Katelijne De Wilde 2 , Kerri Heritage 1 , Richard 

Cuthbert 3 , Elena Jones 3 , Karlijn Debusschere 2 , Dennis 

McGonagle 3 and Dirk Elewaut 2 , 1 KU Leuven and 

University Hospitals Leuven., Leuven, Belgium, 2 VIB, 

Ghent University and Ghent University Hospital, Ghent, 

Belgium, 3 University of Leeds, Leeds, United Kingdom 


Systemic Lupus Erythematosus – Clinical 

Aspects and Treatment I: Epidemiology and 

Prognosis 

Moderators: Lisa R. Sammaritano, MD and Karen H. 

Costenbader, MD, MPH 

2:30 pm 

985. Improved Survival in Systemic Lupus 

Erythematosus: A Population-Based Study 

Kateryna Vostretsova 1 , Sharan K. Rai 2 , Eric C. Sayre 3 , 

Hyon K. Choi 4 , JM Esdaile 3 and J Antonio Avina-Zubieta 5 , 

1 

Arthritis Research Centre, Vancouver, BC, 2 University 

of British Columbia, Vancouver, BC, 3 Arthritis 

Research Canada, Richmond, BC, 4 Massachusetts 

General Hospital, Harvard Medical School, Boston, 

MA, 5 University of British Columbia, Department of 

Medicine, Division of Rheumatology, Vancouver, BC 

2:45 pm 

986. Application of New EULAR Definitions of 

Remission in SLE: Durable 1-Year Remission Is Rare 

Theresa Fischer 1 , Laurence S Magder 2 and Michelle 

Petri 3 , 1 Charité-Universitätsmedizin, Berlin, Germany, 

2 

University of Maryland School of Medicine, Baltimore, 

MD, 3 Johns Hopkins University Hospital, Baltimore, MD 

3:00 pm 

987. Pre-Emptive Renal Transplantation Among End 

Stage Renal Disease Patients with and without SLE 

Anna R. Broder 1 , Wenzhu Mowrey 2 , Ladan Golestaneh 2 , 

Mimi Kim 3 , Karen H. Costenbader 4 and Chaim 

Putterman 2 , 1 Albert Einstein College of Medicine/ 

Montefiore Medical Center, Bronx, NY, 2 Albert Einstein 

College of Medicine, Bronx, NY, 3 Albert Einstein Coll 

Med, Bronx, NY, 4 Brigham & Women’s Hospital, Boston, 

MA 

3:15 pm 

988. Factors Associated with Renal Remission, 

Relapse and Long-Term Renal Function Decline 

in Lupus Nephritis Treated with Combined 

Prednisolone and Mycophenolate Mofetil (MMF) or 

Tacrolimus (Tac) 

Chi Chiu Mok 1 , Ling Yin Ho 2 , Chi Hung To 3 and Kar Li 

Chan 1 , 1 Tuen Mun Hospital, Hong Kong, Hong Kong, 

2 

Tuen Mun Hospital, Hong Kong SAR, Hong Kong, 3 Pok 

Oi Hospital, Hong Kong, Hong Kong 

3:30 pm 

989. Economic Evaluation of Lupus Nephritis in 

an International Inception Cohort: Comparing 

the Hospitalization, Medication, Dialysis, and 

Procedure Costs of Those with and without 

Nephritis 

Megan Barber 1 , John G. Hanly 2 , Aidan O’Keeffe 3 , 

Li Su 4 , Murray Urowitz 5 , Yvan St. Pierre 6 , Juanita 

Romero-Diaz 7 , C. Gordon 8 , Sang-Cheol Bae 9 , Sasha 

Bernatsky 10 , Daniel J Wallace 11 , Joan T. Merrill 12 , David 

A. Isenberg 13 , Anisur Rahman 3 , Ellen M. Ginzler 14 , 

Paul R. Fortin 15 , Dafna D. Gladman 16 , Jorge Sanchez- 

Guerrero 17 , Michelle Petri 18 , Ian N. Bruce 19 , Mary 

Anne Dooley 20 , Rosalind Ramsey-Goldman 21 , Cynthia 

Aranow 22 , Graciela S. Alarcon 23 , W. Winn Chatham 23 , 

Kristján Steinsson 24 , Ola Nived 25 , Gunnar K. Sturfelt 26 , 

Susan Manzi 27 , Munther Khamashta 28 , Ronald F. van 

Vollenhoven 29 , Asad Zoma 30 , Manel Ramos-Casals 31 , 

Guillermo Ruiz-Irastorza 32 , S. Sam Lim 33 , Thomas 

Stoll 34 , Murat Inanc 35 , Kenneth C. Kalunian 36 , Diane L. 

Kamen 37 , Peter Maddison 38 , Christine A. Peschken 39 , 

Søren Jacobsen 40 , Anca Askanase 41 , Jill P. Buyon 42 , 

Chris Theriault 43 , Kara Thompson 43 , Vernon Farewell 2 

and Ann E. Clarke 44 , 1 University of Calgary, Caglary, 

AB, 2 Division of Rheumatology, Capital Health and 



2 0 1 5 


tracker 

plus 

79 


Dalhousie University, Halifax, NS, 3 University College 

London, London, United Kingdom, 4 MRC Biostatistics 

Unit, Institute of Public Health, University Forvie 

Site, Cambridge, UK, Cambridge, United Kingdom, 

5 


Toronto, ON, 6 Research Institute of the McGill 

University Health Centre, Montreal, QC, 7 Instituto 

Nacional de Ciencias Medicas y Nutrición, Mexico 

City, Mexico, 8 University of Birmingham, Birmingham, 

United Kingdom, 9 Hanyang University Hospital for 

Rheumatic Diseases, Seoul, South Korea, 10 McGill 

MUHC/RVH, Montreal, QC, 11 Cedars-Sinai Medical 

Center, West Hollywood, CA, 12 Oklahoma Medical 

Research Foundation, Oklahoma City, OK, 13 Centre for 

Rheumatology Research, UCL Division of Medicine, 

London, United Kingdom, 14 SUNY-Downstate, Brooklyn, 

NY, 15 University of Laval, Quebec, QC, 16 University of 

Toronto, Toronto, ON, 17 Toronto Western Hospital, 

Toronto, ON, 18 Johns Hopkins University, Baltimore, 

MD, 19 Arthritis Research UK Centre for Epidemiology, 

Centre for Musculoskeletal Research, Institute of 

Inflammation and Repair, Manchester Academic 

Health Science Centre, The University of Manchester, 

Manchester, United Kingdom, 20 UNC Kidney Centre, 

Chapel Hill, NC, 21 Northwestern University Feinberg 

School of Medicine, Chicago, IL, 22 Feinstein Institute 

for Medical Research, Mahasset, NY, 23 University of 

Alabama at Birmingham, Birmingham, AL, 24 Centre 

for Rheumatology Research, Landspital University 

Hospital, Reykjavik, Iceland, 25 Inst of Clinical sciences, 

Lund, Sweden, 26 Univ Hospital Lund, Lund, Sweden, 

27 

Division of Rheumatology, University of Pittsburgh 

School of Medicine, Pittsburgh, PA, 28 Graham Hughes 

Lupus Research Laboratory, The Rayne Institute, St 

Thomas’ Hospital, London, United Kingdom, 29 Unit 

for Clinical Therapy Research, Inflammatory Diseases 

(ClinTRID), The Karolinska Institute, Stockholm, Sweden, 

30 

Lanarkshire Centre for Rheumatology, Hairmyres 

Hospital, East Kilbride, United Kingdom, 31 Sjögren 

Syndrome Research Group (AGAUR), Laboratory 

of Autoimmune Diseases Josep Font, Institut 

d’Investigacions Biomèdiques August Pi i Sunyer 

(IDIBAPS), Barcelona, Spain, 32 Hospital de Cruces, UPV/ 

EHU, Barakaldo, Spain, 33 Emory University, Atlanta, 

GA, 34 Kantonsspital Schaffhausen, Schaffhausen, 

Switzerland, 35 Istanbul University, Istanbul Faculty 

of Medicine, Istanbul, Turkey, 36 UCSD School of 

Medicine Center for Innovative Therapy, La Jolla, CA, 

37 

Medical University of South Carolina, Charleston, SC, 

38 

Bangor University, Bangor, United Kingdom, 39 Univ 

of Manitoba, Winnipeg, MB, 40 Copenhagen University 

Hospital, Rigshospitalet, Copenhagen, Denmark, 

41 

Columbia University College of Physicians & 

Surgeons, New York, NY, 42 New York University School 

of Medicine, New York, NY, 43 Queen Elizabeth II Health 

Sciences Centre and Dalhousie University, Halifax, NS, 

44 

University of Calgary, Calgary, AB 

3:45 pm 

990. Performance of the Systemic Lupus 

International Collaborating Clinic Classification 

Criteria Versus the 1982 and Revised 1997 American 

College of Rheumatology Classification Criteria 

for Systemic Lupus Erythematosus: A Population- 

Based Study 

Patompong Ungprasert, Cynthia S. Crowson and 

Vaidehi Chowdhary, Mayo Clinic, Rochester, MN 

West – 2016 

T cell Biology and Targets in Autoimmune 

Disease I 

Moderators: Craig Morita, MD, PhD and Erik J. Peterson, 

MD 

2:30 pm 

991. CaMK4 Facilitates Recruitment of IL-17 

Producing Cells to Target Organs through the CCR6/ 

CCL20 Axis in Th17-Driven Inflammatory Diseases 

Tomohiro Koga 1 , Kotaro Otomo 1 , Masayuki Mizui 1 , 

Nobuya Yoshida 1 , José C. Crispin 1 , Atsushi Kawakami 2 

and George C. Tsokos 1 , 1 Beth Israel Deaconess Medical 

Center, Harvard Medical School, Boston, MA, 2 Nagasaki 

University, Nagasaki, Japan 

2:45 pm 

992. Therapeutic Targeting of CD4 + T Cell 

Metabolism in Murine Models of Lupus 

Laurence Morel 1 , Seung-Chul Choi 1 , Zhiwei Xu 1 , 

Elisabeth Adkins 2 , Byron Croker 1 and Derry Roopenian 2 , 

1 

University of Florida, Gainesville, FL, 2 The Jackson 

Laboratory, Bar Harbor, ME 


80 




3:00 pm 

993. Failure in Nutrient Sensing Supports mTOR 

Hyperactivity and Proinflammatory Functions in T 

Cells from Patients with Rheumatoid Arthritis 

Zhen Yang 1 , Eric L. Matteson 2 , Jison Hong 3 , Jorg 

Goronzy 1 and Cornelia M. Weyand 1 , 1 Stanford 

University School of Medicine, Stanford, CA, 2 Mayo 

Clinic, Rochester, MN, 3 Stanford University, Palo Alto, 

CA 

3:15 pm 

994. Th17/Tfh Cell Predict Disease Severity in 

Rheumatoid Arthritis Patients Receiving TNF 

Inhibitor Therapy 

Deepika Singh 1 , Matthew Henkel 2 , Juan (June) Feng 3 , 

Jason Lyons 2 , Heather Eng 4 , Larry W. Moreland 2 and 

Mandy J. McGeachy 2 , 1 Children’s Hospital of Pittsburgh, 

Pittsburgh, PA, 2 University of Pittsburgh, Pittsburgh, 

PA, 3 University of Pittsburgh, Graduate School of Public 

Health, Pittsburgh, PA, 4 Univ of Pittsburgh, Pittsburgh, 

PA 

3:30 pm 

995. In Rheumatoid Arthritis Only a Few Expanded 

T-Cell Clones Dominate in Joint Inflammation: A 

Study in Seven RA Patients Undergoing Paired 

Synovial Tissue Biopsies in Multiple Joints 

Anne Musters 1 , Paul L. Klarenbeek 1 , Marieke E. 

Doorenspleet 2 , Rebecca E.E. Esveldt 1 , Barbera 

D.C. van Schaik 2 , Sander W. Tas 1 , Antoine H.C. van 

Kampen 2 , Frank Baas 2 and Niek de Vries 2 , 1 Amsterdam 

Rheumatology and immunology Center | Academic 

Medical Center/University of Amsterdam, Amsterdam, 

Netherlands, 2 Academic Medical Center/University of 

Amsterdam, Amsterdam, Netherlands 

3:45 pm 

996. Metabolic Control of Invariant Natural Killer T 

Cell Function 

Kevin Wei 1 , Deepak A. Rao 2 , Pui Y. Lee 3 , Anqi Gao 4 , 

Peter A. Nigrovic 5 and Michael Brenner 6 , 1 Brigham & 

Women’s Hospital, Boston, MA, 2 Brigham & Womens 

Hospital, Boston, MA, 3 Boston Children’s Hospital, 

Boston, MA, 4 Brigham and Women’s Hospital, 

Boston, MA, 5 Department of Medicine, Division of 

Rheumatology, Immunology and Allergy, Brigham and 

Women’s Hospital, Harvard Medical School, Boston, 

MA, 6 Brigham and Women’s Hospital, Harvard Medical 

School, Boston, MA 

ARHP SESSIONS 

2:30 – 4:00 pm 

West – 2008 

How to Manage Difficult Conversations in Your 

Practice 

Moderator: Jill Johnson, MD 

2:30 pm 

How to Manage Difficult Conversations Between 

Physicians and Patients 

Robert H. Shmerling, MD 

3:00 pm 

How to Manage Difficult Discussions Between 

Management and Staff 

Lisa M. Kastanek, RN, CCRC 

3:30 pm 

How to Manage Difficult Discussions About Money 

Mark Post, BSCMB 

West – 2007 

Patient Advocacy: Patient and Professional 

Perspectives PM PS E 

Moderator: Sandra Mintz, BSN 

2:30 pm 

Fostering Patient Advocacy in Clinical Practice 

Liz Morasso, LCSW 

3:00 pm 

Research, Registries and Innovative Design 

Jennifer R. Horonjeff, PhD 

3:30 pm 

Patient Advocacy Impacting Policy Change 

Jennifer Ziegler 

West – 2009 

Practicalities of Pain Management PM PS E PM PS E 

Moderator: Christine A. Stamatos, DNP, ANP-C 

2:30 pm 

Regulatory Changes to Prescribing Controlled 

Substances in the U.S. 

Bob Twillman, PhD 



2 0 1 5 


tracker 

plus 

81 


3:00 pm 

Challenges in Delivering Controlled Substances for 

Chronic Rheumatic Pain 

Steven Passik, PhD 

3:30 pm 

Best Practices for Documentation and Patient 

Empowerment When Prescribing Pain Medication 

Patricia Bruckenthal, PhD, RN, ANP-C 

West – 2006 

Psychoneuroimmunology: The Brain-Behavior 

Connection 

Moderator: Leonard H. Sigal, MD 

2:30 pm 

Psychoneuroimmunology in Relation to Rheumatoid 

Arthritis and Other Inflammatory Disorders 

Michael R. Irwin, MD 

3:15 pm 

Psychoneuroimmunology: Scientific Principles 

Rainer H. Straub, MD 

ARHP CONCURRENT ABSTRACT SESSION 

2:30 – 4:00 pm 

West – 2004 

ARHP: Exemplary Abstracts 

Moderators: Robert R. McLean, DSc, MPH and Marian T. 

Hannan, DSc, MPH 

2:30 pm 

997. Feasibility and Influential Factors in 

Performing Self-Evaluation of DAS28 with Smart 

System of Disease Management (SSDM) By RA 

Patient in China 

Mu Rong 1 , Fei Xiao 2 , Chun Li 1 , Jianlong Guan 3 , Yan 

Shen 3 , Dongbao Zhao 4 , Xia Xu 5 , Lindi Jiang 6 , Huiyong 

Chen 6 , Li Su 7 , Yuhua Jia 2 , Li Zhang 2 , Yuan Liu 2 and 

Zhan-Guo Li 1 , 1 People’s Hospital, Beijing University 

Medical School, Beijing, China, 2 Gothic Internet 

Technology Corporation, Shanghai, China, 3 Huadong 

Hospital Affiliated to Fudan University, Shanghai, 

China, 4 ShangHai ChangHai Hospital, ShangHai, 

China, 5 Changhai Hospital,Second Military Medical 

University,, Shanghai, China, 6 Zhongshan Hospital, 

Fudan University, Shanghai, China, 7 Longhua Hospital 

Shanghai University of TCM, Shanghai, China 

2:45 pm 

998. A Psychometric Analysis of the Social 

Interaction Anxiety Scale (SIAS-6) in Systemic 

Sclerosis: Results from the Scleroderma Patient- 

Centered Intervention Network (SPIN) Cohort 

Shadi Gholizadeh 1 , Sarah D. Mills 1 , Rina S. Fox 1 , Lisa 

Jewett 2 , Linda Kwakkenbos 3 , Marie-Eve Carrier 4 , Brett D. 

Thombs 4 , Scott C. Roesch 1 , Vanessa L. Malcarne 1 , Karen 

Gottesman 5 and SPIN Investigators, 1 SDSU/UC San 

Diego Joint Doctoral Program in Clinical Psychology, 

San Diego, CA, 2 Jewish General Hospital, Montréal, 

QC, 3 McGill University, Montreal, QC, 4 Jewish General 

Hospital, Montreal, QC, 5 Scleroderma Foundation, Los 

Angeles, CA 

3:00 pm 

999. Development of Quality Indicators for Hip and 

Knee Arthroplasty Rehabilitation 

Marie Westby 1 , Deborah Marshall 2 , Jane Squire 

Howden 3 and C. Allyson Jones 1 , 1 University of Alberta, 

Edmonton, AB, 2 University of Calgary, Calgary, AB, 

3 

Edmonton Musculoskeletal Centre, Edmonton, AB 

3:15 pm 

1000. Obesity and Foot Problems in the 

Framingham Foot Study: Does Foot Structure or 

Foot Function Protect Against Hallux Valgus? 

Alyssa B. Dufour 1 , Elena Losina 2 , Michael P. Lavalley 3 , 

David Gagnon 4 , Hylton B. Menz 5 and Marian T. 

Hannan 6 , 1 Hebrew SeniorLife, Harvard Medical School 

& Beth Israel Deaconess Medical Center, Boston, MA, 

2 

Brigham and Women’s Hospital and Harvard Medical 

School, Boston, MA, 3 Boston University, Boston, MA, 

4 

Boston University School of Public Health, Boston, MA, 

5 

La Trobe University, Bundoora, Australia, 6 Institute for 

Aging Research, Hebrew SeniorLife, Dept. of Medicine 

Beth Israel Deaconess Medical Center, Harvard Medical 


3:30 pm 

1001. What Is the Most Cost-Effective Physical 

Therapy Strategy to Treat Knee Osteoarthritis? 

Allyn Bove 1 , Ken Smith 1 , Christopher Bise 1 , Julie Fritz 2 , 


82 




John Childs 3 , Gerard P. Brennan 4 , J. Haxby Abbott 5 

and G. Kelley Fitzgerald 1 , 1 University of Pittsburgh, 

Pittsburgh, PA, 2 University of Utah, Salt Lake City, UT, 

3 

US Army-Baylor University, Schertz, TX, 4 Intermountain 

Healthcare, Murray, UT, 5 University of Otago, Dunedin, 

New Zealand 

3:45 pm 

1002. Aiming for Remission in Early RA: Impact on 

Pain during the First Year of Treatment 

Ellen Moholt 1 , Anna-Birgitte Aga 1 , Inge C Olsen 1 , Hilde 

Berner Hammer 1 , Till Uhlig 1 , Anne Katrine Kongtorp 1 , 

Heidi Lunoe 1 , Elin Mejdell Styrmoe 1 , Tore K. Kvien 1 , 

Espen A. Haavardsholm 1 and the ARCTIC study group, 

1 

Diakonhjemmet Hospital, Oslo, Norway 


4:00 – 6:00 pm 











August 30. 

West – 3004 

*212 – Dermatopathology of Rheumatic 

Diseases 

Speaker: Daniel Miller, MD 

West – 3008 

213 – Magnetic Resonance Imaging (MRI) in the 

Diagnosis and Management of Spondylarthritis: 

A Clinician’s Guide 

Speaker: Walter Maksymowych, MD 

West – 3002 

214 – Musculoskeletal Ultrasound 

Speakers: Eugene Y. Kissin, MD and Amy M. Evangelisto, 

MD 

ACR SESSIONS 

4:30 – 6:00 pm 


Biosimilars in Rheumatology 

Moderator: Kent Kwasind Huston, MD 

4:30 pm 

Identifying Complexities of Adopting Biosimilars in 

the U.S. 

Jonathan Kay, MD 

5:00 pm 

State by State Rules in Biosimilars 

J. Eugene Huffstutter, MD 

5:30 pm 

Regulatory Issues in Regards Biosimilars 

Jonathan Kay, MD 


Function of Non-coding Ribonucleic Acid 

Moderators: Cong-Qiu Chu, MD and Betty Tsao, PhD 

4:30 pm 

Molecular Mechanism of Activating and Repressing of 

Antigene Rbonucleic Acids 

David Corey, PhD 

5:00 pm 

Long Noncoding Ribonucleic Acid in Innate Immunity 

Susan Carpenter, PhD 

5:30 pm 

Micro Ribonucleic Acid in Systemic Lupus 

Erythematosus 

Nan Shen, MD, PhD 


Thieves’ Market: Show Me Your Best Cases 

Moderator: Mathilde H. Pioro, MD 

4:30 pm 

Image Competition Presentation 

Erika H. Noss, MD 



2 0 1 5 


tracker 

plus 

83 


4:50 pm 

Case Presentation 1 

Deepa Gali, MBBS(MD) 

5:00 pm 


Philip J. Hashkes, MD, MSc 

5:10 pm 


Sruthi Kanuru, MD 

5:20 pm 


Carolina Mejia Otero, MD 

5:30 pm 


Emma Mitchell, MBBS 

5:40 pm 


Florentina Berianu, MD 


What Immunodeficiencies Can Teach Us About 

Autoimmunity and the Appropriate Care of 

Immunosuppressed Patients PM Ed Pd PS PrM FIT 

Moderators: Christina Price, MD and James W. Verbsky, 

MD, PhD 

4:30 pm 

What Rare Monogenic Disorders Can Teach Us About 

Autoimmune Diseases 

Megan A. Cooper, MD, PhD 

5:00 pm 

Autoimmune Diseases Associated With Primary 

Disorders of Immune Tolerance 

Troy R. Torgerson, MD, PhD 

5:30 pm 

Clues for Early Detection and Appropriate 

Management of Patients With Autoimmunity in the 

Context of An Underlying Immune Deficiency 

Jolan E. Walter, MD, PhD 


4:30 – 6:00 pm 


Osteoarthritis – Clinical Aspects I: Imaging and 

Epidemiology 

Moderators: David Hunter, MD, PhD and Leena Sharma, 

MD 

4:30 pm 

1003. Use of Nsaids Correlates with the Risk of 

Venous Thromboembolism in Knee OA Patients: A 

UK Population-Based Case-Control Study 

Taeyeon Lee 1 , Na Lu 2 , David T. Felson 1 , Hyon K. 

Choi 2 , Deepan S Dalal 1 , Yuqing Zhang 1 and Maureen 

Dubreuil 1 , 1 Boston University School of Medicine, 

Boston, MA, 2 Massachusetts General Hospital, Harvard 


4:45 pm 

1004. Prevalence and Cross-Sectional Risk Factors 

of Ankle Osteoarthritis in a Community-Based 

Cohort 

Shahmeer Lateef, Yvonne M. Golightly, Jordan B. 

Renner, Joanne M. Jordan and Amanda E. Nelson, 

University of North Carolina, Chapel Hill, NC 

5:00 pm 

1005. Association of Baseline Knee Sagittal Dynamic 

Joint Stiffness during Gait and 2-Year Cartilage 

Damage Progression in Knee Osteoarthritis (OA) 

Alison H. Chang, Joan S. Chmiel, Orit Almagor, Kirsten 

C. Moisio, Laura Belisle, Yunhui Zhang, Karen W. Hayes 

and Leena Sharma, Northwestern University Feinberg 

School of Medicine, Chicago, IL 

5:15 pm 

1006. Incident Frequent Knee Pain Is Associated 

with Changes in Semi-Quantitative Imaging 

Biomarkers of Inflammation 

C.Kent Kwoh 1 , Michael J. Hannon 2 , Tomoko Fujii 3 , 

Frank W Roemer 4 , Ali Guermazi 4 , David Hunter 5 , Felix 

Eckstein 6 and Robert M. Boudreau 3 , 1 The University of 

Arizona Arthritis Center and Division of Rheumatology, 

Tucson, AZ, 2 University of Pittsburgh School of 

Medicine, Pittsburgh, PA, 3 University of Pittsburgh, 

Pittsburgh, PA, 4 Boston University School of Medicine, 


84 




Boston, MA, 5 Institute of Bone and Joint Research, 

Kolling Institute, University of Sydney, Sydney, 

Australia, 6 Paracelsus Med Univ, Chondrometrics 

GmbH, Salzburg, Austria 

5:30 pm 

1007. Change in Semi-Quantitative Imaging 

Biomarkers Predicts Knee Osteoarthritis 

Progression: Data from the Fnih OA Biomarkers 

Consortium 

Jamie E. Collins 1 , Elena Losina 1 , Michael C. Nevitt 2 , Frank 

W. Roemer 3 , Ali Guermazi 3 , John A. Lynch 4 , Jeffrey N. 

Katz 1 , C. Kent Kwoh 5 , Joanne M. Jordan 6 , Virginia Kraus 7 

and David Hunter 8 , 1 Brigham and Women’s Hospital 

and Harvard Medical School, Boston, MA, 2 University 

of California, San Francisco, San Francisco, CA, 3 Boston 

University School of Medicine, Boston, MA, 4 University 

of California San Francisco, San Francisco, CA, 

5 

University of Arizona, Tucson, AZ, 6 University of North 

Carolina, Chapel Hill, NC, 7 Duke University School of 

Medicine, Durham, NC, 8 University of Sydney, Sydney, 

Australia 

5:45 pm 

1008. Morphometric Study of Algerian Hips: An 

Etiological Study to Explain the Low Prevalence of 

Hip Osteoarthritis in Algeria 

Samy Slimani 1 , Aicha Ladjouze-Rezig 2 , Khalid Testas 3 , 

Imen Bencharif 4 , Mohamed Boukredera 5 and Riad 

Chiheub 5 , 1 Department of Medicine, University of 

Batna, Batna, Algeria, 2 Department of Rheumatology, 

EHS Ben Aknoun, Algiers, Algeria, 3 Department of 

Medicine, Khroub Hospital, Constantine, Algeria, 

4 

Department of Medicine, University of Constantine 

1, Constantine, Algeria, 5 Rheumatology office, 

Constantine, Algeria 

West - 2011 

Education PM Ed Pd PS PrM FIT 

Moderators: Deana M. Lazaro, MD and Susan F. Kroop, 

MD 

4:30 pm 

1009. Promoting Professional Development of 

Medical Educators in Rheumatology: Perspectives 

of Clinician Scholar Educators 

Juliet Aizer 1 and Jeanne Bitterman 2 , 1 Hospital for Special 

Surgery, New York, NY, 2 Teachers College, Columbia 

University, New York, NY 

4:45 pm 

1010. Differing Perspectives Between Doctor, 

Nurse and Patient Views on Professionalism 

and Empathy: An Inter-Professional 360-Degree 

Rheumatology Objective Structured Clinical 

Examination 

Jessica Berman 1 , Juliet Aizer 2 , Meng Zhang 2 , Anne R. 

Bass 2 , Irene Blanco 3 , Anne Davidson 4 , Theodore R. 

Fields 2 , Jane Kang 5 , Leslie Kerr 6 , Deana M. Lazaro 7 , 

Stephen A. Paget 2 and Michael H. Pillinger 8 , 1 Hospital 

for Special Surgery, Weill Cornell Medical College, 

New York, NY, 2 Hospital for Special Surgery, New York, 

NY, 3 Albert Einstein College of Medicine, Bronx, NY, 

4 

Feinstein Inst for Med Rsch, Manhasset, NY, 5 Columbia 

School of Medicine, New York, NY, 6 Mount Sinai 

Medical Ctr, New York, NY, 7 SUNY Downstate Medical 

Center, Brooklyn, NY, 8 NYU School of Medicine/NYU 

Hospital for Joint Diseases, New York, NY 

5:00 pm 

1011. Impact of a Musculoskeletal “Mini-Residency” 

Continuing Professional Education Program on 

Knee MRI Orders By Primary Care Providers 

Matthew Call, Andrea M. Barker, Grant W. Cannon, 

Phillip Lawrence and Michael Battistone, Salt Lake City 

VA Medical Center and University of Utah, Salt Lake 

City, UT 

5:15 pm 

1012. Use of Social Media By Rheumatology Fellows 

in North America 

Jonathan S. Hausmann 1 , Jayanth Doss 2 and Laura 

Cappelli 3 , 1 Beth Israel Deaconess Medical Center, 

Boston, MA, 2 Vanderbilt University Medical Center, 

Nashville, TN, 3 Johns Hopkins University, Baltimore, MD 

5:30 pm 

1013. The Fellow As Clinical Teacher Curriculum: 

Improving Rheumatology Fellows’ Teaching Skills 

during Inpatient Consultation 

Eli Miloslavsky 1 , Lisa Criscione-Schrieber 2 , Beth Jonas 3 , 

Kenneth S. O’Rourke 4 , Jakob McSparron 5 and Marcy B. 

Bolster 6 , 1 Massachusetts General Hopsital, Boston, MA, 

2 

Duke University Medical Center, Durham, NC, 



2 0 1 5 


tracker 

plus 

85 


3 

UNC-Chapel Hill, Chapel Hill, NC, 4 Wake Forest 

University School of Medicine, Winston-Salem, NC, 

5 

Beth Israel Deaconess Medical Center, Boston, MA, 

6 

Massachusetts General Hospital, Boston, MA 

5:45 pm 

1014. Improvement in Mentoring Associated with 

Implementation of an Inter-Institutional Mentoring 

Program within Pediatric Rheumatology 

Lakshmi N. Moorthy 1 , Eyal Muscal 2 , Meredith 

Riebschleger 3 , Marisa S. Klein-Gitelman 4 , Lise E. 

Nigrovic 5 , Kelly A. Rouster-Stevens 6 , Polly J. Ferguson 7 , 

B. Anne Eberhard 8 , Hermine I. Brunner 9 , Sampath 

Prahalad 10 , Rayfel Schneider 11 and Peter A. Nigrovic 12 , 

1 

Rutgers-Robert Wood Johnson Medical School, 

New Brunswick, NJ, 2 Baylor College of Medicine, 

Texas Children’s Hospital, Houston, TX, 3 University 

of Michigan, Ann Arbor, MI, 4 Ann & Robert H. Lurie 

Children’s Hospital of Chicago, Chicago, IL, 5 Division 

of Emergency Medicine, Boston Children’s Hospital, 

Boston, MA, 6 Emory Univ School of Medicine, Atlanta, 

GA, 7 University of Iowa, Iowa City, IA, 8 Schneider 

Children’s Hospital, New Hyde Park, NY, 9 Pediatric 

Rheumatology Collaborative Study Group, Cincinnati 

Children’s Hospital Medical Center, Cincinnati, OH, 

10 

Emory University School of Medicine and Children’s 

Healthcare of Atlanta, Atlanta, GA, 11 The Hospital for 

Sick Children and University of Toronto, Toronto, ON, 

12 

Department of Medicine, Division of Rheumatology, 

Immunology and Allergy, Brigham and Women’s 


North – 132 

Pain: Basic Aspects PM PS E 

Moderators: Camilla Svensson, PhD and Carla R. 

Scanzello, MD, PhD 

4:30 pm 

1015. Contribution of TNF and Type I Interferon to 

the Development of Persistent Post-Inflammatory 

Mechanical Allodynia in Arthritic Mice 

Sarah Woller, Cody Ocheltree, Tony Yaksh and Maripat 

Corr, UCSD, La Jolla, CA 

4:45 pm 

1016. Collagen Antibodies Induce Pain-like 

Behavior in Mice Independent of Inflammation and 

Complement Activation but Requires FcÎ³rs 

Gustaf Wigerblad, Katalin Sandor, Kutty Selva 

Nandakumar, Rikard Holmdahl and Camilla Svensson, 

Karolinska Institutet, Stockholm, Sweden 

5:00 pm 

1017. A Novel Mechanism of Arthritis-Induced Pain: 

Activation of Sensory Neurons By Autoantibodies 

Duygu Bas 1 , Alex Bersellini Farinotti 1 , Jon Sinclair 1 , 

Gustaf Wigerblad 1 , Kutty Selva Nandakumar 2 , Rikard 

Holmdahl 3 , Bo Rydqvist 1 and Camilla Svensson 1 , 

1 

Karolinska Institutet, Stockholm, Sweden, 2 Karolinska 

Institutet Department of Biochemistry and Biophysics, 

Stockholm, Sweden, 3 Department of Medical 

Biochemistry and Biophysics, Medical Inflammation 

Research, Karolinska Institute, Stockholm, Sweden 

5:15 pm 

1018. A 32-Mer Aggrecan Fragment Generated 

through Adamts-4/5 and MMP-Mediated Cleavage 

Can Directly Excite Nociceptive Neurons 

Rachel E. Miller 1 , Richard J. Miller 2 , Abdelhak 

Belmadani 2 , Suzanne Golub 3 , Amanda J. Fosang 3 and 

Anne-Marie Malfait 4 , 1 Rush University Medical Center, 

Chicago, IL, 2 Northwestern University, Chicago, IL, 

3 

University of Melbourne, Melbourne, Australia, 4 Rush 

University Medeical Center, Chicago, IL 

5:30 pm 

1019. Brain Functional Connectivity Differentially 

Predicts Response to Two Centrally Acting 

Analgesics in Fibromyalgia 

Eric Ichesco 1 , Johnson Hampson 2 , Lynne Pauer 3 , 

Andrew Clair 4 , Tobias Schmidt-Wilcke 5 , David A. 

Williams 2 , Daniel J. Clauw 2 and Richard E. Harris 1 , 1 U. 

Michigan, Ann Arbor, MI, 2 University of Michigan, Ann 

Arbor, MI, 3 Pfizer Inc, New London, CT, 4 Pfizer Inc., New 

York, NY, 5 Bergmannsheil, Bochum, Germany 

5:45 pm 

1020. Abnormal Resting State Functional 

Connectivity in Chronic Fatigue Syndrome Patients: 

An Arterial Spin-Labeling fMRI Study 

Roland Staud 1 , Song Lai 2 , Donald Price 1 , Michael 

Robinson 1 , Jason Craggs 3 and Jeff Boissoneault 2 , 

1 

Univ of Florida, Gainesville, FL, 2 University of Florida, 

Gainesville, FL, 3 University of Missouri, Columbia, MO 


86 




West – 2014 

Pediatric Rheumatology – Pathogenesis and 

Genetic PM Ed Pd PS PrM FIT 

Moderator: Scott Lieberman, MD, PhD 

4:30 pm 

1021. Nucleic Acids Sensing Receptors RIG-I and 

MDA5 As Potential Amplifiers of the Interferon 

Signature in Childhood Onset Systemic Lupus 

Erythematosus 

Naomi I Maria 1 , M. Javad Wahadat 1 , Cornelia G. van 

Helden-Meeuwsen 1 , Annette van Dijk-Hummelman 2 , 

Radboud JEM Dolhain 1 , Sylvia Kamphuis 2 and Marjan 

A. Versnel 1 , 1 Erasmus Medical Center, Rotterdam, 

Netherlands, 2 Eramus MC Sophia Children’s Hospital, 

Rotterdam, Netherlands 

4:45 pm 

1022. Identification of Shared Genomic Regions 

in Distantly Related Pairs of Cases with Juvenile 

Idiopathic Arthritis 

Sampath Prahalad 1 , K. Alaine Broadaway 2 , John F. 

Bohnsack 3 , Ann Dodd 2 , Aimee O. Hersh 4 , Sheila T. 

Angeles-Han 1 , Se Ryeong Jang 1 , Marc Sudman 5 , Susan 

D. Thompson 5 , Michael Zwick 2 , Karen Conneely 2 

and Michael Epstein 2 , 1 Emory University School of 

Medicine and Children’s Healthcare of Atlanta, Atlanta, 

GA, 2 Emory University School of Medicine, Atlanta, 

GA, 3 University of Utah Health Sciences Center, Salt 

Lake City, UT, 4 University of Utah, Salt Lake City, UT, 

5 

Childrens Hospital Med Ctr, Cincinnati, OH 

5:00 pm 

1023. Tumor Necrosis Factor-a (TNF-a) and 

Interferon Gamma Inducible Protein-10 (IP-10) As 

Predictors of Active Disease Status in Localized 

Scleroderma 

Kathryn S. Torok 1 , Jonathan Yabes 2 , Qi Mi 2 , Christina 

Kelsey 1 and Kelsey Magee 2 , 1 Univ of Pittsburgh Med Ctr, 

Pittsburgh, PA, 2 University of Pittsburgh, Pittsburgh, PA 

5:15 pm 

1024. Disruptions in Folate Homeostasis May Lead 

to Increased Risk for Methotrexate Intolerance in 

Juvenile Idiopathic Arthritis 

Mara L Becker 1 , Leon van Haandel 1 , Ryan Funk 2 , Rodger 

Gaedigk 1 and J.S. Leeder 1 , 1 Children’s Mercy Kansas 

City, Kansas City, MO, 2 University of Kansas Medical 

Center, Kansas City, KS 

5:30 pm 

1025. Interstitial Lung Disease in Sting-Associated 

Vasculopathy with Onset in Infancy (SAVI): 

Genotype-Phenotype Correlation 

Louise Malle 1 , Bernadette Marrero 1 , Yin Liu 2 , Gina A. 

Montealegre Sanchez 1 , Dawn C. Chapelle 1 , Hanna 

Kim 1 , Michelle O’Brien 1 , Suzanne Ramsey 3 , Gregor 

Dueckers 4 , Seza Ozen 5 , Helmut Wittkowski 6 , Dirk Föll 6 , 

Klaus Tenbrock 7 , Olcay Y. Jones 8 , Steven M. Holland 9 , 

Joseph Fontana 10 , Yan Huang 1 , Benito Gonzalez 11 , 

Paul Brogan 12 , Juergen Brunner 13 , Athimalaipet V 

Ramanan 14 , Tom Hilliard 14 , Laisa Santiago 15 , AnneMarie 

Brescia 16 , Amy Paller 17 , Stephen Brooks 18 , Zuoming 

Deng 18 , Adriana Almeida de Jesus 1 and Raphaela 

Goldbach-Mansky 1 , 1 Translational Autoinflammatory 

Diseases Section, NIAMS, NIH, Bethesda, MD, 2 Scientific 

Review Branch, NIAMS, NIH, Bethesda, MD, 3 IWK Health 

Centre, Halifax, NS, 4 Helios Kliniken - Kinderklinik, 

HELIOS Klinikum Krefeld, Krefeld, Germany, 5 Hacettepe 

University, Ankara, Turkey, Ankara, Turkey, 6 University 

of Muenster, Muenster, Germany, 7 University Aachen, 

Aachen, Germany, 8 George Washington University, 

Washington, DC, 9 Laboratory of Clinical Infectious 

Disease, NIAID, NIH, Bethesda, MD, 10 NHLBI, NIH, 

Bethesda, MD, 11 Luis Calvo Mackenna Hospital, 

Santiago, Chile, 12 UCL Institute of Child Health and 

Great Ormond Street Hospital NHS Foundation 

Trust, London, United Kingdom, 13 Universitätsklinik 

für Kinder- u. Jugendheilkunde, Innsbruck, Austria, 

14 

Bristol Royal Hospital for Children, Bristol, United 

Kingdom, 15 All Children’s Hospital Rheumatology, Saint 

Petersburg, FL, 16 Jefferson Medical College/ A.I. Dupont 

Hospital for Children, Willmington, DE, 17 Departments 

of Dermatology and Pediatrics, Feinberg School of 

Medicine, Northwestern University, Chicago, IL, USA;, 

Chicago, IL, 18 NIAMS/NIH, Bethesda, MD 

5:45 pm 

1026. Microrna-125a-5p Has Increased Expression in 

Active Systemic Juvenile Idiopathic Arthritis and Is 

an Essential Modulator of Regulatory Macrophage 

Phenotypes in Vitro 

Grant Schulert 1 , Ndate Fall 2 , Nan Shen 1 , Sherry 

Thornton 2 and Alexei Grom 1 , 1 Cincinnati Children’s 

Hospital Medical Center, Cincinnati, OH, 2 Cincinnati 

Children’s Hospital, Cincinnati, OH 



2 0 1 5 


tracker 

plus 

87 


West – 2016 

Quality Measures and Quality of Care 

Moderators: Eric Newman, MD and John FitzGerald, MD, 

PhD 

4:30 pm 

1027. Rheumatoid Arthritis Disease Activity 

Assessment Frequencies in Clinical Practices Do 

Not Support Treat-to-Target Care 

David Sikes 1 , James Bower 2 , Drew Johnson 3 , 

Timothy Harrington 2 , Rafia Khalil 4 , Edmund LaCour 5 , 

Michael Naarendorp 6 , Hillary Norton 7 and Kathleen 

Thomas 8 , 1 Florida Medical Clinic PA, Zephyrhills, FL, 

2 

Joiner Associates LLC, Madison, WI, 3 Crescendo 

Bioscience, Inc., South San Francisco, CA, 4 Rafia 

Khalil Arthritis & Rheumatology Center, PC, Port 

Huron, MI, 5 Dothan Medical Associates PC, Dothan, 

AL, 6 Harlem Rhematology, LLC, New York, NY, 

7 

Santa Fe Rheumatology, Santa Fe, NM, 8 Community 

Rheumatology, Noblesville, IN 

4:45 pm 

1028. Improving Pneumococcal Immunization Rates 

Among Immunocompromised Adolescent Patients 

at a Tertiary Care Children’s Hospital 

Michal Feldon 1 , Adam Furnier 1 , Corinne Lehmann 1 , 

Bradford Fletcher 1 , Jack Kues 2 , Barbara Speer 2 , Sandy 

Kramer 1 , Pamela Morgan 1 , Lois Siegle 1 , Rebecca 

Brady 1 and Jennifer L. Huggins 1 , 1 Cincinnati Children’s 

Hospital Medical Center, Cincinnati, OH, 2 University of 

Cincinnati, Cincinnati, OH 

5:00 pm 

1029. Improving Gout Outcomes Using a Disease 

Management Program within an Integrated Health 

System 

David Bulbin 1 , Carson Maynard 1 , Tarun Sharma 1 , Alfred 

E. Denio 1 , Jason Brown 2 , Andrea Berger 3 , H. Lester 

Kirchner 3 and William T. Ayoub 4 , 1 Geisinger Medical 

Center, Danville, PA, 2 Geisinger Health System, Danville, 

PA, 3 Geisinger Center for Health Research, Danville, PA, 

4 

Geisinger Medical Group, State College, PA 

5:15 pm 

1030. Unwanted Variations in Rheumatology Clinic 

Rooming: A Time Study Tool and Analysis 

Brad Stroik 1 , Christie M. Bartels 1 , Diane Lauver 2 , 

Patrick McBride 1 , Jon Arnason 1 , Sarah Loring 2 and 

Edmond Ramly 3 , 1 University of Wisconsin School of 

Medicine and Public Health, Madison, WI, 2 University 

of Wisconsin-Madison School of Nursing, Madison, 

WI, 3 University of Wisconsin-Madison College of 

Engineering, Madison, WI 

5:30 pm 

1031. Quantifying the Delays to Rheumatologist 

Consultation and Treatment Among Patients with 

Systemic Inflammatory Rheumatic Diseases 

Jessica Widdifield 1 , Sasha Bernatsky 2 , J Carter Thorne 3 , 

Claire Bombardier 4 , R. Liisa Jaakkimainen 4 , Vandana 

Ahluwalia 5 , J. Michael Paterson 6 , Noah Ivers 4 , Debra 

Butt 7 and Karen Tu 7 , 1 McGill University, Montreal, QC, 

2 

McGill MUHC/RVH, Montreal, QC, 3 Southlake Regional 

Health Centre, Newmarket, ON, 4 University of Toronto, 

Toronto, ON, 5 Past President, Ontario Rheumatology 

Association, Brampton, ON, 6 ICES, Toronto, ON, 

7 

Institute for Clinical Evaluative Sciences, Toronto, ON 

5:45 pm 

1032. Adherence Patterns to American Academy of 

Ophthalmology Guidelines for Hydroxychloroquine 

Baseline Screening: Quality Assurance Assessment 

Utilizing Highmark Claims Data 

Christina Payne 1 , Patricia Gladowski 2 , James Byers Jr. 2 , 

Amy Tang 1 and Mary Chester M. Wasko 3 , 1 Allegheny 

Health Network, Pittsburgh, PA, 2 Highmark Health, 

Pittsburgh, PA, 3 Lupus Center, Pittsburgh, PA 


Rheumatoid Arthritis – Animal Models I 

Moderators: Homaira Rahimi, MD, MTR and Yehuda 

Shoenfeld, MD 

4:30 pm 

1033. Novel Ligand-Independent Peptide Inhibitors 

of Triggering Receptor Expressed on Myeloid Cells 

1 (TREM-1) and T Cell Receptor (TCR): Efficacy in a 

Collagen-Induced Arthritis Model Suggests New 

Targeted Treatment for Rheumatoid Arthritis 

Zu T. Shen and Alexander B. Sigalov, SignaBlok, Inc., 

Shrewsbury, MA 


88 




4:45 pm 

1034. Immunomodulation By a Second-Generation 

Peptidyl Arginine Deiminase Inhibitor Abrogates 

Collagen-Induced Arthritis in a Therapeutic 

Protocol 

Anne-Marie Quirke 1 , Joanna Kawalkowska 1 , Fatemeh 

Ghari 1 , Venkataraman Subramaniam 2 , Paul Thompson 2 , 

Richard O. Williams 1 , Nick La Thangue 1 and Patrick 

J. Venables 1 , 1 University of Oxford, Oxford, United 

Kingdom, 2 University of Massachusetts, Worcester, MA 

5:00 pm 

1035. Synovium-Derived microRNAs Inhibit Bone 

Formation in Rheumatoid Arthritis 

Ellen M. Gravallese 1 , Yukiko Maeda 1 , Nicholas H 

Farina 2 , Paul Fanning 1 and Jane Lian 2 , 1 University 

of Massachusetts Medical School, Worcester, MA, 

2 

University of Vermont, Burlington, VT 

5:15 pm 

1036. Important Role of microRNA-146a in 

Inflammatory Arthritis By Controlling Local Bone 

Destruction 

Victoria Saferding 1 , Antonia Puchner 1 , Eliana Goncalves- 

Alves 1 , Melanie Hofmann 1 , Emine Sahin 2 , Silvia Hayer 1 , 

Philippe Georgel 3 , Marije M. Koenders 4 , Gernot 

Schabbauer 2 , Josef S. Smolen 1 , Guenter Steiner 1 , Kurt 

Redlich 1 and Stephan Blüml 1 , 1 Medical University of 

Vienna, Vienna, Austria, 2 Medical University Vienna, 

Vienna, Austria, 3 Université de Strasbourg, Strasbourg, 

France, 4 Radboud University Nijmegen, Nijmegen, 

Netherlands 

5:30 pm 

1037. Impaired Regulatory T Cell Survival in the 

Pathogenesis of Autoreactive Arthritis Mediated By 

CD11c-Deletion of Flip 

Qi Quan Huang, Renee E. Doyle, Robert Birkett, 

Deyu Fang, Syamal K. Datta and Richard M. Pope, 

Northwestern University Feinberg School of Medicine, 

Chicago, IL 

6:15 pm 

1038. Tumor Necrosis Factor Alpha and 

Peptidylarginine Deiminase 4 in Lung and Joint 

Inflammation 

Mandar Bawadekar 1 , Annette Gendron-Fitzpatrick 1 , 

Thomas F. Warner 1 , Lennart K.A. Lundblad 2 , Paul 

Thompson 3 and Miriam A. Shelef 1 , 1 University of 

Wisconsin, Madison, WI, 2 The University of Vermont, 

Burlington, VT, 3 University of Massachusetts, 

Worcester, MA 

South - Hall A 

Rheumatoid Arthritis - Clinical Aspects I - 

Treatment Advances and Strategies 

Moderators: Grant H. Louie, MD, MHS and Andrew 

Gross, MD 

4:30 pm 

1039. The Safety and Effect on Disease Activity 

of Tocilizumab in Combination with MTX Versus 

Tocilizumab Monotherapy in Patients with Mild 

to Moderate RA: An Attempt to Optimise the 

Treatment Response 

Burkhard Leeb 1 , Raimund Lunzer 2 , Peter Fasching 3 , 

Manfred Herold 4 , O. Zamani 5 , Winfried Graninger 6 and 

OPTIMISE trial Investigators, 1 State Hospital Stockerau, 

Center for Rheumatology Lower Austria, Stockerau, 

Austria, 2 Hospital Barmherzige Brüder Graz-Eggenberg, 

Graz, Austria, 3 Wilhelminen Hospital Vienna, Vienna, 

Austria, 4 Medical University of Innsbruck, Austria, 

Innsbruck, Austria, 5 Rheumazentrum Favoriten, Wien, 

Austria, 6 Medical University of Graz, Graz, Austria 

4:45 pm 

1040. Factors Associated with Long Term Rituximab 

Use in Rheumatoid Arthritis - Results from the 

British Society of Rheumatology Biologics Register 

Alexander G.S. Oldroyd 1 , Deborah P.M. Symmons 1 , 

Lianne Kearsley-Fleet 1 , Kath Watson 1 , Mark Lunt 1 , 

Jamie Sergeant 1 , Kimme L. Hyrich 1 and on behalf 

of the BSRBR-RA, 1 Arthritis Research UK Centre 

for Epidemiology, The University of Manchester, 

Manchester, United Kingdom 

5:00 pm 

1041. Methotrexate Monotherapy and 

Methotrexate Combination Therapy with 

Traditional and Biologic Dmards for Rheumatoid 

Arthritis: A Cochrane Systematic Review and 

Network Meta-Analysis 

Glen S. Hazlewood 1 , Cheryl Barnabe 2 , George A. 

Tomlinson 1 , Deborah Marshall 3 , Daniel Devoe 3 and 

Claire Bombardier 1 , 1 University of Toronto, Toronto, 



2 0 1 5 


tracker 

plus 

89 


ON, 2 Cumming School of Medicine, University of 

Calgary, Calgary, AB, 3 University of Calgary, Calgary, AB 

5:15 pm 

1042. Pragmatic Multicenter Open-Label 

Randomized Controlled Trial of Stopping TNF- 

Inhibitors in Rheumatoid Arthritis Patients in 

Remission or Stable Low Disease Activity in the 

Netherlands 

Marjan Ghiti Moghadam 1 , Harald E. Vonkeman 1 , 

Peter M. ten Klooster 2 , Janneke Tekstra 3 , Dirkjan van 

Schaardenburg 4 , Mirian Starmans-kool 5 , Elisabeth 

Brouwer 6 , Reinhard Bos 7 , Willem F. Lems 8 , Edgar 

Colin 9 , Cornelia F. Allaart 10 , Inger L. Meek 11 , Robert B.M. 

Landewé 12 , Hein J. Bernelot Moens 13 , Piet van Riel 11 , 

Mart A.F.J. van de Laar 1 , Tim Jansen 14 and on behalf 

of the Dutch National POET Collaboration., 1 Medisch 

Spectrum Twente - Arthritis Center Twente, Enschede, 

Netherlands, 2 University of Twente, Enschede, 

Netherlands, 3 University Medical Center Utrecht, 

Utrecht, Netherlands, 4 Jan van Breemen Research 

Institute, Amsterdam, Netherlands, 5 Orbis Medical 

Center, Geleen-Sittard, Netherlands, 6 University 

Medical center Groningen, Groningen, Netherlands, 

7 

Medical Center Leeuwarden, Leeuwarden, 

Netherlands, 8 Amsterdam Rheumatology and 

immunology Center, VU University medical center, 

Amsterdam, Netherlands, 9 Erasmus MC, Rotterdam, 

Netherlands, 10 Department of Rheumatology, Leiden 

Universitary Medical Center, Leiden, Netherlands, 

11 

Radboud University Nijmegen Medical Centre, 

Nijmegen, Netherlands, 12 Amsterdam Rheumatology 

Center, Amsterdam, Netherlands, 13 Ziekenhuisgroep 

Twente, Almelo, Netherlands, 14 VieCuri Medical Center, 

Venlo, Netherlands 

5:30 pm 

1043. Enhancing Comparative Effectiveness 

Research By Combining Observational and 

Randomized Trial Data to Personalize the Choice 

Between Methotrexate and Triple Therapy 

for Methotrexate-Naïve Patients with Early 


Glen S. Hazlewood 1 , Cheryl Barnabe 2 , Gilles Boire 3 , 

Carol Hitchon 4 , Edward C. Keystone 5 , Boulos Haraoui 6 , J 

Carter Thorne 7 , Diane Tin 7 , Janet E. Pope 8 , Daming Lin 5 , 

Vivian Bykerk 9 and CATCH investigators, 1 University of 

Toronto, Toronto, ON, 2 Cumming School of Medicine, 

University of Calgary, Calgary, AB, 3 Université de 

Sherbrooke, Sherbrooke, QC, 4 University of Manitoba, 

Winnipeg, MB, 5 Mount Sinai Hospital, University of 

Toronto, Toronto, ON, 6 Institut de Rhumatologie, 

Montreal, QC, 7 Southlake Regional Health Centre, 

Newmarket, ON, 8 University of Western Ontario, 

London, ON, 9 Hospital for Special Surgery, Weill Cornell 

Medical College, New York, NY 

5:45 pm 

1044. Many Patients with Early Rheumatoid 

Arthritis Want Triple Therapy: An Analysis 

Combining Comparative Effectiveness Research 

and Patients Preferences to Inform Treatment 

Recommendations 

Glen S. Hazlewood 1 , Claire Bombardier 2 , George A. 

Tomlinson 3 and Deborah Marshall 4 , 1 University of 

Toronto, Toronto, ON, 2 Toronto General Hospital 

Research Institute, University Health Network, 

Toronto, ON, 3 University Health Network, Toronto, ON, 

4 

University of Calgary, Calgary, AB 



and Gene Therapy II: Small Molecular Targeted 

Therapies 

Moderators: Peter C. Taylor, MA, PhD and Ronald F. van 

Vollenhoven, MD, PhD 

4:30 pm 

1045. Baricitinib, Methotrexate, or Baricitinib Plus 

Methotrexate in Patients with Early Rheumatoid 

Arthritis Who Had Received Limited or No 

Treatment with Disease-Modifying Anti-Rheumatic 

Drugs (DMARDs): Phase 3 Trial Results 

Roy Fleischmann 1 , Tsutomu Takeuchi 2 , Douglas E. 

Schlichting 3 , William L. Macias 3 , Terence Rooney 3 , Sirel 

Gurbuz 3 , Ivaylo Stoykov 3 , Scott D. Beattie 3 , Wen-Ling 

Kuo 3 and M Schiff 4 , 1 Metroplex Clinical Research 

Center, Dallas, TX, 2 Keio University School of Medicine, 

Tokyo, Japan, 3 Eli Lilly and Company, Indianapolis, IN, 

4 

University of Colorado, Denver, CO 


90 




4:45 pm 

1046. Previous Biologic Disease-Modifying 

Antirheumatic Drug (bDMARD) Exposure and 

Efficacy and Safety Analysis from a Phase 3 Study 

of Baricitinib in Patients with Rheumatoid Arthritis 

and an Inadequate Response to Tumor Necrosis 

Factor Inhibitors 

Mark C. Genovese 1 , Joel M. Kremer 2 , Cynthia Kartman 3 , 

Douglas E. Schlichting 3 , Li Xie 3 , Tara Carmack 4 , 

William L. Macias 3 and Josef S. Smolen 5 , 1 Stanford 

University Medical Center, Palo Alto, CA, 2 Center for 

Rheumatology, Albany, NY, 3 Eli Lilly and Company, 

Indianapolis, IN, 4 Quintiles, Durham, NC, 5 Medical 

University of Vienna, Vienna, Austria 

5:00 pm 

1047. Characterization of Changes in Lymphocyte 

Subsets in Baricitinib-Treated Patients with 

Rheumatoid Arthritis in Two Phase 3 Studies 

Paul Emery 1 , Iain McInnes 2 , Mark C. Genovese 3 , Josef S. 

Smolen 4 , Joel Kremer 5 , Maxime Dougados 6 , Douglas E. 

Schlichting 7 , Terence Rooney 7 , Maher Issa 7 , Stephanie 

de Bono 7 , William L. Macias 7 , Veronica Rogai 7 , Steven H. 

Zuckerman 7 and Peter C. Taylor 8 , 1 University of Leeds, 

Leeds, United Kingdom, 2 Glasgow Biomedical Research 

Centre, Glasgow, United Kingdom, 3 Stanford University 

Medical Center, Palo Alto, CA, 4 Medical University 

of Vienna, Vienna, Austria, 5 Albany Medical College, 

Albany, NY, 6 Paris-Descartes University, Paris, France, 

7 

Eli Lilly and Company, Indianapolis, IN, 8 University 

of Oxford Botnar Research Centre, Oxford, United 

Kingdom 

5:15 pm 

1048. Filgotinib (GLPG0634), an Oral JAK1 Selective 

Inhibitor Is Effective in Combination with 

Methotrexate in Patients with Active Rheumatoid 

Arthritis: Results from a Phase 2B Dose Ranging 

Study 

R Westhovens 1 , Rieke Alten 2 , Dace Pavlova 3 , Favio 

Enríquez-Sosa 4 , Minodora Mazur 5 , Maria Greenwald 6 , 

Annegret Van der Aa 7 , Frédéric Vanhoutte 7 , Chantal 

Tasset 7 and Pille Harrison 7 , 1 KU Leuven, Leuven, 

Belgium, 2 Schlosspark-Klinik, University Medicine 

Berlin, Berlin, Germany, 3 LTD M & M Centrs, Carnikava, 

Latvia, 4 CLINSTILE, S.A. DE C.V, Mexico, Mexico, 5 IMSP 

Institul de Cardiologie, Chisinau, Moldova, 6 Desert 

Medical Advances, Palm Desert, CA, 7 Galapagos NV, 

Mechelen, Belgium 

5:30 pm 

1049. Filgotinib (GLPG0634), an Oral JAK1 Selective 

Inhibitor Is Effective As Monotherapy in Patients 

with Active Rheumatoid Arthritis: Results from a 

Phase 2B Dose Ranging Study 

Arthur Kavanaugh 1 , Lucia Ponce 2 , Regina Cseuz 3 , Olga 

Reshetko 4 , Mykola A Stanislavchuk 5 , Maria Greenwald 6 , 

Annegret Van der Aa 7 , Frédéric Vanhoutte 7 , Chantal 

Tasset 7 and Pille Harrison 7 , 1 University of California 

San Diego, La Jolla, CA, 2 Consulta Privada Dra. Lucia 

Ponce, Temuco, Chile, 3 Revita Reumatologiai Rendelo, 

Budapest, Indonesia, 4 Regional Clinical Hospital, 

Saratov, Russia, 5 Vinnitsa Regional Clinical Hospital n.a. 

Pirogov, Vinnitsa, Ukraine, 6 Desert Medical Advances, 

Palm Desert, CA, 7 Galapagos NV, Mechelen, Belgium 

5:45 pm 

1050. Response to Baricitinib at 4 Weeks Predicts 

Response at 12 and 24 Weeks in Patients with 

Rheumatoid Arthritis: Results from Two Phase 3 

Studies 

Joel Kremer 1 , Maxime Dougados 2 , Mark C. Genovese 3 , 

Paul Emery 4 , Lili Yang 5 , Stephanie de Bono 5 , Thorsten 

Holzkaemper 5 , Noriko Iikuni 5 , Douglas E. Schlichting 5 

and Josef S. Smolen 6 , 1 Center for Rheumatology, Albany 

Medical College, Albany, NY, 2 Service de Rhumatologie 

B, GHU Cochin, F-75014 France, PARIS, France, 

3 

Stanford University Medical Center, Palo Alto, CA, 

4 

University of Leeds, Leeds, United Kingdom, 5 Eli Lilly 

and Company, Indianapolis, IN, 6 Medical University of 

Vienna, Vienna, Austriaa 

West – 2010 

Sjögren’s Syndrome I: Basic Insights 

Moderator: Alan N. Baer, MD 

4:30 pm 

1051. Serum Calprotectin As Biomarker of Carotid 

Atherosclerosis in Patients with Primary Sjögre’s 

Syndrome 

Gabriela Moreira Balarini 1 , Eliana Zandonade 2 , leandro 

tanure 3 , gilda Aparecida ferreira 3 , Wildner Mardegan 



2 0 1 5 


tracker 

plus 

91 


Sardenberg 2 , Érica Vieira Serrano 2 , Cléia Coelho Dias 4 , 

Túlio Pinho Navarro 3 , João Felipe Tonini 2 , Hilde H 

Nordal 5 , Piotr Mydel 6 , Johan Gorgas Brun 7 , Karl Albert 

Brokstad 8 , Eva Gerdts 7 , Roland Jonsson 9 and Valeria 

Valim 2 , 1 Federal University of Espírito Santo (UFES), 

Brazil., cachoeiro de itapemirim, Brazil, 2 Federal 

University of Espírito Santo (UFES), Brazil., vitória, 

Brazil, 3 Federal University of Minas Gerais, Brazil., 

belo horizonte, Brazil, 4 Federal University of Espírito 

Santo (UFES), Brazil., vila velha, Brazil, 5 Broegelmann 

Research Laboratory/University of Bergen, Norway, 

bergen, Norway, 6 Broegelmann Research Laboratory, 

Bergen, Norway, 7 University of Bergen, Norway, 

bergen, Norway, 8 University of Bergen, Norway., 

bergen, Norway, 9 Broegelmann research laboratory, 

Bergen, Norway 

4:45 pm 

1052. Identification of Novel Sjogren’s Syndrome 

Risk Loci in the Regions of TNFAIP3 and PRDM1 

Christopher J. Lessard 1 , He Li 2 , John Ice 2 , Indra 

Adrianto 2 , Astrid Rasmussen 2 , Kiely Grundahl 3 , Jennifer 

A. Kelly 2 , Corinne Miceli 4 , Simon Bowman 5 , Susan 

Lester 6 , Johan G. Brun 7 , Lasse G. Goransson 8 , Erna 

Harboe 8 , Joel M. Guthridge 9 , Kenneth M. Kaufman 10 , 

Per Eriksson 11 , Maija-Leena Eloranta 12 , Marika 

Kvarnström 13 , Deborah S. Cunninghame-Graham 14 , 

A. Darise Farris 2 , Michael T. Brennan 15 , James 

Chodosh 16 , Raj Gopalakrishnan 17 , Andrew J.W. Huang 18 , 

Pamela Hughes 19 , David M. Lewis 1 , Lida Radfar 20 , 

Michael D. Rohrer 19 , Donald U. Stone 1 , Timothy J. 

Vyse 14 , Patrick M. Gaffney 2 , Judith A. James 1 , John B. 

Harley 21 , Roald Omdal 8 , Marie Wahren-Herlenius 13 , 

Gabor G. Illei 22 , Torsten Witte 23 , Roland Jonsson 24 , 

Maureen Rischmueller 25 , Lars Rönnblom 26 , Xavier 

Mariette 27 , Juan-Manuel Anaya 28 , Wan-Fai Ng 29 , Gunnel 

Nordmark 26 , Courtney G. Montgomery 2 , Nelson L. 

Rhodus 19 , Barbara M. Segal 30 , R. Hal Scofield 2 and Kathy 

L. Sivils 2 , 1 University of Oklahoma Health Sciences 

Center, Oklahoma City, OK, 2 Oklahoma Medical 

Research Foundation, Oklahoma City, OK, 3 Oklahoma 

Medical Research Foundation, Oklahoma CIty, OK, 

4 

Rheumatology, PARIS, France, 5 University Hospital 

Birmingham, Birmingham, United Kingdom, 6 Queen 

Elizabeth Hospital, Adelaide, Australia, 7 Haukeland 

University Hospital, Bergen, Norway, 8 Stavanger 

University Hospital, Stavanger, Norway, 9 Arthritis and 

Clinical Immunology Research Program, Oklahoma 

Medical Research Foundation, Oklahoma City, OK, 

10 

US Department of Veterans Affairs Medical Center, 

Cincinnati, OH, 11 Rheumatology/AIR, Linköping 

University, Linköping, Sweden, Linköping, Sweden, 

12 

Department of Medical Sciences, SciLife Lab, 

Rheumatology, Uppsala University, Uppsala, Sweden, 

Uppsala, Sweden, 13 Karolinska Institutet, Stockholm, 

Sweden, 14 King’s College London, London, United 

Kingdom, 15 Carolinas Medical Center, Charlotte, NC, 

16 

Massachusetts Eye and Ear Infirmary, Harvard 

Medical School, Boston, MA, 17 University of Minnesota, 

Minneapolis, MN, 18 Washington University, St Louis, 

MO, 19 University of Minnesota School of Dentistry, 

Minneapolis, MN, 20 University of Oklahoma Health 

Sciences Center College of Dentistry, Oklahoma City, 

OK, 21 Cincinnati Children’s Hospital Medical Center, 

Cincinnati, OH, 22 NIH, Bethesda, MD, 23 Hannover 

Medical School, Hanover, Germany, 24 University of 

Bergen, Bergen, Norway, 25 University of Adelaide, 

Adelaide, Australia, 26 Uppsala University, Uppsala, 

Sweden, 27 Université Paris-Sud, Paris, France, 

28 

Universidad del Rosario, Bogotá, Colombia, 

29 

Newcastle University, Newcastle upon Tyne, United 

Kingdom, 30 University of Minnesota Medical School, 

Minneapolis, MN 

5:00 pm 

1053. Phosphatidylinositol-3-Kinase Delta Pathway 

a Novel Therapeutic Target for Sjogren’s Syndrome 

Saba Nayar 1 , Joana Campos 1 , Christopher Buckley 1 , 

Rodger Allen 2 , W.A. Fahy 2 , Andrew Payne 2 and 

Francesca Barone 1 , 1 University of Birmingham, 

Rheumatology Research Group, Birmingham, United 

Kingdom, 2 UCB Pharma, Slough, United Kingdom 

5:15 pm 

1054. A Potential Role of Type III Interferon in the 

Glandular Involvement of Sjögren’s Syndrome 

Tania Mora, Felipe Alonso Masso Rojas, Araceli Paez, 

Mariana Patlan, Misael Gómez-Mondragón, Alberto 

Aranda-Frausto, Maya Chacón Pérez and Luis M. 

Amezcua-Guerra, National Institute of Cardiology, 

Mexico City, Mexico 


92 




5:30 pm 

1055. Expansions of Salivary Gland CD4 + T Cells 

from Sjögren’s Syndrome Patients: Single-Cell 

Repertoire Analysis and Correlation with Clinical 

Measures of Disease 

Michelle L. Joachims 1 , Kerry M. Leehan 2 , Christina M. 

Lawrence 1 , Astrid Rasmussen 1 , Lida Radfar 3 , David 

M. Lewis 2 , Glen D Houston 4 , Kiely Grundahl 1 , Donald 

U. Stone 5 , Kimberly Hefner 6 , R. Hal Scofield 1 , Kathy 

L. Sivils 2 , Linda F. Thompson 1 and A. Darise Farris 1 , 

1 

Oklahoma Medical Research Foundation, Oklahoma 

City, OK, 2 University of Oklahoma Health Sciences 

Center, Oklahoma City, OK, 3 University of Oklahoma 

Health Sciences Center College of Dentistry, Oklahoma 

City, OK, 4 Heartland Pathology, Oklahoma City, OK, 

5 

King Khaled Eye Specialist Hospital, Riyadh, Saudi 

Arabia, 6 Hefner Eye Care and Optical Center, Oklahoma 

City, OK 

5:45 pm 

1056. Aquaporin Gene Therapy Corrects Bone 

Morphogenetic Protein 6 Associated Exocrine Gland 

Dysfunction in Mouse Model of Sjögren’s Syndrome 

Hongen Yin 1 , Zhennan Lai 2 , Javier Cabrera-Perez 3 , 

Patricia Glenton 4 , Ankur Patel 5 , William Swaim 5 , 

Changyu Zheng 5 , Maria Guimaro 5 , Sandra Afione 6 , 

Cuong Nguyen 5 , Fred Nyberg 7 and John A. Chiorini 2 , 

1 

NIDCR, NIH, Bethesda, MD, 2 NIH/NIDCR, Bethesda, 

MD, 3 National Institute of Dental and Craniofacial 

Research, National Institutes of Health, Bethesda, 

Bethesda, MD, 4 University of Florida, Gaineville, 

FL, 5 National Institute of Dental and Craniofacial 

Research, National Institutes of Health, Bethesda, MD, 

6 

National Institute of Dental and Craniofacial Research, 

Bethesda, MD, 7 Uppsala University, Uppsala, Sweden 

West – 2018 


Clinical Aspects and Treatment: Clinical Aspects 

and CoMorbidities 

Moderators: Robert D. Inman, MD and Lianne S. 

Gensler, MD 

4:30 pm 

1057. Are Ankylosing Spondylitis, Psoriatic Arthritis 

and Undifferentiated Spondylarthritis Associated 

with an Increased Risk of Cardiovascular Disease? 

Karin Bengtsson 1 , Helena Forsblad-d’Elia 2 , Elisabeth 

Lie 1 , Eva Klingberg 1 , Mats Dehlin 1 , Sofia Exarchou 3 , 

Ulf Lindström 1 , Johan Askling 4 and Lennart TH 

Jacobsson 1 , 1 Department of Rheumatology and 

Inflammation Research, Sahlgrenska Academy, 

University of Gothenburg, Gothenburg, Sweden, 

2 

Departments of Public Health and Clinical Medicine, 

Rheumatology, Umeå University, Umeå, Sweden, 

3 

Section of Rheumatology, Department of Clinical 

Sciences, Malmö, Lund University, Malmö, Sweden, 

4 

Clinical Epidemiology Unit and Rheumatology 

Unit, Department of Medicine, Karolinska Institute, 


4:45 pm 

1058. Prevalence of Comorbidities in 

Spondyloarthritis and Evaluation of Their 

Monitoring: Results of the International Cross- 

Sectional ASAS-Comospa Study 

Anna Moltó 1 , Adrien Etcheto 1 , Désirée van der Heijde 2 , 

Robert B. M. Landewé 3 , Filip Van Den Bosch 4 , Maxime 

Dougados 5 and on behalf of the ASAS-COMOSPA 

task force, 1 Paris Descartes University, Rheumatology 

Department, Cochin Hospital, AP-HP. INSERM 

(U1153): Clinical Epidemiology and Biostatistics, PRES 

Sorbonne Paris-Cité,, Paris, France, 2 Department of 

Rheumatology, Leiden University Medical Center, 

Leiden, the Netherlands, Leiden, Netherlands, 

3 

Amsterdam Rheumatology Center, Amsterdam, the 

Netherlands, Amsterdam, Netherlands, 4 Univ Hosp, 

Ghent, Belgium, 5 Université Paris René Descartes and 

Hôpital Cochin, Paris, France 

5:00 pm 

1059. Increased Risk of Atrioventricular Block, 

Atrial Fibrillation and Pacemaker Implantation 

in Ankylosing Spondylitis, Undifferentiated 

Spondylarthritis and Psoriatic Arthritis Compared 

to the General Population 

Karin Bengtsson 1 , Helena Forsblad-d’Elia 2 , Elisabeth 

Lie 1 , Eva Klingberg 1 , Mats Dehlin 1 , Sofia Exarchou 3 , 

Ulf Lindström 1 , Johan Askling 4 and Lennart TH 

Jacobsson 1 , 1 Department of Rheumatology and 



2 0 1 5 


tracker 

plus 

93 


Inflammation Research, Sahlgrenska Academy, 

University of Gothenburg, Gothenburg, Sweden, 

2 

Departments of Public Health and Clinical Medicine, 


3 


Sciences, Malmö, Lund University, Malmö, Sweden, 

4 




5:15 pm 

1060. The View of Healthy Persons on the Impact 

of Spondyloarthritis on Functioning and Health: 

Results of a Best-Worst Scaling Based on the ASAS 

Health Index 

Ivette Essers 1 , Mickaël Hiligsmann 2 , Uta Kiltz 3 , Nick 

Bansback 4 , Juergen Braun 3 , Désirée van der Heijde 5 

and Annelies Boonen 1 , 1 Maastricht University Medical 

Center, Maastricht, Netherlands, 2 University of 

Maastricht, Maastricht, Netherlands, 3 Rheumazentrum 

Ruhrgebiet, Herne, Germany, 4 University of British 

Columbia, Vancouver, BC, 5 Leiden University Medical 

Center, Leiden, Netherlands 

5:30 pm 

1061. Patients with Fibromyalgia (FM) Do Not Fulfill 

Classification Criteria for Axial Spondyloarthritis 

(axSpA) but Patients with Axspa May Fulfill 

Classification Criteria for FM 

Xenofon Baraliakos 1 , Andrea Regel 1 , Uta Kiltz 1 , 

Hans-Jürgen Menne 2 , Friedrich Dybowski 3 , Manfred 

Igelmann 4 , Ludwig Kalthoff 3 , Dietmar Krause 5 , 

Ertan Saracbasi 1 , Elmar Schmitz-Bortz 6 and Jürgen 

Braun 1 , 1 Rheumazentrum Ruhrgebiet, Herne, 

Germany, 2 Rheumatology practice, Dortmund, 

Germany, 3 Private rheumatology office, Herne, 

Germany, 4 Private Rheumatology office, Bochum, 

Germany, 5 Internistische und rheumatologische 

Gemeinschaftspraxis, Gladbeck, Germany, 

6 

Rheumatology practice, Hattingen, Germany 

5:45 pm 

1062. Predictive Validity of the ASAS-Classification 

Criteria for Axial and Peripheral Spondyloarthritis - 

a Final Analysis 

Robert Landewé 1 , Alexandre Sepriano 2 , Martin 

Rudwaleit 3 , Joachim Sieper 3 , Désirée van der Heijde 4 

and on behalf of ASAS , 1 Amsterdam Rheumatology 

Center, Amsterdam, The Netherlands, Amsterdam, 

Netherlands, 2 Hospital de Egas Moniz - CHLO, 

Lisbon, Portugal, Lisbon, Portugal, 3 Charité - Campus 

Benjamin Franklin, Berlin, Germany, Berlin, Germany, 

4 



Netherlands 



Aspects and Treatment II: Patient-Reported 

Measures, Outcomes and Reporting 

Moderators: S. Sam Lim, MD, MPH and Meenakshi Jolly, 

MD, MS 

4:30 pm 

1063. Admissions and Readmissions of Patients 

with Systemic Lupus Erythematosus Is a Major 

Cause of Direct and Indirect Health Care Costs 

Allen P. Anandarajah 1 , Ugo Awa 2 , Christine Izzo 2 , 

Kate Burns 3 , Ummara Shah 4 , Jennifer H. Anolik 2 and 

Christopher T. Ritchlin 2 , 1 Univ of Rochester Medical Ctr, 

Rochester, NY, 2 University of Rochester Medical Center, 

Rochester, NY, 3 University of Rochester, Rochester, NY, 

4 

Strong Memorial Hospital, University of Rochester, 

Rochester, NY 

4:45 pm 

1064. Feasibility and Validity of Patient Reported 

Outcome Measurement Information System 

(PROMIS) in SLE 

Shanthini Kasturi, Jayme C. Burket, Jessica Berman, 

Kyriakos A. Kirou, Alana B. Levine, Lisa R. Sammaritano 

and Lisa Mandl, Hospital for Special Surgery, New York, 

NY 

5:00 pm 

1065. Atherosclerotic Vascular Events in a 

Multinational SLE Inception Cohort: Description 

and Predictive Risk Factors over a 15 Year Period 

Murray Urowitz 1 , Dafna Gladman 1 , Nicole Anderson 1 , 

Jiandong Su 1 and Systemic Lupus Erythematosus 

International Collaborating Clinics (SLICC), 1 University 

of Toronto, Toronto Western Hospital, Toronto, ON 


94 




5:15 pm 

1066. Temporal Trends and Outcomes of 

Acute Myocardial Infarction in Systemic Lupus 

Erythematosus Hospitalizations 

Narender Annapureddy 1 , Achint Patel 2 , Rabi Yacoub 2 , 

Krishna Pakanati 3 , Shiv Agarwal 4 , Priya Simoes 5 , Sunil 

Kamat 6 , Alexandre Benjo 7 and Girish Nadkarni 2 , 

1 

Vanderbilt University, Nashville, TN, 2 Icahn School 

of Medicine at Mount Sinai, New York, NY, 3 Gateway 

Medical Center, Clarksville, TN, 4 University of Arkansas 

Medical Sciences, Little Rock, AR, 5 St.Lukes Roosevelt 

Hospital Center at Mount Sinai, New York, NY, 

6 

Kokilaben Dhirubhai Ambani Hospital and Medical 

Research Institute, Mumbai, India, 7 Ochsner Clinic 

Foundation, New Orleans, NY 

5:30 pm 

1067. Sex Differences in Rates of End-Stage Renal 

Disease and Death Among Medicaid Patients with 

Incident Lupus Nephritis 

Anna R. Broder 1 , Candace H. Feldman 2 , Anand 

Kumthekar 3 , Michail Alevizos 4 , Hongshu Guan 5 , Medha 

Barbhaiya 6 and Karen Costenbader 7 , 1 Albert Einstein 

College of Medicine/Montefiore Medical Center, 

Bronx, NY, 2 Division of Rheumatology, Immunology 


Medical School, Boston, MA, 3 Albert Einstein College 

of Medicine/Jacobi Medical Center, Bronx, NY, 4 Albert 

Einstien College of Medicine/Jacobi Medical Center, 

Bronx, NY, 5 Brigham and Women’s Hospital, Boston, 

MA, 6 Weill Cornell Medical College, New York, NY, 

7 

Brigham & Women’s Hospital, Boston, MA 

5:45 pm 

1068. Assessment of 10-Year Risk of Myocardial 

Infarction or Stroke in SLE 

Michelle Petri 1 and Laurence S Magder 2 , 1 Johns 

Hopkins University School of Medicine, Baltimore, MD, 

2 

University of Maryland School of Medicine, Baltimore, 

MD 

North – 130 

Systemic Lupus Erythematosus – Human 

Etiology and Pathogenesis: Genetics, Gene 

Expression, and Epigenetics 

Moderators: Judith A. James, MD, PhD and Shu Man Fu, 

MD, PhD 

4:30 pm 

1069. Child’s HLA-DRB1 Genotype Increases 

Maternal Risk of Systemic Lupus Erythematosus: 

Results from the Mother-Child Immunogenetic 

Study in Autoimmunity 

Giovanna I. Cruz 1 , Xiaorong Shao 2 , Hong L. Quach 2 , 

Janelle Noble 3 , Nikolaos Patsopoulos 4 , Michael 

Busch 5 , Darrell Triulzi 6 , Wendy S.W. Wong 7 , Benjamin 

Solomon 7 , John Niederhuber 7 , Lindsey Criswell 8 and 

Lisa F. Barcellos 2 , 1 University of California, Berkeley, 

Berkeley, CA, 2 Genetic Epidemiology and Genomics 

Laboratory, University of California, Berkeley, Berkeley, 

CA, 3 Children’s Hospital Oakland Research Institute, 

Oakland, CA, 4 Harvard Medical School, Boston, MA, 

5 

Blood Systems Research Institute, San Francisco, 

CA, 6 University of Pittsburgh, Pittsburgh, PA, 7 Inova 

Translational Medicine Institute, Falls Church, VA, 

8 

Rosalind Russell / Ephraim P. Engleman Rheumatology 

Research Center, University of California, San 

Francisco, San Francisco, CA 

4:45 pm 

1070. CD 14(C-159T) Polymorphism and Soluble 

CD14 Are Associated with Increased Disease 

Activity and Nephritis in SLE 

Sarit sekhar Pattanaik 1 , Aditya kumar Panda 2 , Rashmi 

ranjan Sahoo 1 , Rina Tripathy 1 and Bidyut kumar Das 1 , 

1 

SCB Medical College, Cuttack, India, 2 Central University 

of Jharkand, Ranchi, India 

5:00 pm 

1071. Single-Cell RNA Sequencing of Human 

Podocytes, Endothelial Cells, and Tubular 

Cells Identifies Markers and Gene Profiles 

Differentiating Class IV and Class V Renal Disease in 

Lupus Nephritis 

Evan Der 1 , Kemal Akat 2 , Robert Clancy 3 , Beatrice 

Goilav 4 , Anna R. Broder 5 , H. Michael Belmont 6 , Peter 

M. Izmirly 7 , Nicole Jordan 8 , Tao Wang 1 , James Pullman 1 , 

Daniel Schwartz 1 , Ming Wu 3 , Thomas Tuschl 2 , Jill P. 

Buyon 3 and Chaim Putterman 1 , 1 Albert Einstein College 

of Medicine, Bronx, NY, 2 Rockefeller University, New 

York, NY, 3 New York University School of Medicine, New 

York, NY, 4 Children’s Hospital at Montefiore, Bronx, 

NY, 5 Albert Einstein College of Medicine/Montefiore 

Medical Center, Bronx, NY, 6 Hosp for Joint Disease, 



2 0 1 5 


tracker 

plus 

95 


New York, NY, 7 NYU School of Medicine, New York, NY, 

8 

Montefiore Medical Center, New York, NY 

5:15 pm 

1072. Baseline Gene Expression Profiles in 1760 

Patients from Two Phase III Trials of BAFF/BLyS 

Blockade in SLE 

Robert W Hoffman 1 , Joan T Merrill 2 , Marta E. Marta 

Alarcón Riquelme 3 , Michelle Petri 4 , Ernst R Dow 5 , Eric 

Nantz 1 , Laura K Nisenbaum 5 , Krista M Schroeder 1 , 

Wendy J Komocsar 1 , Narayanan B Perumal 5 , Matthew 

D Linnik 1 , Guilherme V Rocha 1 and Richard E Higgs 1 , 1 Eli 

Lilly and Company, Indianapolis, IN, 2 OMRF, Oklahoma, 

OK, 3 Oklahoma Medical Research Foundation, 

Oklahoma City, OK, 4 Johns Hopkins University School 

of Medicine, Baltimore, MD, 5 Eli Lilly and Company, 

Indiananpolis, IN 

5:30 pm 

1073. B Cell Subsets Are Epigenetically and 

Transcriptionally Dysregulated in Systemic Lupus 

Erythematosus 

Emily Blalock, Chris Scharer, Ben Barwick, Scott Jenks, 

Bridget Neary, Jeremy Boss and Ignacio Sanz, Emory 

University School of Medicine, Atlanta, GA 

5:45 pm 

1074. DNA Methylation Patterns in Naïve CD4+ 

T Cells Identify Epigenetic Susceptibility Loci for 

Malar Rash and Discoid Rash in Systemic Lupus 

Erythematosus 

Paul Renauer 1 , Patrick Coit 1 , Matlock A. Jeffries 2 , Joan 

T. Merrill 3 , W Joseph McCune 1 , Kathleen Maksimowicz- 

McKinnon 4 and Amr H. Sawalha 1 , 1 University of 

Michigan, Ann Arbor, MI, 2 University of Oklahoma 

Health Sciences Center, Oklahoma City, OK, 3 Oklahoma 


4 

Henry Ford Hospital, Detroit, MII 

West – 2001 

Systemic Sclerosis, Fibrosing Syndromes, and 

Raynaud’s – Clinical Aspects and Therapeutics 

I 

Moderators: Sindhu R. Johnson, MD, PhD and Laura K. 

Hummers, MD, ScM 

4:30 pm 

1075. The Scleroderma Lung Study II (SLS II) Shows 

That Both Oral Cyclophosphamide (CYC) and 

Mycophenolate Mofitil (MMF) Are Efficacious in 

Treating Progressive Interstitial Lung Disease (ILD) 

in Patients with Systemic Sclerosis (SSc) 

Philip J. Clements 1 , Donald Tashkin 1 , Michael Roth 1 , 

Dinesh Khanna 2 , Daniel E. Furst 3 , Chi-hong Tseng 1 , 

Elizabeth R. Volkmann 1 and Robert Elashoff 4 , 

1 

University of California Los Angeles, David Geffen 

School of Medicine, Los Angeles, CA, 2 University of 

Michigan, Ann Arbor, MI, 3 University of California, Los 

Angeles, David Geffen School of Medicine, Los Angeles, 

CA, 4 University of California Los Angeles, David Geffen 

School Of Medicine, Los Angeles, CA 

4:45 pm 

1076. Safety and Tolerability of Cyclophosphamide 

Versus Mycophenolate for Systemic Sclerosis- 

Related Interstitial Lung Disease 

Elizabeth R. Volkmann 1 , Michael Roth 2 , Robert Elashoff 3 , 

Philip J. Clements 1 , Daniel E. Furst 2 , Dinesh Khanna 4 , 

Jonathan Goldin 5 , Donald Tashkin 1 and Scleroderma 

Lung Study II Group, 1 University of California Los 

Angeles, David Geffen School of Medicine, Los Angeles, 

CA, 2 University of California, Los Angeles, David Geffen 

School of Medicine, Los Angeles, CA, 3 University of 

California, Los Angeles, Los Angeles, CA, 4 University 

of Michigan, Ann Arbor, MI, 5 David Geffen School of 

Medicine, University of California, Los Angeles, Los 

Angeles, CA 

5:00 pm 

1077. High Levels of CCL-18 Are Associated with 

Deterioration of Lung Function, Increased Annual 

Fibrosis Progression Rate and Decreased Survival in 

Systemic Sclerosis 

Anna-Maria Hoffmann-Vold 1 , Anders Heiervang 

Tennøe 1 , Oyvind Midtvedt 2 , Torhild Garen 3 , May Brit 

Lund 2 , Trond Mogens Aalokken 2 , Cathrine Brunborg 2 , 

Thor Ueland 1 and Øyvind Molberg 4 , 1 University of Oslo, 

Oslo, Norway, 2 Oslo University Hospital, Oslo, Norway, 

3 

Department of Rheumatology, Oslo University 

Hospital, Oslo, Norway, 4 Institute of Clinical Medicine, 

Oslo University Hospital, Oslo, Norway 


96 




5:15 pm 

1078. CXCL4 Does Not Predict Extent or Progression 

of Interstitial Lung Disease in Systemic Sclerosis 

Elizabeth R. Volkmann 1 , Donald P. Tashkin 1 , Michael 

Roth 1 , Chi-hong Tseng 1 , Holly LeClair 1 , Philip J. 

Clements 1 , Daniel E. Furst 2 , Maureen D Mayes 3 , Julio 

Charles 3 , Dinesh Khanna 4 , Robert Elashoff 5 , Shervin 

Assassi 6 and Scleroderma Lung Study II Group, 

1 

University of California Los Angeles, David Geffen 

School of Medicine, Los Angeles, CA, 2 University 


Medicine, Los Angeles, CA, 3 University of Texas - 

Houston Medical School, Houston, TX, 4 University of 

Michigan, Ann Arbor, MI, 5 University of California, Los 

Angeles, Los Angeles, CA, 6 University of Texas Medical 

School at Houston, Houston, TX 

5:30 pm 

1079. The Potential Effect on Recruitment of 

Restricting Skin Scores Eligibility Criteria in Early 

Diffuse Scleroderma Trials 

Robyn T. Domsic 1 , Dinesh Khanna 2 , Mary Lucas 3 , 

Virginia D. Steen 4 , Daniel E. Furst 5 , Robert Lafyatis 6 

and Thomas A. Medsger Jr. 1 , 1 University of Pittsburgh, 

Pittsburgh, PA, 2 Division of Rheumatology, University 

of Michigan, Ann Arbor, MI, 3 University of Pittsburgh 

Scleroderma Center, Pittsburgh, PA, 4 Georgetown 

University Medical Center, Washington, DC, 5 University 


Medicine, Los Angeles, CA, 6 Boston University School of 

Medicine, Boston, MA 

5:45 pm 

1080. Modified Rodnan Skin Score Thresholds for 

the Optimization of Cohort Enrichment in Clinical 

Trials in Skin Fibrosis in Patients with Diffuse 

Cutaneous Systemic Sclerosis 

Rucsandra Dobrota 1 , Britta Maurer 1 , Nicole Graf 2 , 

Suzana Jordan 3 , Carmen Marina Mihai 4 , Otylia 

Kowal-Bielecka 5 , Yannick Allanore 6 , Oliver Distler 1 

and EUSTAR co-authors, 1 Division of Rheumatology, 

University Hospital Zurich, Zurich, Switzerland, 2 graf 

biostatistics, Winterthur, Switzerland, 3 Department 

of Rheumatology, University Hospital Zurich, Zurich, 

Switzerland, 4 Cantacuzino Hospital, Carol Davila 

University of Medicine and Pharmacy, Bucharest, 

Romania, 5 Department of Rheumatology and Internal 

Medicine, Medical University of Bialystok, Bialystok, 

Poland, 6 Department of Rheumatology, University Paris 

Descartes and Cochin Hospital, Paris, France 

West – 2022 

Vasculitis I 

Moderators: Peter C. Grayson, MD and Philip Seo, MD 

4:30 pm 

1081. Administration of Patient Reported Outcome 

Measurement Information System (PROMIS) 

Instruments By Computer Adaptive Testing in 

Patients with Systemic Vasculitis 

Gunnar Tomasson 1 , John T. Farrar 2 , David 

Cuthbertson 3 , Carol McAlear 4 , Susan Asdown 5 , Don 

Gebhart 6 , Georgia Lanier 7 , Nataliya Milman 8 , Jacqueline 

Peck 9 , Joanna Robson 10 , Simon Carette 11 , Gary S. 

Hoffman 12 , Nader A. Khalidi 13 , Curry L. Koening 14 , Carol 

A. Langford 12 , Larry W. Moreland 15 , Paul A. Monach 16 , 

Christian Pagnoux 11 , Ulrich Specks 17 , Antoine G. 

Sreih 18 , Steven R. Ytterberg 17 and Peter A. Merkel 19 , 

1 

University of Iceland, Reykiavik, Iceland, 2 Universitiy 

of Pennsylvania, Philadelphia, PA, 3 University of South 

Florida, Tampa, FL, 4 The University of Pennsylvania, 

Philadelphia, PA, 5 NONE, Branbury, United Kingdom, 

6 

NONE, Columbus, OH, 7 NONE, Framingham, MA, 

8 

University of Ottawa, Ottawa, ON, 9 Oxford University, 

Oxford, United Kingdom, 10 University of Oxford, 

Oxford, United Kingdom, 11 Mount Sinai Hospital, 

Toronto, ON, 12 Cleveland Clinic, Cleveland, OH, 

13 

McMaster University, Hamilton, ON, 14 George E. 

Wahlen Department of Veterans Affairs Medical Center 

Salt Lake City and University of Utah, University of Utah 

School of Medicine, Salt Lake City, UT, 15 University of 

Pittsburgh, Pittsburgh, PA, 16 Boston University School 

of Medicine, Boston, MA, 17 Mayo Clinic College of 

Medicine, Rochester, MN, 18 Hospital of the University 

of Pennsylvania, Philadelphia, PA, 19 University of 

Pennsylvania, Philadelphia, PA 

4:45 pm 

1082. ANCA-Negative and Myeloperoxidase- 

ANCA-Positive Patients with Granulomatosis with 

Polyangiitis: Clinical Manifestations and Risk of 

Relapse 

Eli Miloslavsky 1 , Na Lu 2 , Sebastian Unizony 2 , Hyon K. 

Choi 2 , Peter A. Merkel 3 , Philip Seo 4 , Robert F. Spiera 5 , 



2 0 1 5 


tracker 

plus 

97 


Carol A. Langford 6 , Gary S. Hoffman 6 , Cees Kallenberg 7 , 

E. William St.Clair 8 , Nadia Tchao 9 , Fernando Fervenza 10 , 

Paul A. Monach 11 , Ulrich Specks 12 and John H. Stone 13 , 

1 

Massachusetts General Hospital, Boston, MA, 

2 

Massachusetts General Hospital, Harvard Medical 

School, Boston, MA, 3 University of Pennsylvania, 

Philadelphia, PA, 4 Johns Hopkins, Baltimore, MD, 

5 

Hospital for Special Surgery, New York, NY, 6 Cleveland 

Clinic, Cleveland, OH, 7 Univer Med Center Groningen, 

Groningen, Netherlands, 8 Duke University, Durham, 

NC, 9 ITN, San Francisco, CA, 10 Mayo Clinic, Rochester, 

MN, 11 Boston University School of Medicine, Boston, 

MA, 12 Mayo Clinic College of Medicine, Rochester, MN, 

13 

Massachusetts General Hospital Rheumatology Unit, 


5:00 pm 

1083. Nationwide Trends in Hospitalization and in- 

Hospital Mortality Associated with Granulomatosis 

with Polyangiitis (GPA) 

Zachary Wallace 1 , John H. Stone 2 , Hyon K. Choi 3 , 

Na Lu 3 , Sebastian Unizony 3 and Eli Miloslavsky 4 , 

1 

Massachusetts General Hospital, Boston, MA, 

2 

Massachusetts General Hospital Rheumatology Unit, 

Harvard Medical School, Boston, MA, 3 Massachusetts 

General Hospital, Harvard Medical School, Boston, MA, 

4 

Massachusetts General Hopsital, Boston, MA 

5:15 pm 

1084. Improved Survival in Granulomatosis with 

Polyangiitis: A General Population-Based Study 

Zachary Wallace 1 , Sebastian Unizony 2 , Na Lu 2 , Hyon 

K. Choi 2 and John H. Stone 3 , 1 Massachusetts General 

Hospital, Boston, MA, 2 Massachusetts General Hospital, 

Harvard Medical School, Boston, MA, 3 Massachusetts 

General Hospital Rheumatology Unit, Harvard Medical 


5:30 pm 

1085. Levamisole Triggers Neutrophil Extracellular 

Trap Formation through Muscarinic Receptors in 

Patients with Drug-Induced Vasculitis 

Peter C. Grayson 1 , Carmelo Carmona-Rivera 2 , 

Meryl Waldman 2 , Karran Phillips 3 , Venkataraman 

Subramaniam 4 , Paul Thompson 5 , Jonathan D. Graf 6 and 

Mariana J. Kaplan 1 , 1 National Institute of Arthritis and 

Musculoskeletal and Skin Diseases, National Institutes 

of Health, Bethesda, MD, 2 National Institutes of Health, 

Bethesda, MD, 3 National Institutes of Health, Baltimore, 

MD, 4 University of Massachusetts, Worcester, MA, 

5 

University of Masshachussetts, Worcester, MA, 

6 

Rosalind Russell / Ephraim P. Engleman Rheumatology 

Research Center, University of California, San 


5:45 pm 

1086. Does Adding Azathioprine to Glucocorticoid 

Induction Increase the Remission Rate and Prevent 

Relapses in Patients with Systemic Necrotizing 

Vasculitides without Poor-Prognosis Factors? a 

Multicenter, Double-Blind Randomized Controlled 

Trial 

Xavier Puéchal 1 , Christian Pagnoux 2 , Gabriel Baron 3 , 

Thomas Quémeneur 4 , Antoine Néel 5 , Christian Agard 5 , 

François Lifermann 6 , Eric Liozon 7 , Marc Ruivard 8 , 

Pascal Godmer 9 , Nicolas Limal 10 , Arsène Mékinian 11 , 

Thomas Papo 12 , Anne-Marie Ruppert 13 , Anne Bourgarit- 

Durand 14 , Boris Bienvenu 15 , Loïck Geffray 16 , Jean-Luc 

Saraux 17 , Elisabeth Diot 18 , Bruno Crestani 12 , Xavier 

Delbrel 19 , Laurent Sailler 20 , Pascal Cohen 1 , Véronique 

Le Guern 21 , Benjamin Terrier 1 , Matthieu Groh 21 , 

Claire Le Jeunne 21 , Luc Mouthon 21 , Philippe Ravaud 3 

and Loïc Guillevin for The French Vasculitis Study 

Group 21 , 1 National Referral Center for Rare Systemic 

Autoimmune Diseases, Hôpital Cochin, Paris, France, 

2 

Mount Sinai Hospital, Toronto, ON, 3 Hôpital Hôtel 

Dieu, Paris, France, 4 CH Valenciennes, Valenciennes, 

France, 5 CHU Nantes, Nantes, France, 6 CH Dax, 

Dax, France, 7 CHU Limoges, Limoges, France, 8 CHU 

Clermont-Ferrand, Clermont–Ferrand, France, 9 CH 

Vannes, Vannes, France, 10 CHU Créteil, Créteil, France, 

11 

Service de médecine interne. Hôpital Saint-Antoine., 

Paris, France, 12 CHU Bichat, Paris, France, 13 CHU Tenon, 

Paris, France, 14 CHU Bondy, Bondy, France, 15 Hospital 

Caen, Caen, France, 16 CH Lisieux, Lisieux, France, 

17 

CH Eaubonne, Eaubonne, France, 18 CHU Tours, 

Tours, France, 19 CH Pau, Pau, France, 20 CHU Toulouse, 

Toulouse, France, 21 National Referral Center for Rare 

Systemic Autoimmune Diseases, Hôpital Cochin, AP– 

HP, Université Paris Descartes, Paris, France 


98 





4:30 – 6:00 pm 











August 30. 

West – 3003 


Speaker: Doruk Erkan, MD 

West – 3005 

*022 – Controversies in Sjögren’s Syndrome 

Speaker: Frederick B Vivino, MD, MS 

West – 3007 

*023 – Fibromyalgia 2015: Update on 

Management PM PS E 

Speaker: Daniel J. Clauw, MD 

West – 3009 

024 – Hereditary Angioedema Update 

Speaker: Bruce L. Zuraw, MD 

West – 3011 

025 – Hypermobility 

Speaker: Eric Gall, MD 

West – 3016 

026 – Imaging of Crystal Arthritis 

Speaker: Ralf G. Thiele, MD, RhMSUS 

West – 3018 

*027 – Inflammatory Eye Disease/Uveitis 

Speaker: Debra Anne Goldstein, MD 

West – 3020 

028 – Pain: Evaluation and Treatment of Back 

Pain 

Speaker: Rajiv Dixit, MD 

West – 3022 

*029 – Pediatric Rheumatology for Adult 

Rheumatologists 

Speaker: Daniel Lovell, MD 

West – 3024 

030 – Systemic Lupus Erythematosus: Novel 

Treatments 

Speakers: Richard Furie, MD and Liz Lightstone, PhD 

ACR/ARHP COMBINED ABSTRACT 

SESSION 

4:30 – 6:00 pm 

West – 2004 

ACR/ARHP Combined Abstract Session: 

Rehabilitation 

Moderator: Nadine M. Fisher, EdD 

4:30 pm 

1087. “It Was Just My Right Pace”: A Qualitative 

Study Exploring Yoga Practice in Adults with 


Heather Greysen, University of California San 


4:45 pm 

1088. Effect of Training on Knee Torsional Stiffness 

and Its Relationship to Tibial Compressive and 

Anterior Shear Forces in Recreational Female 

Runners 

Bhushan Thakkar 1 and D. S. Blaise Williams III 2 , 

1 

VIRGINIA COMMONWEALTH UNIVERSITY, RICHMOND, 

VA, 2 Virginia Commonwealth University, Richmond, VA 

5:00 pm 

1089. Responsiveness of Physical Activity Measures 

Following Exercise Intervention in Individulas after 

Total Knee Arthroplasty 

Gustavo J. Almeida, James J. Irrgang and Sara R. Piva, 

University of Pittsburgh, Pittsburgh, PA 



2 0 1 5 


tracker 

plus 

99 


5:15 pm 

1090. Characteristics and Trajectories of Child 

Pain, Function, and Psychological Outcomes 

Associated with Conversion Disorder in Intensive 

Interdisciplinary Pediatric Pain Rehabilitation 

Cara Hoffart and Dustin Wallace, Children’s Mercy 

Hospital, Kansas City, MO 

5:30 pm 

1091. Effectiveness of Multidisciplinary Pain 

Rehabilitation Programs for Patients with 

Fibromyalgia Syndrome: A Systematic Review 

Niall Halliday 1 , Caroline Treanor 2 , Rose Galvin 3 and 

Jason Brooks 4 , 1 Queens University Belfast, Belfast, 

Northern Ireland, 2 Beaumont Hospital, Dublin, Ireland, 

3 

University of Limerick, Limerick, Ireland, 4 Queens 

University Belfast, Belfast, Ireland 

5:45 pm 

1092. Illicit Drug Use in US Adults with Chronic Low 

Back Pain: Nhanes 2009-2010 

Anna Shmagel 1 and Robert Foley 2 , 1 University 

of Minnesota Medical School, Minneapolis, MN, 

2 

University of Minnesota, Minneapolis, MN 

ARHP SESSIONS 

4:30 – 6:00 pm 

West – 2007 

Emotional Distress: Tips to Help Your Patients 

Moderator: Victoria Ruffing, RN 

4:30 pm 

Prevalence of and Reasons for Emotional Distress 

Susan J. Bartlett, PhD 

5:00 pm 

Emotional Distress: Tips to Help Your Patients 

Emma Dures, PhD 

5:30 pm 

Patients Seen and Skills Used in a Nurse Support 

Clinic 

Sarah Hewlett, MA, PhD, RN 

West – 2008 

Exercise After Total Knee Arthroplasty: 

Progressive Resistance PM PS E 

Moderator: Dina Jones, PT, PhD 

4:30 pm 

Are Total Knee Arthroplasty Exercise Trials Designed 

for Optimal Patient Outcomes? 

Marie Westby, PT, PhD 

5:00 pm 

How “Progressive” Are We? What Physical Therapy 

Records Show 

Carol Oatis, PT, PhD 

5:30 pm 

Making Exercise Work for Your Total Knee 

Arthroplasty Patients: Practical Progression Strategies 

Kimberly F. Kimpton, PT 

West – 2009 

Pediatric Lupus Transitional Care: An 

Interactive Experience PM Ed Pd PS PrM FIT 

Moderator: Thuy T. Beam, BSN, RN 

4:30 pm 

A Fly On the Wall: The Emerging Adult Perspective 

Dah Dah 

5:00 pm 

A Fly On the Wall: The Young Adult Perspective 

Kiana Johnson, PhD 

5:30 pm 

A Fly On the Wall: The Adolescent Perspective 

Breanna Vasquez 

West – 2006 

Vaccinations: Update and Controversies 


4:30 pm 

Use of Vaccination for Patients Receiving Biologic 

Therapies 

David A. Isenberg, MD 


100 




5:15 pm 

Current Anxiety and Confusion in Patient 

Understanding of Vaccination 

William Schaffner, MD 


4:30 – 6:00 pm 

West – 2000 

Annual Meeting Tweet Up 

It’s a great way to get connected and stay connected to 

the latest trends, research and ideas pulsing through the 

rheumatology community! 

INDUSTRY-SUPPORTED SYMPOSIA 

6:30 – 9:30 pm 

These symposia are both CME-accredited and non- 

CME company-directed programs. For CME-accredited 

symposia, the sponsoring organization is responsible for 

planning and providing CME credit. All non-CME programs 

are wholly sponsored and supported by commercial 

entities. Please visit the organization’s exhibit booth, the 

industry-supported symposia booth or download the 

ACR Annual Meeting App for more information on each 

symposium. 

ACR SESSIONS 

7:30 – 8:30 am 



Clinicopathologic Conference (CPC): Can’t 

Stomach the Diagnosis PM Ed Pd PS PrM PM Ed PM Ed FIT Pd PS Pd PS PrM PrM FIT FIT 

Moderator: David Daikh, MD and Gregory Gardner, MD 

Speaker: Andrew Gross, MD 


Maintenance Therapy in ANCA-associated 

Vasculitis: Evaluation and Treatment of 

Patients in Remission 

Moderators: Eli Miloslavsky, MD and Paul A. Monach, 

MD, PhD 

Speaker: Peter A. Merkel, MD, MPH 


Negative Regulation of Inflammation in 

Autoimmunity 

Moderators: Xavier Mariette, MD, PhD and J. Michelle 

Kahlenberg, MD, PhD 

Speaker: Averil Ma, MD 


Tips for Publishing Your Work in a Peer- 

Reviewed Medical Journal 


Moderators: Richard Bucala, MD, PhD and Marian T. 

Hannan, DSc, MPH 

7:30 am 

Publishing in Arthritis & Rheumatology 

Richard Bucala, MD, PhD 

7:50 am 

Publishing in Arthritis Care & Research 

Marian T. Hannan, DSc, MPH 

8:10 am 

Panel Discussion 

Robert Terkeltaub, MD and Karen Costenbader, MD, 

MPH 

West – 2018 

Wearable Biosensors to Advance Rheumatology 


7:30 am 

Wearable Biosensors and the Quantified Self 

Movement 

Brennan Spiegel, MD, MSHS, FACG, AGAF 



2 0 1 5 


tracker 

plus 

101 


8:00 am 

Applying Biosensors to Advance Clinical and Research 

Settings in Rheumatology 

Jeffrey R. Curtis, MD, MPH 

ARHP SESSIONS 

7:30 – 8:30 am 

West – 2007 

Analysis and Interpretation of 

Meta-Analyses 

Moderators: Kamil E. Barbour, PhD and Janet L. Poole, 

OTR, PhD 

Speaker: Nancy A. Baker, ScD, MPH, OTR/L 

West – 2006 

How Much and Who Said So? Evaluating 

Cost-of-Illness Studies 

Moderator: Kristina A. Theis, PhD 

7:30 am 

Building Blocks of a Cost-of-Illness Study: More Than 

Meets The Eye 

Nancy Neil, PhD 

7:50 am 

Reading Cost-of-Illness Studies: What To Look For And 

Why You Should Care 

Miriam G. Cisternas, MA 

8:10 am 


West – 2001 

Immunology Boot Camp II: Basic Mechanisms 

of Autoimmunity 



West – 2004 

New Therapeutics On the Horizon 


7:30 am 

New Therapeutic Approaches for Rheumatoid 

Arthritis and the Seronegative Spondyloarthropathies 

Mark C. Genovese, MD 

8:00 am 

New Therapeutic Approaches for Systemic Lupus 

Erythematosus and Systemic Sclerosis 

Jennifer M. Grossman, MD 


7:45 – 9:15 am 











August 30. 

West – 3003 

031 – Ankylosing Spondylitis: 2015 Update 

Speaker: Lianne S. Gensler, MD 

West – 3005 

032 – Challenging Cases in Osteoporosis 

Management 

Speaker: Jeffrey Lisse, MD 

West – 3007 

033 – Crystal: Diagnosis and Management 

of Gout PM PS E 

Speaker: Saima Chohan, MD 

West – 3009 

034 – Cutaneous Vasculitis 

Speaker: Ruth Ann Vleugels, MD, MPH 


102 



SUNDAY & MONDAY, NOVEMBER 8, 9, 2015 

West – 3011 

*035 – Dermatological Manifestations of 


Speaker: Laura Winterfield, MD, MPH 

West – 3016 

036 – Infections With Biologics 

Speaker: Kathryn H. Dao, MD 

West – 3018 


Digital Ischemia 

Speaker: Fredrick M. Wigley, MD 

West – 3020 

038 – Psoriatic Arthritis 

Speaker: Dafna D. Gladman, MD 

West – 3022 


Arthritis 

Speaker: Jeffrey D. Greenberg, MD, MPH 

West – 3024 

*040 – Systemic Lupus Erythematosus: Novel 

Treatments – How to Treat Systemic Lupus 

Erythematosus 

Speakers: Richard Furie, MD and Liz Lightstone, PhD 


7:45 – 9:45 am 











August 30. 

West – 3002 

*215 – Advanced Musculoskeletal Ultrasound: 

Image Optimization and Pathology Recognition 

Speakers: Jay B. Higgs, MD and Catherine Bakewell, MD 

West – 3004 

216 – Dermatopathology of Rheumatic Diseases 

Speaker: Daniel Miller, MD 

West – 3008 

*217 – Joint Injections (Knee, Ankle, Shoulder 

and Wrist) 

Speakers: Jemima Albayda, MD and Pari Basharat, MD 

West – 3006 

218 – Magnetic Resonance Imaging of 

Peripheral Joints in Rheumatology Practice 

Speakers: Philip G. Conaghan, MD, PhD and Mikkel 

Østergaard, MD, PhD, DMSc 

ACR SESSIONS 

8:30 – 10:00 am 


Genetics and Epigenetics in Osteoarthritis: 

Update 2015 

Moderators: Carla R. Scanzello, MD, PhD and Matlock A. 

Jeffries, MD 

8:30 am 

Overview of Genetics and Epigenetics in 

Osteoarthririts: Recent Advances 

Ana M. Valdes, PhD 

9:00 am 

Impact and Challenges of Large-scale Genetic and 

Epigenetic Studies in Osteoarthritis 

Timothy D. Spector, MD, MSc 

9:30 am 

Deoxyribonucleic Acid Methylation Dynamics in 

Osteoarthritic Cartilage 

Nidhi Bhutani, PhD 



2 0 1 5 


tracker 

plus 

103 



Nuts and Bolts of Macrophage Activation 

Syndrome Pediatrics 

Moderators: Bita Shakoory, MD and Randy Q. Cron, MD, 

PhD 

8:30 am 

Macrophage Activation Syndrome (MAS): Recognizing 

and Diagnosing the Adult Patient With MAS 

W. Winn Chatham, MD 

9:00 am 

Childhood Onset Macrophage Activation Syndrome 

(MAS): Applying the New Diagnostic Criteria to 

Evaluate Children With MAS With and Without 

Ongoing Biologic Therapy 

Alexei Grom, MD 

9:30 am 

Targeted Anti-cytokine Therapy for Macrophage 

Activation Syndrome (MAS) 

Edward M. Behrens, MD 

West – 2022 

RISE Registry: How Is It Impacting Patient Care? 

Moderator: Melissa Francisco, MBA 

8:30 am 

Overview of the RISE Registry 

Salahuddin Kazi, MD 

8:50 am 

Application of the RISE Registry in the Practice Setting 

Alan K. Matsumoto, MD 

9:10 am 

The Value of RISE Registry Data 

Jinoos Yazdany, MD, MPH 

ACR SESSIONS 

9:00 – 10:00 am 


Fatty Liver and the Rheumatology Patient 

Moderators: Kristine M. Lohr, MD, MS and Gregory 

Gardner, MD 

Speaker: Jacquelyn J Maher, MD 

North – 132 

How to Make Learning More Effective: New 

Insights into the Science of Learning and 

Application to Teaching PM Ed Pd PS PrM FIT 

Moderators: Eli Miloslavsky, MD and Juliet Aizer, MD, 

MPH 

Speaker: Keith Baker, MD, PhD 

West – 2000 

T cell-based Treatments: The Next Generation 

of Immunotherapies 

Moderators: Paul J. Utz, MD and Mehrdad Matloubian, 

MD, PhD 

Speaker: Jeffrey Bluestone, PhD 

ARHP SESSION 

9:00 – 10:00 am 

West – 2004 

ARHP Distinguished Lecturer: Reclaim 

Life! Celebrating 50 Years of Advances in 

Rheumatology Health Professional Practice 

PM PS E 


Speaker: Teresa J. Brady, PhD 

ACR/ARHP POSTER SESSION B AND 

POSTER TOURS 

8:30 am – 4:00 pm 


(abstracts # 1093-1993). Poster tours will be held 9:00 

– 9:45 am and 10:15 – 11:00 am. Morning snacks will be 

available at 10:00 am and 2:30 pm. 


104 





Thieves’ Market Posters 

Clinically Amyopathic Dermatomyositis (CADM) With 

Rapidly Progressive Interstitial Lung Disease (ILD) 

Asha Mariam Alex, MD 

Alkaptonuria – A Rare Autosomal Recessive Metabolic 

Disease 

Erin Bauer, MD 

Osseous Lymphovascular Proliferative Disorder 

Kimberly DeQuattro, MD, MM 

Paraneoplastic Rapidly Progressive Systemic Sclerosis 

Secondary to Extra-gonadal Seminoma 

Mohammadomid Edrissian, MD 

Disseminated Sarcoidosis 

Ritesh Kohli, MD 

Erdheim-Chester Disease with a BRAF V600E Mutation 

Matthew J. Koster, MD 

Sarcoidosis 

Megan L. Krause, MD 

Dystrophic Calcinosis in Overlap Syndrome (Systemic 

Sclerosis With Rheumatoid Arthritis) Treated With 

Leflunomide 

Sang-Yeob Lee, MD 























returned within 15 minutes of the end of the tour. Please 

check the annual meeting app for the most current poster 

tour titles. 

9:00 – 9:45 am 


Please check the annual meeting app for the most current 

poster tour titles. 

10:15 – 11:00 am 




EXHIBITS 

10:00 am – 5:00 pm 


Join your colleagues in the Exhibit Hall for morning 

and afternoon refreshments at 10:00 am and 2:30 pm. 


Exhibit Hall 






Theater A presentations will be held from 10:30 – 11:15 

am, 12:30 – 1:15 pm and 2:30 – 3:15 pm. Innovation Theater 

B presentations will be held from 11:30 am – 12:15 pm, 

1:30 – 2:15 pm and 3:30 – 4:15 pm. For a complete listing of 

Innovation Theater presentations, see page 193. 



2 0 1 5 


tracker 

plus 

105 



10:30 am – 12:30 pm 











August 30. 

West – 3008 

219 – Knee Braces, Foot Orthoses, and Shoe 

Gear for Managing Knee Osteoarthritis 

Speakers: Howard J. Hillstrom, PhD and Kelly D. Krohn, 

M.D. 

West – 3002 

220 – Musculoskeletal Ultrasound 

Speakers: Eugene Y. Kissin, MD and Amy M. Evangelisto, 

MD 

West – 3004 


Erythematosus and Vasculitis 

Speaker: Anthony Chang, MD 

West – 3006 

222 – X-ray Challenges in Rheumatic Diseases 

Speaker: Donald J. Flemming, MD 

ACR SESSIONS 

11:00 am – Noon 


ACR Knowledge Bowl: Final Round 

Moderator: Rebecca L. Manno, MD, MHS 


Regulatory Dendritic Cells in Inflammation 

Moderators: Cong-Qiu Chu, MD and Theresa Lu, MD, 

PhD 

Speaker: Elodie Segura, PhD 

North – 132 

What’s New in Localized Scleroderma: 

Viewpoints from a Dermatologist and 

Rheumatologist PM Ed Pd PS PrM FIT 

Moderators: Kathryn S. Torok, MD and Suzanne C. Li, 

MD, PhD 

11:00 am 

A Dermatologist’s Perspective of Localized 

Scleroderma (Morphea) 

Heidi Jacobe, MD 

11:30 am 

A Rheumatologist’s Perspective of Localized 

Scleroderma 

Francesco Zulian, MD 

ARHP SESSIONS 

11:00 am – Noon 

West – 2006 

ARHP Debate: Opiods for the Treatment of 

Chronic Non Cancer Pain… Use or Abuse? PM PS E 

PM PS E 

Moderators: David A. Williams, PhD and Christine A. 

Stamatos, DNP, ANP-C 

11:00 am 

Pro or Con 

Daniel J. Clauw, MD 

11:30 am 

Pro or Con 

John Markman, MD 

West – 2007 

Getting Patients Back to Work: Resources for 

Clinicians 

Moderator: Ross Wilkie, PhD 


106 




11:00 am 

Return to Work: Past and Future Implications for 

Clinicians 

Glenn Pransky, MD, MPH 

11:20 am 

Return to Work and Work Entry: What We Know From 

Research and Practice 

Julie J. Keysor, PhD, PT 

11:40 am 

Vocational Rehabilitation Contributions to Return to 

Work 

Alison Stewart, MA, RRP 

11:00 am 

To Cut or Not to Cut: Appropriateness Criteria for 

Arthroplasty 

Jeffrey N. Katz, MD, MSc 

11:30 am 

Unusual Complications in Arthoplasty for the 

Rheumatologist 

Michael Dohm, MD 

Noon 

Outcomes After Arthroplasty: Rheumatoid Arthritis 

vs. Osteoarthritis 

Lisa Mandl, MD, MPH 

West – 2009 

Keep It Compliant: Tools for Researchers 

Moderator: Donah Z. Crawford, BS, MA 

11:00 am 

Keep It Compliant – Part I 

Lisa M. Kastanek, RN, CCRC 

11:30 am 

Keep It Compliant – Part II 

Deborah McCloskey, BSN, RN 

West – 2008 

Psychosocial Components of Living with 

Psoriasis 

Moderator: Susan Chrostowski, DNP, ANP-C 

Speaker: Kristina Gorbatenko, PhD, LP 

ACR SESSION 

11:00 am – 12:30 pm 


All Things Arthroplasty: Outcomes and 

Complications PM PS E PM PS E 

Moderators: C.Kent Kwoh, MD; Raymond Scalettar, MD, 

DSc and Jasvinder A. Singh, MD, MPH 


11:00 am – 12:30 pm 


ACR Plenary Session II: Discovery 2015 

Moderators: Mary K. Crow, MD and Gregory Gardner, 

MD 

11:00 am 

1994. Electronic Patient Reported Outcome 

Measures in Systemic Lupus Erythematosus : 

A Potential Disease Modifying Impact on the 

Management of Disease Activity Flares and 

Damage Accrual 

Yasser M. El Miedany 1 , Sami Bahlas 2 , Maha El Gaafary 3 , 

Sally Youssef 4 and Ihab Ahmed 5 , 1 Darent Valley 

Hospital, Dartford, United Kingdom, 2 King Abdulaziz 

University, Jeddah, Saudi Arabia, 3 Ain Shams University, 

Abbassia, Egypt, 4 Ain Shams University, Cairo, Egypt, 

5 

Cairo University, Cairo, Egypt 

11:15 am 

1995. Does the Risk of Serious Infections Among 

Elderly RA Patients Differ By Age of Disease Onset? 

Sofia Pedro 1 , Ted R. Mikuls 2 and Kaleb Michaud 2 , 

1 

National Data Bank for Rheumatic Diseases, Wichita, 

KS, 2 University of Nebraska Medical Center, Omaha, NE 



2 0 1 5 


tracker 

plus 

107 


11:30 am 

1996. Complement Activation Predicts Adverse 

Pregnancy Outcome in Patients with SLE and/or 

aPL Antibodies 

Jane E. Salmon 1 , Mimi Kim 2 , Marta Guerra 1 , Elianna 

Kaplowitz 1 , Carl Laskin 3 , Michelle Petri 4 , Ware D. 

Branch 5 , Michael Lockshin 1 , Lisa R. Sammaritano 1 , Joan 

T. Merrill 6 , Mary D. Stephenson 7 , Munther Khamashta 8 , 

Alan M. Peaceman 9 , Anne Lynch 10 and Jill P. Buyon 11 , 

1 

Hospital for Special Surgery, New York, NY, 2 Albert 

Einstein Coll Med, Bronx, NY, 3 University of Toronto 

and LifeQuest Centre for Reproductive Medicine, 

Toronto, ON, 4 Johns Hopkins University School of 

Medicine, Baltimore, MD, 5 Intermountain Healthcare, 

Salt Lake City, UT, 6 Oklahoma Medical Research 

Foundation, Oklahoma City, OK, 7 University of Illinois 

College of Medicine, Chicago, IL, 8 Graham Hughes 

Lupus Research Laboratory, The Rayne Institute, 

St Thomas’ Hospital, London, United Kingdom, 

9 


Chicago, IL, 10 Colorado School of Public Health, Aurora, 

CO, 11 NYU School of Medicine, New York, NY 

11:45 am 

1997. Underuse of Methotrexate (MTX) in the 

Treatment of Rheumatoid Arthritis (RA) in the 

United States (US): Results of a Comprehensive 

Pharmaceutical Claims Analysis 

James R. O’Dell 1 , Melanie Rohr 1 , Stanley B. Cohen 2 , 

J Carter Thorne 3 and Ted R. Mikuls 1 , 1 University of 

Nebraska Medical Center, Omaha, NE, 2 Metroplex 

Clinical Research Center, Dallas, TX, 3 Southlake 

Regional Health Centre, Newmarket, ON 

12:00 pm 

1998. A National Electronic Health Record-Enabled 

Registry in Rheumatology: The ACR’s Rheumatology 

Informatics System for Effectiveness (RISE) 

Jinoos Yazdany 1 , Rachel Myslinski 2 , Melissa Francisco 3 , 

Nick Bansback 4 , Megan E. B. Clowse 5 , Deborah 

Collier 6 , Karen Law 7 , Katherine Liao 8 , Kaleb Michaud 9 , 

Esi Morgan-DeWitt 10 , Jim Oates 11 , Catalina Orozco 12 , 

Andreas Reimold 13 , Julia F Simard 14 and Salahuddin 

Kazi 12 , 1 University of California, San Francisco, San 

Francisco, CA, 2 Amer College of Rheumatology, Atlanta, 

GA, 3 American College of Rheumatology, Atlanta, 

GA, 4 The University of British Columbia, Vancouver, 

BC, 5 Duke University Medical Center, Durham, NC, 

6 


School, Boston, MA, 7 Emory University School of 

Medicine, Atlanta, GA, 8 Brigham & Women’s Hospital, 

Boston, MA, 9 University of Nebraska Medical Center 

and National Data Bank, Omaha, NE, 10 Cincinnati 


11 

Medical University of South Carolina, Charleston, 

SC, 12 Arthritis Consultation Ctr, Dallas, TX, 13 VAMC, 

University of Texas Southwestern Medical Center, 

Dallas, TX, 14 Stanford School of Medicine, Stanford, CA 

12:15 pm 

1999. Improvement in Mortality in RA Compared to 

the General Population - Closing the Mortality Gap 

Diane Lacaille 1 , Eric C. Sayre 1 and Michal 

Abrahamowicz 2 , 1 Arthritis Research Canada, Richmond, 

BC, 2 McGill University, Montreal, QC 


Noon – 2:00 pm 

Marriott Marquis – Yerba Buena 8 

ARHP Topic Round Tables: Networking Forum 

Sit down with your colleagues over a complimentary lunch, 

and participate in open discussion on various research, 

practice and clinical topics. Each roundtable discussion will 

be facilitated by a rheumatology expert. All ARHP attendees 

are welcome to participate in this event. This session is not 

eligible for CME credit. 

ACR SESSION 

12:30 – 2:00 pm 


CARE: MOC Sessions 2015 – Session 2 – 

Nonrheumatic and Systemic Diseases and 

Crystal-Induced Arthropathies 


12:30 pm 

Nonrheumatic and Systemic Diseases 

Simon M. Helfgott, MD 


108 




1:15 pm 

Crystal-Induced Arthropathies 

Hyon K. Choi, MD, DrPH 


12:45 – 2:15 pm 











August 30. 

West – 3003 


Speaker: Doruk Erkan, MD 

West – 3005 

042 – Biomechanical Interventions for 

Managing Orthoarthritis 

Speaker: Najia Shakoor, MD, MS 

West – 3007 

043 – Juvenile Dermatomyositis 

Speaker: Angela Robinson, MD, MPH 

West – 3009 

*044 – Myopathy: Issues in Diagnosis and 

Treatment 

Speaker: Rohit Aggarwal, MD, MS 

West – 2011 

*045 – Osteoarthritis: Update 2015 

Speaker: Timothy E. McAlindon, MD, MPH, MRCP 

West – 3016 


Speaker: Michael Weinblatt, MD 

West – 3018 

*047 – Systemic Lupus Erythematosus: Central 

Nervous System 

Speaker: Meggan C. Mackay, MD 

West – 3020 

*048 – Systemic Lupus Erythematosus: Lupus 

Nephritis 

Speaker: Rosalind Ramsey-Goldman, MD, DrPH 

West – 3022 

049 – Vaccinations for Patients on Biologic 

Therapies 

Speaker: Jeffery R. Curtis, MD, MPH 

West – 3024 

*050 – Vasculitis: Update 

Speaker: Raashid A. Luqmani, DM 

ACR SESSIONS 

1:00 – 2:00 pm 

West – 2000 

An Hour Well Spent: Successful Stories of 

Members Enhancing Patient Care Through State 

Advocacy 

Moderator: Gwenesta Melton, MD 

1:00 pm 

The Importance of Advocacy on the State Level 

Gary Feldman, MD 

1:20 pm 

An Advocate for Patients and Physicians 

Howard Blumstein, MD 

1:40 pm 

Addressing Healthcare Reform and Beyond Through 

State Advocacy 

Starla Tanner 



2 0 1 5 


tracker 

plus 

109 



Current State of the Art in Spondyloarthritides 

(SpA): Tough Questions Your SpA Patients Might 

Ask You 

Moderators: Shawn Slack, MD and Sindhu R. Johnson, 

MD PhD 

Speaker: Robert D Inman, MD 

West – 2001 

Pathways of Innate Immune System Activation 

by Nucleic Acid 

Moderators: Cong-Qiu Chu, MD and Timothy B. 

Niewold, MD 

Speaker: Glen N. Barber, PhD 


Rheumatology Research Foundation Oscar 

S. Gluck, MD, Memorial Lecture: Close to the 

Bone: Schnurri-3 – A Novel Gene that Remodels 

the Skeleton 

Moderator: Michael Maricic, MD 

Speaker: Laurie H. Glimcher, MD 

STUDY GROUPS 

1:00 – 2:00 pm 






West – 2011 

Building Research Infrastructure in 

Spondylarthropathy – Focus on Trainees and 

Junior Investigators 

Speakers: Katherine D. Wysham, MD; R. Eric Gracey; 

Maureen Dubreuil, MD and Liron Caplan, MD, PhD 

North – 132 

Capillaroscopy Study Group: Where Are We and 

Where Do We Want to Go? 

1:00 pm 

Can We Distinguish a Primary from Secondary 

Raynaud’s Phenomenon by Capillaroscopy? 

Vanessa Smith 

1:25 pm 

Can Capillaroscopy Predict Clinical Complications in 

Rheumatic Diseases? 

Maurizio Cutolo, MD 

1:50 pm 

Can Capillaroscopy Monitor Microcirculatory 

Therapies? 

Alberto Sulli, MD 

2:15 pm 

Active in Vivo Demonstration of Capillaroscopy 

Vanessa Smith 

West – 2004 

Giant Cell Arteritis Study Group 

Speakers: Bhaskar Dasgupta, MD and Eric L. Matteson, 

MD, MPH 

West – 2007 

Hypermobility Study Group 

Speakers: Jamie F. Bravo, MD and Rodney Graham, MD 

West – 3014 

Medication Adherence and Decision-Making in 

Lupus Study Group 

Speakers: Liana Fraenkel, MD, MPH; Jinoos Yazdany, 

MD, MPH and Lars Osterberg, MD, MPH 

West – 2018 

Myositis Study Group 

Moderators: Andrew Mammen, MD, PhD and Ira 

Targoff, MD 

Speakers: Neil J. McHugh, MD and Johan Rönnelid, MD, 

PhD 

West – 2008 

Osteoarthritis Study Group 

Speakers: Christopher B. Little, BSc, MSc, PhD and Philip 

G. Conaghan, MD, PhD 


110 




West – 2009 

Pediatric Rheumatology Imaging Study Group 

Speakers: Johannes Roth, MD; Xenofon Baraliakos, MD; 

Karen Rosendahl, MD, PhD and Clara Malattia, MD 

West – 2006 

Reproductive Issues in Rheumatology Patients 

Study Group 

Speakers: Bonnie Bermas, MD; Eliza Chakravarty, MD, 

MS; Christina D. Chambers, PhD, MPH; Megan E. B. 

Clowse, MD, MPH and Lisa R. Sammaritano, MD 

West – 2014 

Sjögren Syndrome Study Group 

Speakers: Natalie Porat Shliom, PhD; Thomas Mandl, 

MD, PhD and Tom Gordon, MD, PhD 

West – 2016 

Wellbeing in Rheumatic Diseases Study Group 

Speakers: Mary L. Jurisson, MD and Deborah Bowes, 

DPT, GCFT 


1:15 – 3:15 pm 











August 30. 

West – 3002 

*223 – Joint Injection Techniques 

Speakers: Atul A. Deodhar, MD and Kenneth S. 

O’Rourke, MD 

West – 3006 

224 – Muscle Involvement in Inflammatory 

Muscle Disease: How Muscle Biopsy Can Help 

Speaker: Sakir Humayun Gultekin, MD 

West – 3004 

225 – Synovial Fluid Analysis and Crystal 

Identification 

Speakers: Brian F. Mandell, MD, PhD; Lan Chen, MD, 

PhD and Gilda M. Clayburne, MLT 

West – 3008 

226 – The Rheumatologic Musculoskeletal 

Screening Exam, With Emphasis on Objective 

Disease-specific Measurements 

Speaker: Arthur M. Mandelin II, MD, PhD 

ACR SESSIONS 

2:30 – 3:30 pm 

West – 2000 

Demonstrating the Value of Rheumatology 

Within Various Payment Models for 

Practice 


Moderator: Neal Birnbaum, MD 

2:30 pm 

Payment Models for Practice 

Janet Coffman, PhD 

2:55 pm 

Rheumatology and Value-based Delivery 

Andrew Snyder, MD 


Immunology Update on Cytokine Signaling 

in Rheumatic Disease 


Moderator: Gary S. Firestein, MD 

Speaker: John J. O’Shea, MD 

ACR SESSIONS 

2:30 – 4:00 pm 


Curbside Consults: Ask the Professors 

Moderator: Zsuzsanna McMahan, MD 

2:30 pm 

Your Patient With Enthesitis and Dactylitis: Let’s Take 

a Closer Look 

M. Elaine Husni, MD, MPH 



2 0 1 5 


tracker 

plus 

111 


3:00 pm 

Calcinosis Associated With Dermatomyositis and 

Other Connective Tissue Diseases 

Lorinda Chung, MD, MS 

3:30 pm 

Paget’s Disease of Bone: Lessons Learned 

Margaret Seton, MD 


Evidence Based Assessment and Treatment 

Options for Interstitial Lung Disease in Patients 

with Systemic Sclerosis 

Moderators: Shervin Assassi, MD, MS and Daniel E. 

Furst, MD 

2:30 pm 

Diagnosis and Assessment of Systemic Sclerosis – 

Interstitial Lung Disease 

Aryeh Fischer, MD 

3:00 pm 

Effect and Safety of Immunoablation Followed by 

Autologous Stem Cell Transplantation on Interstitial 

Lung Disease in Systemic Sclerosis 

Keith Sullivan, MD 

3:30 pm 

Efficacy and Safety of Mycophenolate Mofetil for 

Treatment of Interstitial Lung Disease in Systemic 

Sclerosis 

Donald Tashkin, MD 


Tumor Necrosis Factor (TNF) and Beyond: The 

TNF-Tumor Necrosis Factor Receptor Cytokine 

Superfamily From Bench to Bedside 


Moderator: Patrick Gaffney, MD 

2:30 pm 

The Tumor Necrosis Factor Receptor Superfamily 

Ligand TNF-Like Ligand 1A: From Lymphocyte 

Costimulator to Disease Co-conspirator 

Richard Siegel, MD, PhD 

3:00 pm 

Tumor Necrosis Factor Receptor Superfamily 

Ligands that Costimulate T cells: Clinical Targets of 

Inflammatory Disease 

Michael Croft, PhD 

3:30 pm 

Seeing the LIGHT: The Promiscuous Nature of the 

Tumor Necrosis Factor Receptor Superfamily in 

Human Disease 

Sarah Hymowitz, PhD 

North – 132 

Where is the Money? Funding for Rheumatology 

Training and Research 

Moderator: Bruce N. Cronstein, MD 

2:30 pm 

The State of Funding for Rheumatology Research and 

Training 

S. Louis Bridges Jr., MD, PhD 

2:50 pm 

Advocating for Rheumatology Research and Training 

Funding 

William F. Harvey, MD, MSc 

3:10 pm 

Rheumatic Disease Research Funding Opportunities 

From Private Foundations 

Speaker to be Determined 

3:30 pm 

Resources Available to You Through the ACR 

S. Louis Bridges Jr., MD, PhD 


2:30 – 4:00 pm 

South – 300 

Antiphospholipid Syndrome: Recent Findings 

Moderators: Joyce Rauch, PhD and Roger A. Levy, MD 


112 




2:30 pm 

2000. Immune Response Against Â Î²2GPI Drives 

Th1 Inflammation in Atherosclerotic Plaques of 

Patients with Primary Antiphospholipid Syndrome 

Pier Luigi Meroni 1 , Marisa Benagiano 2 , Maria Gerosa 3 , 

Jacopo Romagnoli 4 , Michael Mahler 5 , Maria Orietta 

Borghi 6 , Alessia Grassi 2 , Chiara Della Bella 2 , Giacomo 

Emmi 2 , Amedeo Amedei 7 , Elena Silvestri 2 , Lorenzo 

Emmi 7 , Domenico Prisco 7 and Mario Milco D’Elios 7 , 

1 

Laboratory of Immuno-rheumatology, IRCCS 

Istituto Auxologico Italiano, Cusano Milanino, Italy, 

2 

Department of Experimental and Clinical Medicine, 

University of Florence, Florence, Italy, 3 Division of 

Rheumatology, Department of Clinical Sciences and 

Community Health, Ospedale Gaetano Pini, University 

of Milan, Milano, Italy, 4 Department of Surgery, Catholic 

University of Rome, Rome, Italy, 5 Inova Diagnostics, 

San Diego, CA, 6 Department of Clinical Sciences 

and Community Health, University of Milan, Milan, 

Italy, 7 Internal Interdisciplinary Medicine Center for 

Autoimmune Systemic Diseases, Lupus Clinic, AOU 

Careggi, Florence, Italy 

2:45 pm 

2001. Reduction of HLA Class II Expression and 

Beta-2-Glycoprotein I Presentation By Fluvastatin 

in Vitro and in Vivo: Possible Mechanism of Statin- 

Induced-Deprocoagulation in the Antiphospholipid 

Syndrome 

Toshiyuki Watanabe 1 , Kenji Oku 2 , Olga Amengual 2 , 

Ryo Hisada 2 , Kazumasa Ohmura 2 , Haruki Shida 2 , Yuka 

Shimizu 2 , Masaru Kato 2 , Toshiyuki Bohgaki 2 , Tetsuya 

Horita 2 , Shinsuke Yasuda 2 , Akihiro Ishizu 3 , Hisashi 

Arase 4 and Tatsuya Atsumi 2 , 1 Hokkaido P.W.F.A.C 

Obihiro-Kosei General Hospital, Obihiro, Japan, 

2 

Hokkaido University Graduate School of Medicine, 

Sapporo, Japan, 3 Hokkaido University, Sapporo, Japan, 

4 

WPI Immunology Frontier Research Center, Osaka 

University, Suita, Japan 

3:00 pm 

2002. Dnase Treatment Protects Against DVT 

Formation in a Mouse Model of Antiphospholipid 

Syndrome 

He Meng, Srilakshmi Yalavarthi, Levi F. Mazza, Megan 

A. Elfline, Catherine E. Luke, Peter K. Henke and Jason 

S. Knight, University of Michigan, Ann Arbor, MI 

3:15 pm 

2003. Primary Antiphospholipid Syndrome 

Is Characterized By Endothelial Progenitor 

Dysfunction and a Type I Interferon Signature 

Robert C. Grenn, Srilakshmi Yalavarthi, Paula L. 

Bockenstedt and Jason S. Knight, University of 

Michigan, Ann Arbor, MI 

3:30 pm 

2004. Procoagulant Property of a Novel Patient- 

Derived Autoimmune IgG Type Monoclonal 

Anticardiolipin Antibody That Binds to Beta 2 

Glycoprotein Domain I but Not to Total Beta 2 

Glycoprotein I Molecule 

Kenji Oku 1 , Yusaku Kanetsuka 1 , Olga Amengual 1 , 

Hiroyuki Nakamura 1 , Kazumasa Oomura 1 , Toshiyuki 

Bohgaki 1 , Tetsuya Horita 1 , Shinsuke Yasuda 1 , Bas 

deLaat 2 and Tatsuya Atsumi 1 , 1 Hokkaido University 

Graduate School of Medicine, Sapporo, Japan, 

2 

Maastricht University, Maastricht, Netherlands 

3:45 pm 

2005. Circulating Mirnas As Potential Disease 

Biomarkers in Antiphospholipid Syndrome Patients 

Carlos Perez-Sanchez 1 , Mihaela Diana Ivanoiu 1 , Maria 

Ángeles Aguirre Zamorano 1 , Patricia Ruiz-Limon 1 , 

Nuria Barbarroja 1 , Yolanda Jiménez Gómez 1 , Maria 

Carmen Abalos-Aguilera 1 , Rocio Gonzalez-Conejero 2 , 

Constantino Martinez 2 , Eduardo Collantes-Estevez 1 , 

Mª Jose Cuadrado 3 and Chary Lopez-Pedrera 1 , 1 IMIBIC- 

Reina Sofia University Hospital, Rheumatology Unit, 

Cordoba, Spain, 2 Regional Centre for Blood Donation, 

University of Murcia, Murcia, Spain, 3 The Rayne 

Institute, St Thomas’ Hospital, London, United Kingdom 

West – 2014 

Biology and Pathology of Bone and Joint: 

Ostearthritis Pathogenesis 

Moderators: Rik Lories, MD, PhD and Ru Liu-Bryan, PhD 

2:30 pm 

2006. Effect Size of the Anti-Aggrecanase-2 

Monoclonal Antibody CRB0017 in Rodent Models of 


Gianfranco Caselli 1 , Riccardo Chiusaroli 1 , Michela 

Visintin 2 , Marco Lanza 1 , Flora Ferrari 1 , Dario 

Tremolada 1 , Beatrice Barbetta 1 , Giampaolo Giacovelli 1 , 



2 0 1 5 


tracker 

plus 

113 


Albino Bonazzi 1 and Lucio Claudio Rovati 1 , 1 Rottapharm 

Biotech Srl, Monza, Italy, 2 Rottapharm Biotech Srl, 

Trieste, Italy 

2:45 pm 

2007. Discovery of an Intra-Articular Injection Small 

Molecule Inhibitor of the Wnt Pathway (SM04690) 

As a Potential Disease Modifying Treatment for 

Knee Osteoarthritis 

Charlene Barroga, Yong Hu, Vishal Deshmukh and John 

Hood, Samumed, San Diego, CA 

3:00 pm 

2008. WISP1 Aggravates Osteoarthritis By 

Modulation of TGF-Î²Â Signaling and Positive 

Regulation of Canonical Wnt Signaling 

Martijn van den Bosch 1 , Arjen Blom 1 , Azusa Maeda 2 , 

Tina Kilts 2 , Wim van den Berg 1 , Floris Lafeber 3 , Peter 

van Lent 1 , Marian Young 2 and Peter van der Kraan 1 , 

1 

Radboud university medical center, Nijmegen, 

Netherlands, 2 NIDCR/NIH, Bethesda, MD, 3 University 

Medical Center Utrecht, Utrecht, Netherlands 

3:15 pm 

2009. CC-Chemokine Receptor 7 (CCR7) Deficiency 

Reduces Early Structural and Functional Features 

of Disease in a Murine Model of Osteoarthritis 

Nisha Sambamurthy 1 , Vu Nguyen 1 , Patrick Diviney 2 , 

Justin Gan 3 , Charles Bush-Joseph 3 , Susanna 

Chubinskaya 3 , Anne-Marie Malfait 4 , George Dodge 1 

and Carla R. Scanzello 1 , 1 Philadelphia VA Medical 

Center, Philadelphia, PA, 2 University of Pennsylvania, 

Philadelphia, PA, 3 Rush University Medical Center, 

Chicago, IL, 4 Rush University Medeical Center, Chicago, 

IL 

3:30 pm 

2010. Adenosine A2A Receptor, but Not A2B 

Receptor, Deletion Leads to Development of 

Osteoarthritis (OA) in Mice and Administration of 

a Liposomal Suspension of Adenosine Prevents/ 

Treats Osteoarthritis in Rats 

Carmen Corciulo 1 , Matin Lendhey 1 , Austin Ramme 1 , 

Tuere Wilder 2 , Oran Kennedy 1 and Bruce Cronstein 3 , 

1 

NYU-School of Medicine, New York, NY, 2 NYU School of 

Medicine, New York, NY, 3 NYU School of Medicine, New 

York, NY 

3:45 pm 

2011. Disruption of the Molecular Clock in 

Mesenchymal Cells Causes an Osteoarthritis-like 

Disease in Mice 

Joerg Ermann and Antonios Aliprantis, Brigham and 

Women’s Hospital, Harvard Medical School, Boston, MA 


Cytokines, Mediators, Cell-cell Adhesion, Cell 

Trafficking and Angiogenesis II 

Moderators: Laurie Davis, PhD and Hendrik Schulze- 

Koops, MD, PhD 

2:30 pm 

2012. TNF Confers Pathogenic Memory in Synovial 

Fibroblasts Via Chromatin Remodeling, NF-Kb- 

Dependent Transcription and MAPK-Mediated 

mRNA Stabilization 

Konstantinos Loupasakis 1 , Christopher Sohn 2 , Lionel B. 

Ivashkiv 2 and George D. Kalliolias 2 , 1 Hospital for Special 

Surgery Weill Cornell Medical College, New York, NY, 

2 

Hospital for Special Surgery, New York, NY 

2:45 pm 

2013. TIARP Attenuates Autoantibody-Mediated 

Arthritis Via the Suppression of Neutrophil 

Infiltration into the Joint 

Asuka Inoue 1 , Isao Matsumoto 1 , Yuki Tanaka 1 , Naoto 

Umeda 1 , Hoshimi Kawaguchi 1 , Hiroshi Ebe 1 , Yoshihiro 

Matsumoto 2 and Takayuki Sumida 1 , 1 University of 

Tsukuba, Tsukuba, Japan, 2 Chugai Pharmaceutical Co., 

Ltd., Gotemba, Japan 

3:00 pm 

2014. Deficiency of IL-27 Exacerbate Sjögren’s 

Syndrome through Inhibiting Differentiation of 

Type 1 Regulatory T Cells 

Genhong Yao, Bingyu Shi, Jingjing Qi, Ying Wang, 

Weiwei Chen, Xiaojun Tang, Dandan Wang, Xuebing 

Feng and Lingyun Sun, The Affiliated Drum Tower 

Hospital of Nanjing University Medical School, Nanjing, 

China 

3:15 pm 

2015. Targeting Non-Canonical NF-Kappa B 

Signaling Inhibits Angiogenesis in a Novel 3D Model 

of Rheumatoid Arthritis Synovial Angiogenesis 

Chrissta X. Maracle 1 , Paulina Kucharzewska 2 , Boy 


114 




Helder 1 , Arjan W. Griffioen 3 , Henric K. Olsson 2 and 

Sander W. Tas 4 , 1 Amsterdam Rheumatology and 

immunology Center | Academic Medical Center, 

Amsterdam, Netherlands, 2 Astra Zeneca, Mölndal, 

Sweden, 3 Medical Oncology, VU University Medical 

Center, Amsterdam, Netherlands, 4 Amsterdam 

Rheumatology and immunology Center | Academic 

Medical Center/University of Amsterdam, Amsterdam, 

Netherlands 

3:30 pm 

2016. Functional Tertiary Lymphoid Structures 

within the Kidneys of Lupus Prone Mice Resembles 

Lymph Nodes in Gene Expression Profiling Analysis 

and Are Detected By in Vivo Imaging 

Premasany Kanapathippillai, Sayed Esmaeil Dorraji and 

Kristin A Fenton, UIT, The Artic University of Norway, 

Tromso, Norway 

3:45 pm 

2017. DNA Methylation Governs the Ability of 

Apoptotic Cells to Suppress Inflammatory Arthritis 

Via Reciprocal Regulation of IL-6 and TGF-Beta 

Clare Notley 1 , Christine Jordan 1 , Jenny McGovern 1 , Mark 

Brown 1 and Michael R. Ehrenstein 2 , 1 UCL, London, 

United Kingdom, 2 University College London, London, 


West – 2010 

Epidemiology and Public Health II: RA and 

Lifestyle Factors 

Moderator: Yvonne C. Lee, MD, MMSc 

2:30 pm 

2018. Sodium Chloride Consumption, 

Together with Smoking, Is Associated with ACPA 

Positivity 

Xia Jiang 1 , Björn Sundström 2 , Lars Alfredsson 1 , Lars 

Klareskog 3 , Solbritt Rantapaa-Dahlqvist 4 and Camilla 

Bengtsson 5 , 1 Karolinska Institutet, Stockholm, Sweden, 

2 

2. Department of Public Health and Clinical Medicine, 


3 

Karolinska University Hospital, Stockholm, Sweden, 

4 

Umeå University, Umeå, Sweden, 5 The Institute 

of Environmental Medicine, Karolinska Institutet, 


2:45 pm 

2019. Serum Biomarkers of Inflammatory 

Arthritis in First Degree Relatives of Patients with 

Rheumatoid Arthritis and Their Association with 

Lifestyle Risk Factors 

Jamie C Sergeant and RA-MAP Consortium, University 

of Manchester, Manchester, United Kingdom 

3:00 pm 

2020. Elevated BMI and ACPA Together Increase RA 

Risk and Independently Accelerate Time to RA 

Sara K. Tedeschi 1 , Jing Cui 1 , Elizabeth V. Arkema 2 , 

Jeffrey A. Sparks 1 , Elizabeth W. Karlson 1 and Karen 

Costenbader 1 , 1 Brigham & Women’s Hospital, Boston, 

MA, 2 Karolinska Institutet, Stockholm, Sweden 

3:15 pm 

2021. Omega-3 Fatty Acids Are Associated with a 

Lower Prevalence of Autoantibody Positivity in 

HLA-DR Shared Epitope Positive Subjects Who Are 

at Increased Risk for Future RA 

Ryan W. Gan 1 , M. Kristen Demoruelle 2 , Kevin D. Deane 3 , 

Michael H. Weisman 4 , Jane H. Buckner 5 , Peter K. 

Gregersen 6 , Ted R. Mikuls 7 , James R. O’Dell 7 , Richard 

M. Keating 8 , Tasha Fingerlin 9 , Gary O. Zerbe 10 , Michael 

J. Clare-Salzler 11 , V. Michael Holers 12 and Jill M. Norris 1 , 

1 

University of Colorado Denver, Aurora, CO, 2 University 

of Colorado School of Medicine, Aurora, CO, 3 U Colo 

Denver, Aurora, CO, 4 Cedars-Sinai Medical Center, Los 

Angeles, CA, 5 Benaroya Research Institute at Virginia 

Mason, Seattle, WA, 6 Feinstein Insititute for Medical 

Research, Manhasset, NY, 7 University of Nebraska 

Medical Center, Omaha, NE, 8 Scripps Health, La Jolla, 

CA, 9 National Jewish Health, Denver, CO, 10 Colorado 

School of Public Health / University of Colorado 

Anschutz Medical Campus, Aurora, CO, 11 University of 

Florida, College of Medicine, Gainesville, FL, 12 Univ of 

Colorado School of Med, Aurora, CO 

3:30 pm 

2022. Adherence to the Dietary Guidelines for 

Americans and Risk of Developing Rheumatoid 

Arthritis in Young and Middle-Aged Women 

Yang Hu 1 , Jeffrey A. Sparks 2 , Karen H. Costenbader 2 , 

Frank Hu 1 , Elizabeth W. Karlson 2 and Bing Lu 2 , 1 Harvard 

School of Public Health, Boston, MA, 2 Brigham and 




2 0 1 5 


tracker 

plus 

115 


3:45 pm 

2023. Breastfeeding, Oral Contraceptive and the 

Risk of Rheumatoid Arthritis: Results from the 

Swedish Epidemiological Investigation of RA Study 

Cecilia Orellana 1 , Lars Klareskog 2 , Lars Alfredsson 1 

and Camilla Bengtsson 1 , 1 Institute of Environmental 

Medicine, Stockholm, Sweden, 2 Department of 

Medicine, Karolinska University Hospital, Stockholm, 

Sweden 

West – 2018 

Imaging of Rheumatic Diseases II: MRI, PET and 

CT 

Moderators: Charles Peterfy, MD, PhD and Orrin M 

Troum, MD 

2:30 pm 

2024. Replacing Radiographic Sacroiliitis By 

Structural Lesions on MRI of the Sacroiliac Joints in 

Two Early Axial Spa Cohorts: What Is the Impact on 

the Classification of Patients According to the ASAS 

Axial Spa Criteria? 

Pauline Bakker 1 , Rosaline van den Berg 1 , Manouk de 

Hooge 2 , Zineb Ez-Zaitouni 3 , Miranda van Lunteren 3 , 

Karen M. Fagerli 4 , Roberta Ramonda 5 , Robert B. 

M. Landewé 6 , Maikel van Oosterhout 7 , Monique 

Reijnierse 1 , Floris van Gaalen 1 , Pascal Claudepierre 8 , 

Daniel Wendling 9 , Maxime Dougados 10 and Désirée 

van der Heijde 11 , 1 Leiden University Medical Center, 

Leiden, Netherlands, 2 Department of Rheumatology, 

Leiden University Medical Centre, Leiden, Netherlands, 

3 

Leiden University Medical Centre, Leiden, Netherlands, 

4 

Diakonhjemmet Hospital, Oslo, Norway, 5 University 

of Padua, Padova, Italy, 6 University Hospital 

Maastricht, Maastricht, Netherlands, 7 GHZ Hospital, 

Gouda, Netherlands, 8 Hôpital Henri Mondor, Créteil, 

France, 9 Université de Franche-Comté, Besançon, 

France, 10 Paris-Descartes University, Paris, France, 

11 



Netherlands 

2:45 pm 

2025. Modification of Structural Lesions on 

Magnetic Resonance Imaging By Etanercept: A 12- 

Week Randomized Placebo-Controlled Trial 

Walter Maksymowych 1 , Stephanie Wichuk 1 , Maxime 

Dougados 2 , Heather Jones 3 , Annette Szumski 3 , Lisa 

Marshall 3 , Jack F Bukowski 3 and Robert G Lambert 1 , 

1 

University of Alberta, Edmonton, AB, 2 Hôpital Cochin, 

Paris, France, 3 Pfizer, Collegeville, PA 

3:00 pm 

2026. A Novel Technique for Quantifying Synovial 

Enhancement of Temporomandibular Joints from 

Mris of Patients with Juvenile Idiopathic Arthritis 

Cory M. Resnick 1 , Pouya Vakilian 2 , Micheal Breen 3 , 

David Zurakowski 4 , Zachary S. Peacock 5 and Leonard 

B. Kaban 5 , 1 Boston Children’s Hospital, boston, MA, 

2 

Harvard School of Dental Medicine, Boston, MA, 

3 

Boston Children’s Hospital, Boston, MA, 4 Boston 

Children’s Hospital, Boston, MA, 5 Massachusetts 

General Hospital, Boston, MA 

3:15 pm 

2027. Development of a Dual Energy Computed 

Tomography Scoring System for Measurement of 

Urate Deposition in Gout 

Sara Bayat 1 , Opetaia Aati 2 , Juergen Rech 1 , Alexander 

Cavallaro 3 , Michael Lell 3 , Elizabeth Araujo 1 , Christina 

Petsch 1 , Lisa Stamp 4 , Georg A. Schett 1 , Bernhard 

Manger 1 and Nicola Dalbeth 2 , 1 University of Erlangen- 

Nuremberg, Erlangen, Germany, 2 University of 

Auckland, Auckland, New Zealand, 3 University of 

Erlangen-Nuremberg, Department of Radiology, 

Erlangen, Germany, 4 University of Otago, Christchurch, 

Christchurch, New Zealand 

3:30 pm 

2028. Contribution of 18 f-Fluoro-Dexoxyglucose 

Positron Emission Tomography for the Diagnosis of 

Polymyalgia Rheumatica: A Controlled Study 

Maxime Sondag 1 , Xavier Guillot 2 , Frank Verhoeven 2 , 

Clément Prati 3 , Hatem Boulahdour 1 and Daniel 

Wendling 4 , 1 University Teaching Hospital, Besançon, 

France, 2 Service de Rhumatologie, CHRU J Minjoz, 

Besançon, France, 3 CHU J Minjoz, Besancon, France, 

4 

Université de Franche-Comté, Besançon, France 

3:45 pm 

2029. Fever of Unknown Origin (FUO) and 

Inflammation of Unknown Origin (IUO): Is 18 f-FDG- 

PET/CT a Useful First Line Diagnostic Strategy? 

Verena Schönau, Kristin Vogel, Matthias Englbrecht, 


116 




Bernhard Manger, Daniela Schmidt, Torsten Kuwert 

and Georg Schett, University of Erlangen-Nuremberg, 

Erlangen, Germany 


Infection-related Rheumatic Disease 

Moderators: Jose U. Scher, MD and John Carter, MD 

2:30 pm 

2030. MRI Changes Associated with Neurological 

Compromise in Acute Pyogenic Vertebral 

Osteomyelitis: A Retrospective Study of 121 

Patients 

Géraldine Bart 1 , Herve Redon 2 , David Boutoille 1 , 

Olivier Hamel 1 , Yves Maugars 1 and Benoit Le Goff 1 , 

1 

Nantes University Hospital, Nantes, France, 2 Nouvelles 

cliniques nantaises, Nantes, France 

2:45 pm 

2031. Tuberculosis in Patients Treated with 

Biological Drugs 

Nadia Benzaquén 1 , Maria Haye Salinas 2 , Juan Pablo 

Pirola 1 , Laura mariela Encinas 2 , Francisco Caeiro 2 , 

Alejandro J. Alvarellos 2 , Maria Celina de la Vega Sr. 3 , 

Gustavo Casado 4 , Gimena Gomez Sr. 5 , Gustavo Citera 6 , 

Maria de los Angeles Gallardo 7 , Ana Quinteros 8 , 

Ida Elena Exeni 9 , María Alejandra Medina 10 , Pablo 

Astesana 11 , Carolina Sanchez Andia 12 , Graciela Gómez 13 , 

Amelia Granel 14 , Diana Dubinsky 15 , Ana Capuccio 16 , 

Alicia Eimon 5 , R. Quintana 17 , Bernardo Pons-Estel 18 , 

Eduardo Mussano 19 , Santiago Scarafia 20 , Mercedes 

Argentina García 21 , Mercedes De La Sota 22 , Karin 

Kirmayr 23 , Edson Javier Velozo 24 , Sergio Paira 25 , Ana 

M. Bertoli 26 , Cesar Caprarulo 27 , Santiago Aguero 28 , 

Cristina Battagliotti 29 , Sidney Soares de Souza 30 , 

Emilia Cavillion 31 , A. Perez Davila 32 , J. C. Barreira 33 , 

Maria Larroude 34 , Francisco Tamaño 35 , Alejandra 

Peluzzoni 36 and Veronica Saurit 2 , 1 Hospital Privado 

Centro Médico de Córdoba, Córdoba, Argentina, 

2 

Hospital Privado de Córdoba, Córdoba, Argentina, 

3 

Hospital Argerich, Buenos Aires, Argentina, 4 Hospital 

Militar Central, Buenos Aires, Argentina, 5 CEMIC, 

Buenos Aires, Argentina, 6 Consultorios Reumatológicos 

Pampa, Buenos Aires, Argentina, 7 Rheumatology 

Unit, Internal Medicine Service, Hospital Italiano de 

Buenos Aires, Instituto Universitario Hospital Italiano 

de Buenos Aires, and Fundacion PM Catoggio, Buenos 

Aires, Argentina, 8 Centro Integral De Reumatologia, 

Tucumán, Argentina, 9 SANATORIO PARQUE CORDOBA, 

CORDOBA, Argentina, 10 Hospital General de Agudos, 

Ciudad Autónoma de Buenos Aires, Argentina, 11 Unit 

of Rheumatology, Córdoba, Argentina, 12 Hospital 

Penna, CABA, Argentina, 13 Instituto de Investigaciones 

Medicas Alfredo Lanari, Buenos Aires, Argentina, 

14 

Hospital San Roque De Gonnet, Buenos Aires, 

Argentina, 15 Hospital de Clinicas, CABA, Argentina, 

16 

Hospital Cesar Milstein, CABA, Argentina, 17 Hospital 

Provincial, Rosario, Argentina, 18 Sanatorio Parque, 

Rosario, Argentina, 19 Servicio de Reumatología. 

Hospital Nacional de Clínicas. Facultad de Ciencias 

Médicas. Universidad Nacional de Córdoba, Córdoba, 

Argentina, 20 Hospital Bernardino Rivadavia, Buenos 

Aires, Argentina, 21 HIGA San Martín, La Plata, Argentina, 

22 

Reumatología, Bahia Blanca, Argentina, 23 Centro 

Bariloche, Río Negro, Argentina, 24 Sanatorio Adventista 

del Plata, Entre Rios, Argentina, 25 Hospital Jose Maria 

Cullen, Santa Fe, Argentina, 26 Clínica Universitaria Reina 

Fabiola, Córdoba, Argentina, 27 French Hospital, Buenos 

Aires, Argentina, 28 Sanatorio Pasteur, Catamarca, 

Argentina, 29 Hospital de Niños Dr Orlando Alasia, 

Santa Fé, Argentina, 30 Reumatología, Buenos Aires, 

Argentina, 31 Consultorio, Cordoba, Argentina, 32 Hospital 

Manuel Rocca, Ciudad Autonoma de Buenos Aires, 

Argentina, 33 Buenos Aires British Hospital, Buenos 

Aires, Argentina, 34 Tiempo, CABA, Argentina, 35 Atención 

Integral de Reumatología:, Capital Federal, Argentina, 

36 

Hospital Clínica José de San Martín, CABA, Argentina 

3:00 pm 

2032. Chaperonin Protein 14-3-3eta, Cyclic 

Citrullinated Peptide Antibody, and Rheumatoid 

Factor in the Differential Diagnosis of Chikungunya 

Arthritis Versus Rheumatoid Arthritis 

Olga S. Zhukov 1 , Rania W. Abolhosn 1 , Jonnielyn G. 

Rivera 1 , Mary Lape Nixon 2 , Robert J. Lagier 3 , Harry E. 

Prince 2 , Hollis J. Batterman 2 and Stanley J. Naides 1 , 

1 

Quest Diagnostics Nichols Institute, San Juan 

Capistrano, CA, 2 Quest Diagnostics Focus Clinical 

Reference Laboratory, San Juan Capistrano, CA, 3 Quest 

Diagnostics Alameda, Alameda, CA 



2 0 1 5 


tracker 

plus 

117 


3:15 pm 

2033. Clinical Manifestations Associated with 

Peripheral Joint Involvement in Patients with Acute 

Chikungunya Virus Infection 

Mariangelí Arroyo-Ávila, Amanda Cabán, Marisela 

Irizarry-Pérez, Hilda Torres, Enid J. García, Héctor 

Gorbea and Luis M. Vilá, University of Puerto Rico 

Medical Sciences Campus, San Juan, PR 

3:30 pm 

2034. Nontuberculous Mycobacterial Diseases Do 

Not Cause Positive Autoantibody Testing, Results 

from a Tertiary Pulmonary Care Center 

Barbara Goldstein, Jeffery J. Swigris, Shannon 

Kasperbauer, Pearlanne Zelarney and JoAnn Zell, 

National Jewish Health, Denver, CO 

3:45 pm 

2035. Clinical Characteristics and Outcomes of 

Polyarticular Septic Arthritis 

Sarah B. Lieber 1 , Clara Zhu 2 , Andrew Moore 3 , Mary 

Louise Fowler 2 , Robert H. Shmerling 1 and Ziv Paz 1 , 

1 

Beth Israel Deaconess Medical Center, Boston, MA, 

2 


3 

Cambridge Health Alliance, Harvard Medical School, 

Cambridge, MA 

West – 2011 

Miscellaneous Rheumatic and Inflammatory 

Diseases Oral Session II 

Moderators: Mehrdad Maz, MD and Loic Guillevin, MD 

2:30 pm 

2036. Infliximab Versus Adalimumab in Severe 

Uveitis: Multicenter Study from the French Uveitis 

Network 

Hélène Vallet 1 , Pascal Sève 2 , Lucie Biard 3 , Elodie 

Feurer 4 , Sophie Rivière 5 , Philip Bielfeld 6 , Laurent 

Perard 7 , Boris Bienvenu 8 , Sébastien Abad 9 , Aude 

Rigolet 10 , Alban Deroux 11 , Antoinette Perlat 12 , Damien 

Sène 13 , Isabelle Marie 14 , Emmanuel Heron 15 , Eric 

Hachulla 16 , Olivier Fain 17 , Gaëlle Clavel 18 , Jean Sibilia 19 , 

Nathalie Tieulié 20 , Yoland Schoindre 21 , Jean Baptiste 

Fraison 22 , Guillaume Moulis 23 , Thomas Papo 24 , Gilles 

Blaison 25 , Julie Gueudry 26 , Olivier Lidove 27 , Phuc LE 

Hoang 28 , Catherine Chapelon 29 , Mathieu Resche 

Regon 30 , Patrice Cacoub 13 , Bahram Bodaghi 28 and 

David Saadoun 31 , 1 DHU 2iB Internal Medicine Referal 

Center for Autoimmune diseases Pitie Hospital, Paris, 

France, 2 CHU Lyon, Lyon, France, 3 Saint-Louis Hospital, 

Paris, France, 4 Hôpital de la Croix Rousse, Lyon, France, 

5 

CHU de Montpellier, Montpellier Cedex 5, France, 

6 

CHU de Dijon, Dijon, France, 7 Hôpital Edouard Herriot, 

Lyon, France, 8 Hospital Caen, Caen, France, 9 Hôpital 

Avicenne, Bobigny, France, 10 Hôpital Pitié-Salpêtrière, 

Paris, France, 11 CHU Grenoble, Grenoble, France, 12 CHU 

de Rennes, Rennes, France, 13 Department of Internal 

Medicine, Pitié-Salpêtrière Hospital, Paris, France, 

14 

Service de médecine interne, CHU de Rouen, Rouen, 

France., Rouen, France, 15 Hôpital des XV-XX, Paris, 

France, 16 CHU Lille, Lille, France, 17 Hospital J. Verdier, 

Bondy, France, 18 Fondation Rothschild, Paris, France, 

19 

Hôpital de Hautepierre, Strasbourg, France, 20 CHU 

Nice, Nice, France, 21 Department de Internal Medicine 

and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP- 

PH, UPMC, Paris, France, 22 Hôpital Jean Verdier, Bondy, 

France, 23 CHU Purpan, Toulouse, France, 24 CHU Bichat, 

Paris, France, 25 Hopital de Colmar, Colmar, France, 

26 

CHU de Rouen, Rouen, France, 27 Bichat-Claude 

Bernard Hospital, University Paris-7, Paris, France, 

28 

Assistance Publique-Hôpitaux de Paris, Hôpital Pitié 

Salpétrière, Paris, France, 29 CHU Pitié-Salpêtrière, 

Paris, France, 30 biostatistics Saint Louis Hospital, paris, 

France, 31 Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ 

Paris 06, Paris, France 

2:45 pm 

2037. Rheumatic Manifestations May be the First 

Clinical Presentation of Arterial Calcification Due to 

CD73 Deficiency 

Kam Newman 1 , megha Sawhney 2 , James D. Katz 3 , 

richard siegel 4 , alessandra brofferio 5 and Manfred 

Boehm 6 , 1 National Institutes of Health, Bethesda, 

MD, 2 national institutes of health, Bethesda, MD, 

3 

The George Washington University, Washington, DC, 

4 

National Institute of Arthritis and Musculoskeletal 

and Skin Diseases, Bethesda, MD, 5 national institutes 

of health, Bethesda,, MD, 6 National Heart, Lung, and 

Blood Institute, National Institutes of Health, Bethesda, 

MD 


118 




3:00 pm 

2038. Adalimumab in Patients with Active, 

Noninfectious Uveitis Using High-Dose 

Corticosteroids 

Antoine P. Brezin 1 , Phillippe Kestelyn 2 , Joachim Van 

Calster 3 , Glenn J. Jaffe 4 , Jennifer E. Thorne 5 , David 

Scales 6 , Pablo Franco 7 , Andrew D. Dick 8 , Quan Dong 

Nguyen 9 , Eric B. Suhler 10 , Anne Camez 11 , Alexandra 

P. Song 12 , Martina Kron 11 , Samir Tari 12 , James T. 

Rosenbaum 13 and Arnd Heiligenhaus 14 , 1 Université 

Paris Descartes, Hôpital Cochin, Paris, France, 2 Ghent 

University Hospital, Ghent, Belgium, 3 University 

Hospitals Leuven, Leuven, Belgium, 4 Duke University, 

Durham, NC, 5 Johns Hopkins Medical Institute, 

Baltimore, MD, 6 University of Texas Health Science 

Center, San Antonio, TX, 7 Organización Médica de 

Investigación (OMI), Buenos Aires, Argentina, 8 National 

Institute for Health Research (NIHR) Biomedical 

Research Centre at Moorfields Eye Hospital, London, 

United Kingdom, 9 Truhlsen Eye Institute, University 

of Nebraska Medical Center, Omaha, NE, 10 VA 

Portland Health Care System, Portland, OR, 11 Abbvie 

Deutschland GmbH & Co KG, Ludwigshafen, Germany, 

12 

AbbVie Inc., North Chicago, IL, 13 Devers Eye Institute, 

Legacy Hospital system, Portland, OR, 14 Department 

of Ophthalmology at St. Franziskus Hospital Muenster, 

University of Duisberg-Essen, Muenster, Germany 

3:15 pm 

2039. Effect of Adalimumab on Visual Functioning 

(VFQ-25) in Visual-1 Trial Patients with Non- 

Anterior Non-Infectious Uveitis 

John Sheppard 1 , Avani D. Joshi 2 , Manish Mittal 2 , Keith 

Betts 3 , Samir Tari 2 , Yanjun Bao 2 and Andrew D Dick 4 , 

1 

Virginia Eye Consultants and Eastern Virginia Medical 

School, Norfolk, VA, 2 AbbVie Inc., North Chicago, IL, 

3 

Analysis Group, Inc., Boston, MA, 4 University of Bristol, 

Bristol Eye Hospital, Bristol, United Kingdom 

3:30 pm 

2040. T Follicular Helper like CD4 + CXCR5 + pd-1 + Cells 

and T Follicular Helper like Type 2 Cells Subsets Are 

Increased in IgG4-Related Disease Patients 

Aurélie Grados 1 , Mikael Ebbo 1 , Christelle Piperoglou 2 , 

Matthieu Groh 3 , Alexis Regent 4 , Maxime Samson 5 , 

Benjamin Terrier 6 , Nathalie Morel 7 , Sylvain Audia 5 , 

Francois Maurier 8 , Julie Graveleau 9 , Mohamed 

Hamidou 10 , Amandine Forestier 11 , Sylvain Palat 12 , 

Emanuelle Bernit 1 , Gilles Kaplanski 13 , Frederique 

Retornaz 14 , Bernard Bonotte 15 , Catherine Farnarier 16 , 

Jean-Robert Harle 17 , Nathalie Costedoat-Chalumeau 7 , 

Frederic Vely 18 and Nicolas Schleinitz 1 , 1 Aix-Marseille 

Université, AP-HM, Marseille, France, 2 CIML, AP-HM, 

Marseille, France, 3 National Referral Center for Rare 

Systemic Autoimmune Diseases, Hôpital Cochin, 

AP–HP, Université Paris Descartes, Paris, France, 

4 

Service de médecine interne, Hôpital Cochin, Paris, 

France, 5 Department of Internal Medicine and 

Clinical Immunology, Dijon University Hospital, Dijon, 

France, 6 National Referral Center for Rare Systemic 

Autoimmune Diseases, Hôpital Cochin, Paris, France, 

7 

Internal Medicine Department, Cochin Hospital, 

“René-Descartes Paris V” University, Paris, France, 

8 

Medecine Interne, Metz, France, 9 Medecine Interne 

Hotel Dieu Nantes, Nantes, France, 10 Nantes University 

Hospital, Nantes, France, 11 Groupe Hospitalier 

Mutualiste de Grenoble, Grenoble, France, 12 Service 

de Medecine Interne, CHU limoges, Limoges, France, 

13 

Aix-Marseille Université, Marseille, France, 14 Conseil 

General 13 cellule recherche, Marseille, France, 

15 

Department of Internal medicine and Clinicla 

Immunology Dijon University Hospital, Dijon, France, 

16 

Hopital de la Conception, Marseille, France, 17 Aix- 

Marseille Université, APHM, Marseille, France, 18 CIML, 

Laboratoire d’Immunologie Conception AP-HM, Aix- 

Marseille université, Marseille, France 

3:45 pm 

2041. Baseline Clinical and Laboratory Features 

of IgG4-Related Disease: Retrospective Japanese 

Multicenter Study of 333 Cases 

Kazunori Yamada 1 , Motohisa Yamamoto 2 , Takako 

Saeki 3 , Ichiro Mizushima 1 , Shoko Matsui 4 , Hiroki 

Takahashi 2 , Mitsuhiro Kawano 5 and Shigeyuki Kawa 6 , 

1 

Kanazawa University Hospital, Kanazawa, Japan, 

2 

Sapporo Medical University School of Medicine, 

Sapporo, Japan, 3 Nagaoka Red Cross Hospital, 

Nagaoka, Japan, 4 University of Toyama, Toyama, Japan, 

5 

Kanazawa University Graduate School of Medicine, 

Kanazawa, Japan, 6 Shinshu University, Matsumoto, 

Japan 



2 0 1 5 


tracker 

plus 

119 




Therapeutic Aspects II: Pediatric Systemic 

Lupus Erythematosus PM Ed Pd PS PrM FIT 

Moderators: Jennifer L. Huggins, MD and Natasha M. 

Ruth, MD, MS 

2:30 pm 

2042. Pancreatitis Subtypes Survey in 852 

Childhood-Onset Systemic Lupus Erythematosus 

Patients: A Multicenter Cohort 

Victor L Marques 1 , Natali W. Gormezano 1 , Eloisa 

Bonfá 1 , Nadia E Aikawa 2 , Maria Teresa Terreri 3 , Rosa 

M R Pereira 4 , Claudia Saad-Magalhães 5 , Andressa 

Guariento 6 , Simone Appenzeller 7 , Virgínia Ferriani 8 , 

Cássia M. Barbosa 9 , Valéria C. Ramos 10 , Simone 

Lotufo 11 and Clovis A Silva 2 , 1 Faculdade de Medicina 

da Universidade de São Paulo, São Paulo, Brazil, 

2 

Faculdade de Medicina da Universidade de São Paulo, 

Sao Paulo, Brazil, 3 Universidade Federal de Sao Paulo, 

São Paulo, Brazil, 4 Faculdade de Medicina da USP, 

São Paulo, Brazil, 5 Brazil, Brazil, Brazil, 6 Irmandade da 

Santa Casa de Misericórdia de São Paulo, São Paulo, 

Brazil, 7 Faculty of Medical Science, State University of 

Campinas, São Paulo, Brazil, 8 University of São Paulo 

(USP-RP), Ribeirão Preto, Brazil, 9 Hospital Infantil Darcy 

Vargas, São Paulo, Brazil, 10 Pontifical Catholic University 

of Sorocaba, São Paulo, Brazil, 11 Hospital Municipal 

Infantil Menino Jesus, São Paulo, Brazil 

2:45 pm 

2043. Cell-Bound Complement Activation Products 

Have High Sensitivity and Specificity in Childhood- 

Onset Systemic Lupus Erythematosus and Juvenile 


Anca Askanase 1 , Joyce Hui-Yuen 2 , John Conklin 3 , Derren 

Barken 4 , Tyler O’Malley 3 , Xiao Qing Li 2 , Liza Mariel 

Bermudez 2 , Andrew Eichenfield 5 , Amy J. Starr 2 , Lisa F. 

Imundo 2 and Thierry Dervieux 4 , 1 Columbia University 

College of Physicians & Surgeons, New York, NY, 

2 

Columbia University Medical Center, New York, NY, 

3 

Exagen Diagnostics, Vista, CA, 4 Exagen Diagnostics, 

Inc., Vista, CA, 5 Columbia University, New York, NY 

3:00 pm 

2044. Axonal Dysfunction in Childhood-Onset 

Systemic Lupus Erythematosus. Association with 

Neuropsychiatric Manifestations and Disease 

Activity 

Renan Frittoli 1 , Mariana Postal 1 , Karina Pelicari 1 , Nailu 

Sinicato 1 , Aline Tamires Lapa 2 , Fernando Peres 1 , 

Fernando Cendes 1 , Roberto Marini Sr. 3 , Gabriela 

Castellano 1 , Leticia Rittner 1 and Simone Appenzeller 1 , 

1 

State University of Campinas, Campinas, Brazil, 

2 

Fcm09-Baraogeraldo, Campinas, Brazil, 3 State 

University of Campinas, São Paulo, Brazil 

3:15 pm 

2045. Cross-Validation of the Pediatric Automated 

Neuropsychological Assessment Metrics- 

Cognitive Performance Scores in the Screening of 

Neurocognitive Impairment in Childhood-Onset 

Systemic Lupus Erythematosus 

Jasmine Nguyen 1 , Tricia Williams 2 , Earl Silverman 3 

and Deborah M. Levy 4 , 1 Royal College of Surgeons in 

Ireland, Dublin, Ireland, 2 Hospital for Sick Children, 

Toronto, ON, 3 Hospital for Sick Children and University 

of Toronto, Toronto, ON, 4 The Hospital for Sick 

Children, Toronto, ON 

3:30 pm 

2046. Long-Term Outcomes in Cardiac Neonatal 

Lupus and Associated Risk Factors for Morbidity 

Amit Saxena 1 , Peter M. Izmirly 1 , Sara Sahl 1 , Deborah 

Friedman 2 and Jill P. Buyon 1 , 1 New York University 

School of Medicine, New York, NY, 2 New York Medical 

College, Valhalla, NY 

3:45 pm 

2047. A Randomised Double-Blind Placebo- 

Controlled Trial of Vitamin D Supplementation in 

Juvenile-Onset Systemic Lupus Erythematosus: 

Effects on Microarchitecture Measured By HR-pQCT 

Glauce Lima, Juliane Paupitz, Nadia E Aikawa, Jackeline 

Couto Alvarenga, Eloisa Bonfá and Rosa M R Pereira, 

Faculdade de Medicina da Universidade de São Paulo, 

São Paulo, Brazil 


120 





Rheumatoid Arthritis – Clinical Aspects II: 

Infection, Malignancy and Other Comorbidites 

in RA 

Moderators: Lin Brown, MD and James Galloway, MD 

PhD 

2:30 pm 

2048. Hospitalization Trends of Rheumatoid 

Arthritis and Gout in the United States: A Crossroad 

Sian Yik Lim 1 , Na Lu 1 , Mark Fisher 1 , Amar Oza 1 , 

Sharan K. Rai 2 , Mariano E Menendez 1 and Hyon Choi 1 , 

1 


School, Boston, MA, 2 University of British Columbia, 

Vancouver, BC 

2:45 pm 

2049. Long Term Effectiveness of Herpes Zoster 

Vaccine Among Patients with Autoimmune and 

Inflammatory Diseases 

Huifeng Yun 1 , Fenglong Xie 1 , John Baddley 1 , Kevin L. 

Winthrop 2 , Lang Chen 3 and Jeffrey R. Curtis 1 , 1 University 

of Alabama at Birmingham, Birmingham, AL, 2 Oregon 

Health and Science University, Portland, OR, 3 University 

of Alabama at Bimingham, Birmingham, AL 

3:00 pm 

2050. Herpes Zoster during the Tofacitinib Clinical 

Development Program for RA: Characterization of 

Herpes Zoster Incidence and Evaluation of Whether 

Herpes Zoster Predicts Subsequent Serious 

Infections or Malignancy 

Kevin L. Winthrop 1 , Yoshiya Tanaka 2 , Kunihiro 

Yamaoka 3 , Jeffrey R. Curtis 4 , Chudy Nduaka 5 , Haiyun 

Fan 5 , Pinaki Biswas 6 , Tomohiro Hirose 7 , Sriram 

Krishnaswami 8 , Hernan Valdez 6 , Shigeyuki Toyoizumi 7 , 

Koshika Soma 8 and Connie Chen 6 , 1 Oregon Health 

& Science University, Portland, OR, 2 University of 

Occupational and Environmental Health, Kitakyushu, 

Japan, 3 Keio University, Tokyo, Japan, 4 University of 

Alabama at Birmingham, Birmingham, AL, 5 Pfizer Inc, 

Collegeville, PA, 6 Pfizer Inc, New York, NY, 7 Pfizer Japan 

Inc, Tokyo, Japan, 8 Pfizer Inc, Groton, CT 

3:15 pm 

2051. Risk for Lower Intestinal Perforations in RA 

Patients Treated with Tocilizumab in Comparison 

to Treatment with TNF Inhibitors, Rituximab, 

Abatacept or Conventional Synthetic Dmards 

Anja Strangfeld 1 , Adrian Richter 1 , Peter Herzer 2 , 

Karin Rockwitz 3 , Winfried Demary 4 , Martin Aringer 5 , 

Angela Zink 6 and Joachim Listing 7 , 1 German 

Rheumatism Research Center, Berlin, Germany, 

2 

Rheumatologist, Scientific Advisory Board, München, 

Germany, 3 Rheumatologic Practice, Goslar, Germany, 

4 

Rheumatologist, Hildesheim, Germany, 5 University 

Clinical Center, Technical University Dresden, Dresden, 

Germany, 6 Deutsches Rheuma-Forschungszentrum, 

Berlin, Germany, 7 DRFZ, Berlin, Germany 

3:30 pm 

2052. Lymphoma in Patients with Rheumatoid 

Arthritis Treated with Biologic Drugs: Long-Term 

Follow-up of Risks and Lymphoma Subtypes 

Karin Hellgren 1 , Christer Sundström 2 , Johan Askling 3 , 

Eva Baecklund 4 and on behalf of the ARTIS study 

group, 1 Clinical Epidemiology Unit and Rheumatology 

Unit, Department of Medicine, Karolinska Institute at 


2 

Department of Genetics and Pathology, Uppsala 

University, Uppsala, Sweden, 3 Clinical Epidemiology 

Unit and Rheumatology Unit, Department of 

Medicine, Karolinska Institute, Stockholm, Sweden, 

4 

Rheumatology, Department of Medical Sciences, 

University Hospital, Uppsala, Sweden 

3:45 pm 

2053. Adjustment of Skeletal Muscle Mass 

Estimates for the Extent of Adiposity Strengthens 

Relationships with Functional Outcomes in 


Joshua Baker 1 , Jon Giles 2 , Mary Leonard 3 , David 

Weber 4 , Jin Long 5 , Erik Jorgenson 1 and Patricia P. 

Katz 6 , 1 University of Pennsylvania, Philadelphia, PA, 

2 

Columbia University Medical Center, NY, NY, 3 Stanford 

University, Palo Alto, CA, 4 Rochester University, 

Rochester, NY, 5 Children’s Hospital of Philadelphia, 

Philadelphia, PA, 6 UCSF, SF, CA 



and Gene Therapy III: Biosimilars 

Moderators: Edward C. Keystone, MD and Sergio 

Schwartzman, MD 



2 0 1 5 


tracker 

plus 

121 


2:54 pm 

2048. Randomized, Double-Blind, Phase 3 

Study of Efficacy and Safety of ABP 501 Compared 

with Adalimumab in Subjects with Moderate to 

Severe Rheumatoid Arthritis 

Stanley B. Cohen 1 , Mark C. Genovese 2 , Ernest H. 

Choy 3 , Fernando Perez-Ruiz 4 , Jose L. Pablos 5 , Nan 

Zhang 6 and Primal Kaur 6 , 1 Metroplex Clinical Research 

Center, Dallas, TX, 2 Stanford University Medical 

Center, Palo Alto, CA, 3 Cardiff University, Institute of 

Infection and Immunity, Tenovus Building, University 

Hospital of Wales, Cardiff, United Kingdom, 4 Servicio 

de Reumatología, Vizcaya, Spain, 5 Instituto de 

Investigacion Hospital, Madrid, Spain, 6 Amgen, Inc., 

Thousand Oaks, CA 

2:45 pm 

2055. A Phase III, Randomized, Double-Blind Clinical 

Study Comparing SB4, an Etanercept Biosimilar, 

with Etanercept Reference Product (Enbrel ® ) in 

Patients with Moderate to Severe Rheumatoid 

Arthritis Despite Methotrexate Therapy (52-week 

Results) 

Jiri Vencovsky 1 , Anna Sylwestrzak 2 , Piotr Leszczyñski 3 , 

Wieslawa Porawska 4 , Asta Baranauskaite 5 , Vira 

Tseluyko 6 , Vyacheslav Zhdan 7 , Barbara Stasiuk 8 , Roma 

Milasiene 9 , Aaron Alejandro Barrera Rodriguez 10 , 

Soo Yeon Cheong 11 , Jeehoon Ghil 11 and Paul Emery 12 , 

1 

Institute of Rheumatology, Charles University, 

Prague, Czech Republic, 2 NZOZ Medica Pro Familia 

Sp. z o.o., Warsaw, Poland, 3 Poznan University of 

Medical Sciences, Poznan, Poland, 4 Poznanski Osrodek 

Medyczny NOVAMED, Poznan, Poland, 5 Lithuanian 

University of Health Sciences, Kaunas, Lithuania, 

6 

Kharkiv Medical Academy of Postgraduate Education, 

Kharkiv, Ukraine, 7 M.V.Sklifosovskyi Poltava Regional 

Clinical Hospital, Poltava, Ukraine, 8 Medicome Sp. z 

o.o., Oswiecim, Poland, 9 Klaipeda University Hospital, 

Klaipeda, Lithuania, 10 Unidad de Atención Medica e 

Investigación en Salud (UNAMIS), Yucatán, Mexico, 

11 

Samsung Bioepis Co., Ltd., Incheon, South Korea, 

12 

University of Leeds, Leeds, United Kingdom 

3:00 pm 

2056. A Randomized, Double-Blind, Phase III Study 

Comparing SB2, an Infliximab Biosimilar, to the 

Infliximab Reference Product (Remicade ® ) in 

Patients with Moderate to Severe Rheumatoid 

Arthritis Despite Methotrexate Therapy: 54-Week 

Results 

Jung-Yoon Choe 1 , Nenad Prodanovic 2 , Jaroslaw 

Niebrzydowski 3 , Ivan Staykov 4 , Eva Dokoupilova 5 , 

Asta Baranauskaite 6 , Roman Yatsyshyn 7 , Mevludin 

Mekic 8 , Wieslawa Porawska 9 , Hana Ciferska 10 , Krystyna 

Jedrychowicz-Rosiak 11 , Agnieszka Zielinska 12 , Jasmine 

Choi 13 , Young Hee Rho 13 and Josef S. Smolen 14 , 1 Daegu 

Catholic University Medical Center, Daegu, South 

Korea, 2 Clinical Center Banja Luka, Banja Luka, Bosnia, 

3 

Medica Pro Familia, Gdynia, Poland, 4 MHAT “Dr. 

Ivan Seliminski”, AD, Sliven, Bulgaria, 5 MEDICAL PLUS 

s.r.o, Uherske Hradiste, Czech Republic, 6 Lithuanian 

University of Health Sciences, Kaunas, Lithuania, 

7 

SHEI Ivano-Frankivsk NMU, Ivano-Frankivsk, Ukraine, 

8 

University Clinic Centre Sarajevo, Sarajevo, Bosnia, 

9 

Poznanski Osrodek Medyczny NOVAMED, Poznan, 

Poland, 10 Revmatologicky ustav, Praha 2, Czech 

Republic, 11 MCBK S.C., Grodzisk Mazowiecki, Poland, 

12 

Medica Pro Familia Sp. z o.o. Spolka Komandytowo- 

Akcyjna, Warszawa, Poland, 13 Samsung Bioepis Co., 

Ltd., Incheon, South Korea, 14 Medical University of 

Vienna, Vienna, Austria 

3:15 pm 

2057. Antibodies to Infliximab in Remicade-Treated 

Rheumatic Patients Show Identical Reactivity 

Towards Biosimilars 

Begoña Ruiz-Argüello 1 , Ainara Maguregui 1 , Ainhoa 

Ruiz del Agua 1 , Dora Pascual-Salcedo 2 , Ana Martínez 2 , 

Teresa Jurado 3 , Chamaida Plasencia 4 , Alejandro 

Balsa 5 , Francisca Llinares-Tello 6 , José Rosas 7 , Nerea 

Torres 1 , Antonio Martínez 1 and Daniel Nagore 1 , 

1 

Progenika-Grifols, Derio, Spain, 2 La Paz University 

Hospital-Immunology, Madrid, Spain, 3 La Paz 

University Hospital-Idipaz, Madrid, Spain, 4 La Paz 

University Hospital-Rheumatology, Madrid, Spain, 5 La 

Paz University Hospital-Rheumatology Department, 

Madrid, Spain, 6 Hospital Marina Baixa, Clinical Analysis, 

Villajoyosa, Spain, 7 Hospital Marina Baixa, Villajoyosa, 

Spain 

3:30 pm 

2058. Efficacy and Safety of Rituximab Biosimilar 

Candidate (CT-P10) and Innovator Rituximab in 

Patients with Rheumatoid Arthritis: Results from 


122 




Phase I Randomized Controlled Trial over 72 Weeks 

Dae-Hyun Yoo 1 , Won Park 2 , Chang-Hee Suh 3 , Seung- 

Cheol Shim 4 , Slawomir Jeka 5 , Fidencio Cons Molina 6 , 

Pawel Hrycaj 7 , Wolfgang Spieler 8 , Piotr Wiland 9 , 

Jan Brzezicki 10 , Eun Young Lee 11 , Francisco G. 

Medina-Rodriguez 12 , Pavel Shesternya 13 , Sebastiao 

Radominski 14 , Marina Stanislav 15 , Volodymyr 

Kovalenko 16 , Donghyuk Sheen 17 , Leysan Myasoutova 18 , 

Mie Jin Lim 19 , Jung-Yoon Choe 20 , Taek S. Kwon 21 

and Sang Joon Lee 21 , 1 Hanyang University Hospital 

for Rheumatic Diseases, Seoul, South Korea, 2 Inha 

University Hospital, Incheon, South Korea, 3 Ajou 

University Hospital, Suwon, South Korea, 4 Chungnam 

National University Hospital, Daejeon, South Korea, 

5 

Clinic of Rheumatology and Connective Tissue 

Diseases, Bydgoszcz, Poland, 6 Centro de Investigacion 

en Artritis y Osteoporosis, Mexicali, Mexico, 7 Poznan 

University of Medical Sciences, Poznan, Poland, 8 ZeFOR 

GmbH Zentrum für Forschung, Zerbst, Germany, 

9 

Medical University of Wroclaw, Wroclaw, Poland, 

10 

Wojewodzki Szpital Zespolony w Elablagu, Elblag, 

Poland, 11 Seoul National University College of Medicine, 

Seoul, South Korea, 12 LaSalle University, Mexico 

City, Mexico, 13 Krasnoyarsk State Medical University, 

Krasnoyarsk, Russia, 14 Universidade Federal do Parana, 

Curitiba, Brazil, 15 Research Rheumatology Institute n. a. 

V.A. Nassonova, Moscow, Russia, 16 National Scientific 

Center, Kiev, Ukraine, 17 Eulji University Hospital, 

Daejeon, South Korea, 18 Research Medical Complex 

Vashe Zdorovie, Kazan, Russia, 19 Inha University 

Hospital, Incheion, South Korea, 20 Catholic University 

of Daegu, School of Medicine, Daegu, South Korea, 

21 

CELLTRION, Inc., Incheon, South Korea 

3:45 pm 

2059. Tumor Necrosis Factor Inhibitor Tapering 

Induced Radiographic Progression Is Driven By 

Weighted Mean Disease Activity over Time, Not 

Flaring or Lower TNFi Exposition 

Alfons A. den Broeder 1 , Chantal A.M. Bouman 1 , Aatke 

van der Maas 1 , Frank H.J. van den Hoogen 1 , Noortje van 

Herwaarden 1 and R. Landewe 2 , 1 Sint Maartenskliniek, 

Nijmegen, Netherlands, 2 University Hospital Maastricht, 

Maastricht, Netherlands 

West – 2022 


Clinical Aspects and Treatment: Clinical Aspects 

Moderators: John D. Reveille, MD and Jürgen Braun, MD 

2:30 pm 

2060. Microscopic Bowel Inflammation in 

Spondyloarthritis As a Baseline Predictor of Anti- 

TNF Response 

Heleen Cypers, Gaëlle Varkas, Filip van den Bosch and 

Dirk Elewaut, Ghent University Hospital, VIB, Ghent, 

Belgium 

2:45 pm 

2061. Uncovering Crohn’s Disease in Patients 

with Spondyloarthropathies Using Videocapsule 

Endoscopy 

Uri Kopylov 1 , Craig Watts 2 , Michael Starr 3 , Serge 

Dionne 1 , Jamie Koenekoop 1 and Ernest Seidman 1 , 

1 

Research Institute of the McGill University Health 

Centre, Montreal, QC, 2 McGill University and Montreal 

General Hospital, Sainte-Anne-de-Bellevue, QC, 3 McGill 

University, Montreal, QC 

3:00 pm 

2062. How Reliable Is Self-Evaluation of Symptoms 

of Inflammatory Back Pain By Patients? 

Denis Poddubnyy 1 , Inge Spiller 1 , Joachim Sieper 1 

and Martin Rudwaleit 2 , 1 Charité Universitätsmedizin 

Berlin, Berlin, Germany, 2 Klinikum Bielefeld, Bielefeld, 

Germany 

3:15 pm 

2063. The Survival Impact of Statins in Psoriasis 

and Psoriatic Arthritis: A General Population-Based 

Cohort Study 

Sian Yik Lim, Na Lu and Hyon K. Choi, Massachusetts 

General Hospital, Harvard Medical School, Boston, MA 

3:64 pm 

2058. Increase in IL-31 Serum Level in Recent Onset 

Spondyloarthritis - Data from the DESIR Cohort 

Nicolas Rosine Jr. 1 , Adrien Etcheto 2 , Anna Moltó 3 , 

Yassine Taoufik 4 , Houria Chavez 4 , Christian Roux 5 , 

Karine Briot 5 , Maxime Dougados 6 and Corinne 

Miceli 5 , 1 Rheumatology Department, Hôpital Kremlin 

Bicêtre, Paris, France, 2 Rheumatology B Department, 



2 0 1 5 


tracker 

plus 

123 


Paris-Descartes University, Cochin Hospital, Paris, 

France, 3 Paris Descartes University, Rheumatology 

Department, Cochin Hospital, AP-HP. INSERM 

(U1153): Clinical Epidemiology and Biostatistics, PRES 

Sorbonne Paris-Cité,, Paris, France, 4 Hopital Bicetre, 

Université Paris Sud, AP-HP, Kremlin Bicetre, France, 

5 

Rheumatology B Department, Hôpital Cochin, Paris, 

France, 6 Paris-Descartes University, APHP, Cochin 

Hospital, Paris, France 

3:45 pm 

2065. Verification of Novel Soluble Biomarkers That 

Differentiate Patients with Psoriatic Arthritis from 

Those with Psoriasis without Psoriatic Arthritis 

Vinod Chandran 1 , Daniela Cretu 2 , Lisa Gao 3 , Kun Liang 3 , 

Antoninus Soosaipillai 4 and Eleftherios Diamandis 5 , 

1 


Toronto, ON, 2 Department of Laboratory Medicine 

and Pathobiology, University of Toronto, Toronto, 

ON, 3 Department of Statistics and Actuarial Science, 

University of Waterloo, Waterloo, ON, 4 Department 

of Pathology and Laboratory Medicine, Mount Sinai 

Hospital, Toronto, ON, 5 Department of Clinical 

Biochemistry, University Health Network, Toronto, ON 

West – 2001 


Aspects and Treatment III: Biomarkers 

Moderators: Maureen A. McMahon, MD and Maria 

Dall’Era, MD 

2:30 pm 

2066. Elevated Innate, Adaptive, and TNF- 

Superfamily Soluble Inflammatory Mediators 

Mark Impending Disease Flare, While Regulatory 

Mediators Distinguish Lack of Impending Disease 

Flare in African-American SLE Patients with Active 

Disease 

Melissa E. Munroe 1 , Evan G. Vista 2 , Joan T. Merrill 1 , Joel 

M. Guthridge 1 , Virginia C. Roberts 1 and Judith A. James 3 , 

1 


City, OK, 2 University of Santo Tomas, Taguig City, 

Philippines, 3 University of Oklahoma Health Sciences 

Center and Oklahoma Medical Research Foundation, 

Oklahoma City, OK 

2:45 pm 

2067. De-Convolution of Whole Blood 

Transcriptomic Data from a Phase IIb, Randomized, 

Double-Blind, Placebo-Controlled Trial of Abatacept 

in Systemic Lupus Erythematosus 

S Bandyopadhyay 1 , SE Connolly 1 , O Jabado 1 , S Kelly 1 , 

M Maldonado 1 , R Westhovens 2 , P Nash 3 , JT Merrill 4 

and R Townsend 1 , 1 Bristol-Myers Squibb, Princeton, 

NJ, 2 University Hospitals KU Leuven, Leuven, Belgium, 

3 

University of Queensland, Brisbane, Australia, 

4 


City, OK 

3:00 pm 

2068. Low Complement Is Associated with SLE 

Classification Criteria and Organ Damage 

Laura Durcan 1 , Wei Fu 2 and Michelle Petri 1 , 1 Johns 

Hopkins University Hospital, Baltimore, MD, 2 Johns 

Hopkins University School of Medicine, Baltimore, MD 

3:15 pm 

2029. High Interferon Gene Signature Is 

Associated with Increased Disease Activity, 

Reduced Complement C3 and C4, and Increased 

Oral Corticosteroid Use in Systemic Lupus 

Erythematosus (SLE) 

K Ranade, L Wang, P Brohawn, W Greth, J Drappa and 

G Illei, MedImmune, Gaithersburg, MD 

3:30 pm 

2070. Urinary Biomarker Based “a-RAIL” Study in 

Adults with Lupus Nephritis 

Gaurav Gulati 1 , Khalid Abulaban 2 , Jun Ying 3 , Huijuan 

Song 4 , Xiaolan Zhang 5 , Qing Ma 6 , Christopher Haffner 6 , 

Kasha Wiley 2 , Michael Bennett 7 , Brad H. Rovin 4 and 

Hermine I. Brunner 8 , 1 University of Cincinnati College 

of Medicine, Cincinnati, OH, 2 Cincinnati Children’s 

Hospital Medical Center, Cincinnati, OH, 3 University 

of Cincinnati, Cincinnati, OH, 4 Ohio State University 

Medical Center, Columbus, OH, 5 Ohio State University, 

Columbus, OH, 6 Cincinnati Children’s Hospital and 

Medical Center, Cincinnati, OH, 7 Cincinnati Children`s 

Hospital Medical Center, Cincinnati, OH, 8 Pediatric 


Children’s Hospital Medical Center, Cincinnati, OH 


124 




3:45 pm 

2071. Urinary Osteoprotegerin As Biomarker of 

Lupus Nephritis Disease Activity: Cross Sectional 

and Longitudinal Study 

Ranjan Gupta 1 , Amita Aggarwal 1 , Sudhir sinha 2 , Liza 

Rajasekhar 3 , Akhilesh Yadav 1 , Priyanka Gaur 1 , Ramnath 

Misra 1 and Virsingh Negi 4 , 1 Sanjay Gandhi Postgraduate 

Institute of Medical Sciences, Lucknow, India, 2 CSIRcentral 

drug research institute, Lucknow, India, 3 Nizam 

Institute of Medical Sciences, Hyderabad, India, 

4 

JIPMER, Puducherry, India 

North – 130 

Systemic Lupus Erythematosus – Human 

Etiology and Pathogenesis: Modulators of 

Disease 

Moderators: William Stohl, MD, PhD and Westley 

Reeves, MD 

2:30 pm 

2072. Mitochondrial Reactive Oxygen Species 

Modulate Autoimmunity in Systemic Lupus 

Erythematosus 

Luz P. Blanco 1 , Christian Lood 2 , Monica Purmalek 1 , Suk 

See DeRavin 3 , Carolyne K. Smith 1 , Carmelo Carmona- 

Rivera 1 , Harry Malech 3 , Jeffrey Ledbetter 2 , Keith B. 

Elkon 2 and Mariana J. Kaplan 1 , 1 National Institutes 

of Health, Bethesda, MD, 2 University of Washington, 

Seattle, WA, 3 NIAID/NIH, Bethesda, MD 

2:45 pm 

2073. Mitochondrial ROS Is a Novel Regulator of 

Sting-Mediated Type I IFN Production By Governing 

Extrusion of Oxidized Mitochondrial DNA upon 

Neutrophil Extracellular Trap Formation. 

Christian Lood 1 , Luz P. Blanco 2 , Monica Purmalek 2 , 

Carolyne K. Smith 2 , Carmelo Carmona-Rivera 2 , Jeffrey 

Ledbetter 1 , Mariana J. Kaplan 2 and Keith B. Elkon 3 , 

1 

University of Washington, Seattle, WA, 2 National 

Institutes of Health, Bethesda, MD, 3 Division of 

Rheumatology, University of Washington, Seattle, WA 

3:00 pm 

2074. Dominant Chilblain Lupus Due to an 

Activating Mutation of Sting - Suppression of 

Constitutive Type I Interferon Activation By JAK 

Inhibition 

Christoph Fiehn 1 , Nadja König 2 , Christine Wolf 2 , Mathias 

Lesche 2 , Andreas Dahl 2 , Claudia Guenther 3 , Hanns- 

Martin Lorenz 4 and Min Ae Lee-Kirsch 2 , 1 ACURA Centre 

for Rheumatic Diseases, Baden-Baden, Germany, 

2 

Medizinische Fakultät Carl Gustav Carus, Technische 

Universität Dresden, Dresden, Germany, 3 Technische 

Universität Dresden, Dresden, Germany, 4 University of 

Heidelberg, Heidelberg, Germany 

3:15 pm 

2075. A Unique Naturally-Occurring Regulatory 

T Cell Subset Associated with Disease Activity in 

Patients with Systemic Lupus Erythematosus 

Tetsuya Nishimoto 1 , Yuka Okazaki 2 , Hironari Hanaoka 1 , 

Tsutomu Takeuchi 1 and Masataka Kuwana 2 , 1 Keio 

University School of Medicine, Tokyo, Japan, 2 Nippon 

Medical School Graduate School of Medicine, Tokyo, 

Japan 

3:30 pm 

2076. Development of Lupus Nephritis: Preclinical 

Evaluation of Patients Who Subsequently Develop 

Systemic Lupus Erythematosus Demonstrate 

Elevation of Select Soluble Mediators Prior to and 

at Disease Classification in Patients with Nephritis 

Melissa E. Munroe 1 , Jourdan R. Anderson 1 , Julie M. 

Robertson 1 , Timothy B. Niewold 2 , George C. Tsokos 3 , 

Michael P. Keith 4 , Joan T. Merrill 1 , Jill P. Buyon 5 , John 

B. Harley 6 and Judith A. James 7 , 1 Oklahoma Medical 

Research Foundation, Oklahoma City, OK, 2 Mayo 

Clinic, Rochester, MN, 3 Beth Israel Deaconess Medical 

Center, Harvard Medical School, Boston, MA, 4 Walter 

Reed National Military Medical Center, Bethesda, MD, 

5 

New York University School of Medicine, New York, 

NY, 6 Cincinnati Children’s Hospital Medical Center, 

Cincinnati, OH, 7 University of Oklahoma Health 

Sciences Center and Oklahoma Medical Research 

Foundation, Oklahoma City, OK 

3:45 pm 

2077. Does Dysbiosis within the Intestinal 

Microbiome Contribute to SLE Pathogenesis? 

Gregg J. Silverman 1 , Lelise Getu 2 , Haitao Niu 1 , Hanane El 

Bannoudi 1 , Adriana Heguy 1 , Alexander Alekseyenko 3 , Jill 

P. Buyon 2 and Doua Azzouz 1 , 1 NYU School of Medicine, 

New York, NY, 2 New York University School of Medicine, 

New York, NY, 3 NYU SChool of Medicine, New York, NY 



2 0 1 5 


tracker 

plus 

125 


ARHP SESSIONS 

2:30 – 4:00 pm 

West – 2007 

Evidence to Action: Translation of 

Rheumatology Research to Influence Programs, 

Policies, and Practice 

Moderator: Kelli D. Allen, PhD 

2:30 pm 

Theoretical Framework for Knowledge Translation 

Linda C. Li, PT, MSc, PhD 

3:00 pm 

Evidence to Action in the Public Health Setting 

Teresa J. Brady, PhD 

3:30 pm 

Evidence to Action in the Clinical Setting 

Joy Macdermid, PT, MSc, PhD 

West – 2009 

Integrating Support and Education Programs 

Into Your Practice: Five Innovative Models 


Moderator: Paul Adam, MSW 

2:30 pm 

The Premise and Promise of Model Support and 

Education Programs: An Overview 

Roberta Horton, LCSW, ACSW 

2:50 pm 

Rheumatoid Arthritis Support and Education 

Programs 

Adena Batterman, LCSW, MS 

3:10 pm 

LupusLine ® , Charla de Lupus (lLupus Chat) ® Programs: 

Using a Peer Health Model to Foster Provider Patient 

Partnership in New Ways 

Jillian A. Rose, LCSW 

3:30 pm 

LANtern ® (Lupus Asian Network): Servicing the Asian 

American Community 

My-Lan Tran, MSW, LCSW-R 

West – 2008 

Pain in the Older Adult: An International 

Perspective on Improving Quality of Life PM PS 

Moderator: Daniel J. Clauw, MD 

2:30 pm 

U.S. National Perspective on Pain 

Charles G. Helmick, MD 

3:00 pm 

Pain In Older People: Predictors and Impact 

Ross Wilkie, PhD 

3:30 pm 

Pain, Quality-of-life and Participation Among Older 

Adults With Arthritis 

Nancy E. Lane, MD 

West – 2006 

Pregnancy and Infertility in Rheumatic Disease 

Moderator: Jessica F. Farrell, PharmD 

2:30 pm 

Pregnancy in Rheumatic Disease 

Lisa R. Sammaritano, MD 

3:15 pm 

Fertility in Rheumatic Disease 

Megan E. B. Clowse, MD, MPH 


2:30 – 4:00 pm 

West – 2004 

ARHP II: Lupus 

Moderators: Charmayne M. Dunlop-Thomas, MS, MPH 

and Diane Gross, MPH 

2:30 pm 

2078. Reserve Capacity: Explaining the Link Between 

Socioeconomic Status and Depression/Anxiety Among 

Patients with Systemic Lupus Erythematosus 

Desiree Azizoddin 1 , Julia Ayeroff 2 , Geraldine Zamora- 

Racaza 3 , Taylor Draper 4 , Sarah R. Ormseth 1 , Michael H. 

Weisman 3 , Lekeisha Sumner 5 and Perry M. Nicassio 6 , 


126 




1 

University of California, Los Angeles, Los Angeles, CA, 

2 

University of Southern California, Los Angeles, CA, CA, 

3 

Cedars-Sinai Medical Center, Los Angeles, CA, 4 Loma 

Linda University, Loma Linda, CA, 5 Alliant University, 

Alhambra, CA, 6 Cousins Center for PNI, UCLA, LA, CA 

2:45 pm 

2079. Effectiveness of Renoprotective 

Approaches in Lupus Nephritis: More Than Just 

Immunosuppression 

Maite Castro 1 , Eduardo Ferreira Borba 1 , Michelle 

Lopes 1 , Sandra G. Pasoto 2 , Eloisa Bonfá 1 and Luciana 

Seguro 2 , 1 Hospital das Clinicas, Faculdade de Medicina, 

University of São Paulo, São Paulo, Brazil, 2 Faculdade 

de Medicina da Universidade de São Paulo, São Paulo, 

Brazil 

3:00 pm 

2080. Teaching Fellows in Lupus: Rheumatology 

Fellows Are Successful Educators in Improving 

Lupus Recognition By Frontline Healthcare 

Providers 

Amy Caron 1 , S. Sam Lim 2 , Lexi Rene 3 , Diane Gross 4 , 

Maria Dall’Era 5 , Rosalind Ramsey-Goldman 6 and 

Amanda Sammut 7 , 1 Lupus Research Institute, New York 

City, NY, 2 Emory University, Atlanta, GA, 3 Rollins School 

of Public Health, Emory University, Atlanta, GA, 4 S.L.E. 

Lupus Foundation, New York, NY, 5 UCSF, San Francisco, 

CA, 6 Northwestern University Feinberg School of 

Medicine, Chicago, IL, 7 Columbia University Medical 

Center, New York, NY 

3:15 pm 

2081. The SLE Workshop: An Evaluation of a Long- 

Standing Hospital-Based Psychoeducational 

Program 

Melissa T. Flores, Roberta Horton, Jillian A. Rose, 

Stephen A. Paget and Michael Lockshin, Hospital for 

Special Surgery, New York, NY 

3:30 pm 

2082. Evaluations of Social Support Are Associated 

with Well-Being Outcomes in Women with Systemic 

Lupus Erythematosus (SLE) 

Stacey E. Morrison 1 , Monique A.M. Gignac 2 , Paul R. 

Fortin 3 and Dorcas Beaton 4 , 1 Toronto Western Hospital, 

Toronto, ON, 2 Instititue for Work and Health, Toronto, 

ON, 3 CHU de Québec - Université Laval, Québec, QC, 4 St 

Michael’s Hospital, Toronto, ON 

3:45 pm 

2083. Predictors of Health Perceptions Among 

Women with Lupus 

Patricia P. Katz 1 , Eliza Chakravarty 2 , Robert S. Katz 3 and 

Kaleb Michaud 4 , 1 University of California San Francisco, 

San Francisco, CA, 2 Oklahoma Medical Research 

Foundation, Oklahoma City, OK, 3 Rush University 

Medical Center, Chicago, IL, 4 University of Nebraska 

Medical Center, Omaha, NE 


4:00 – 6:00 pm 











August 30. 

West – 3002 

227 – Musculoskeletal Ultrasonography: Basic 

Speakers: Janak R. Goyal, MD and Gurjit S. Kaeley, 

MBBS, MRCP 

West – 3006 

228 – Osteoporosis: Interpreting Dual Energy 

X-ray Absorptiometry and Clinical Risk Factors: 

The New Fracture Risk Assessment Algorithm 

Speaker: Stuart L. Silverman, MD 

West – 3008 

229 – Physical Examination Skills for 

Improved Detection of Synovitis and Cervical 

Thoracolumbar Disorders 

Speaker: Edward C. Keystone, MD 



2 0 1 5 


tracker 

plus 

127 


ACR SESSIONS 

4:30 – 5:30 pm 


Fibrosis and New Therapeutic Approaches 

Moderators: Oliver Distler, MD and Francesco Boin, MD 

Speakers: Paul W. Noble, MD 

West – 2009 

Upper Extremity Arthritis: Epidemiology and 

Ergonomic Interventions PM PS E 

Moderator: Kristina A. Theis, PhD 

4:30 pm 

Hands and Upper Extremities 

Jin Qin, ScD 

5:00 pm 

Upper Extremity Joints and Occupations 

Nancy A. Baker, ScD, MPH, OTR/L 

ACR SESSIONS 

4:30 – 6:00 pm 

West – 2001 

Career Opportunities in Rheumatology: Making 

a PM Choice 


Moderator: Chaim Putterman, MD 

4:30 pm 

Clinical Research 

Diane L. Kamen, MD 

4:50 pm 

Basic Science Research 

Speaker Carla R. Scanzello, MD, PhD 

5:10 pm 

Private Practice 

Alan Brown, MD 

5:30 pm 

Clinician Educator 

Karen Law, MD 


New ACR-EULAR Sjögren’s Syndrome 

Classification Criteria and Updates 

Moderators: Simon Bowman, PhD and Lindsey A. 

Criswell, MD, MPH 

4:30 pm 

Development and Validation of ACR-EULAR 

Classification Criteria for Sjögren’s Syndrome 

Caroline H. Shiboski, DDS, MPH, PhD 

4:55 pm 

Diagnosing Sjögren’s Syndrome in the Clinic 

Alan N. Baer, MD 

5:20 pm 

Implication of Evolving Classification Criteria for 

Sjögren’s Syndrome for Therapeutic Trials 

Raphaèle Seror, MD, PhD 


Osteoimmunology: Cross-talk Between Bone 


and Immune Cells 

Moderator: Marina N. Magrey, MD 

4:30 pm 

Bone and the Innate Immune System: Rheumatology 

Update 

Mary C. Nakamura, MD 

5:00 pm 

Targeting Epigenetic Mechanisms to Suppress 

Inflammatory Bone Resorption 

Lionel B. Ivashkiv, MD 

5:30 pm 

Immunoreceptors on Osteoclasts and Signaling: 

Impact on Osteoporosis and other Rheumatic 

Diseases 

Mary Beth Humphrey, MD, PhD 

West – 2000 

Practice Without Walls 

Moderators: Colin Edgerton, MD and Ruy Carrasco, MD 


128 




4:30 pm 

Patient Centered Medical Home-Neighbor Model 

Overview 

Neil Kirschner, PhD 

5:15 pm 

Accountable Care Organization Model Impact on 

Physician Practices 

Alex Limanni, MD 


4:30 – 6:00 pm 


Biology and Pathology of Bone and Joint: Bone 

Remodeling 

Moderators: to be Determined 

4:30 pm 

2084. Dendritic Cell-Specific Transmembrane 

Protein (DC-STAMP) Modulates Bone Resorption in 

Inflammatory Arthritis and Fracture Repair 

Yahui Grace Chiu 1 , Tzong-Ren Sheu 1 , Jinbo Li 1 , Dongge 

Li 1 , Michael Thullen 1 , Brendan Boyce 1 , Christopher 

T. Ritchlin 2 and Javier Rangel-Moreno 1 , 1 University of 

Rochester, Rochester, NY, 2 University of Rochester 

Medical Center, Rochester, NY 

4:45 pm 

2085. DC-STAMP Regulates Osteoclastogenesis 

through the Ca 2+ /NFATc1 Axis 

Yahui Grace Chiu 1 , Dongge Li 1 , Yue-Xin Xu 1 , Tzong- 

Ren Sheu 1 , Minsoo Kim 1 and Christopher T. Ritchlin 2 , 

1 

University of Rochester, Rochester, NY, 2 University of 

Rochester Medical Center, Rochester, NY 

5:00 pm 

2086. Inhibition of Macrophage Inflammatory 

Protein 1-Alpha (CCL3) Significantly Reduced Bone 

Resorption in Vitro and the Development of Erosive 

Joint Pathology in Collagen-Induced Arthritis 

Lauren A. Jordan 1 , Ruth Davies 1 , Alastair J. D. 

Robertson 2 , Ann K. Harvey 1 , Ernest H. Choy 1 , Malin 

Erlandsson 3 , Maria I. Bokarewa 3 , Rachel J. Errington 1 

and Anwen S. Williams 1 , 1 Cardiff University, Institute of 

Infection and Immunity, Tenovus Building, University 

Hospital of Wales, Cardiff, United Kingdom, 2 William 

Harvey Hospital, Willesborough, Ashford, United 

Kingdom, 3 University of Goteborg, Goteborg, Sweden 

5:15 pm 

2087. Defective Circadian Control in Mesenchymal 

Cells Reduces Adult Bone Mass 

Julia F. Charles and Joerg Ermann, Brigham and 


5:30 pm 

2088. Immature Dendritic Are Potent OC Precursors 

in RA and Are Targeted By RA-Specific Antibodies 

Akilan Krishnamurthy 1 , Vijay Joshua 2 , Heidi Wähämaa 1 , 

Vivianne Malmström 1 , Khaled Amara 1 , Jimmy Ytterberg 1 

and Anca I Catrina 1 , 1 Rheumatology Unit, Department 

of Medicine, Karolinska Institute, Karolinska University 

Hospital, Stockholm, Sweden, 2 Unit of Rheumatology, 

Department of Medicine Solna, Karolinska University 

Hospital, Karolinska Institutet, Stockholm, Sweden 

5:45 pm 

2089. Netrin-1 and Its Receptors Unc5b and DCC 

May be Useful Targets for Preventing Multiple 

Myeloma Bone Lesions 

Aranzazu Mediero 1 , Tuere Wilder 2 and Bruce 

Cronstein 3 , 1 NYU School of Medicine, New York City, 

NY, 2 NYU School of Medicine, New York, NY, 3 NYU 

School of Medicine, NEW YORK, NY 

West – 2018 

Epidemiology and Public Health III: Risk 

Factors, Treatment and Outcomes of Gout and 


Moderators: Jasvinder Singh, MD and Kristine Phillips, 

MD, PhD 

4:30 pm 

2090. Gender-Specific Pathways Linking Arthritis, 

Activity Limitation and Incident Heart Disease: 

A Causal Mediation Analysis of the Canadian 

Longitudinal National Population Health Survey 

Orit Schieir 1 , Sheilah. Hogg-Johnson 2 , Richard H Glazier 3 

and Elizabeth M. Badley 1 , 1 University of Toronto, 

Toronto, ON, 2 Institute for Work and Health, Toronto, 

ON, 3 St. Michael’s Hospital, Toronto, ON 



2 0 1 5 


tracker 

plus 

129 


4:45 pm 

2091. Influence of Increasing Physical Activity on 

Longitudinal Changes in Disability Status Among 

Inactive Older Adults 

Jing Song 1 , Abigail Gilbert 2 , Rowland W. Chang 3 , 

Christine Pellegrini 2 , Linda S. Ehrlich-Jones 4 , Julia 

(Jungwha) Lee 2 , Daniel Pinto 1 , Pamela Semanik 5 , 

Leena Sharma 2 , C. Kent Kwoh 6 , Rebecca D. Jackson 7 

and Dorothy D. Dunlop 3 , 1 Northwestern University, 

Chicago, IL, 2 Northwestern University Feinberg School 

of Medicine, Chicago, IL, 3 Northwestern Univ, Chicago, 

IL, 4 Rehabilitation Institute Chicago, Chicago, IL, 5 Rush 

University, Chicago, IL, 6 University of Arizona, Tucson, 

AZ, 7 Ohio State University, Columbus, OH 

5:00 pm 

2092. Knee Pain Burden Is Associated with 

Decreased Moderate to Vigorous Physical Activity: 

Data from the Osteoarthritis Initiative 

Javad Razjouyan 1 , Bijan Najafi 1 , Erin Ashbeck 1 , Dorothy 

D. Dunlop 2 , Julia (Jungwha) Lee 2 , Lynn Hamilton 1 and 

C. Kent Kwoh 1 , 1 University of Arizona, Tucson, AZ, 

2 


Chicago, IL 

5:15 pm 

2093. Are General and Central Adiposity Associated 

with MRI-Assessed Structural Changes in the Knees 

of Older Adults? 

Tomoko Fujii 1 , Iva Miljkovic 1 , Robert M. Boudreau 1 , Ali 

Guermazi 2 , Sara R. Piva 1 , Elsa S. Strotmeyer 1 , Laura 

Carbone 3 , Tamara B. Harris 4 , Elisa A. Marques 4 , M Kyla 

Shea 5 , Michael C. Nevitt 6 , Anne B. Newman 1 and C 

Kent Kwoh 7 , 1 University of Pittsburgh, Pittsburgh, PA, 

2 


3 

Georgia Regents University, Augusta, GA, 4 National 

Institute on Aging, Bethesda, MD, 5 Tuffs University, 

Boston, MA, 6 UCSF, San Francisco, CA, 7 University of 

Arizona, Tucson, AZ 

5:30 pm 

2094. Identification of Gout Flare Using an 

Administrative Claims Based Algorithm 

Lindsey MacFarlane, Daniel H. Solomon and Seoyoung 

C. Kim, Brigham and Women’s Hospital, Boston, MA 

5:45 pm 

2095. Dietary Patterns (DASH, Prudent, Western 

Diets) and the Risk of Gout in US Women - the 

Nurses Health Study 

Jeewoong Choi 1 , Na Lu 2 , Yuqing Zhang 3 , Sharan K. Rai 4 , 

Gary C. Curhan 5 and Hyon K. Choi 2 , 1 Massachusetts 

College of Pharmacy and Health Sciences, Boston, MA, 

2 


School, Boston, MA, 3 BUSM, Boston, MA, 4 University 

of British Columbia, Vancouver, BC, 5 Brigham and 

Women’s Hospital, Boston, MA 

West – 2011 

Genetics, Genomics, and Proteomics 

Moderators: Timothy B. Niewold, MD and Patrick M. 

Gaffney, MD 

4:30 pm 

2096. Immune Dysregulation in Patients with 

TRNT1 Deficiency 

Angeliki Giannelou 1 , Qing Zhou 2 , Hong-Wei Sun 3 , Dan 

Yang 4 , Susan Moir 5 , Jehad H. Edwan 3 , Wanxia L. Tsai 3 , 

Elisavet Serti 6 , Monique Stoffels 2 , Deborah L. Stone 7 , 

Amanda K. Ombrello 7 , Karyl Barron 5 , Helen C. Su 5 , 

Abdullah Al Sonbul 8 , Sarita Joshi 9 , Kimberly Risma 10 , 

Lucie Sramkova 11 , Martha M. Quezado 12 , Katherine 

Calvo 13 , Abu-Asab Mones 14 , Gustavo Gutierrez- 

Cruz 3 , Massimo G. Gadina 3 , Markus Hafner 3 , Ivona 

Aksentijevich 2 and Daniel Kastner 2 , 1 National Human 

Genome Research Institute, National Institute of 

Arthritis and Musculoskeletal and Skin Diseases, 

National Institutes of Health, Bethesda, MD, 2 NIH/ 

NHGRI, Metabolic, Cardiovascular, and Inflammatory 

Disease Genomics Branch, Bethesda, MD, 3 National 

Institute of Arthritis and Musculoskeletal and Skin 

Diseases, National Institutes of Health, Bethesda, MD, 

4 

National Heart, Lung, and Blood Institute, National 

Institutes of Health, Bethesda, MD, 5 National Institute 

of Allergy and Infectious Diseases, National Institutes 

of Health, Bethesda, MD, 6 Immunology Section, Liver 

Diseases Branch, NIDDK, NIH, Bethesda, MD, 7 National 

Human Genome Research Institute, National Institutes 

of Health, Bethesda, MD, 8 King Faisal Specialist Hospital 

& Research Center, Riyadh, Saudi Arabia, 9 Nationwide 

Children’s Hospital, Columbus, OH, 10 Cincinnati 



130 




11 

Charles University 2nd Faculty of Medicine and 

UH Motol, Prague, Czech Republic, 12 Laboratory of 

Pathology/National Cancer Institute, National Institutes 

of Health, Bethesda, MD, 13 Department of Laboratory 

Medicine, National Institutes of Health, Bethesda, MD, 

14 

National Eye Institute, National Institutes of Health, 

Bethesda, MD 

4:45 pm 

2097. HLA-B27 Expression Profoundly Shapes the 

Host-Microbiota Metabolome 

Mark Asquith 1 , Patrick Stauffer 2 , Sean Davin 3 , Stephen 

R. Planck 2 , Phoebe Lin 3 and James T. Rosenbaum 4 , 

1 

OHSU, Portland, OR, 2 Oregon Health & Science 

University, Portland, OR, 3 Oregon Health and Science 

University, Portland, OR, 4 Devers Eye Institute, Legacy 

Hospital system, Portland, OR 

5:00 pm 

2098. Prioritizing Likely Causative Genes in 

Genome-Wide Association Studies (GWAS) 

Identified Risk Loci for Immune-Mediated 

Inflammatory Disorders Using Cell-Type Specific 

Expression Quantitative Loci (eQTL) Information 

Elisa Docampo 1 , Ming Fang 1 , Julia Dmitrieva 1 , Emilie 

Théâtre 1 , Mahmoud Elansary 1 , Rob Mariman 1 , Ann- 

Stephan Gori 1 , Myriam Mni 1 , François Crins 1 , Wouter 

Coppieters 1 , Edouard Louis 2 and Michel Georges 1 , 

1 

GIGA-R Université de Liège, Liège, Belgium, 2 University 

Hospital CHU of Liège, Liège, Belgium 

5:15 pm 

2099. Genome-Wide Association Study of Clinically- 

Defined Gout Identifies Multiple Risk Loci: A Clue 

for Future Companion Diagnostics of Gout 

Hirotaka Matsuo 1 , Ken Yamamoto 2 , Hirofumi Nakaoka 3 , 

Akiyoshi Nakayama 1 , Masayuki Sakiyama 1 , Atsushi 

Takahashi 4 , Takahiro Nakamura 5 , Yusuke Kawamura 1 , 

Nobuyuki Hamajima 6 , Ituro Inoue 3 , Michiaki Kubo 4 , 

Kimiyoshi Ichida 7 , Hiroshi Ooyama 8 , Toru Shimizu 9 

and Nariyoshi Shinomiya 1 , 1 National Defense Medical 

College, Tokorozawa, Japan, 2 Kurume University School 

of Medicine, Kurume, Japan, 3 National Institute of 

Genetics, Mishima, Japan, 4 RIKEN, Yokohama, Japan, 

5 

Laboratory for Mathematics, Tokorozawa, Japan, 

6 

Nagoya University Graduate School of Medicine, 

Nagoya, Japan, 7 Tokyo University of Pharmacy and Life 

Sciences, Hachioji, Japan, 8 Ryougoku East Gate Clinic, 

Tokyo, Japan, 9 Midorigaoka Hospital, Takatsuki, Japan 

5:30 pm 

2100. Hypomethylation in Enhancer and Promoter 

Regions of Interferon Regulated Genes in Multiple 

Tissues Is Associated with Primary Sjögren’s 

Syndrome 

Juliana Imgenberg-Kreuz 1 , Johanna K Sandling 1 , Jonas 

Carlsson Almlöf 1 , Jessica Nordlund 1 , Linnea Signér 2 , 

Katrine B Norheim 3 , Roald Omdal 3 , Majia-Leena 

Eloranta 2 , Lars Rönnblom 2 , Ann-Christine Syvänen 1 and 

Gunnel Nordmark 2 , 1 Molecular Medicine and Science 

for Life Laboratory, Department of Medical Sciences, 

Uppsala University, Uppsala, Sweden, 2 Rheumatology 

and Science for Life Laboratory, Department of Medical 

Sciences, Uppsala University, Uppsala, Sweden, 3 Clinical 

Immunology Unit, Department of Internal Medicine, 

Stavanger University Hospital, Stavanger, Norway 

5:45 pm 

2101. HLA Associations in Mothers of Children with 

Cardiac Manifestations of Neonatal Lupus 

Hannah C. Ainsworth 1 , Carl D. Langefeld 1 , Miranda 

C. Marion 2 , Nathalie Costedoat-Chalumeau 3 , Antonio 

Brucato 4 , Jill P. Buyon 5 and Robert M. Clancy 5 , 1 Wake 

Forest School of Medicine, Winston-Salem, NC, 2 Wake 

Forest University Health Sciences, Winston-Salem, NC, 

3 

Internal Medicine Department, Cochin Hospital, “René- 

Descartes Paris V” University, Paris, France, 4 Internal 

Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy, 

5 

New York University School of Medicine, New York, NY 

North – 130 

Health Services Research II: Rheumatoid 

Arthritis Treatment and Healthcare Utilization 

Moderator: Candace H. Feldman, MD, MPH 

4:30 pm 

2102. Higher Persistence and Adherence with 

Combination Therapy with Tumor Necrosis Factor 

Inhibitor+Methotrexate Combination Versus Triple 

Therapy in US Veterans with Rheumatoid Arthritis 

Brian Sauer 1 , Chia-Chen Teng 1 , Jianwei Leng 1 , Ted R. 

Mikuls 2 , Jeffrey R. Curtis 3 , Bradley S. Stolshek 4 , Derek 

Tang 4 and Grant W. Cannon 5 , 1 HSR&D SLC VA Medical 

Center and University of Utah, Salt Lake City, UT, 



2 0 1 5 


tracker 

plus 

131 


2 

University of Nebraska Medical Center, Omaha, NE, 

3 

University of Alabama at Birmingham, Birmingham, 

AL, 4 Amgen, Inc., Thousand Oaks, CA, 5 Salt Lake City VA 

Medical Center and University of Utah, Salt Lake City, 

UT 

4:45 pm 

2103. Temporal Trends in Drug Prescription, 

Utilization and Costs Among Rheumatoid Arthritis 

(RA) Patients Show Wide Regional Variation Despite 

Universal Drug Coverage 

Mark Tatangelo 1 , Michael Paterson 2 , George A. 

Tomlinson 3 , Nick Bansback 4 , Jessica Widdifield 5 , Tara 

Gomes 2 and Claire Bombardier 1 , 1 University of Toronto, 

Toronto, ON, 2 Institute of Clinical Evaluative Sciences, 

Toronto, ON, 3 Mount Sinai Hospital, Toronto, ON, 

4 

Centre for Health Evaluation and Outcome Sciences, 

Vancouver, BC, 5 University Health Network, Toronto, 

ON 

5:00 pm 

2104. Influence on Treatment Decision Making of 

Providing Numerical Ranges of Side-Effect Risks 

Nick Bansback 1 , Mark Harrison 2 , William G Dixon 3 and 

Paul Han 4 , 1 University of British Columbia, Vancouver, 

BC, 2 Centre for Health Evaluation and Outcomes 

Sciences, St Paul’s Hospital, Vancouver, BC, 3 Arthritis 

Research UK Centre for Epidemiology, The University 

of Manchester, Manchester, United Kingdom, 4 Maine 

Medical Center, Portland, ME 

5:15 pm 

2105. Drug Survival and Cost Effectiveness in 

Patients on Reduced Dose Anti-TNF: Results of a 4 

Year Prospective Observational Study 

John Stack 1 , Claire-Louise Murphy 2 , Clara Bannon 1 , 

Eithne Murphy 1 , Trevor Duffy 1 and Maurice Barry 1 , 

1 

Connolly Hospital Blanchardstown, Dublin, Ireland, 

2 

Connolly Hospital Blanchardstow, Dublin, Ireland 

5:30 pm 

2106. Intensification to Triple Therapy Non- 

Biologic Disease-Modifying Antirheumatic Drugs 

for Rheumatoid Arthritis in the United States from 

2009 to 2014 

Jeffrey A. Sparks 1 , Alexis A. Krumme 1 , Olga S. Matlin 2 , 

Gregory Brill 1 , William H. Shrank 2 , Niteesh K. Choudhry 1 

and Daniel H. Solomon 1 , 1 Brigham and Women’s 

Hospital, Harvard Medical School, Boston, MA, 2 CVS 

Caremark, Woonsocket, RI 

5:45 pm 

2107. Initiation of Combination Triple Therapy in 

Real World Clinical Practice Rarely Replicates the 

Protocols Used in Randomized Controlled Trials. 

Grant W. Cannon 1 , Chia-Chen Teng 2 , Ted R. Mikuls 3 , 

Jeffrey R. Curtis 4 , Derek Tang 5 , Bradley S. Stolshek 5 

and Brian Sauer 1 , 1 Salt Lake City VA Medical Center 

and University of Utah, Salt Lake City, UT, 2 HSR&D 

SLC VA Medical Center and University of Utah, Salt 

Lake City, UT, 3 Veteran Affairs Nebraska-Western 

Iowa Health Care System and University of Nebraska 

Medical Center, Omaha, NE, 4 University of Alabama at 

Birmingham, Birmingham, AL, 5 Amgen, Inc., Thousand 

Oaks, CA 

West – 2010 

Metabolic and Crystal Arthropathies I: 

Therapeutics 

Moderators: N. Lawrence Edwards, MD and Geraldine 

M. McCarthy, MD 

4:30 pm 

2108. A Pragmatic Cluster-Randomized Controlled 

Trial of an Automated, Pharmacy-Based 

Intervention to Optimize Allopurinol Therapy in 

Gout 

Ted R. Mikuls 1 , T C Cheetham 2 , Nazia Rashid 2 , Gerald 

D. Levy 2 , Artak Kerimian 2 , KJ Low 2 , Brian Coburn 1 , David 

T. Redden 3 , S. Louis Bridges Jr. 3 , Kenneth G. Saag 3 

and Jeffrey R. Curtis 3 , 1 University of Nebraska Medical 

Center, Omaha, NE, 2 Kaiser Permanente Southern 

California, Downey, CA, 3 University of Alabama at 

Birmingham, Birmingham, AL 

4:45 pm 

2109. Racial Disparities in the Risk of Hospitalized 

Severe Allopurinol Hypersensitivity Syndrome - a 

US Nationwide Study (2009-2011) 

Na Lu 1 , Sharan K. Rai 2 , Jeewoong Choi 3 and Hyon K. 

Choi 1 , 1 Massachusetts General Hospital, Harvard 

Medical School, Boston, MA, 2 University of British 

Columbia, Vancouver, BC, 3 Massachusetts College of 

Pharmacy and Health Sciences, Boston, MA 


132 




5:00 pm 

2110. Imaging and Safety Assessments Following 

Treatment with Febuxostat and Placebo for 2 Years 

in Subjects with Early Gout 

Nicola Dalbeth 1 , Kenneth G. Saag 2 , William Palmer 3 , 

Hyon Choi 3 , Barbara Hunt 4 , Patricia MacDonald 4 , 

Ulrich Thienel 4 and Lhanoo Gunawardhana 4 , 

1 

University of Auckland, Auckland, New Zealand, 

2 


AL, 3 Massachusetts General Hospital/Harvard Medical 

School, Boston, MA, 4 Takeda Pharmaceuticals 

International, Deerfield, IL 

5:15 pm 

2111. A Study to Evaluate the Efficacy and Safety of 

Arhalofenate for Preventing Flares and Reducing 

Serum Uric Acid in Gout Patients 

Alexandra Steinberg 1 , Harinder Chera 1 , Yun-Jung Choi 1 , 

Robert Martin 1 , Charles McWherter 1 , Yunbin Zhang 2 , 

Pol Boudes 1 and on behalf of the Arhalofenate Anti- 

Flare Therapy Study Group, 1 Cymabay Therapeutics, 

Newark, CA, 2 INC Research, Raleigh, NC 

5:30 pm 

2112. Analysis of Gout Subjects Receiving Lesinurad 

and Allopurinol Combination Therapy By Baseline 

Renal Function 

Kenneth G. Saag 1 , Thomas Bardin 2 , Alexander So 3 , 

Puja Khanna 4 , Chris Storgard 5 , Scott Baumgartner 5 , 

Maple Fung 5 , Nihar Bhakta 5 , Scott Adler 6 , Jeff Kopicko 5 

and Michael A. Becker 7 , 1 University of Alabama at 

Birmingham, Birmingham, AL, 2 Lariboisière Hospital, 

Paris, France, 3 Centre Hospitalier Universitaire Vaudois, 

University of Lausanne, Lausanne, Switzerland, 

4 

University of Michigan Medical Center, Ann Arbor, MI, 

5 

Ardea Biosciences, Inc., San Diego, CA, 6 AstraZeneca 

Pharmaceuticals, Wilmington, DE, 7 University of 

Chicago, Chicago, IL 

5:45 pm 

2113. Lesinurad, a Novel Selective Uric Acid 

Reabsorption Inhibitor, in Combination with 

Febuxostat, in Patients with Tophaceous Gout 

Nicola Dalbeth 1 , Graeme Jones 2 , Robert Terkeltaub 3 , 

Dinesh Khanna 4 , Jeff Kopicko 5 , Nihar Bhakta 5 , 

Maple Fung 5 , Chris Storgard 5 , Scott Baumgartner 5 

and Fernando Perez-Ruiz 6 , 1 University of Auckland, 

Auckland, New Zealand, 2 Menzies Institute for 

Medical Research, University of Tasmania, Hobart, 

Australia, 3 University of California, San Diego, La Jolla, 

CA, 4 University of Michigan, Ann Arbor, MI, 5 Ardea 

Biosciences, Inc., San Diego, CA, 6 Hospital Universitario 

Cruces, Baracaldo, Spain 


Orthopedics, Low Back Pain and Rehabilitation 

Moderators: M. Elaine Husni, MD, MPH and Martin 

Englund, MD, PhD 

4:30 pm 

2114. Higher Total Knee Arthroplasty Revision 

Rates in Black Americans: A Systematic Literature 

Review and Meta-Analysis 

Anne R. Bass, Kelly McHugh, Kara Fields, Rie Smethurst, 

Michael Parks and Susan M. Goodman, Hospital for 

Special Surgery, New York, NY 

4:45 pm 

2115. Intra-Operative Synovitis Predicts Worse Pain 

and Function 2 Years after Total Knee Arthroplasty 

for Osteoarthritis 

Lisa Mandl 1 , Shivi Duggal 1 , Kelly McHugh 1 , Xian Wu 2 , 

Geoffrey H. Westrich 1 , Thomas Sculco 1 , John A. 

Carrino 3 , Edward F. DiCarlo 1 , Steven R. Goldring 1 and 

Charles Cornell 1 , 1 Hospital for Special Surgery, New 

York, NY, 2 Weill Cornell Medical College, New York, 

NY, 3 Johns Hopkins University School of Medicine, 

Baltimore, MD 

5:00 pm 

2116. Advice to Remain Active While Awaiting 

Physiotherapy Is Associated with Superior Long- 

Term Outcome Among Patients with Distal Arm 

Pain - Results from a Randomised Controlled Trial 

Gareth T Jones 1 , Gary J. Macfarlane 1 , Keith Palmer 2 , 

David Coggon 2 , Karen Walker-Bone 2 , Kim Burton 3 , Peter 

Heine 4 , Candida McCabe 5 , Paul McNamee 6 and Alex 

McConnachie 7 , 1 Arthritis Research UK / MRC Centre 

for Musculoskeletal Health and Work, Aberdeen, 

United Kingdom, 2 Arthritis Research UK / MRC Centre 

for Musculoskeletal Health and Work, Southampton, 

United Kingdom, 3 University of Huddersfield, 

Huddersfield, United Kingdom, 4 University of Warwick, 

Coventry, United Kingdom, 5 Royal United Hospital NHS 



2 0 1 5 


tracker 

plus 

133 


Foundation Trust, Bath, United Kingdom, 6 University of 

Aberdeen, Aberdeen, United Kingdom, 7 University of 

Glasgow, Glasgow, United Kingdom 

5:15 pm 

2117. Weight Predicts Back Pain in Young Adult 

Women, Independent of Physical Activity: Data from 

the Australian Longitudinal Study on Women’s Health 

Sharmayne Brady 1 , Sultana Monira Hussain 1 , Wendy 

Brown 2 , Stephane Heritier 1 , Baki Billah 1 , Yuanyuan 

Wang 1 , Helena Teede 3 , Donna Urquhart 1 and Flavia 

Cicutinni 1 , 1 School of Public Health and Preventive 

Medicine, Monash University, Melbourne, Australia, 

2 

School of Human Movement Studies, University of 

Queensland, Brisbane, Australia, 3 Monash Centre 

for Health Research and Implementation, Monash 

University, Melbourne, Australia 

5:30 pm 

2118. Prescription Medication Use in Community- 

Based US Adults with Chronic Low Back Pain: 

Nhanes 2009-2010 

Anna Shmagel 1 and Robert Foley 2 , 1 University 

of Minnesota Medical School, Minneapolis, MN, 

2 

University of Minnesota, Minneapolis, MN 

5:45 pm 

2119. Findings and Therapeutic Impact of Magnetic 

Resonance Imaging (MRI) Studies for Patients with 

Lower Back Pain with Neurologic Symptoms. Are 

We Choosing Wisely? 

Patrick Nguyen, Nathalie Carrier and Ariel Masetto, 

Université de Sherbrooke, Sherbrooke, QC 

West – 2014 

Reproductive Issues in Rheumatic Disorders: 

Basic and Clinical Aspects 

Moderators: Megan E. B. Clowse, MD, MPH and Jane E. 

Salmon, MD 

4:30 pm 

2120. Alterations in Complement C3 and iC3b in SLE 

Pregnancies 

Marta M. Guerra 1 , Martin Schmidt 2 , Elianna Kaplowitz 1 , 

Vibeke Strand 3 and Jane E. Salmon 4 , 1 Hospital for 

Special Surgery, New York, NY, 2 Kypha, Inc., St. Louis, 

MO, 3 Stanford University School of Medicine, Portola 

Valley, CA, 4 Hospital for Special Surgery, Weill Cornell 

Medical College, New York, NY 

4:45 pm 

2121. Placentas of Lupus Pregnancies Are 

Characterized By Marked Inflammatory Changes 

Despite Good Disease Control 

Wendy Marder 1 , Jason S. Knight 1 , Mariana J. Kaplan 2 , 

Emily C. Somers 1 , Xu Zhang 1 , Alexander A. O’Dell 1 , 

Vasantha Padmanabhan 1 and Richard W. Lieberman 1 , 

1 

University of Michigan, Ann Arbor, MI, 2 National 

Institute of Arthritis and Musculoskeletal and Skin 

Diseases, National Institutes of Health, Bethesda, MD 

5:00 pm 

2122. A Novel Severity Score Based on Cardiac 

Neonatal Lupus Manifestations Serves As a 

Predictor and Outcome Measure of Morbidity in 

Anti-Ro Exposed Fetuses 

Amit Saxena 1 , Peter M. Izmirly 1 , Sung Won Han 1 , 

Paraskevi Briassouli 1 , Tania Rivera 2 , Mark Halushka 3 , 

Hua Zhong 1 , Deborah Friedman 4 , Robert Clancy 1 and 

Jill P. Buyon 1 , 1 New York University School of Medicine, 

New York, NY, 2 Scripps Memorial Hospital La Jolla, La 

Jolla, CA, 3 John Hopkins Pathology, Baltmore, MD, 4 New 

York Medical College, Valhalla, NY 

5:15 pm 

2123. Incidence and Prognosis of Neonatal and 

Late-Onset Dilated Cardiomyopathy Associated 

with Cardiac Neonatal Lupus 

Kateri Levesque 1 , Nathalie Morel 2 , Alice Maltret 3 , 

Gabriel Baron 4 , Mohamed Hamidou 5 , Pauline 

Orquevaux 6 , Jean Charles Piette 7 , Francois Barriere 8 , 

Jérome Lebidois 3 , Laurent Fermont 3 , Olivier Fain 9 , 

Arnaud Theulin 10 , Francois Sassolas 11 , Philippe Pézard 12 , 

Gaëlle Guettrot-Imbert 13 , Delphine Le Mercier 14 , Sophie 

Georgin-Lavialle 15 , Christophe Deligny 16 , Eric Hachulla 17 , 

Luc Mouthon 18 , Philippe Ravaud 19 , Elisabeth Villain 3 , 

Damien Bonnet 14 and Nathalie Costedoat-Chalumeau 2 , 

1 

CHU Ste-Justine, Montréal, QC, 2 Internal Medicine 

Department, Cochin Hospital, “René-Descartes Paris V” 

University, Paris, France, 3 Groupe Hospitalier Necker 

- Enfants Malades, Paris, France, 4 Hôpital Hôtel Dieu, 

Paris, France, 5 Nantes University Hospital, Nantes, 

France, 6 CHU Reims, Reims, France, 7 Internal Medicine 

Department, University Hospital “Pitié-Salpêtrière”, 

“Pierre et Marie Curie Paris VI” University, Paris, France, 

8 

CHU Nantes, Nantes, France, 9 Hospital J. Verdier, 


134 




Bondy, France, 10 CHRU Strasbourg, Strasbourg, France, 

11 

CHU Lyon, Lyon, France, 12 CHU Angers, Angers, 

France, 13 Hopital Saint-Antoine, Paris, France, 14 Hopital 

Necker, Paris, France, 15 Hopital Tenon, Paris, France, 

16 

Centre hospitalier Universitaire de Fort de France, 

Fort de France, Martinique, 17 Service de Médecine 

Interne, Centre National de Référence des Maladies 

Systémiques Rares, Hôpital Claude Huriez, CHRU 

Lille, Lille, France, 18 National Referral Center for Rare 

Systemic Autoimmune Diseases, Hôpital Cochin, Paris, 

France, 19 Rheumatology, Paris, France 

5:30 pm 

2124. Racial Disparities in Lupus Pregnancy 

Megan E. B. Clowse and Chad Grotegut, Duke 


5:45 pm 

2125. Rheumatic and Non-Rheumatic Autoimmune 

Diseases in SLE Offspring 

Julie Couture 1 , Sasha Bernatsky 1 , Susan Scott 2 , Christian 

A. Pineau 1 and Evelyne Vinet 1 , 1 McGill University Health 

Centre, Montreal, QC, 2 Research Institute of the McGill 

University Health Centre, Montreal, QC 


Rheumatoid Arthritis – Clinical Aspects III: 

Cardiovascular Disease and RA 

Moderators: Jennifer Barton, MD and Kevin D. Deane, 

MD, PhD 

4:30 pm 

2126. Trial of Atorvastatin for the Primary 

Prevention of Cardiovascular Events in Patients 

with Rheumatoid Arthritis 

George D. Kitas 1 , Peter Nightingale 2 , Jane Armitage 3 , 

Naveed Sattar 4 , Jill Belch 5 , Deborah P.M. Symmons 6 and 

TRACE RA Consortium, 1 Dudley Group NHS Foundation 

Trust, Dudley, and Arthritis Research Campaign 

Epidemiology Unit, University of Manchester, 

Manchester, United Kingdom, 2 University Hospitals 

Birmingham NHS Foundation Trust, Birmingham, 

United Kingdom, 3 University of Oxford, Oxford, United 

Kingdom, 4 BHF Glasgow Cardiovascular Research 

Centre, Glasgow, United Kingdom, 5 University of 

Dundee, Dundee, United Kingdom, 6 NIHR Manchester 

Musculoskeletal Biomedical Research Unit, Central 

Manchester University Hospitals NHS Foundation 

Trust, Manchester, United Kingdom 

4:45 pm 

2127. Exploring the Lipid Paradox Theory in 

Rheumatoid Arthritis: Subclinical Coronary 

Atherosclerosis Is Higher Among Rheumatoid 

Arthritis Patients with the Lowest Circulating Low 

Density Lipoprotein Concentrations Compared with 

Controls 

Jon T. Giles 1 , Mary Chester M. Wasko 2 , Cecilia P. 

Chung 3 , Amy Kao 4 , Sabahat Bokhari 5 , Afshin Zartoshti 5 , 

C. Michael Stein 6 and Joan M. Bathon 7 , 1 Columbia 

University, College of Physicians & Surgeons, New York, 

NY, 2 Temple University School of Medicine, Pittsburgh, 

PA, 3 Vanderbilt University School of Medicine, 

Nashville, TN, 4 Biogen, Cambridge, MA, 5 Columbia 

University Medical Center, NY, NY, 6 Vanderbilt 

University, Nashville, TN, 7 Columbia University College 

of Physicians & Surgeons, New York, NY 

5:00 pm 

2128. The Role of Insulin Resistance in the 

Development of Premature Atherosclerosis in 

Patients with Rheumatoid Arthritis 

Gorica Ristic 1 , Vesna Subota 1 , Toplica Lepic 1 , Dejana 

Stanisavljevic 2 , Branislava Glisic 1 , Milan Petronijevic 1 , 

Arsen Ristic 3 and Dusan Stefanovic 1 , 1 Military Medical 

Academy, Belgrade, Serbia, 2 Belgrade University School 

of Medicine, Belgrade, Serbia, 3 Clinical Center of Serbia 

& Belgrade University School of Medicine, Belgrade, 

Serbia 

5:15 pm 

2129. Treatment-Naïve, Early Rheumatoid Arthritis 

Patients Demonstrate Abnormalities of Vascular 

and Myocardial Function on Cardiac MRI 

Bara Erhayiem 1 , Adam McDiarmid 1 , Peter Swoboda 1 , 

Ananth Kidambi 1 , David Ripley 1 , Tarique Musa 1 , 

Laura Dobson 1 , Pankaj Garg 1 , Sarah Horton 1 , Raluca 

Dumitru 2 , Jacqueline Andrews 3 , John Greenwood 1 , Paul 

Emery 3 , Sven Plein 1 and Maya Buch 4 , 1 University of 

Leeds, Leeds, United Kingdom, 2 University of Leeds, 

Leeds Institute of Molecular Medicine and LMBRU, 

Leeds, United Kingdom, 3 NIHR-Leeds Musculoskeletal 

Biomedical Research Unit and Leeds Institute of 

Rheumatic and Musculoskeletal Medicine, University 

of Leeds, Leeds, United Kingdom, 4 NIHR - Leeds 



2 0 1 5 


tracker 

plus 

135 


Musculoskeletal Biomedical Research Unit, Leeds, 


5:30 pm 

2130. Primary Prevention of Myocardial Infarction 

in Rheumatoid Arthritis Using Low-Dose Aspirin: A 

Case-Crossover Study 

Josefina Durán Santa Cruz 1 , Yuqing Zhang 2 and David T. 

Felson 2 , 1 Pontificia Universidad Católica de Chile School 

of Medicine, Santiago, Chile, 2 Boston University School 

of Medicine, Boston, MA 

5:45 pm 

2131. Younger Age and Female Gender Are the 

Main Determinants of Underestimation of 

Cardiovascular Risk in Rheumatoid Arthritis 

Patients 

Calin Popa 1 , Alexander Rennings 1 , Alfons A. den 

Broeder 2 , Frank H.J. van den Hoogen 2 , Inger L. Meek 1 

and Jaap Fransen 1 , 1 Radboud University Nijmegen 

Medical Centre, Nijmegen, Netherlands, 2 Sint 

Maartenskliniek, Nijmegen, Netherlands 

North – 132 


Pathogenesis II 

Moderators: Cem Gabay, MD and Alessandra B. Pernis, 

MD 

4:30 pm 

2132. Monocarboxylate Transporter 4, Associated 

with the Acidification of Synovial Fluid, Is a Novel 

Therapeutic Target for Inflammatory Arthritis 

Wataru Fujii 1 , Eishi Ashihara 2 , Hidetake Nagahara 1 , Yuji 

Kukida 1 , Takahiro Seno 1 , Aihiro Yamamoto 1 , Masataka 

Kohno 1 , Ryo Oda 3 , Daigo Taniguchi 1 , Hiroyoshi 

Fujiwara 3 , Tsunao Kishida 1 , Osam Mazda 1 and Yutaka 

Kawahito 1 , 1 Graduate School of Medical Science, Kyoto 

Prefectural University of Medicine, Kyoto, Japan, 2 Kyoto 

Pharmaceutical University, Kyoto, Japan, 3 Graduate 

School of Medical Science, Kyoto Prefectural University 

of Medicine, kyoto, Japan 

4:45 pm 

2133. Receptor Protein Tyrosine Phosphatase Alpha 

Enhances Rheumatoid Synovial Fibroblast Signaling 

and Promotes Arthritis in Mice 

Stephanie M. Stanford 1 , Mattias N. D. Svensson 1 , 

Cristiano Sacchetti 1 , Caila A. Pilo 1 , Dennis J. Wu 1 , William 

B. Kiosses 2 , Annelie Hellvard 3 , Brith Bergum 3 , German 

R. Aleman Muench 1 , Christian Elly 1 , Yun-Cai Liu 1 , Jeroen 

den Hertog 4 , Ari Elson 5 , Jan Sap 6 , Piotr Mydel 3 , David 

L. Boyle 7 , Maripat Corr 7 , Gary S. Firestein 7 and Nunzio 

Bottini 1 , 1 La Jolla Institute for Allergy and Immunology, 

La Jolla, CA, 2 The Scripps Research Institute, La Jolla, CA, 

3 

Broegelmann Research Laboratory, Bergen, Norway, 

4 

Institute of Biology Leiden, Leiden, Netherlands, 

5 

Weizmann Institute of Science, Rehovot, Israel, 

6 

Université Paris Diderot Sorbonne Paris Cité, Paris, 

France, 7 University of California at San Diego School of 

Medicine, La Jolla, CA 

5:00 pm 

2134. Metabolic Reprogramming in the Inflamed 

Joint Inhibits Pro-Inflammatory Mechanisms 

Monika Biniecka 1 , Mary Canavan 1 , Chin Teck Ng 2 , 

Wei Gao 1 , Thomas Smith 3 , Trudy McGarry 4 , Douglas 

J. Veale 4 and Ursula Fearon 4 , 1 Centre for Arthritis and 

Rheumatic Diseases, Dublin Academic Medical Centre, 

Dublin, Ireland, 2 University of Malaya, Kuala Lumpur, 

Malaysia, 3 St Vincent’s University Hospital, Dublin, 

Ireland, 4 Centre for Arthritis and Rheumatic Diseases, 

Dublin Academic Medical Centre, Dublin 4, Ireland 

5:15 pm 

2135. miRNA-223 Delivery to Synovial Fibroblasts 

Via Monocyte-Derived Extracellular Vesicles 

Promotes Their Proliferation 

Florian M.P. Meier 1 , Derek S. Gilchrist 1 , Derek Baxter 2 , 

Diane Vaughan 1 , Margaret Mullin 1 , David W. McCarey 3 , 

Pawel Herzyk 1 , Julie Galbraith 1 , Donna McIntyre 1 , 

Russka Shumnalieva 4 , Ulf Müller-Ladner 5 , Iain B. 

McInnes 1 and Mariola Kurowska-Stolarska 1 , 1 University 

of Glasgow, Glasgow, United Kingdom, 2 University 

Hospital Ayr, Ayr, United Kingdom, 3 Glasgow Royal 

Infirmary, Glasgow, United Kingdom, 4 Clinic of 

Rheumatology, Sofia, Bulgaria, 5 Justus-Liebig-University 

of Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany 

5:30 pm 

2136. Identification of Synovial Fibroblast Subsets 

That Define Pathology in Rheumatoid Arthritis 

Fumitaka Mizoguchi 1 , Kamil Slowikowski 1 , Sook Kyung 

Chang 1 , Deepak A. Rao 1 , Hung Nguyen 1 , Erika H. Noss 1 , 

Brandon E. Earp 1 , Philip E. Blazar 1 , John Wright 1 , Barry 

P. Simmons 1 , Nir Hacohen 2 , Peter A. Nigrovic 1 , Soumya 


136 




Raychaudhuri 3 and Michael B. Brenner 1 , 1 Brigham and 


MA, 2 Harvard Medical School, Boston, MA, 3 Broad 

Institute of MIT and Harvard, Cambridge, MA 

5:45 pm 

2137. Critical Role of Fibroblast-like Synoviocytes 

Glycolytic Metabolism in Rheumatoid Arthritis 

Ricard Garcia-Carbonell 1 , Ajit Divakaruni 1 , Alessia Lodi 2 , 

Ildefonso Vicente-Suarez 3 , Hilde Cheroutre 3 , Gerry 

Boss 1 , Arindam Saha 1 , Stefano Tiziani 2 , Anne Murphy 1 , 

Gary S. Firestein 1 and Monica Guma 1 , 1 University of 

California, San Diego, La Jolla, CA, 2 University of Texas 

at Austin, Austin, TX, 3 LIAI, La Jolla, CA 


Rheumatoid Arthritis – Small Molecules, 

Biologics and Gene Therapy IV: Safety of 

Targeted Therapies 

Moderators: Howard Fuchs, MD and Piet L. van Riel, 

MD, PhD 

4:30 pm 

2138. Safety and Efficacy Results of a Phase 2, 

Double-Blind, Placebo-Controlled Clinical Study of 

Duvelisib with Background Methotrexate (MTX) 

in Adults with Moderate-to-Severe Rheumatoid 

Arthritis (RA) 

Richard Leff 1 , Sunil Kumar 2 , Natalia Nikulenkova 3 , 

Igor Kaidashev 4 , Kerstin Allen 1 , Joi Dunbar 1 , Howard 

Stern 1 , Julian Adams 1 and Michael Weinblatt 5 , 1 Infinity 

Pharmaceuticals, Inc., Cambridge, MA, 2 Centre for 

Clinical Research and Effective Practice (CCRep), 

Auckland, New Zealand, 3 State Budgetary Healthcare 

Institution of Vladimir Region, Regional Clinical 

Hospital, Vladimir, Russia, 4 City Clinical Hospital #1 of 

Poltava City, Poltava, Ukraine, 5 Brigham and Women’s 


4:45 pm 

2139. Results of a Phase 1b/2a Study of the 

Safety, Tolerability, Pharmacokinetics and 

Pharmacodynamics of XmAb ® 5871 in Patients with 

Rheumatoid Arthritis (RA) 

Debra Zack 1 , Maria Jaraczewska Baumann 2 , Mariusz 

Korkosz 3 , Gabriella Suljok 4 , Petr Sramek 5 , Bernadette 

Rojkovich 6 , Stafan Daniluk 7 , Janos Bartalos 8 and Paul 

Foster 1 , 1 Xencor, Inc., San Diego, CA, 2 NZOZ Centrum 

Medyczne HCP, Poznan, Poland, 3 The University 

Hospital in Krakow, Krakow, Poland, 4 Drug Research 

Center Ltd., Baltonfüred, Hungary, 5 PRA CZ, Praha, 

Czech Republic, 6 Polyclinic of the Hospitaller Brothers 

of St John of God, Budapest, Hungary, 7 NZOZ Center 

of Osteoporosis and Osteoarticular Diseases, 

Bialystok, Poland, 8 PRA Hungary Ltd, Budapest, 

Hungary 

5:00 pm 

2140. Drug Specific Risk and Associated Factors 

for Vasculitis-like Events in Patients Exposed to 

Tumour Necrosis Factor-Î± Inhibitor Therapy: 

Results from the British Society for Rheumatology 

Biologics Register for Rheumatoid Arthritis 

Meghna Jani 1 , William G Dixon 2 , Lianne Kearsley- 

Fleet 2 , Ian N. Bruce 3 , Hector Chinoy 4 , Anne Barton 5 , 

Mark Lunt 1 , Kath Watson 2 , Deborah P.M. Symmons 1 , 

Kimme L. Hyrich 2 and on behalf of the BSRBR-RA, 

1 

Arthritis Research UK Centre for Epidemiology, 

Manchester, United Kingdom, 2 Arthritis Research 

UK Centre for Epidemiology, The University of 

Manchester, Manchester, United Kingdom, 3 NIHR 

Manchester Musculoskeletal Biomedical Research 

Unit, Manchester, United Kingdom, 4 Centre for 

Musculoskeletal Research, University of Manchester, 

Manchester, United Kingdom, 5 NIHR Manchester 

Musculoskeletal Biomedical Research Unit, Central 

Manchester Foundation Trust and University of 

Manchester, Manchester Academy of Health Sciences, 

Manchester, United Kingdom 

5:15 pm 

2141. Risk of Cancer in Non-TNFi Biologics-Treated 

RA 

Hjalmar Wadström 1 , Johan Askling 2 and the ARTIS 

study group, 1 Clinical Epidemiology Unit, Department 

of Medicine, Karolinska Institute, Stockholm, Sweden, 

2 




5:30 pm 

2142. Comparison of Interferon-y Release 

Assay Versus Tuberculin Skin Test in the 

Golimumab UC and the Golimumab SC 

Rheumatology (RA, PsA, and AS) Clinical Study 

Programs 



2 0 1 5 


tracker 

plus 

137 


Elizabeth C. Hsia 1 , Neil Schluger 2 , John J. Cush 3 , Eric 

L. Matteson 4 , Stephen Xu 1 , William Sandborn 5 , Paul 

Rutgeerts 6 and Colleen Marano 1 , 1 Janssen Research 

& Development, LLC, Spring House, PA, 2 Columbia 

U College of Physicians & Surgeons, New York, 

NY, 3 Baylor Research Institute, Dallas, TX, 4 Mayo 

Clinic, Rochester, MN, 5 Inflammatory Bowel Disease 

Center, Division of Gastroenterology, Department 

of Medicine, University of California San Diego, La 

Jolla, California, La Jolla, CA, 6 University Hospital 

Gasthuisberg, Leuven, Belgium 

5:45 pm 

2143. A Safety Analysis of Tofacitinib 5mg Twice 

Daily Administered As Monotherapy or in 

Combination with Background Conventional 

Synthetic Dmards in a Phase 3 Rheumatoid 

Arthritis Population 

Alan J Kivitz 1 , Boulos Haraoui 2 , Jeffrey Kaine 3 , Vanessa 

Castellano 4 , Eustratios Bananis 4 , Carol A Connell 5 , 

Elaine Hoffman 5 and Liza Takiya 6 , 1 Altoona Center 

for Clinical Research, Duncansville, PA, 2 Institut de 

Rhumatologie de Montréal, Montréal, QC, 3 Sarasota 

Arthritis Research Center, Sarasota, FL, 4 Pfizer Inc, 

Collegeville, PA, 5 Pfizer Inc, Groton, CT, 6 Pfizer Inc, 

New York, NY 


Spondylarthropathies (SpA) and Psoriatic 

Arthritis (PsA)- Clinical Aspects and 

Treatment:Treatment of PsA and SpA 

Moderators: Atul A. Deodhar, MD and Dafna D. 

Gladman, MD 

4:30 pm 

2144. Efficacy and Safety of Different Dose 

Regimens of a Selective IL-23p19 Inhibitor (BI 

655066) Compared with Ustekinumab in Patients 

with Moderate-to-Severe Plaque Psoriasis with and 

without Psoriatic Arthritis 

Kim Papp 1 , Alan Menter 2 , Howard Sofen 3 , Stephen 

Tyring 4 , Jean-Philippe Lacour 5 , Beate Berner 6 , Nathan 

Bennett 7 , Stella Aslanyan 7 , Mary Flack 7 and Paul 

Scholl 7 , 1 Probity Clinical Research, Waterloo, ON, 

2 

Baylor Research Institute, Dallas, TX, 3 Dermatology 

Research Associates, Los Angeles, CA, 4 Center for 

Clinical Studies, Houston, TX, 5 Hôpital de L’Archet, 

Nice, France, 6 Boehringer Ingelheim Pharma GmbH 

& Co. KG, Biberach, Germany, 7 Boehringer Ingelheim 

Pharmaceuticals Inc., Ridgefield, CT 

4:45 pm 

2145. Ixekizumab Improves Physical Function, 

Quality of Life, and Work Productivity in Biologic 

Disease-Modifying Antirheumatic Drug-Naive 

Patients with Active Psoriatic Arthritis 

Alice B. Gottlieb 1 , Philip J. Mease 2 , Raquel S. 

Cuchacovich 3 , Catherine L. Shuler 3 , Chen-Yen Lin 3 , 

Russel T. Burge 3 , Suvajit Samanta 3 , Chin H. Lee 3 and 

Dafna D. Gladman 4 , 1 Tufts Medical Center, Boston, MA, 

2 

Swedish Medical Center and University of Washington, 

Seattle, WA, 3 Eli Lilly and Company, Indianapolis, IN, 

4 

University of Toronto, Toronto, ON 

5:00 pm 

2146. Secukinumab Provides Sustained 

Improvements in the Signs and Symptoms of Active 

Psoriatic Arthritis in Anti-TNF-Naive Patients and 

Those Previously Exposed to Anti-TNF Therapy: 

52-Week Results from a Randomized, Double- 

Blind, Placebo-Controlled Phase 3 Trial with 

Subcutaneous Dosing 

Arthur Kavanaugh 1 , Iain B. McInnes 2 , Philip J. Mease 3 , 

Stephan Hall 4 , Hector Chinoy 5 , Alan J Kivitz 6 , Manmath 

Patekar 7 , Zailong Wang 8 and Shephard Mpofu 9 , 

1 

University of California, San Diego School of Medicine, 

LaJolla, CA, 2 University of Glasgow, Glasgow, United 

Kingdom, 3 Swedish Medical Center and University of 

Washington School of Medicine, Seattle, WA, 4 Monash 

University, Melbourne, Australia, 5 University of 

Manchester, Manchester, United Kingdom, 6 Altoona 

Center for Clinical Research, Duncansville, PA, 7 Novartis 

Healthcare Pvt. Ltd., Hyderabad, India, 8 Novartis 


9 


5:15 pm 

2147. The Effect of Sulfasalazine and Methotrexate 

on the Immunogenicity of Infliximab and 

Adalimumab in Patients with Spondyloarthritis 

Ana Martínez 1 , Chamaida Plasencia-Rodriguez 2 , Dora 

Pascual-Salcedo 3 , Eva L. Kneepkens 4 , Gertjan Wolbink 4 , 

Alejandro Villalba 2 , Teresa Jurado 1 , Diana Peiteado 2 , 

Laura Nuño 2 , Andrea Jochems 1 and Alejandro Balsa 2 , 


138 




1 

La Paz University Hospital-IdiPaz, MADRID, Spain, 2 La 

Paz University Hospital-Rheumatology Department, 

Madrid, Spain, 3 La Paz University Hospital-Immunology, 

Madrid, Spain, 4 Jan van Breemen Research Institute | 

Reade, Amsterdam, Netherlands 

5:30 pm 

2148. Secukinumab Provides Sustained 

Improvements in Psoriatic Arthritis: 2-Year Efficacy 

and Safety Results from a Phase 3 Randomized, 

Double-Blind, Placebo-Controlled Trial 

Philip J. Mease 1 , Iain B. McInnes 2 , Bruce Kirkham 3 , 

Arthur Kavanaugh 4 , Proton Rahman 5 , Désirée van 

der Heijde 6 , Robert B.M. Landewé 7 , P Nash 8 , Luminita 

Pricop 9 , Zailong Wang 9 and Shephard Mpofu 10 , 

1 

Swedish Medical Center and University of Washington 

School of Medicine, Seattle, WA, 2 Institute of Infection, 

Immunity and Inflammation, College of Medicine, 

Veterinary Medicine and Life Sciences, University 

of Glasgow, Glasgow, United Kingdom, 3 Guy’s and 

St Thomas’ NHS Foundation Trust, London, United 

Kingdom, 4 University of California, San Diego School 

of Medicine, LaJolla, CA, 5 Memorial University, St 

John’s, NF, 6 Leiden University Medical Center, Leiden, 

Netherlands, 7 University of Amsterdam and Atrium 

Medical Center, Amsterdam, Netherlands, 8 University 

of Queensland, Brisbane, Australia, 9 Novartis 


10 


5:45 pm 

2149. Dose Reduction Compared with Standard 

Dosing for Maintenance of Remission in Patients 

with Spondyloarthropathies and Clinical Remission 

with Anti-TNF: A Randomised Real-Life Trial 

Jorge Gratacos-Masmitja 1 , Caridad Pontes 1 , Ferran 

Torres 2 , Xavier Juanola 3 , Antoni Vallano 4 , TC 

Salman-Monte 5 , Francisco J. Blanco 6 , Agusti Sellas- 

Fernandez 7 , Raimon Sanmarti 8 , Gonzalo Calvo 9 , Teresa 

Clavaguera 10 , Raul Veroz Gonzalez 11 , Juan Carlos 

Torre Alonso 12 , Jesus Sanz 13 , Cristina Avendaño 14 , 

Carlos Rodriguez-Lozano 15 , Luis Francisco Linares 16 , 

Ana Urruticoechea 17 , Eduardo Collantes-Estévez 18 , 

Rosa Morla Novell 19 , Delia Reina 20 , Eduardo Cuende 21 , 

Pedro Zarco 22 , Cruz Fernández- Espartero 23 , Rosario 

Garcia-Vicuña 24 , Carlos Alberto Montilla Morales 25 , 

Eugenio De Miguel 26 , Roser Vives 1 and Mireia Moreno 1 , 

1 

Hospital de Sabadell - Institut Universitari Parc 

Taulí, Sabadell, Spain, 2 IDIBAPS - Hospital Clínic de 

Barcelona, Barcelona, Spain, 3 Hospital Universitari 

de Bellvitge, Barcelona, Spain, 4 Hospital de Bellvitge, 

Barcelona, Spain, 5 Hospital del Mar/Parc de Salut Mar, 

Barcelona, Spain, 6 Rheumatology Division, Proteomics 

Group-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, 

Spain, 7 Hospital Universitario Valle Hebron, Barcelona, 

Spain, 8 Hospital Clinic i Provincial, Barcelona, Spain, 

9 

Hospital Clínic de Barcelona, Barcelona, Spain, 

10 

CapiCAT group (Nailfold Capillaroscopy group from 

the Catalan Society for Rheumatology)., Catalonia, 

Spain, 11 Hospital de Mérida, Mérida, Spain, 12 H. Monte 

Naranco, Oviedo, Spain, 13 Hospital Puerta de Hierro 

Majadahonda, Madrid, Spain, 14 Hospital Puerta de 

Hierro - Majadahonda, Madrid, Spain, 15 Hospital 

Ubniversitario Dr. Negrin, Las Palmas de Gran Canaria, 

Spain, 16 Hospital Virgen de la Arrixaca, Murcia, Spain, 

17 

Hospital Can Misses, Ibiza, Spain, 18 IMIBIC-Reina Sofia 

University Hospital, Rheumatology Unit, Cordoba, 

Spain, 19 Hospital Sta Tecla, Tarragona, Spain, 20 Hospital 

de Sant Joan Despí Moisès Broggi, Barcelona, Spain, 

21 

University Hospital Príncipe de Asturias, Immune 

System Diseases, Rheumatology department, Alcalá 

de Henares, Madrid, Spain, 22 H Fundación Alcorcón, 

Alcorcón, Spain, 23 Hospital La Zarzuela, Madrid, Spain, 

24 

Hospital Universitario de La Princesa. IIS La Princesa, 

Madrid, Spain, 25 Hospital Universitario de Salamanca, 

Salamanca, Spain, 26 University Hospital La Paz, Madrid, 

Spain 

West – 3001 

Systemic Sclerosis, Fibrosing Syndromes and 

Raynaud’s – Pathogenesis, Animal Models and 

Genetics I 

Moderators: Jessica K. Gordon, MD, MSc and Robert 

Lafyatis, MD 

4:30 pm 

2150. Treatment with Abatacept Prevents 

Experimental Dermal Fibrosis and Induces 

Regression of Established Inflammation-Driven 

Fibrosis 

Matthieu Ponsoye 1 , Camelia Frantz 2 , Nadira Ruzehaji 3 , 

Muriel Elhai 1 , Barbara Ruiz 1 , Anne Cauvet 1 , Yannick 

Allanore 4 and Jerome Avouac 1 , 1 Paris Descartes 



2 0 1 5 


tracker 

plus 

139 


University, Cochin Hospital, Paris, France, 2 Paris 

Descartes University, Rheumatology A department, 

Cochin Hospital, Paris, France, 3 Paris Descartes 

University, Paris, France, 4 Paris Descartes University, 

Rheumatology A department, Cochin Hospital, And 

Eular Scleroderma Trials And Research (EUSTAR) 

Board, Paris, France 

4:45 pm 

2151. Inhibition of Myeloid-Associated Gene 

Expression in Skin Biopsy Samples of Systemic 

Sclerosis Patients Treated with Tocilizumab 

Thierry Sornasse 1 , Haiyin Chen 1 , Lisa Rice 2 , Giuseppina 

Stifano 2 , Angelika Jahreis 1 , Jeffrey Siegel 1 and Robert 

Lafyatis 2 , 1 Genentech, South San Francisco, CA, 2 Boston 

University School of Medicine, Boston, MA 

5:00 pm 

2152. Long Noncoding H19X Is a Key Mediator 

of Tgf-Beta Induced Pro-Fibrotic Effects in the 

Pathogenesis of Systemic Sclerosis and Other 

Fibrotic Diseases 

Elena Pachera 1 , Shervin Assassi 2 , Gloria Salazar 2 , Mojca 

Frank Bertoncelj 3 , Rucsandra Dobrota 4 , Matthias 

Brock 1 , Serena Vettori 5 , Claus Hellerbrand 6 , Carol 

A. Feghali-Bostwick 7 , Jeorg HW Distler 8 , Gabriela 

Kania 9 and Oliver Distler 10 , 1 University Hospital 

Zurich, Schileren, Switzerland, 2 University of Texas 

Medical School at Houston, Houston, TX, 3 Center 

of Experimental Rheumatology, University Hospital 

Zurich, University Zurich, Zurich, Switzerland, 4 Division 

of Rheumatology, University Hospital Zurich, Zurich, 

Switzerland, 5 Rheumatology Unit, Second University 

of Naples, Naples, Italy, 6 University of Regensburg, 

Regensburg, Germany, 7 University of Pittsburgh, 

Pittsburgh, PA, 8 University of Erlangen-Nuremberg, 

Erlangen, Germany, 9 University Hospital Zurich, 8952 

Schlieren, Switzerland, 10 Division of Rheumatology, 

University Hospital And Eular Scleroderma Trials And 

Research (EUSTAR) Board, Zurich, Switzerland 

5:15 pm 

2153. Nintedanib Ameliorates Fibrotic and Vascular 

Manifestations in Preclinical Models of Systemic 

Sclerosis 

Jingang Huang 1 , Christian Beyer 2 , Yun Zhang 2 , Katrin 

Palumbo-Zerr 1 , Clara Dees 1 , Oliver Distler 3 , Georg 

A. Schett 1 , Stefan Lutz Wollin 4 and Jorg HW. Distler 1 , 

1 

Department of Internal Medicine 3 and Institute 

for Clinical Immunology, University of Erlangen- 

Nuremberg, Erlangen, Germany, 2 University of 

Erlangen-Nuremberg, Erlangen, Germany, 3 Research 

of Systemic Autoimmune Diseases, University Hospital 

Zurich, Zurich, Switzerland, 4 Boehringer-Ingelheim 

Pharma, Div. Research Germany, Bad Biberach, 

Germany 

5:30 pm 

2154. Inhibition of Gli Ameliorates the Pro-Fibrotic 

Effects of Transforming Growth Factor-Î² in 

Systemic Sclerosis 

Ruifang Liang 1 , Clara Dees 1 , Katrin Palumbo-Zerr 1 , Yun 

Zhang 1 , Oliver Distler 2 , Georg Schett 1 and Jeorg HW 

Distler 1 , 1 University of Erlangen-Nuremberg, Erlangen, 

Germany, 2 Division of Rheumatology, University 

Hospital And Eular Scleroderma Trials And Research 

(EUSTAR) Board, Zurich, Switzerland 

5:45 pm 

2155. Inhibition of Sphingosine-1-Phosphate 

Signaling By AB22 As a Novel Strategy in the 

Treatment of Pulmonary Fibrosis Associated with 

Scleroderma 

Ilia Atanelishvili 1 , Yuichiro Shirai 2 , Tanjina Akter 3 , Erik 

Stolarzewicz 4 , Rolf E Swenson 5 , Richard Silver 6 and 

Galina S. Bogatkevich 6 , 1 Medical University of South 

Carolina,Charleston,USA, Charleston, SC, 2 Nippon 

Medical School, Tokyo, Japan, Tokyo, Japan, 3 Medical 

University of South Carolina, charleston, SC, 4 Chem- 

Master International Inc, Stony Brook, NY, 5 Arroyo 

BioSciences, Silver Spring, MD, 6 Medical University of 

South Carolina, Charleston, SC 

West – 2022 

Vasculitis II 

Moderators: Andreas P. Diamantopoulos, MD, PhD and 

Robert F. Spiera, MD 

4:30 pm 

2156. Damage Assessment in Giant Cell Arteritis 

Tanaz A. Kermani 1 , Antoine G. Sreih 2 , David 

Cuthbertson 3 , Simon Carette 4 , Gary S. Hoffman 5 , 

Nader A. Khalidi 6 , Curry L. Koening 7 , Carol A. 

Langford 5 , Carol A. McAlear 8 , Paul A. Monach 9 , Larry 

W. Moreland 10 , Christian Pagnoux 4 , Philip Seo 11 , 


140 




Kenneth J. Warrington 12 , Steven R. Ytterberg 12 and 

Peter A. Merkel 8 , 1 University of California Los Angeles, 

Santa Monica, CA, 2 Hospital of the University of 

Pennsylvania, Philadelphia, PA, 3 University of South 

Florida, Tampa, FL, 4 Mount Sinai Hospital, University 

of Toronto, Toronto, ON, 5 Cleveland Clinic, Cleveland, 

OH, 6 McMaster University, Hamilton, ON, 7 University 

of Utah, Salt Lake City, UT, 8 University of Pennsylvania, 

Philadelphia, PA, 9 Boston University School of 

Medicine, Boston, MA, 10 University of Pittsburgh, 

Pittsburgh, PA, 11 Johns Hopkins University, Baltimore, 

MD, 12 Mayo Clinic, Rochester, MN 

4:45 pm 

2157. Relapse Characteristics and Glucocorticoid 

Use in Patients with Biopsy-Proven Giant Cell 

Arteritis 

Matthew J. Koster 1 , Cristian Labarca 2 , Cynthia S. 

Crowson 1 , Ashima Makol 1 , Steven R. Ytterberg 3 , Eric L. 

Matteson 1 and Kenneth J. Warrington 1 , 1 Mayo Clinic, 

Rochester, MN, 2 Clinica Alemana Universidad del 

Desarrollo, Santiago, Chile, 3 Mayo Clinic College of 

Medicine, Rochester, MN 

5:00 pm 

2158. Mortality Associated with Giant Cell Arteritis 

from 1980 to 2011: An Analysis of the French 

National Death Certificate Database 

Achille Aouba 1 , Solange Gonzalez-Chiappe 2 , Mireille 

Eb 3 , Claire Delmas 1 , Grégoire Rey 3 , Alfred Mahr 2 

and Boris Bienvenu 1 , 1 Hospital Caen, Caen, France, 

2 

Hospital Saint-Louis, Paris, France, 3 Hospital Bicêtre, 

Le Kremlin-Bicêtre, France 

5:15 pm 

2159. Second Temporal Artery Biopsies in Patients 

with Temporal Arteritis (TA) 

John Fritzlen 1 , Brian Younge 1 , Cornelia M. Weyand 2 , 

Gene G. Hunder 1 , Jorg Goronzy 3 , Kenneth J. Warrington 1 

and Joseph Maleszewski 1 , 1 Mayo Clinic, Rochester, MN, 

2 

Stanford, Stanford, CA, 3 Lowance Center for Human 

Immunology and Rheumatology, Atlanta, GA 

5:30 pm 

2160. The Role of Ultrasound Compared to Biopsy of 

Temporal Arteries in the Diagnosis and Treatment 

of Giant Cell Arteritis: A Diagnostic Accuracy and 

Cost-Effectiveness Study 

Raashid Luqmani 1 , Ellen Lee 2 , Surjeet Singh 1 , Michael 

Gillett 2 , Wolfgang A. Schmidt 3 , Mike Bradburn 2 , 

Bhaskar Dasgupta 4 , Andreas P Diamantopoulos 5 , 

Wulf Forrester-Barker 1 , William Hamilton 6 , Shauna 

Masters 1 , Brendan McDonald 7 , Eugene McNally 1 , Colin 

T. Pease 8 , Jennifer Piper 1 , John Salmon 7 , Allan Wailoo 2 , 

Konrad Wolfe 4 , Andrew Hutchings 9 and TABUL Study 

group, 1 University of Oxford, Oxford, United Kingdom, 

2 

University of Sheffield, Sheffield, United Kingdom, 

3 

Immanuel Krankenhaus Berlin, Berlin, Germany, 

4 

Southend University Hospital, Essex, United Kingdom, 

5 

Hospital of Southern Norway Trust, Kristiansand, 

Norway, 6 University of Exeter, Exeter, United Kingdom, 

7 

Oxford University Hospitals NHS Trust, Oxford, United 

Kingdom, 8 Leeds Teaching Hospitals NHS Trust, Leeds, 

United Kingdom, 9 London School of Hygiene and 

Tropical Medicine, London, United Kingdom 

5:45 pm 

2161. Ustekinumab for the Treatment of Refractory 

Giant Cell Arteritis 

Richard Conway 1 , Lorraine O’Neill 2 , Eileen O’Flynn 2 , 

Geraldine M. McCarthy 3 , Conor Murphy 4 , Douglas J. 

Veale 5 , Ursula Fearon 5 and Eamonn S. Molloy 6 , 1 CARD 

Newman Research Fellow, University College Dublin, 

Dublin, Ireland, 2 Dublin Academic Medical Centre, 

St. Vincent’s University Hospital, Dublin, Ireland, 

3 

University College Dublin, Dublin, Ireland, 4 Royal 

Victoria Eye and Ear Hospital, Dublin, Ireland, 5 Centre 

for Arthritis and Rheumatic Diseases, Dublin Academic 

Medical Centre, Dublin 4, Ireland, 6 Centre for Arthritis 

and Rheumatic Diseases, Dublin Academic Medical 

Centre, St Vincent’s University Hospital, Dublin 4, 

Dublin 4, Ireland 


4:30 – 6:00 pm 











2 0 1 5 


tracker 

plus 

141 




August 30. 

West – 3003 

051 – Adult Inflammatory Myopathy 

Speaker: Robert L. Wortmann, MD, MACR 

West – 3005 

052 – Behçet’s Syndrome 

Speaker: Yusuf Yazici, MD 

West – 3007 

053 – Imaging of Crystal Arthritis 

Speaker: Ralf G. Thiele, MD, RhMSUS 

West – 3009 

054 – Pediatrics: Periodic Fevers in Children 

PM Ed Pd PS PM PrM PS FIT E 

Speaker: Philip Kahn, MD 

West – 3011 

055 – Polymyalgia Rheumatica 

Speaker: Antoine G. Sreih, MD 

West – 3016 

056 – Rheumatology Practice 101: Starting Out 

in Practice for the Graduating PM Ed Fellow Pd PS PrM FIT 

Speaker: Alexandru F. Kimel, MD 

West – 3018 

057 – Systemic Lupus Erythematosus: Difficult 

to Treat Systemic Lupus Erythematosus 

Speaker: Eliza Chakravarty, MD, MS 

West – 3020 

058 – Systemic Sclerosis: Disease Staging and 

Subsetting in Clinical Practice 

Speaker: Robyn T. Domsic, MD, MPH 

West – 3022 

*059 – Vasculitis Mimics 

Speaker: Peter A. Merkel, MD, MPH 

West – 3024 

060 – Vasculitis: Factors That Influence Disease 

Patterns 

Speaker: Kenneth J. Warrington, MD 

ACR/ARHP COMBINED ABSTRACT 

SESSION 

4:30 – 6:00 pm 

West – 2004 

ACR/ARHP Combined Abstract Session: 

Epidemiology and Pubic Health 

Moderators: Elizabeth G. Salt, PhD and Murray Urowitz, 

MD 

4:30 pm 

2162. Associations Between Education and Health 

Status Among Hispanics with Self-Reported 

Arthritis and/or Joint Pain 

Leigha Vilen 1 , Rebecca J. Cleveland 1 , Alfredo 

Rivadeneira 1 , Mary Altpeter 1 , Betsy Hackney 2 , Victoria 

Sepulveda 1 and Leigh F. Callahan 2 , 1 University of North 

Carolina at Chapel Hill, Chapel Hill, NC, 2 University of 

North Carolina, Chapel Hill, NC 

4:45 pm 

2163. Associations Between Sex Differences, Pain, 

Insomnia, and Depression in Older Adults with 

Osteoarthritis: A Cross-Sectional Study 

Minhui Liu 1 , Susan McCurry 1 , Michael Vitiello 2 , 

Basia Belza 1 and Michael Von Korff 3 , 1 University of 

Washington School of Nursing, Seattle, WA, 2 University 

of Washington School of Medicine, Seattle, WA, 3 Group 

Health Research Institute, Seattle, WA 

5:00 pm 

2164. Burden of Symptomatic Knee Osteoarthritis 

in the United States: Impact of Race/Ethnicity, Age 

and Sex 

Bhushan Deshpande 1 , Jeffrey N. Katz 2 , Daniel H. 

Solomon 2 , Edward H. Yelin 3 and Elena Losina 2 , 


142 




1 

Brigham and Women’s Hospital, Boston, MA, 2 Brigham 

and Women’s Hospital and Harvard Medical School, 

Boston, MA, 3 University of California, San Francisco, 

San Francisco, CA 

5:15 pm 

2165. Awareness and Reasons for Lack of Post- 

Fracture Osteoporosis Therapy: A Survey of Post- 

Menopausal Women 

Denise Boudreau 1 , Onchee Yu 1 , Akhila 

Balasubramanian 2 , Jane Grafton 1 , Heidi Wirtz 3 , Andreas 

Grauer 3 , D. Barry Crittenden 3 and Delia Scholes 1 , 

1 

Group Health Research Institute, Seattle, WA, 2 Amgen, 

Inc., Thousand Oaks, CA, 3 Amgen Inc., Thousand Oaks, 

CA 

5:30 pm 

2166. Work Productivity in Newly Diagnosed, 

Untreated Rheumatoid Arthritis Patients 

Siri Lillegraven 1 , Nina P. Sundlisæter 1 , Anna-Birgitte 

Aga 1 , Inge C Olsen 1 , Till Uhlig 1 , Tore K. Kvien 1 , Espen 

A. Haavardsholm 1 and The ARCTIC study group, 

1 

Diakonhjemmet Hospital, Oslo, Norway 

5:45 pm 

2167. Application of Combined Reporting of 

Benefit and Harm (OMERACT 3x3 methodology) 

to the Rheumatoid Arthritis Comparison of Active 

Therapies Trial 

Maarten Boers 1 , Sarah Leatherman 2 , James R. O’Dell 3 

and Jeffrey R. Curtis 4 , 1 VU University Medical Center, 

Amsterdam, Netherlands, 2 VA Boston Healthcare 

System, Boston, MA, 3 University of Nebraska Medical 

Center, Omaha, NE, 4 Birmingham VAMC, Birmingham, 

AL 

ARHP SESSIONS 

4:30 – 6:00 pm 

West – 2006 

Ethical Issues of the Consent Process PM PS E 

Moderator: Bruce Hoffman, MD 

5:00 pm 

The Role of the Physician in the Consent Process 

Leyka Barbosa, MD 

5:30 pm 

The Role of the Research Coordinator in the Consent 

Process 

Deborah McCloskey, BSN, RN 

West – 2007 

Men, Masculinity and Rheumatoid Arthritis 

Moderator: Susan J. Bartlett, PhD 

4:30 pm 

To Focus on the Clinical Differences between Men and 

Women With Rheumatoid Arthritis 

Theodore Pincus, MD 

5:00 pm 

“That’s Why We all Keep Schtum”: The Experiences 

and Coping Styles of Men With Rheumatoid Arthritis 

Caroline Flurey, PhD MSc BSc (hons) 

5:30 pm 

Men in Medical Settings: Isolation or Inclusion? 

James May, BA, MEd, MA 

West – 2008 

Resilience: Functional and Neurobiological 

Influences PM PS E 


4:30 pm 

Pain and Affect: Where Experience and Neurobiology 

Merge 

Afton L. Hassett, PsyD 

5:15 pm 

Self-Regulation of Pain, Pain Measurement and 

Biomarkers 

Tor Wager, PhD 

4:30 pm 

The Role of the Institutional Review Board in the 

Consent Process 

Patricia P. Katz, PhD 


MONDAY & TUESDAY NOVEMBER 9, 10, 2015 

2 0 1 5 


tracker 

plus 

143 



4:30 – 6:00 pm 

West – 2016 

ARHP III: Epidemiology and Public Health 

Moderators: Kamil E. Barbour, PhD and Alyssa B. 

Dufour, PhD 

4:30 pm 

2168. The Smoking Paradox in the Development of 

Myocardial Infarction Among Rheumatoid Arthritis 

Patients 

Uyen Sa D.T. Nguyen 1 , Yuqing Zhang 2 , Na Lu 3 , Jingbo 

Niu 2 , David T. Felson 2 , Michael P. Lavalley 4 , Jeffrey A. 

Sparks 5 , Shun-Chiao Chang 6 , Elizabeth W. Karlson 5 and 

Hyon K. Choi 3 , 1 University of Massachusetts Medical 

School, Worcester, MA, 2 Boston University School 

of Medicine, Boston, MA, 3 Massachusetts General 

Hospital, Harvard Medical School, Boston, MA, 4 Boston 

University, Boston, MA, 5 Brigham & Women’s Hospital, 

Boston, MA, 6 Brigham and Women’s Hospital, Harvard 


4:45 pm 

2169. Low Education Is Associated with Mortality 

Among Individuals with Knee and/or Hip OA: The 

Johnston County Osteoarthritis Project 

Rebecca J. Cleveland 1 , Todd A. Schwartz 2 , Jordan B. 

Renner 2 , Joanne M. Jordan 2 and Leigh F. Callahan 2 , 

1 

University of North Carolina at Chapel Hill, Chapel Hill, 

NC, 2 University of North Carolina, Chapel Hill, NC 

5:00 pm 

2170. Sleep Efficiency and Cardiovascular Risk 

Burden in Rheumatoid Arthritis 

Samannaaz S. Khoja 1 , Gustavo J. Almeida 1 , Mary 

Chester M. Wasko 2 and Sara R. Piva 1 , 1 University of 

Pittsburgh, Pittsburgh, PA, 2 Lupus Center, Pittsburgh, 

PA 

5:15 pm 

2171. A Comparison of Maternal Outcomes in 

Women with and without Juvenile Idiopathic 

Arthritis 

Debbie Ehrmann Feldman 1 , Sasha Bernatsky 2 , 

Evelyne Vinet 3 , Ciarán M. Duffy 4 , Elizabeth Hazel 3 , 

Garbis Meshefedjian 5 , Marie-Pierre Sylvestre 6 and 

Anick Bérard 1 , 1 Université de Montréal, Montréal, QC, 

2 

McGill MUHC/RVH, Montreal, QC, 3 McGill University 

Health Centre, Montreal, QC, 4 Children’s Hospital of 

Eastern Ontario and University of Ottawa, Ottawa, ON, 

5 

Public Health Department of Montreal, Montreal, QC, 

6 

Université de Montréal, Montreal, QC 

5:30 pm 

2172. Distribution of Clinical Osteoarthritis and 

Associations to Health-Related Quality of Life in a 

Population-Based Osteoarthritis Cohort 

Guro Økelsrud Lombnæs 1 , Karin Magnusson 2 and 

Kåre Birger Hagen 1 , 1 Diakonhjemmet Hospital, Oslo, 

Norway, 2 National Advisory Unit on Rehabilitation in 

Rheumatology, Diakonhjemmet Hospital, Oslo, Norway 

5:45 pm 

2173. Impact of Smoking on Patient-Reported 

Disease Status and Symptoms Among Women with 

Lupus 

Patricia P. Katz 1 , Eliza Chakravarty 2 , Robert S. Katz 3 and 

Kaleb Michaud 4 , 1 University of California San Francisco, 

San Francisco, CA, 2 Oklahoma Medical Research 

Foundation, Oklahoma City, OK, 3 Rush University 

Medical Center, Chicago, IL, 4 University of Nebraska 

Medical Center, Omaha, NE 

ACR SESSIONS 

7:30 – 8:30 am 



Pathophysiology Synovitis in Rheumatoid 

Arthritis 

Moderator: Gregg J. Silverman, MD 

Speaker: Costantino Pitzalis, MD, PhD 


Rheumatology Research Foundation Paul 

Klemperer, MD Memorial Lecture: Old Dogs, 

New Tricks: Autoinflammatory Disease 

Reloaded 

Moderator: David R. Karp, MD, PhD 

Speaker: Daniel L. Kastner, MD, PhD 


144 




ARHP SESSIONS 

7:30 – 8:30 am 

West – 2007 

Environmental Influences and Rheumatic 

Diseases 

Moderator: Julia F Simard, ScD 

7:30 am 

Environmental Risk Factors for Rheumatoid Arthritis, 

Translating Epidemiology to Intervention 

Elizabeth W. Karlson, MD 

7:55 am 

Emerging Evidence on Environmental Risk Factors for 

Systemic Autoimmune Diseases, Leveraging Existing 

Cohorts to Identify Novel Risk Factors 

Christine Parks, PhD 

8:20 am 

Questions and Answers 

West – 2001 

Immunology Boot Camp III: Applying principles 

of Immunology to Treatment Decisions 



West – 2008 

Sexual Issues in Rheumatology: Assessment 

and Intervention 

Moderator: Jacob N. Ablin, MD 

7:30 am 

Overcoming the Barriers to Treat Sexual Dysfunction 

in the Rheumatology Patient 

Sharon Nesher Peleg, RN 

8:00 am 

Sexual Dysfunction in Rheumatic Diseases: Disease 

Impact and Management Strategies 

Mijal Luria, MD 

West – 2009 

What Do the Numbers Mean: Tools to Interpret 

Medical Literature 

Moderator: Uyen Sa D.T. Nguyen, DSc, MPH 

Speaker: Alyssa B. Dufour, PhD 


7:45 – 9:15 am 











August 30. 

West – 3003 

061 – Behçet’s Syndrome 

Speaker: Yusuf Yazici, MD 

West – 3005 

062 – Controversies in Sjögren’s Syndrome 

Speaker: Frederick B Vivino, MD, MS 

West – 3007 

063 – Dermatological Manifestations of 


Speaker: Laura Winterfield, MD, MPH 

West – 3009 

064 – Infections With Biologics 

Speaker: Kathryn H. Dao, MD 

West – 3011 

*065 – Pregnancy and Rheumatic Diseases 

Speaker: Jill P. Buyon, MD 



2 0 1 5 


tracker 

plus 

145 


West – 3016 

066 – Reactive Arthritis: An Update 

Speaker: Siba Raychaudhuri, MD 

West – 3018 

067 – Rheumatoid Arthritis: Challenging Cases 

Speaker: Stephen A. Paget, MD 

West – 3020 

068 – Scleroderma Mimics 

Speaker: Virginia D. Steen, MD 

West – 3022 

069 – Still’s Disease and Autoinflammatory 

Syndromes 

Speaker: Arturo Diaz, MD 

West – 3024 

070 – Systemic Lupus Erythematosus: Central 

Nervous System 

Speaker: Jorge Sanchez-Guerrero, MD, MSc 


7:45 – 9:45 am 











August 30. 

West – 3002 

230 – Musculoskeletal Ultrasonography: Basic 

Speakers: Janak R. Goyal, MD and Gurjit S. Kaeley, 

MBBS, MRCP 

West – 3004 


Erythematosus and Vasculitis 

Speaker: Anthony Chang, MD 

West – 3008 

232 – Tai Chi, Yoga and Other Movement in 

Intervention in Disease 

Speakers: Mary L. Jurisson, MD and Deborah Bowes, 

DPT, GCFT 

ACR SESSIONS 

8:30 – 10:00 am 


Current Challenges in the Treatment of 

Systemic Lupus Erythematosus: Hope for the 

Future 

Moderators: Mary E. Cronin, MD and Meenakshi Jolly, 

MD, MS 

8:30 am 

Fatigue and Neurologic Lupus: Functional Versus 

Immune Mediated 

Meggan C. Mackay, MD 

9:00 am 

Anti-phospholipid Syndrome in Systemic Lupus 

Erythematosus 

Doruk Erkan, MD 

9:30 am 

Unmet Needs in the Therapy of Systemic Lupus 

Erythematosus: Development of Targeted Therapies 

Richard Furie, MD 

West – 2004 

Novel Approaches for Intra-articular Arthritis 

Therapy 

Moderators: Carla R. Scanzello, MD, PhD and Nico 

Wulffraat, MD 

8:30 am 

Approaches to Intra-articular Arthritis Therapy: 

Benefits, Challenges and Possible Solutions 

Christopher Evans, PhD, DSc 


146 



MONDAY & TUESDAY, NOVEMBER 9, 10, 2015 

9:00 am 

Novel Methods for Delivery of Therapeutic Agents 

Intra-articularly 

Alan Grodzinsky, ScD 

9:30 am 

Engineered Nanoparticles for Therapeutic Delivery to 

Chondrocytes 

Massimo Bottini, PhD 

ACR SESSIONS 

9:00 – 10:00 am 


Lipid Lowering in 2015: How Low Can You Go 

Moderators: Alison Bays, MD and Nicole Kieffer, DC, DO 

Speaker: Savitha Subramanian, MD 

West – 2000 

Medial Education: The Tension Between 

Emerging Needs and Enduring Values PM PS 

Moderator: David I. Daikh, MD, PhD 

Speaker: Catherine Lucey, MD 

North – 132 

Pediatric Rheumatology Year in Review and 

Awards Pediatrics 

Moderator: Polly J. Ferguson, MD 

9:00 am 

Basic Science Review 

Leonard L. Dragone, MD, PhD 

9:15 am 

Translational Research Review 

Anna Huttenlocher, MD 

9:30 am 

Clinical Review 

Seza Ozen, MD 

9:45 am 

Pediatric Rheumatology Awards 

Polly J. Ferguson, MD 

Ed Pd PrM FIT 


SESSION CANCELED – Public Medical 

Communication: An Essential Skill for 21st 

Century Health Professionals 

Moderator: Nicole Kieffer, DC, DO 

Speaker: Louise Aronson, MD 


Rheumatology Research Foundation Memorial 

Lecture Honoring Dr. L. Emmerson Ward: 

Rheumatoid Arthritis (RA) Mechanisms and 

Predictors of Pre-clinical RA 

Moderators: Eric L. Matteson, MD, MPH and Timothy B. 

Niewold, MD 

Speaker: V. Michael Holers, MD 

ARHP SESSIONS 

9:00 – 10:00 am 

West – 2008 

ARHP Daltroy Memorial Lecture: Arthritis 

Self-Management – Where We Have Been and 

Where We Are Going? PM PS E 


Speaker: Kate Lorig, DrPH 

West – 2007 

Less Scary Care for the Pediatric Patient 

Pediatrics 

Moderator: Brandon Young, DNP, NP-C 

9:00 am 


Alicia Furler, RN 

9:30 am 


Andrea Brown, BS, CCLS 

West – 2011 

Pharmacotherapy: What’s New in 

Rheumatology 


Moderator: Susan Bruce, PharmD 

Speaker: Jessica F. Farrell, PharmD 



2 0 1 5 


tracker 

plus 

147 


West – 2009 

What You Know About Your Patients’ Feet 

Could Make You A Superhero – Treat the Feet: 

Improve Foot Health in Rheumatology Patients 

PM PS E 

Moderator: K. Douglass Gross, MPT, MSc, ScD 

9:00 am 

What You Know About Your Patients’ Feet Could 

Make You A Superhero – Treat the Feet: Improve Foot 

Health in Rheumatology Patients 

Lori S. Weisenfeld, DPM 

10:00 am 

What You Know About Your Patients’ Feet Could 

Make You A Superhero – Treat the Feet: Improve Foot 

Health in Rheumatology Patients 

Bob Thompson, DPed, BOC 

ACR/ARHP POSTER SESSION C AND 

POSTER TOURS 

8:30 am – 4:00 pm 


(abstracts # 2174-3073). Poster tours will be held 9:00 

– 9:45 am and 10:15 – 11:00 am. Morning snacks will be 

available at 10:00 am and 2:30 pm. 


ACR Late-Breaking Abstract Poster 

Presentations 

View accepted late-breaking abstract titles in the annual 

meeting app. 

Thieves’ Market Posters 

A Case of Clinical Mimicry? 

Nadine Mbuyi, MD 

“Fluffy” Shoulder Pain 

Sunita Paudyal, MD 

Is the Obvious Always so Obvious? 

Piyush Poddar, MD 

Keep Looking… Don’t Settle! 

Piyush Poddar, MD 

Rocky Abdomen 

Priya Prakash, MD 

Difficulties in Diagnosis and Treatment of a Case of 

Cerebrotendinous Xanthomatosis 

Teodora Mazdrag, MD 

Foot That Broke Both Hips 

Tarun S. Sharma, MD 

A Day Care Center Experience 

Ian Ward, MD 























returned within 15 minutes of the end of the tour. Please 

check the annual meeting app for the most current poster 

tour titles. 

9:00 – 9:45 am 



tour titles. 


148 




10:15 – 11:00 am 




EXHIBITS 

10:00 am – 2:30 pm 


Join your colleagues in the Exhibit Hall for morning 

refreshments at 10:00 am. 


Exhibit Hall 






Theater A presentations will be held from 10:30 – 11:15 am 

and 12:30 – 1:15 pm. Innovation Theater B presentations 

will be held from 11:30 am – 12:15 pm and 1:30 – 2:15 pm. 

For a complete listing of Innovation Theater presentations, 

see page 193. 


10:30 am – 12:30 pm 











August 30. 

West – 3002 

233 – Joint Injection Techniques 

Speakers: Atul A. Deodhar, MD and Kenneth S. 

O’Rourke, MD 

West – 3006 

234 – Osteoporosis: Interpreting Dual 

Energy X-ray Absorptiometry and Clinical Risk 

Factors: The New Fracture Risk Assessment 

Algorithm 

Speaker: Stuart L. Silverman, MD 

West – 3008 

235 – The Rheumatologic Musculoskeletal 

Screening Exam, With Emphasis on Objective 

Disease-specific Measurements 

Speaker: Arthur M. Mandelin II, MD, PhD 

ACR SESSIONS 

11:00 am– Noon 

North – 132 

Controversies in Kawasaki Disease: Implications 

for Long-Term Outcomes PM Ed Pd PS PrM FIT 

Moderators: Robert Sundel, MD and Adriana H. 

Tremoulet, MD, MAS 

11:00 am 

How the Pathogenesis of Kawasaki Disease Informs 

Novel Treatment Approaches 

Rae S.M. Yeung, MD, PhD 

11:30 am 

Optimizing the Long-Term Outcome in Kawasaki 

Disease: Novel Biomarkers and Treatments 

Jane C. Burns, MD 


Systemic Lupus Erythematosus 2015: Arthritis, 

Bone Loss, Pregnancy and Nephritis 

Moderator: Daniel E. Furst, MD 

Speaker: Bevra H. Hahn, MD 


Using Twitter Effectively: Healthcare, Hashtags 

and Twitter Chats 




2 0 1 5 


tracker 

plus 

149 


11:00 am 

Twitter Chats and Rheumatology 

Christopher Collins, MD 

11:30 am 

Healthcare Hashtags: The Power Tool of Twitter 

Shashank Akerkar, MD, MBBS 

ACR SESSION 

11:00 am – 12:30 pm 


Prospects for Treating Rheumatic Diseases 

through Modification in the Microbiome 


11:00 am 

Dietary Factors and Nutritional Compounds and Their 

Influence on the Microbiome 

Peter Turnbaugh, PhD 

11:30 am 

Use of Nematodes to Treat Human Disease 

Joel Weinstock, MD 

Noon 

Fecal Tranplantation in Human Diseases 

Michael Sadowsky, PhD 


11:00 am – 12:30 pm 


ACR Plenary Session III: Discovery 2015 

Moderators: Victoria K. Shanmugam, MBBS, MRCP and 

Lindsey A. Criswell, MD, MPH 

11:00 am 

3074. The Shared Rheumatoid Arthritis HLA-DRB1 

Susceptibility Epitope Shapes the Molecular Orientation 

of Citrulline and the Autoreactive T Cell Receptor 

Repertoire 

Jurgen van Heemst 1 , Stephen Scally 2 , Soi Cheng Law 3 , 

Diane van der Woude 1 , Carol Hitchon 4 , David B. 

Robinson 4 , TW Huizinga 1 , Hugh H Reid 5 , R.E.M. Toes 1 , 

Hani El-Gabalawy 6 , Jamie Rossjohn 7 and Ranjeny 

Thomas 8 , 1 Leiden University Medical Center, Leiden, 

Netherlands, 2 Monash University, Melbourne, Australia, 

3 


Translational Research Institute, Princess Alexandra 

Hospital, Brisbane, Australia, 4 University of Manitoba, 

Winnipeg, MB, 5 Department of Biochemistry and 

Molecular Biology, School of Biomedical Sciences, 

Monash University, Clayton, Melbourne, Australia, 

6 

University of Manitoba Arthritis Center, Winnipeg, MB, 

7 

Institute of Infection and Immunity, Cardiff University, 

School of Medicine, Heath Park, Cardiff, England, 

8 


Brisbane, Australia 

11:15 am 

3075. Salivary Gland FcRL4 + B-Cells Are a Potential 

Source of Progenitor Cells for MALT Lymphoma in Primary 

Sjögren’s Syndrome 

Erlin A. Haacke 1 , Frans G.M. Kroese 1 , Philip Kluin 2 , 

Petra M. Meiners 3 , Annie Visser 4 , Fred K.L. Spijkervet 1 

and Hendrika Bootsma 3 , 1 University Medical Center 

Groningen, Groningen, Netherlands, 2 UMCG 

Groningen, Groningen, Netherlands, 3 University 

Medical Center Groningen, University of Groningen, 

Groningen, Netherlands, 4 UMC Groningen, Groningen, 

Netherlands 

11:30 am 

3076. Interferon Gamma (IFNg) Is the Driving Mediator of 

Secondary Hemophagocytic Lymphohistiocytosis (sHLH) 

in TLR9-Mediated Pathogenesis in Mice and Is Correlated 

to Disease Parameters in Children 

Cristina De Min 1 , Vanessa Buatois 1 , Laurence Chatel 1 , 

Laura Cons 2 , Francoise Richard 3 , Claudia Bracaglia 4 , 

Fabrizio De Benedetti Sr. 5 , Marie Kosco-Vilbois 1 and 

Walter Ferlin 1 , 1 NovImmune S.A., Geneva, Switzerland, 

2 

NovImmune S.A., Plan-Les-Ouates, Geneva, 

Switzerland, 3 NovImmune SA, Geneva, Switzerland, 

4 

Division of Rheumatology, Rome, Italy, 5 Division of 

Rheumatology, Department of Pediatric Medicine, 

IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy 

11:45 am 

3077. Anakinra in Patients with Cortico-Dependent 

Idiopathic Recurrent Pericarditis: A Randomised Double- 

Blind Placebo-Controlled Withdrawal Trial 

Antonio Brucato 1 , Massimo Imazio 2 , Silvia Maestroni 1 , 


150 




Davide Faustino Cumetti 1 , Anna Valenti 1 , Renzo 

Marcolongo 3 , George Lazaros 4 , Mara Carraro 2 , 

Fiorenzo Gaita 2 , Gian Luca Erre 5 , Martina Finetti 6 , 

Marco Gattorno 6 and Alberto Martini 7 , 1 Internal 

Medicine, Hospital Papa Giovanni XXIII, Bergamo, 

Italy, 2 Cardiology, Maria Vittoria Hospital, Torino, Italy, 

3 

Clinical Immunology, Hospital of Padova, Padova, 

Italy, 4 Hippokration General Hospital, Athens, Greece, 

5 

Rheumatology, Hospital of Sassari, Sassari, Italy, 

6 

Pediatry, G. Gaslini Institute, Genova, Italy, 7 Istituto G. 

Gaslini, Pediatria II, PRINTO, and University of Genoa, 

Genoa, Italy 

Noon 

3078. ABCG2 rs2231142 predicts Poor Response to 

Allopurinol in Patients with Gout 

Lisa Stamp 1 , Mary Wallace 2 , Tony R. Merriman 2 , 

Amanda Phipps-Green 2 , Ruth Topless 2 , Jill Drake 3 , 

Paul Tan 4 , Nicola Dalbeth 4 and Rebecca Roberts 2 , 

1 

University of Otago, Christchurch, Christchurch, New 

Zealand, 2 University of Otago, Dunedin, New Zealand, 

3 

Christchurch Hospital, Christchurch, New Zealand, 

4 

University of Auckland, Auckland, New Zealand 

12:15 pm 

3079. Efficacy and Safety of Riociguat in Patients with 

Pulmonary Arterial Hypertension (PAH) Associated with 

Connective Tissue Disease (CTD) 

Christopher P. Denton 1 , J. Gerry Coghlan 2 , Hossein- 

Ardeschir Ghofrani 3 , Friedrich Grimminger 3 , Jianguo 

He 4 , Gabriela Riemekasten 5 , Dario Vizza 6 , Annette 

Boeckenhoff 7 , Christian Meier 8 , Janethe de Oliveira 

Pena 9 and Marc Humbert 10 , 1 UCL Medical School 

Royal Free Campus, London, United Kingdom, 

2 

Royal Free London NHS Foundation Trust, London, 

England, 3 University of Giessen and Marburg Lung 

Center, Giessen, Germany, 4 Chinese Academy of 

Medical Sciences and Peking Union Medical College, 

Beijing, China, 5 Clinic of Rheumatology and Clinical 

Immunology, Berlin, Germany, 6 La Sapienza University 

of Rome, Rome, Italy, 7 Bayer Pharma AG, Wuppertal, 

Germany, 8 Bayer Pharma AG, Berlin, Germany, 9 Bayer 

HealthCare Pharma, Whippany, NJ, 10 Université Paris- 

Sud, Laboratoire d’Excellence en Recherche sur le 

Médicament et Innovation Thérapeutique, and INSERM 

Unité 999, Le Kremlin–Bicêtre, France 

ACR SESSION 

12:30 – 2:00 pm 


CARE: MOC Sessions 2015 – Session 3 – Other 

Rheumatic and Connective Tissue Diseases 


Speaker: Alan N. Baer, MD 


12:45 – 2:15 pm 











August 30. 

West – 3003 

071 – Crystal: Diagnosis and Management of 

Gout PM PS E 

Speaker: John S. Sundy, MD, PhD 

West – 3005 

072 – Immunodeficiency Syndromes 


West – 3007 

*073 – Management of Patients with Hepatitis C 

and Rheumatic Diseases 

Speaker: Timothy B. Niewold, MD 

West – 3009 

074 – Myopathy: Issues in Diagnosis and 

Treatment 

Speaker: Rohit Aggarwal, MD, MS 



2 0 1 5 


tracker 

plus 

151 


West – 3011 

075 – Osteoarthritis: Update 2015 

Speaker: Timothy E. McAlindon, MD, MPH, MRCP 

West – 3016 

*076 – Psoriatic Arthritis 

Speaker: Philip J. Mease, MD 

West – 3018 

077 – Pulmonary Manifestations of Rheumatic 

Disease 

Speaker: Aryeh Fischer, MD 

West – 3020 

078 – Spondylarthropathy: An Update 

Speaker: Christopher T. Ritchlin, MD, MPH 

West – 3022 

*079 – Systemic Lupus Erythematosus: Novel 

Treatments – How to Treat Systemic Lupus 

Erythematosus 

Speaker: Richard Furie, MD 

West – 3024 

*080 – Vasculitis: Update 

Speaker: Raashid A. Luqmani, DM 

ACR SESSIONS 

1:00 – 2:00 pm 

North – 132 

Advocacy Training: How-to From a U.S. Senator 

and the New Age of Digital Advocacy 

Moderator: William F. Harvey, MD, MSc 

Speaker: The Honorable Tim Hutchinson (U.S. House 

1993-1997, U.S. Senate 1997-2003) 

West – 2001 

Immunology Update on Immunological 

Mechanisms in Sjögren’s 


Moderator: Gregg J. Silverman, MD 

Speaker: Xavier Mariette, MD, PhD 


Osteoporosis Update 

Moderator: Mathilde H. Pioro, MD 

Speaker: Chad Deal, MD 


Pearls and Pitfalls in Fibromyalgia and Central 

Pain Syndromes 

PM Ed Pd PS PrM PM Ed FIT Pd PS PrM FIT 

Moderators: Irene Tan, MD and Rula A. Hajj-Ali, MD 

1:00 pm 

The Fibromyalgia Fingerprint: What Can Functional 

MRI Tell Us About Pathogenesis and Diagnosis 

Carmen E. Gota, MD 

1:40 pm 

Treat to Target in Fibromyalgia? 

Mary-Ann Fitzcharles, MBChB, MD 


Utilizing Big Data to Advance Rheumatology 

Moderators: Yukinori Okada, MD, PhD and Pravitt 

Gourh, MD 

Speaker: Atul Butte, MD, PhD 

STUDY GROUPS 

1:00 – 2:00 pm 






West – 2016 

Autonomic Neuroregulation of Rheumatoid 

Arthritis Study Group 

Speakers: Kevin Tracey, MD; Andrew Holman, MD 

and Gary S. Firestein, MD 


152 




West – 2000 

Extra-Articular Manifestations of Rheumatic 

Diseases Study Group 

1:00 pm 


– Part 1 

Nevine Mohannad Abbas, MD 

1:25 pm 


– Part 2 

Amira El Gerby, MD 

West – 2006 

Global Musculoskeletal Health Initiaitives Study 

Group 

1:00 pm 

Addressing Global Inequities in the Prioritization 

and Provision of Services for Rheumatic and 

Musculoskeletal Conditions – the World Forum for 

Rheumatic and Musculoskeletal Diseases 

Mustafa Al Maini 

1:25 pm 

Reducing Impact of Musculoskeletal Conditions in an 

Ageing Population: World Report on Aging and Health 

– The Burden 

Emma Smith, PhD 

1:50 pm 

Reducing Impact of Musculoskeletal Conditions in an 

Aging population: World Report on Ageing and Health 

– Recommendations 

Marita Cross, PhD 

2:15 pm 

What is the Impact of Musculoskeletal Conditions on 

Individuals: Providing the Evidence to Support WHO 

Disability Action Plan and Other Global Initiatives 

Lyn March, FRACP, MBBS, MSc, PhD 

2:40 pm 

Working With WHO: Global Alliance for 

Musculoskeletal Health of the Bone and Joint 

Anthony D. Woolf, MBBS 

West – 2007 

Interstitial Lung Disease Study Group 

Speakers: Paul Dellaripa, MD and Aryeh Fischer, MD 

West – 2008 

Pediatric Rheumatologists Interested in 

Medical Education Study Group 

Speakers: Megan Curran, MD and Kristen Hayward, MD, MS 

West – 2009 

Polymyalgia Rheumatica Study Group 

Speakers: Bhaskar Dasgupta, MD and Eric L. Matteson, 

MD, MPH 

West – 2004 

The Challenges and Opportunities of Defining 

Axial Psoriatic Arthritis (axPsA) Study Group 

Speakers: Philip S. Helliwell, MA, PhD; Joseph Merola, 

MD, MPH; Alexis Ogdie-Beatty, MD MSCE; Oliver 

FitzGerald, MD and Deepak R. Jadon, MBBCh, MRCP 

West – 2011 

Transparent Pain – Identifying Centralized Pain 

in the Rheumatology Patient Study Group 

Speaker: Jacob N. Ablin, MD 


1:15 – 3:15 pm 











August 30. 

West – 3002 

*236 – Advanced Musculoskeletal Ultrasound 

Speakers: Jay B. Higgs, MD and Catherine Bakewell, MD 



2 0 1 5 


tracker 

plus 

153 


West – 3008 

237 – Magnetic Resonance Imaging (MRI) in the 

Diagnosis and Management of Spondylarthritis: 

A Clinician’s Guide 

Speaker: Walter Maksymowych, MD 

West – 3006 

238 – MDHAQ/RAPID3 and RHEUMDOC: 

Quantitative, Standard, Scientific Summaries 

of Patient History and Physical Exam, Toward 

Better Clinical Decisions and Outcomes 

Speaker: Theodore Pincus, MD 

West – 3004 

239 – Nailfold Capillarscopy 

Speaker: Maurizio Cutolo, MD 

ACR SESSION 

2:30 – 3:00 pm 


ACR Business Meeting 

This session is not eligible for CME credit. 

Moderator: E. William St.Clair, MD 

2014-2015 College Year in Review 

Confirmation of ACR Treasurer 

Confirmation of ACR Board of Directors Members 

Installation of 79th ACR President 

ACR SESSIONS 

2:30 – 4:00 pm 


Current Topics in Myositis 

Moderators: Rebecca L. Manno, MD, MHS and Jemima 

Albayda, MD 

2:30 pm 

Immune Mediated Necrotizing Myopathy: A Little 

Inflammation, but a Lot of Weakness 

Andrew L. Mammen, MD, PhD 

3:00 pm 

The Anti-Synthetase Syndrome 

Chester V. Oddis, MD 

3:30 pm 

Update in Myositis Specific Antibodies 

Neil J. McHugh, MB, ChB 


Gout Management in 2015: Nonpharmacological 

Treatments, Treat-to-Target Strategy and 

Emerging Therapies for PM Ed Gout Pd PS PrM FIT PM PS E 

Moderators: Jasvinder A. Singh, MD, MPH and Alex So, 

MD 

2:30 pm 

Nutraceuticals for Gout 

Speaker Lisa K. Stamp, MBChB, PhD 

3:00 pm 

Treat-to-target: Use of Allopurinol for Improving Gout 

Outcomes Including Nephroprotection 

Brian F. Mandell, MD, PhD 

3:30 pm 

New Emerging Therapies for Gout 

John FitzGerald, MD, PhD 

North – 132 

Innovative Educators, Novel Techniques: A 

Rheumatology Research Foundation Special 

Session PM Ed Pd PS PrM FIT 

Moderators: Deana M. Lazaro, MD and Sharon L. 

Kolasinski, MD 

2:30 pm 

Introductory Talk 

Deana M. Lazaro, MD 

2:45 pm 

E-Support for Pediatric Residency Rheumatology 

Teaching 

Megan Curran, MD 

3:15 pm 

Rheumatology 101: Ambulatory Based Curriculum 

Development 

Susan F. Kroop, MD 


154 




3:45 pm 

Where Are They Now? A Look at the Long Term 

Impacts of the Clinician Scholar Educator Award 

Kenneth S. O’Rourke, MD 


Next Generation Sequencing: A Novel Tool for 

Genomic Discovery 

Moderators: Pravitt Gourh, MD and Lindsey A. Criswell, 

MD, MPH 

2:30 pm 

Targeted Resequencing for Rare Variant Discovery 

Soumya Raychaudhuri, MD, PhD 

3:00 pm 

Whole Exome Sequencing for Defining New Diseases 

Ivona Aksentijevich 

3:30 pm 

Sequencing to Understand Gene Defects in 

Autoimmune Disorders 

Speaker to be Determined 

West – 2014 

Update on Safety Issues in the Treatment of 

Rheumatic Diseases: From the FDA and Beyond 

PM PS E 

Moderators: Michael H. Weisman, MD and Arthur 

Kavanaugh, MD 

2:30 pm 

FDA 101: Understanding FDA’s Role in Drug 

Development and Safety Evaluation 

Rachel Glaser, MD 

2:50 pm 

Update and Safety Issues on Recently Approved 

Agents for Rheumatic Diseases 

Juwaria Waheed, MD 

3:15 pm 

The Year in Review—Update on Safety Issues at the 

FDA for the Last 12 Months 

Janet W. Maynard, MD, MHS 


2:30 – 4:00 pm 


2015 Rheumatology Research Foundation 

Edmond L. Dubois, MD Memorial Lectureship 

Moderator: Susan A. Boackle, MD and Keith B. Elkon, 

MD 

2:30 pm 

3080. Histone H2AX Phosphorylation As a Measure 

of DNA Double Strand Breaks and a Marker of 

Environmental Stress and Disease Activity in Lupus 

Speaker: Amr H. Sawalha, MD 

Rajaie Namas 1 , Paul Renauer 1 , Mikhail Ognenovski 1 , 

Pei-Suen Tsou 2 and Amr H. Sawalha 2 , 1 University of 

Michigan, Ann Arbor, MI, 2 Division of Rheumatology, 

University of Michigan, Ann Arbor, MI 

2:45 pm 

3081. IRF5 Deletion Prevents the SLE-like Disease 

Initiated By Dendritic Cell-Specific Loss of Caspase 8 

Carla M. Cuda and Harris R. Perlman, Northwestern 

University, Chicago, IL 

3:00 pm 

3082. Nanogel Based Delivery of an Inhibitor of Calcium/ 

Calmodulin- Dependent Protein Kinase 4 Suppresses 

Experimental Autoimmune Encephalomyelitis and Lupuslike 

Disease in Mice 

Kotaro Otomo 1 , Tomohiro Koga 2 , Nobuya Yoshida 1 , 

Masayuki Mizui 3 , Christina Kriegel 4 , Tarek Fahmy 4 and 

George C. Tsokos 1 , 1 Beth Israel Deaconess Medical 

Center, Harvard Medical School, Boston, MA, 2 Unit of 

Translational Medicine, Graduate School of Biomedical 

Sciences, Nagasaki University, Nagasaki, Japan, 3 Osaka 

University Graduate School of Medicine, Osaka, Japan, 

4 

Yale University, New Heaven, CT 

3:15 pm 

3083. Antibody Array Based Proteomic Screening of 274 

Serum Markers in Systemic Lupus Erythematosus 

Tianfu Wu 1 , Huihua Ding 1 , Cristina Arriens 2 , Chungwen 

Wei 3 , Jennifer H. Anolik 4 , David R. Karp 2 , Nancy J. Olsen 5 , 

Michelle Petri 6 , Ignacio Sanz 3 , Ramesh Saxena 2 and 

Chandra Mohan 1 , 1 University of Houston, Houston, 

TX, 2 University of Texas Southwestern Medical Center, 



2 0 1 5 


tracker 

plus 

155 


Dallas, TX, 3 Emory University, Atlanta, GA, 4 University 

of Rochester Medical Center, Rochester, NY, 5 Penn 

State MS Hershey Medical Center, Hershey, PA, 6 Johns 

Hopkins University Hospital, Baltimore, MD 

3:30 pm 

3084. Progression of Lupus Pathology Is Correlative with 

Cardiac Magnetic Resonance Imaging Abnormalities, 

Diminished Function, and Inflammatory Histopathology 

in an Animal Model 

Nicholas Young 1 , Jeffrey Hampton 1 , Saba Aqel 1 , Jessica 

Pyles 1 , Anna Bratasz 1 , Anuradha Kalyanasundaram 1 , 

Wael N. Jarjour 1 and Stacy P. Ardoin 2 , 1 The Ohio State 

University Medical Center, Columbus, OH, 2 Ohio State 

University, Columbus, OH 

3:45 pm 

3085. Platelet Activation and Endothelial Reactivity in the 

Pathogenesis of Tissue Inflammation/Injury in Systemic 

Lupus Erythematosus 

Robert Clancy, Sokha Nhek, Jonathan Newman, Janet 

Nwaukoni, Sara Rasmussen, Jill P. Buyon, Maya Rubin, 

Kristen Lee and Jeffrey Berger, New York University 

School of Medicine, New York, NY 

West – 2016 

Fibromyalgia: Clinical Issues PM PS E 

Moderator: Dennis Ang, MD 

2:30 pm 

3086. The Same Multidimensional Patient Health 

Assessment Questionnaire Used to Assess RAPID3 in 

Rheumatoid Arthritis, Osteoarthritis and Other Rheumatic 

Diseases Can Provide Quantitative Clues to Recognize and 

Document Comorbid Fibromyalgia 

Kathryn A. Gibson 1 , Annie Huang 2 and Theodore 

Pincus 2 , 1 Liverpool Hospital, Liverpool, Australia, 2 Rush 

University Medical Center, Chicago, IL 

2:45 pm 

3087. Cell Bound Complement Activation Products 

in Multianalyte Assay with Algorithm Have Utility in 

Distinguishing Primary Fibromyalgia from Systemic Lupus 

Erythematosus 

Daniel Wallace 1 , Stuart L. Silverman 2 , Derren Barken 3 , 

John Conklin 3 and Thierry Dervieux 3 , 1 Cedars-Sinai/ 

UCLA, Los Angeles, CA, 2 OMC Clinical Research Center, 

Beverly Hills, CA, 3 Exagen Diagnostics, Vista, CA 

3:00 pm 

3088. Genome Wide Expression Analyses Reveal 

Potentially Novel Drug Targets in Fibromyalgia 

Kim Jones 1 , Robert Bennett 2 and Sunil Kurian 3 , 1 Oregon 

Health Sciences Univ, Portland, OR, 2 Oregon Health 

& Science Univ, Portland, OR, 3 The Scripps Research 

Institute, La Jolla, CA 

3:15 pm 

3089. Evaluation of Learned Helplessness, Perceived 

Self-Efficacy and Functional Capacity in Patients with 

Fibromyalgia and Rheumatoid Arthritis 

Sebastian Moyano 1 , Marina Scolnik 1 , Facundo Vergara 1 , 

Maria Victoria Garcia 1 , Mirtha Sabelli 1 , Javier Rosa 2 

and Enrique R. Soriano 2 , 1 Rheumatology Unit, Internal 

Medicine Service, Hospital Italiano de Buenos Aires, 

Instituto Universitario Hospital Italiano de Buenos 

Aires, and Fundacion PM Catoggio, Buenos Aires, 

Argentina, 2 Hospital Italiano de Buenos Aires, Buenos 

Aires, Argentina 

3:30 pm 

3090. Fibromyalgia Predicts Two-Year Changes in 

Functional Status in Rheumatoid Arthritis Patients 

Hyein Kim 1 , Jing Cui 2 , M Frits 2 , C Iannaccone 3 , Jonathan 

S. Coblyn 2 , N Shadick 4 , Michael Weinblatt 3 and Yvonne 

C. Lee 3 , 1 Western University, London, ON, 2 Brigham & 

Women’s Hospital, Boston, MA, 3 Brigham and Women’s 

Hospital, Boston, MA, 4 Brigham and Women’s Hospital, 


3:45 pm 

3091. A Randomized, Controlled Trial of Pregabalin in 

Adolescent Patients (12-17 years) with Fibromyalgia 

Lesley Arnold 1 , Lucinda Bateman 2 , Kenneth N. Schikler 3 , 

Tahira Khan 4 , Lynne Pauer 4 , Pritha Bhadra Brown 5 , 

Marci L. Chew 4 , Andrew Clair 5 and Joseph Scavone 4 , 

1 

University of Cincinnati, Cincinnati, OH, 2 Bateman 

Horne Center, Salt Lake City, UT, 3 University of 

Louisville, Louisville, KY, 4 Pfizer Inc, Groton, CT, 5 Pfizer 

Inc., New York, NY 



Therapeutic Aspects III: Miscellaneous Pediatric 

Rheumatic Diseases PM Ed Pd PS PrM FIT 

Moderators: Peter Chira, MD and Bryce A. Binstadt, MD, 

PhD 


156 




2:30 pm 

3092. Deficiency of Adenosine Deaminase Type II - 

Expanding the Clinical Spectrum 

Karyl Barron 1 , Amanda Ombrello 2 , Deborah Stone 2 , 

Patrycja Hoffmann 2 , Ivona Aksentijevich 2 , Qing Zhou 2 , 

Anne Jones 2 and Daniel L. Kastner 2 , 1 NIAID/NIH, 

Bethesda, MD, 2 NHGRI/NIH, Bethesda, MD 

2:45 pm 

3093. Development and Validation of Diagnostic 

Criteria for Cryopyrin Associated Periodic 

Syndromes 

Jasmin B. Kuemmerle-Deschner 1 , Seza Ozen 2 , Pascal 

N. Tyrrell 3 , Isabelle Koné-Paut 4 , Raphaela Goldbach- 

Mansky 5 , Helen Lachmann 6 , Norbert Blank 7 , Hal 

M. Hoffman 8 , Elisabeth Weissbarth-Riedel 9 , Boris 

Huegle 10 , Tilmann Kallinich 11 , Marco Gattorno 12 , 

Ahmet Gul 13 , Nienke M. ter Haar 14 , Marlen Oswald 15 , 

Fatma Dedeoglu 16 and Susanne M. Benseler 17 , 

1 

Universitätsklinikum Tübingen, Klinik fuer Kinderund 

Jugendmedizin, Tübingen, Germany, 2 Hacettepe 

University, Ankara, Turkey, Ankara, Turkey, 3 University 

of Toronto, Toronto, ON, 4 CHU Bicêtre, Le Kremlin 

Bicêtre, France, 5 NIH | NIAMS, Bethesda, MD, 

6 

University College London Medical School, London, 

United Kingdom, 7 University of Heidelberg, Heidelberg, 

Germany, 8 University of California at San Diego, 

San Diego, CA, 9 Universitaetskinderklinik Hamburg, 

Hamburg, Germany, 10 German Center for Pediatric and 

Adolescent Rheumatology, Garmisch-Partenkirchen, 

Germany, 11 Charite, University Medicine Berlin, Berlin, 

Germany, 12 Pediatry, G. Gaslini Institute, Genova, Italy, 

13 

Istanbul University, Istanbul Faculty of Medicine, 

Istanbul, Turkey, 14 University Medical Center Utrecht, 

Utrecht, Netherlands, 15 University Hospital Tuebingen, 

Tuebingen, Germany, 16 Boston Children’s Hospital, 

Boston, MA, 17 Alberta Children’s Hospital, University of 

Calgary, Calgary, AB 

3:00 pm 

3094. Dose Adjustment of Anakinra (Kineret®) 

Based on Clinical Response in Patients with Severe 

Cryopyrin-Associated Periodic Syndromes 

Bengt Hallen 1 , Torbjörn Kullenberg 1 , Mika Leinonen 2 , 

Margareta Wiken 1 , Raphaela Goldbach-Mansky 3 

and Hans Olivecrona 1 , 1 Swedish Orphan Biovitrum, 

Stockholm, Sweden, 2 4Pharma AB, Stockholm, Sweden, 

3 

Translational Autoinflammatory Diseases Section, 

NIAMS, NIH, Bethesda, MD 

3:15 pm 

3095. Initial Results of a Pilot Juvenile Localized 

Scleroderma (jLS) Comparative Effectiveness Study 

Suzanne C. Li 1 , Kathryn S. Torok 2 , Sandy D. Hong 3 , Polly 

J. Ferguson 4 , C. Egla Rabinovich 5 , Mara L Becker 6 , Fatma 

Dedeoglu 7 , Maria F. Ibarra 8 , Robert C. Fuhlbrigge 9 , Katie 

G. Stewart 10 , Marilynn G. Punaro 10 , Thomas Mason II 11 , 

Elena Pope 12 , Ronald Laxer 13 , Gloria C. Higgins 14 and 

Brian Feldman 15 , 1 Joseph M Sanzari Children’s Hospital, 

Hackensack University Medical Center, Hackensack, 

NJ, 2 Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 3 U 

of Iowa Children’s Hosp, Iowa City, IA, 4 University of 

Iowa, Iowa City, IA, 5 Duke Univ Med Ctr, Durham, NC, 

6 

Children’s Mercy Kansas City, Kansas City, MO, 7 Boston 

Children’s Hospital, Boston, MA, 8 Children’s Mercy 

Hospital, Kansas City, MO, 9 Boston Children’s Hospital, 

Boston, MA, 10 Texas Scottish Rite Hospital, Dallas, 

TX, 11 Mayo Clinic, Rochester, MN, 12 Hospital for Sick 

Children, Toronto, ON, 13 The Hospital for Sick Children, 

Toronto, ON, 14 Nationwide Childrens Hosp, Columbus, 

OH, 15 Division of Rheumatology, The Hospital for Sick 

Children, Toronto, ON 

3:30 pm 

3096. Interferon-Gamma (IFNg) in Macrophage 

Activation Syndrome (MAS): CXCL9 Levels As a 

Biomarker for IFNg Production in MAS 

Claudia Bracaglia 1 , Denise Pires Marafon 2 , Ivan Caiello 1 , 

Kathy De Graaf 3 , Florence Guilhot 4 , Walter Ferlin 4 , 

Sergio Davì 5 , Grant Schulert 6 , Angelo Ravelli 5 , Alexei A. 

Grom 6 , Robert Nelson 4 , Cristina de Min 4 and Fabrizio 

De Benedetti Sr. 1 , 1 Division of Rheumatology, Ospedale 

Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 2 IRCCS 

Ospedale Pediatrico Bambino Gesù, Rome, Italy, 

3 

Novimmune S.A., Geneva, Switzerland, 4 NovImmune 

S.A., Geneva, Switzerland, 5 Istituto Giannina Gaslini 

and University of Genova, Genova, Italy, 6 Cincinnati 


3:45 pm 

3097. Innovative Approach for the Identification 

of an Appropriate Dose Regimen of a Targeted 

Treatment, NI-0501, an Anti-Interferon Gamma 

(IFNg) Antibody, in Patients with Hemophagocytic 

Lymphohistiocytosis (HLH) 



2 0 1 5 


tracker 

plus 

157 


Cristina De Min 1 , Philippe Jacqmin 2 , Christian Laveille 3 , 

Robert Nelson 1 , Florence Guilhot 1 , Maureen Deehan 1 , 

Marie Kosco-Vilbois 1 , Walter Ferlin 1 and Genevieve 

Lapeyre 1 , 1 NovImmune S.A., Geneva, Switzerland, 

2 

SGS Exprimo, Mechelen, Belgium, 3 SGS Exprimo NV, 

Mechelen, Belgium 


Rheumatoid Arthritis – Clinical Aspects 

IV: Biomarkers, Disease Progression and 

Treatment Response 

Moderators: Clifton O. Bingham III, MD and N. Shadick, 

MD, MPH 

2:30 pm 

3098. Synovial Lymphocytic Aggregates Associate 

with Highly Active RA and Predict Erosive Disease 

at 12 Months: Results from the Pathobiology of 

Early Arthritis Cohort 

Maria DiCicco 1 , Frances Humby 1 , Stephen Kelly 2 , 

Rebecca Hands 1 , nora ng 3 , Arti Mahto 3 , Illias Lazarou 3 , 

Vidalba Rocher 1 , Lu Zou 3 , Michele Bombardieri 4 , 

Christopher Buckley 5 , A.H.M. van der Helm- van Mil 6 , 

Robert B.M. Landewé 7 , Désirée van der Heijde 6 , Iain 

B. McInnes 8 , Peter C. Taylor 9 and Costantino Pitzalis 10 , 

1 

William Harvey Research Institute, Queen Mary 

University of London, London, United Kingdom, 2 Centre 

for Experimental Medicine and Rheumatology, Queen 

Mary University of London, London, United Kingdom, 

3 

Centre for Experimental Medicine and Rheumatology, 

London, United Kingdom, 4 Queen Mary University 

of London, London, United Kingdom, 5 University 

of Birmingham, Rheumatology Research Group, 

Birmingham, United Kingdom, 6 Leiden University 

Medical Center, Leiden, Netherlands, 7 University of 

Amsterdam and Atrium Medical Center, Amsterdam, 

Netherlands, 8 Institute of Infection, Immunity and 

Inflammation, College of Medicine, Veterinary Medicine 

and Life Sciences, University of Glasgow, Glasgow, 

United Kingdom, 9 University of Oxford Botnar Research 

Centre, Oxford, United Kingdom, 10 Queen Mary’s 

School of Medicine and Dentistry, London, United 

Kingdom 

2:45 pm 

3099. Differential Effects of IL-6 Blockade 

Tocilizumab and TNF Inhibitors on the Reduced 

Angiogenesis and Lining Layer Degeneration in 

Synovial Tissues from Patients with Rheumatoid 

Arthritis 

Hirohata Shunsei 1 , Asami Abe 2 , Akira Murasawa 2 , 

Tetsuya Tomita 3 and Hideki Yoshikawa 3 , 1 Kitasato 

University School of Medicine, Kanagawa, Japan, 

2 

Niigata Rheumatic Center, Shibata, Japan, 3 Osaka 

University Graduate School of Medicine, Suita Osaka, 

Japan 

3:00 pm 

3100. Anti-RA33 Citrullinated/Native Double- 

Reactive Antibodies Identify Patients with the 

Highest Risk of Radiographic Progression in 


Maximilian F. Konig 1 , Jon Giles 2 , Peter A. Nigrovic 3 and 

Felipe Andrade 1 , 1 The Johns Hopkins University School 

of Medicine, Baltimore, MD, 2 Columbia University 

Medical Center, NY, NY, 3 Department of Medicine, 

Division of Rheumatology, Immunology and Allergy, 

Brigham and Women’s Hospital, Harvard Medical 


3:15 pm 

3101. Receptor Activator of Nuclear Factor Kappa-B 

Ligand (RANKL) and Sclerostin Are Related to 

Joint Destruction in Early Rheumatoid Arthritis 

Unrelated to Polymorphisms of the Genes 

Antonia Boman, Heidi Kokkonen, Ewa Berglin, Lisbeth 

Ärlestig and Solbritt Rantapaa-Dahlqvist, Umeå 

University, Umeå, Sweden 

3:30 pm 

3102. Increasing Circulating Adiponectin after 

DMARD Initiation Is Associated with Radiographic 

Progression in Early Aggressive RA, Regardless of 

Treatment Strategy 

Jon T. Giles 1 , S. Louis Bridges Jr. 2 , James R. O’Dell 3 , 

Stacey Cofield 2 , George Howard 4 , Jeffrey R. Curtis 5 and 

Larry W. Moreland 6 , 1 Columbia University, College of 

Physicians & Surgeons, New York, NY, 2 University of 

Alabama at Birmingham, Birmingham, AL, 3 University 

of Nebraska Medical Center, Omaha, NE, 4 The 


AL, 5 University of Alabama at Birmingham, Division of 

Clinical Immunology and Rheumatology, Birmingham, 

AL, 6 University of Pittsburgh, Pittsburgh, PA 


158 




3:45 pm 

3103. Carbamylated Human Albumin Is One of 

the Target Antigens of Anti-Carbamylated Protein 

Antibodies 

Shuichiro Nakabo 1 , Koichiro Ohmura 1 , Kosaku 

Murakami 1 , Ran Nakashima 1 , Moritoshi Furu 2 , Masahiro 

Ishikawa 2 , Motomu Hashimoto 2 , Yoshitaka Imura 1 , 

Naoichiro Yukawa 1 , Hajime Yoshifuji 1 , Hiromu Ito 2 , 

Takao Fujii 2 and Tsuneyo Mimori 2 , 1 Department of 

Rheumatology and Clinical Immunology, Graduate 

School of Medicine, Kyoto University, Kyoto, Japan, 

2 

Department of the Control for Rheumatic Diseases, 

Graduate School of Medicine, Kyoto University, Kyoto, 

Japan 

West – 2011 


Pathogenesis III 

Moderators: Maripat Corr, MD and Kevin D. Deane, MD, 

PhD 

2:30 pm 

3104. Abnormal DNA Methylation in a Novel 

PTPN11 Enhancer Increases Destructive Potential 

of Rheumatoid Arthritis (RA) Fibroblast-like 

Synoviocytes (FLS) and Joint Inflammation 

Keisuke Maeshima 1 , Stephanie M. Stanford 2 , Deepa 

Hammaker 1 , Cristiano Sacchetti 2 , Rizi Ai 3 , Vida Zhang 2 , 

David L. Boyle 4 , Lifan Zeng 5 , German Muench 2 , Gen- 

Sheng Feng 3 , John Whitaker 6 , Zhong-Yin Zhang 5 , Wei 

Wang 4 , Nunzio Bottini 2 and Gary S. Firestein 4 , 1 UCSD 

School of Medicine, La Jolla, CA, 2 La Jolla Institute for 

Allergy and Immunology, La Jolla, CA, 3 UC San Diego, 

La Jolla, CA, 4 University of California, San Diego, La 

Jolla, CA, 5 Indiana University School of Medicine, 

Indianapolis, IN, 6 Janssen Pharmaceuticals, La Jolla, CA 

2:45 pm 

3105. The RA Immune System Recreated in 

Immunodeficient Mice By Thymic Differentiation 

from RA Patients’ Hematopoietic Stem Cells 

Exhibits Marked CD4 T Cell Activation and 

Differentiation 

Robert Winchester 1 , Chiara Borsotti 1 , Nichole Danzl 1 , 

Jon Giles 2 , Joan M. Bathon 3 and Megan Sykes 1 , 

1 

Columbia University, New York, NY, 2 Columbia 

University Medical Center, NY, NY, 3 Columbia 

University, College, New York, NY 

3:00 pm 

3106. Regulation of ASK1 Expression By 

microRNA-17 and Their Correlation with 

Rheumatoid Arthritis Pathogenesis 

Nahid Akhtar and Salahuddin Ahmed, Washington 

State University College of Pharmacy, Spokane, WA 

3:15 pm 

3107. Investigating the Ameliorating Effect of 

Pregnancy on Rheumatoid Arthritis Using Whole 

Transcriptome Analysis 

Anuradha Mittal 1 , Lior Pachter 2 , J. Lee Nelson 3 , Hanne 

Kjaergaard 4 , Mette Smed 4 , Vibeke Zoffmann 4 , Jørn 

Olsen 5 , Merete Lund Hetland 6 , Ingileif Hallgrimsdottir 2 

and Damini Jawaheer 1 , 1 Children’s Hospital Oakland 

Research Institute, Oakland, CA, 2 University of 

California, Berkeley, Berkeley, CA, 3 Fred Hutchinson 

Cancer Rsch, Seattle, WA, 4 Juliane Marie Center, 

Copenhagen, Denmark, 5 Aarhus University, Aarhus, 

Denmark, 6 DANBIO, Glostrup Hospital, Glostrup, 

Denmark 

3:30 pm 

3108. Serum 14-3-3eta Are Elevated in Indigenous 

North Americans with Rheumatoid Arthritis and 

May Predict Imminent Synovitis in Their at-Risk 

First Degree Relatives 

Carol A. Hitchon, Irene Smolik, Xiaobo Meng, David 

Robinson and Hani S. El-Gabalawy, University of 

Manitoba, Winnipeg, MB 

3:45 pm 

3109. Single Cell Gene Expression in Classical 

Monocytes Correlates with Treatment Response 

Groups to TNF-Alpha Inhibition in Rheumatoid 

Arthritis 

Theresa Wampler Muskardin 1 , Wei Fan 2 , Jessica M. 

Dorschner 1 , Zhongbo Jin 1 , Mark A. Jensen 1 and Timothy 

B. Niewold 1 , 1 Mayo Clinic, Rochester, MN, 2 Ren Ji 

Hospital, School of Medicine, Shanghai Jiao Tong 

University, China, Shanghai, China 

West – 2001 


Biologics and Gene Therapy V: Immunogenecity 




2 0 1 5 


tracker 

plus 

159 


2:30 pm 

3110. In the Multicenter Randomized Controlled 

Rotation or Change Trial, a Non-TNF Targeted 

Therapy Has a Higher Efficacy Than a Second Anti- 

TNF at 3, 6 and 12 Months 

Jacques Gottenberg 1 , Olivier Brocq 2 , Aleth Perdriger 3 , 

Slim Lassoued 4 , Jean-Marie Berthelot 5 , Daniel 

Wendling 6 , Liana Euller-Ziegler 7 , Martin Soubrier 8 , 

Christophe Richez 9 , Bruno Fautrel 10 , Arnaud 

Constantin 11 , Xavier Mariette 12 , Jacques Morel 13 , 

Mélanie Gilson 14 , Gregoire Cormier 15 , Jean Hugues 

Salmon 16 , Stephanie Rist Bouillon 17 , Frederic Lioté 18 , 

Hubert Marotte 19 , Christine Bonnet 20 , Christian 

Marcelli 21 , Jeremie Sellam 22 , Olivier Meyer 23 , Elisabeth 

Solau-Gervais 24 , Sandrine Guis 25 , Jean Marc Ziza 26 , 

Charles Zarnitsky 27 , Isabelle Chary-Valckenaere 28 , O 

Vittecoq 29 , Alain Saraux 30 , Yves-Marie Pers 31 , Martine 

Gayraud 32 , Gilles Bolla 33 , Pascal Claudepierre 34 , Marc 

Ardizzone 35 , Emmanuelle Dernis Labous 36 , Maxime 

A. Breban 37 , Olivier Fain 38 , Jean Charles Balblanc 39 , 

Ouafaa Aberkane 40 , Marion Vazel 40 , Christelle Back 40 , 

Elodie Perrodeau 41 , Jean Sibilia 42 and Philippe Ravaud 32 , 

1 

Hautepierre, Strasbourg, France, 2 Hospital Center 

Princesse Grâce, Monaco, Monaco, 3 CHU de Rennes, 

Rennes, France, 4 Rheumatology, Cahors, France, 

5 

University Hospital, Nantes, France, 6 Université de 

Franche-Comté, Besançon, France, 7 Rheumatology, 

Nice, France, 8 Rheumatology department CHU 

Clermont-Ferrand, Clermont-Ferrand, France, 

9 

Rheumatology, Bordeaux, France, 10 AP-HP Pitié- 

Salpêtrière Hospital / Pierre and Marie Curie University 

Paris 6 GRC-08 (EEMOIS), Paris, France, 11 CHU Purpan 

- Hopital Pierre-Paul Riquet, Toulouse, France, 

12 

Université Paris-Sud, AP-HP, Hôpitaux Universitaires 

Paris-Sud, Paris, France, 13 Lapeyronie Hospital and 

Montpellier University, Montpellier, France, 14 Hospital 

Center, Grenoble, France, 15 Rheumatology, La Roche 

Sur Yon, France, 16 Rheumatology, REIMS, France, 

17 

Hopital La Source, La Source, France, 18 Rheumatology, 

Lariboisière, France, 19 INSERM 1059 / LBTO, Université 

de Lyon, Saint-Etienne; Rheumatology Department, 

Saint-Etienne, France, 20 CHU Dupuytren, Limoges, 

France, 21 Rheumatology, Caen, France, 22 Rheumatology, 

PARIS, France, 23 Hopital Bichat, Paris, France, 

24 

University Hospital, Poitiers, France, 25 Rheumatology, 

Marseille, France, 26 Hopital Croix-Saint-Simon, Paris 

Cedex 20, France, 27 Rheumatology, Le Havre, France, 

28 

Rheumatology, Nancy, France, 29 University Hospital, 

Rouen, France, 30 Rheumatology, Brest, France, 

31 

Rheumatology, Montpellier, France, 32 Rheumatology, 

Paris, France, 33 Rheumatology, Cannes, France, 

34 

Université Paris Est Créteil, Créteil, France, 35 Centre 

Hospitalier de Mulhouse, Mulhouse, France, 36 Réseau 

Hôpital et Ville en Rhumatologie (RHEVER) Network, 

Paris, France, 37 A. Paré University Hospital, Boulogne- 

Billancourt, France, 38 Internal Medicine Department, 

Saint Antoine Hospital, Paris, France, 39 Rheumatology, 

Belffort, France, 40 Rheumatology, Strasbourg, France, 

41 

Epidemiologist, Paris, France, 42 Department of 

Rheumatology, Strasbourg University Hospital, 

Strasbourg, France 

2:45 pm 

3111. Long-term Safety and Efficacy of 

Mavrilimumab, a Fully Human Granulocyte- 

Macrophage Colony-Stimulating Factor Receptor-α 

(GM–CSFR-α) Monoclonal Antibody, in Patients with 

Rheumatoid Arthritis (RA) 

Gerd Burmester 1 , IB McInnes 2 , JM Kremer 3 , P Miranda 4 , 

J Vencovský 5 , A Godwood 6 , M Albulescu 6 , D Close 6 and 

Michael Weinblatt 7 , 1 Charité - Universitätsmedizin 

Berlin, Berlin, Germany, 2 Glasgow Biomedical Research 

Centre, Glasgow, United Kingdom, 3 The Albany 

Medical College, Albany, NY, 4 Centro De Estudios 

Reumatológicos, Santiago, Chile, 5 Charles University, 

Prague, Czech Republic, 6 MedImmune, Cambridge, 

United Kingdom, 7 Brigham and Women’s Hospital, 

Boston, MA 

3:00 pm 

3112. Incidence of Anti-Drug Antibodies in 

Rheumatoid Arthritis Patients Treated with 

Adalimumab, Etanercept, or Infliximab in a Real- 

World Setting 

RJ Moots 1 , Ricardo Xavier 2 , Chi Chiu Mok 3 , Mahboob 

U Rahman 4 , Wen-Chan Tsai 5 , Mustafa Al Maini 6 , Karel 

Pavelka 7 , Ehab Mahgoub 8 , Sameer Kotak 9 , Joan Korth- 

Bradley 8 , Ronald Pedersen 8 , Linda Mele 8 , Qi Shen 8 and 

Bonnie Vlahos 8 , 1 University of Liverpool, Liverpool, 

United Kingdom, 2 Hospital de Clínicas de Porto Alegre, 

Porto Alegre, Brazil, 3 Tuen Mun Hospital, Hong Kong, 

Hong Kong, 4 Perelman School of Medicine, University 


160 




of Pennsylvania, Philadephia, PA, 5 Kaohsiung Medical 

University, Kaohsiung, Taiwan, 6 Mafraq Hospital, Abu 

Dhabi, United Arab Emirates, 7 Charles University 

Prague, Prague, Czech Republic, 8 Pfizer, Collegeville, 

PA, 9 Pfizer, New York, NY 

3:15 pm 

3113. Interest of Assessing Anti-Drug Antibodies for 

the Choice Between a Second Anti-TNF and a Non- 

TNF-Targeted Biologic in Patients with Inadequate 

Response to a First Anti-TNF : Results from 

the Randomized Controlled Trial « Rotation or 

Change » 

Sophie Candon 1 , Lucienne Chatenoud 1 , Olivier 

Brocq 2 , Aleth Perdriger 3 , Slim Lassoued 4 , Jean-Marie 

Berthelot 5 , Daniel Wendling 6 , Liana Euller-Ziegler 7 , 

Martin Soubrier 8 , Christophe Richez 9 , Bruno Fautrel 10 , 

Arnaud Constantin 11 , Xavier Mariette 12 , Jacques 

Morel 13 , Mélanie Gilson 14 , Gregoire Cormier 15 , Jean 

Hugues Salmon 16 , Stephanie Rist Bouillon 17 , Frederic 

Liote 18 , Hubert Marotte 19 , Christine Bonnet 20 , Christian 

Marcelli 21 , Jeremie Sellam 1 , Olivier Meyer 22 , Elisabeth 

Solau-Gervais 23 , Sandrine Guis 24 , Jean Marc Ziza 25 , 

Charles Zarnitsky 26 , Isabelle Chary-Valckenaere 27 , O 

Vittecoq 28 , Alain Saraux 29 , Yves-Marie Pers 30 , Martine 

Gayraud 31 , Gilles Bolla 32 , Pascal Claudepierre 33 , Marc 

Ardizzone 34 , Emmanuelle Dernis Labous 35 , Maxime 

A. Breban 36 , Olivier Fain 37 , Jean Charles Balblanc 38 , 

Elodie Perrodeau 39 , Jean Sibilia 40 , Philippe Ravaud 31 

and Jacques-Eric Gottenberg 41 , 1 Rheumatology, 

PARIS, France, 2 Hospital Center Princesse Grâce, 

Monaco, Monaco, 3 CHU de Rennes, Rennes, France, 

4 

Rheumatology, Cahors, France, 5 University Hospital, 

Nantes, France, 6 Université de Franche-Comté, 

Besançon, France, 7 Rheumatology, Nice, France, 

8 

Rheumatology department CHU Clermont-Ferrand, 

Clermont-Ferrand, France, 9 Rheumatology, Bordeaux, 

France, 10 AP-HP Pitié-Salpêtrière Hospital / Pierre 

and Marie Curie University Paris 6 GRC-08 (EEMOIS), 

Paris, France, 11 CHU Purpan - Hopital Pierre-Paul 

Riquet, Toulouse, France, 12 Université Paris-Sud, AP- 

HP, Hôpitaux Universitaires Paris-Sud, Paris, France, 

13 

Lapeyronie Hospital and Montpellier University, 

Montpellier, France, 14 Hospital Center, Grenoble, 

France, 15 Rheumatology, La Roche Sur Yon, France, 

16 

Rheumatology, REIMS, France, 17 Hopital La Source, 

La Source, France, 18 Rheumatology, Lariboisière, 

France, 19 INSERM 1059 / LBTO, Université de Lyon, 

Saint-Etienne; Rheumatology Department, Saint- 

Etienne, France, 20 CHU Dupuytren, Limoges, France, 

21 

Rheumatology, Caen, France, 22 Hopital Bichat, 

Paris, France, 23 University Hospital, Poitiers, France, 

24 

Rheumatology, Marseille, France, 25 Hopital Croix- 

Saint-Simon, Paris Cedex 20, France, 26 Rheumatology, 

Le Havre, France, 27 Rheumatology, Nancy, France, 

28 

University Hospital, Rouen, France, 29 Rheumatology, 

Brest, France, 30 Rheumatology, Montpellier, France, 

31 

Rheumatology, Paris, France, 32 Rheumatology, 

Cannes, France, 33 Université Paris Est Créteil, Créteil, 

France, 34 Centre Hospitalier de Mulhouse, Mulhouse, 

France, 35 Réseau Hôpital et Ville en Rhumatologie 

(RHEVER) Network, Paris, France, 36 A. Paré University 

Hospital, Boulogne-Billancourt, France, 37 Internal 

Medicine Department, Saint Antoine Hospital, 

Paris, France, 38 Rheumatology, Belffort, France, 

39 

Epidemiologist, Paris, France, 40 Department of 

Rheumatology, Strasbourg University Hospital, 

Strasbourg, France, 41 Hautepierre, Strasbourg, France 

3:30 pm 

3114. Immunogenicity of Subcutaneous and 

Intravenous Tocilizumab As Monotherapy or in 

Combination with Dmards 

Mark C. Genovese 1 , Atsushi Ogata 2 , Akira Nomura 3 , 

Min Bao 4 , Elena Hitraya 4 , Stuart Lacey 5 and Gerd 

Burmester 6 , 1 Stanford University Medical Center, 

Palo Alto, CA, 2 Osaka University Graduate School 

of Medicine and NTT West Osaka Hospital, Osaka, 

Japan, 3 Chugai Pharmaceutical Co Ltd, Tokyo, Japan, 

4 

Genentech, South San Francisco, CA, 5 Roche, 

Welwyn Garden City, United Kingdom, 6 Charité - 

Universitätsmedizin Berlin, Berlin, Germany 

3:45 pm 

3115. Autoantibodies of the IgA Type a Link 

Between the Gut and the Anti-TNF Therapy 

Response in Rheumatoid Arthritis Patients 

Analysed in Two Clinical Trials 

Zoltan Konthur 1 , Ute Nonhof 2 , Melvin Michael 

Wiemkes 3 , Jacqueline Detert 3 , Tanja Braun 3 , Jörg 

Hollidt 2 , Gerd Burmester 3 and Karl Skriner 3 , 1 Max 

Planck Institute for Molecular Genetics, Berlin, 

Germany, 2 Drug Response DX GmbH, Berlin, Germany, 



2 0 1 5 


tracker 

plus 

161 


3 

Charité - Universitätsmedizin Berlin, Berlin, Germany 

West – 2022 

Spondylarthropathies and Psoriatic Arthritis 

– Clinical Aspects and Treatment: Psoriatic 

Arthritis – CoMorbidities 

Moderators: Alexis Ogdie-Beatty, MD, MSCE and Siba 

Raychaudhuri, MD 

2:30 pm 

3116. High Level of Inflammation Predicts the 

Development of Diabetes Mellitus in Patients with 


Lihi Eder 1 , Vinod Chandran 1 , Richard J. Cook 2 and 

Dafna D. Gladman 1 , 1 University of Toronto, Toronto 

Western Hospital, Toronto, ON, 2 University of Waterloo, 

Waterloo, ON 

2:45 pm 

3117. Under-Treatment of Cardiovascular Risk 

Factors in Patients with Psoriatic Disease - an 

International Multicentre Study 

Lihi Eder 1 , Vinod Chandran 1 , Cheryl Rosen 1 , Jan Dutz 2 , 

James T. Elder 3 , Proton Rahman 4 , Christopher T. 

Ritchlin 5 , Francisco A. Tausk 5 , Sherry Rohekar 6 , Richard 

Hayday 7 , Snezana Barac 8 , Devy Zisman 9 , Joy Feld 9 and 

Dafna D. Gladman 1 , 1 University of Toronto, Toronto 

Western Hospital, Toronto, ON, 2 University of British 

Columbia, Vancouver, BC, 3 University of Michigan 

Medical School, Ann Arbor, MI, 4 Memorial University of 

Newfoundland, St. John’s, NF, 5 University of Rochester 

Medical Center, Rochester, NY, 6 Western University, 

London, ON, 7 University of Manitoba, Winnipeg, MB, 

8 

Winnipeg Clinic, Winnipeg, MB, 9 Carmel Medical 

Center, Haifa, Israel 

3:00 pm 

3118. Clinical Characteristics and Disease Outcomes 

in Psoriatic Arthritis Patients By Extent of Body 

Surface Area Affected By Psoriasis: Results from 

Corrona Registry 

Philip J. Mease 1 , Chitra Karki 2 , Carol J. Etzel 3 , Arthur 

Kavanaugh 4 , Christopher T. Ritchlin 5 , Wendi Malley 2 , 

Vivian Herrera 6 , Jacqueline B. Palmer 6 and Jeffrey D. 

Greenberg 2 , 1 Swedish Medical Center and University of 

Washington School of Medicine, Seattle, WA, 2 Corrona, 

LLC, Southborough, MA, 3 University of Texas M.D. 

Anderson Cancer Center, Houston, TX, 4 University 

of California San Diego, La Jolla, CA, 5 University of 

Rochester Medical Center, Rochester, NY, 6 Novartis 

Pharmaceuticals Corporation, East Hanover, NJ 

3:15 pm 

3119. The Risk of Venous Thromboembolism in 

Psoriatic Arthritis, Psoriasis and Rheumatoid 

Arthritis 

Alexis Ogdie-Beatty 1 , Daniel Shin 1 , Junko Takeshita 1 , 

Zelma ChiesaFuxench 1 and Joel Gelfand 2 , 1 University 

of Pennsylvania, Philadelphia, PA, 2 University of 

Pennsylvania Health System , Philadelphia, PA 

3:30 pm 

3120. The Prevalence, Incidence and Management 

of Hypertension, Diabetes and Hyperlipidemia 

in Psoriatic Arthritis, Psoriasis and Rheumatoid 

Arthritis 

Kashif Jafri 1 , Christie M. Bartels 2 , Daniel Shin 1 and 

Alexis Ogdie-Beatty 1 , 1 University of Pennsylvania, 

Philadelphia, PA, 2 University of Wisconsin School of 

Medicine and Public Health, Madison, WI 

3:45 pm 

3121. Gender Differences in Patient Reported 

Outcomes (PROs) in Psoriatic Arthritis 

Tawnie Braaten 1 , Brian Breviu 1 , Jessica Walsh 1 , 

Angela Presson 2 , Chong Zhang 2 and Daniel Clegg 1 , 

1 

Salt Lake City Veteran Affairs and University of Utah 

Medical Centers, Salt Lake City, UT, 2 University of Utah 

Hospitals and Clinics, Salt Lake City, UT 

West – 2000 


Aspects and Treatment V: Neuropsychiatric 

Lupus 

Moderator: Eliza Chakravarty, MD, MS 

2:30 pm 

3122. A Longitudinal Analysis of Change in Lupus 

Nephritis in an International Inception Cohort 

Using a Multistate Markov Model Approach 

John G. Hanly 1 , Li Su 1 , Murray Urowitz 2 , Juanita 

Romero-Diaz 3 , C. Gordon 4 , Sang-Cheol Bae 5 , Sasha 

R Bernatsky 6 , Ann Clarke 7 , Daniel J Wallace 8 , Joan T. 

Merrill 9 , David A. Isenberg 10 , Anisur Rahman 11 , Ellen 

M. Ginzler 12 , Paul Fortin 13 , Dafna D. Gladman 14 , Jorge 


162 




Sanchez-Guerrero 15 , Michelle Petri 16 , Ian N. Bruce 17 , 

Mary Anne Dooley 18 , Rosalind Ramsey-Goldman 19 , 

Cynthia Aranow 20 , Graciela S. Alarcon 21 , Barri J. 

Fessler 22 , Kristján Steinsson 23 , Ola Nived 24 , Gunnar 

K. Sturfelt 25 , Susan Manzi 26 , Munther Khamashta 27 , 

Ronald F. van Vollenhoven 28 , Asad Zoma 29 , Guillermo 

Ruiz-Irastorza 30 , Manuel Ramos-Casals 31 , S. Sam Lim 32 , 

Thomas Stoll 33 , Murat Inanc 34 , Kenneth C. Kalunian 35 , 

Diane L. Kamen 36 , Peter Maddison 37 , Christine A. 

Peschken 38 , Søren Jacobsen 39 , Anca Askanase 40 , Chris 

Theriault 41 , Kara Thompson 41 and Vernon Farewell 1 , 

1 

Division of Rheumatology, Capital Health and 

Dalhousie University, Halifax, NS, 2 TWH, Toronto, ON, 

3 

Instituto Nacional de Ciencias Médicas y Nutrición 

Salvador Zubirán, Mexico city, Mexico, 4 University of 

Birmingham, Birmingham, United Kingdom, 5 Hanyang 

University Hospital for Rheumatic Diseases, Seoul, 

South Korea, 6 McGill Unversity Health Cener, Montreal, 

QC, 7 University of Calgary, Calgary, AB, 8 Cedars-Sinai 

Medical Center, West Hollywood, CA, 9 Oklahoma 


10 

Centre for Rheumatology Research, UCL Division 

of Medicine, London, United Kingdom, 11 U College of 

London, London, United Kingdom, 12 SUNY-Downstate, 

Brooklyn, NY, 13 Division of Rheumatology, Centre 

Hospitalier Universitaire de Quebec et Universite 

Laval, Quebec, QC, 14 University of Toronto, Toronto, 

ON, 15 Toronto Western Hospital, Toronto, ON, 16 Johns 

Hopkins University Hospital, Baltimore, MD, 17 Arthritis 

Research UK Centre for Epidemiology, Centre for 

Musculoskeletal Research, Institute of Inflammation 

and Repair, Manchester Academic Health Science 

Centre, The University of Manchester, Manchester, 

United Kingdom, 18 UNC Kidney Centre, Chapel Hill, 

NC, 19 Northwestern University Feinberg School of 

Medicine, Chicago, IL, 20 Feinstein Institute for Medical 

Research, Manhasset, NY, 21 University of Alabama at 

Birmingham, Birmingham, AL, 22 UAB, Birmingham, AL, 

23 

Univ. Hospital, Reykjavik, Iceland, 24 Inst of Clinical 

sciences, Lund, Sweden, 25 Univ Hospital Lund, Lund, 

Sweden, 26 Allegheny Health Network, Pittsburgh, 

PA, 27 Graham Hughes Lupus Research Laboratory, 

The Rayne Institute, St Thomas’ Hospital, London, 

United Kingdom, 28 Unit for Clinical Therapy Research, 

Inflammatory Diseases (ClinTRID), The Karolinska 

Institute, Stockholm, Sweden, 29 Hairmyres Hospital, 

East Kilbride, United Kingdom, 30 Hospital de Cruces, 

Bizkaia, Spain, 31 IDIBAPS, Hospital Clinic, Barcelona, 

Spain, 32 Emory University, Atlanta, GA, 33 Kantonsspital 

Schaffhausen, Schaffhausen, Switzerland, 34 Istanbul 

University, Istanbul Faculty of Medicine, Istanbul, 

Turkey, 35 UCSD School of Medicine, La Jolla, CA, 

36 

Medical University of South Carolina, Charleston, SC, 

37 

School of Sport, Health and Exercise Sciences, Bangor 

University, George Building, Bangor, Gwynedd, LL57 

2PZ, UK., Bangor, United Kingdom, 38 Univ of Manitoba, 

Winnipeg, MB, 39 Rigshospitalet, Copenhagen University 

Hospital, Copenhagen, Denmark, 40 NYU School of 

Medicine, New York, NY, 41 Dept of Medicine, Queen 

Elizabeth II Health Sciences Centre and Dalhousie 

University, Halifax, NS 

2:45 pm 

3123. Evidence of Altered Blood Brain Barrier 

Permeability in Systemic Lupus Erythematosus 

Using Magnetic Resonance Imaging 

Gaurav Gulati 1 , Jordan T. Jones 2 , Mekibib Altaye 3 , Jamie 

Meyers Eaton 3 , Kasha Wiley 2 , Mark DiFrancesco 2 and 

Hermine I. Brunner 4 , 1 University of Cincinnati College of 

Medicine, Cincinnati, OH, 2 Cincinnati Children’s Hospital 

Medical Center, Cincinnati, OH, 3 Cincinnati Children’s 

Hospital and Medical Center, Cincinnati, OH, 4 Pediatric 



3:00 pm 

3124. Associations of Circulating Cell-Free Micro- 

RNA with Vasculopathy and Vascular Events in SLE 

Patients 

Susan Due Kay 1 , Anting L. Carlsen 2 , Anne Voss 1 , Mikael 

Kjær Poulsen 1 , Axel Cosmus Pyndt Diederichsen 1 

and Niels H. H. Heegaard 1 , 1 Odense University 

Hospital, Odense C, Denmark, 2 Statens Serum Institut, 

Copenhagen, Denmark 

3:15 pm 

3125. White Matter Magnetization Transfer 

Ratio Histogram Peak Height Helps Identifying 

Inflammatory Neuropsychiatric Systemic Lupus 

Erythematosus 

César Magro Checa 1 , Ece Ercan 2 , Bart J Emmer 3 , Ron 

Wolterbeek 4 , Itamar Ronen 2 , Mark A. Van Buchem 2 , 

Tom W.J. Huizinga 1 and Gerda M. Steup-Beekman 1 , 

1 




2 0 1 5 


tracker 

plus 

163 


Medical Center, Leiden, Netherlands, 2 C.J. Gorter 

Center for High Field MRI, Department of Radiology, 

Leiden University Medical Center, Leiden, Netherlands, 

3 

Department of Radiology, Erasmus Medical Center, 

Rotterdam, Netherlands, 4 Department of Medical 

Statistics and Bioinformatics, Leiden University Medical 

Center, Leiden, Netherlands 

3:30 pm 

3126. Biomarkers Associated with Hyperintense 

White Matter Lesions in Systemic Lupus 

Erythematosus 

Mariana Postal, Aline Tamires Lapa, Karina O. Peliçari, 

Nailu A. Sinicato, Fernando A. Peres, Angela C. Gomes, 

Lilian TL Costallat, Fernando Cendes and Simone 

Appenzeller, State University of Campinas, Campinas, 

Brazil 

3:45 pm 

3127. Serologic Diagnosis of Human 

Neuropsychiatric Lupus Using the Immunarray 

ICHIP ® 

Chaim Putterman 1 , D. Scott Batty 2 , I.R. Cohen 3 , Nicole 

Jordan 4 , Debbie Rybak 1 , Tamar Rubinstein 1 , Keren 

Jakobi 5 , Rachel Sorek 5 , Anat Reiner-Benaim 5 , Yakov 

Blumenstein 5 and Pennina Safer 5 , 1 Albert Einstein 

College of Medicine, Bronx, NY, 2 ImmunArray Inc., 

Richmond, VA, 3 Weizmann Institute of Science, 

Rehovot, Israel, 4 Montefiore Medical Center, New York, 

NY, 5 ImmunArray LTD, Rehovot, Israel 


Systemic Sclerosis, Fibrosing Syndromes and 

Raynaud’s – Pathogenesis, Animal Models and 

Genetics II 

Moderators: Romy Christmann, MD, PhD and Shervin 

Assassi, MD, MS 

2:30 pm 

3128. Genome-Wide DNA Methylation Analysis 

in Blood and Dermal Fibroblasts from Twin Pairs 

Discordant for Systemic Sclerosis 

Paula S. Ramos 1 , Thomas A. Medsger Jr. 2 and Carol 

A. Feghali-Bostwick 1 , 1 Medical University of South 

Carolina, Charleston, SC, 2 University of Pittsburgh, 

Pittsburgh, PA 

2:45 pm 

3129. Integrative Analysis of the Colonic Microbiota 

in Systemic Sclerosis 

Elizabeth R. Volkmann 1 , Yu-Ling Chang 2 , Nashla 

Barroso 2 , Daniel E. Furst 2 , Philip J. Clements 1 , Alan 

Gorn 3 , Bennett Roth 2 , Jeffrey Conklin 2 , Terri Getzug 2 , 

Maomeng Tong 2 , Jonathan Jacobs 2 and Jonathan 

Braun 2 , 1 University of California Los Angeles, David 

Geffen School of Medicine, Los Angeles, CA, 2 University 


Medicine, Los Angeles, CA, 3 UCLA David Geffen School 

of Medicine, Division of Rheumatology, Los Angeles, CA 

3:00 pm 

3130. Epstein-Barr Virus Induces Activation of 

Infammatory Markers Via the TLR8 Transduction 

Pathway in Infected Scleroderma Monocytes 

Antonella Farina 1 , Giovanna Peruzzi 2 , Valentina 

Lacconi 3 , Edoardo Rosato 4 , Silvia Quarta 4 , Stefania 

Morrone 1 , Alberto Faggioni 1 , Maria Trojanowska 3 and 

Giuseppina Alessandra Farina 3 , 1 Sapienza University, 

Department of Experimental Medicine, Rome, Italy, 

2 

Istituto Italiano di Tecnologia (IIT), CLNS@Sapienza, 

Rome, Italy, 3 Boston University, Arthritis Center, 

Boston, MA, 4 Sapienza University,Department of 

Clinical Medicine, Rome, Italy 

3:15 pm 

3131. Interferon Regulatory Factor 7 (IRF7): The 

Possible Link Between Inflammation and Fibrosis in 

SSc Pathogenesis 

Minghua Wu 1 , Gloria Salazar 1 , Xiaodong Zhou 1 , Xinjian 

Guo 1 , John D. Reveille 1 , Sandeep K. Agarwal 2 , Michael 

R. Blackburn 3 , Maureen D Mayes 1 and Shervin Assassi 1 , 

1 

University of Texas Medical School at Houston, 

Houston, TX, 2 Baylor College of Medicine, Houston, TX, 

3 

The University of Texas Medical School at Houston, 

Houston, TX 

3:30 pm 

3132. Histone Deacetylase 5 Is Overexpressed 

in Scleroderma Endothelial Cells and Impairs 

Angiogenesis Via Repressing Pro-Angiogenic Factors 

Pei-Suen Tsou 1 , M. Asif Amin 2 , Elena Schiopu 1 , David A. 

Fox 2 , Dinesh Khanna 1 and Amr H. Sawalha 1 , 1 Division 

of Rheumatology, University of Michigan, Ann Arbor, 

MI, 2 Division of Rheumatology, University of Michigan 

Medical Center, Ann Arbor, MI 


164 




3:45 pm 

3133. The Anti-Fibrotic Effect of Endostatin-Derived 

Peptide Is Mediated By the Urokinase Pathway Via 

Binding to Enolase-1 and Urokinase Plasminogen 

Activator Receptor 

Tetsuya Nishimoto 1 , Takahisa Takihara 2 , Logan Mlakar 1 , 

Yunyun Su 1 , Roger Chambers 1 and Carol Feghali- 

Bostwick 1 , 1 Medical University of South Carolina, 

Charleston, SC, 2 Tokai University School of Medicine, 

Kanagawa, Japan 




II 

Moderator: Francesco Boin, MD 

2:30 pm 

3134. Safety and Tolerability of Pirfenidone in 

Patients with Systemic Sclerosis Interstitial Lung 

Disease 

Dinesh Khanna 1 , Carlo Albera 2 , Aryeh Fischer 3 , James 

R. Seibold 4 , Nader A. Khalidi 5 , Ganesh Raghu 6 , Lorinda 

Chung 7 , Elena Schiopu 1 , Dan Chen 8 and Eduard 

Gorina 9 , 1 University of Michigan, Ann Arbor, MI, 

2 

University of Turin, Turin, Italy, 3 National Jewish Health 

and University of Colorado, Denver, CO, 4 Scleroderma 

Research Consultants LLC, Litchfield, CT, 5 McMaster 

University, Hamilton, ON, 6 University of Washington, 

Seattle, WA, 7 Stanford University School of Medicine, 

Stanford, CA, 8 Jazz Pharmaceuticals (formerly of 

InterMune), Palo Alto, CA, 9 Formerly of InterMune, 

Brisbane, CA 

2:45 pm 

3135. Incidences and Predictors of Organ 

Manifestations in the Early Course of Systemic 

Sclerosis: A Longitudinal Study 

Veronika K. Jaeger 1 , Elina G. Wirz 2 , Yannick 

Allanore 3 , Gabriela Riemekasten 4 , Eric Hachulla 5 , 

Oliver Distler 6 , Paolo Airo 7 , Patricia E. Carreira 8 , 

Alexandra Balbir-Gurman 9 , Mohammed Tikly 10 , 

Serena Vettori 11 , Nemanja Damjanov 12 , Ulf Müller- 

Ladner 13 , Jorg HW. Distler 14 , Mangtao Li 15 , Ulrich A. 

Walker 16 and EUSTAR collaborators, 1 Department 

of Rheumatology, University Hospital Basel, Basel, 

Switzerland, 2 Department of Dermatology, University 

Hospital Basel, Basel, Switzerland, 3 Department of 

Rheumatology A, Paris Descartes University, Cochin 

Hospital, Paris, France, 4 Clinic of Rheumatology, 

University of Luebeck, Lübeck, Germany, 5 Service 

de Médecine Interne, Hôpital Huriez, Université de 

Lille, Lille, France, 6 Department of Rheumatology, 

University Hospital Zurich, Zurich, Switzerland, 7 UO 

Reumatologia ed Immunologia Clinica, Spedali Civili, 

Brescia, Italy, 8 Servicio de Reumatologia, Hospital 

Universitario 12 de Octubre, Madrid, Spain, 9 B. Shine 

Rheumatology Unit, Rambam Health Care Campus, 

Rappaport Faculty of Medicine, Technion - Institute of 

Technology, Haifa, Israel, 10 Division of Rheumatology, 

Chris Hani Baragwanath Academic Hospital, Faculty 

of Health Sciences, University of the Witwatersrand, 

Johannesburg, South Africa, 11 Rheumatology Unit, 

Second University of Naples, Naples, Italy, 12 Institute of 

Rheumatology, University of Belgrade Medical School, 

Belgrade, Serbia, 13 Justus-Liebig-University of Giessen, 

Kerckhoff-Klinik, Bad Nauheim, Germany, 14 Department 

of Internal Medicine 3, University of Erlangen- 

Nuremberg, Erlangen, Germany, 15 Department of 

Rheumatology, Peking Union Medical College Hospital, 

Chinese Academy of Medical Sciences, Beijing, China, 

16 

University Hospital, Basel, Basel, Switzerland 

3:00 pm 

3136. Impact of Prokinetic Agents on Systemic 

Sclerosis-Associated Gastrointestinal Disease: A 

Systematic Review 

Annaliese Tisseverasinghe 1 , Ahmad Kadhim 2 , Ambica 

Parmar 2 , Louis Liu 2 and Sindhu R. Johnson 1 , 1 Toronto 

Scleroderma Program, Division of Rheumatology, 

Toronto Western Hospital, Mount Sinai Hospital, 

Institue of Health Policy, Management and Evaluation, 

University of Toronto, Toronto, ON, 2 Division of 

Gastroenterology, Toronto Western Hospital, University 

of Toronto, Toronto, ON 

9:45 am 

3137. Scleroderma Hand Contracture Study 

Joyce Joseph, Univeristy of Teas Health Science Center 

at Houston, Houston, TX 

3:15 pm 

3138. Prognostic Role of Ventricular Ectopic Beats 

in Systemic Sclerosis 

Giacomo De Luca 1 , Silvia Laura Bosello 1 , Francesca 



2 0 1 5 


tracker 

plus 

165 


Gabrielli 2 , Giorgia Berardi 1 , Federico parisi 1 , Manuela 

Rucco 1 , Giovanni Canestrari 1 , Leonarda Galiuto 3 , 

Filippo Crea 3 , Francesco Loperfido 2 and Gianfranco 

Ferraccioli 1 , 1 Division of Rheumatology, Catholic 

University of the Sacred Heart, Rome, Italy, 2 Division 

of Heart Failure and Cardiac Rehabilitation, Catholic 

University - Rome, Rome, Italy, 3 Institute of Cardiology, 

Catholic University of the Sacred Heart, Rome, Italy 

3:30 pm 

3139. Screening Algorithm for Pulmonary 

Hypertension in Systemic Sclerosis - Comparison of 

Predictive Accuracy of Three Algorithms 

Vivek Nagaraja 1 , Scott H. Visovatti 2 , Heather Gladue 3 , 

Veronica J. Berrocal 2 , Jennifer Serrano 2 , Vallerie 

McLaughlin 2 and Dinesh Khanna 4 , 1 University of 

Toledo, Toledo, OH, 2 University of Michigan, Ann 

Arbor, MI, 3 Emory University, Atlanta, GA, 4 Division of 

Rheumatology, University of Michigan, Ann Arbor, MI 

West – 2018 

Vasculitis III 

Moderator: Eli Miloslavsky, MD 

2:30 pm 

3140. A Meta-Immunochip Analysis Suggests IL12B 

As a Common Susceptibility Factor for Large-Vessel 

Vasculitides 

Francisco David Carmona 1 , Patrick Coit 2 , Güher 

Saruhan-Direskeneli 3 , Maria C. Cid 4 , Roser Solans 5 , 

Santos Castañeda 6 , Augusto Vaglio (on behalf of the 

Italian GCA Study Group) 7 , Haner Direskeneli (on 

behalf of the Turkish Takayasu Study Group) 8 , Peter 

A. Merkel 9 , Carlo Salvarani 10 , Miguel A. Gonzalez- 

Gay 11 , Javier Martín 12 , Amr H. Sawalha 2 and Spanish 

GCA consortium, 1 Instituto de Parasitología y 

Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, 

Granada, Spain, 2 University of Michigan, Ann 

Arbor, MI, 3 Istanbul University, Istanbul Faculty of 

Medicine, Istanbul, Turkey, 4 Hospital Clínic. IDIBAPS. 

University of Barcelona, Barcelona, Spain, 5 Hospital 

Vall d’Hebron, Barcelona, Spain, 6 H.U. La Princesa, 

Madrid, Spain, 7 Università di Parma, Parma, Italy, 

8 

Marmara University, School of Medicine, Istanbul, 

Turkey, 9 University of Pennsylvania, Philadelphia, 

PA, 10 Azienda Ospedaliera ASMN, Istituto di Ricovero 

e Cura a Carattere Scientifico, Reggio Emilia, Italy, 

11 

Hospital Universitario Marqués de Valdecilla, IDIVAL, 

University of Cantabria, Santander, Spain, 12 Instituto de 

Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, 

Armilla (Granada), Spain 

2:45 pm 

3141. Endothelial Cells Regulate Proinflammatory 

T Cell Responses in Large Vessel Vasculitis Via 

NOTCH-NOTCH Ligand Interactions 

Zhenke Wen 1 , Hui Zhang 1 , Joyce Liao 2 , Gerald Berry 1 , 

Lindsy J. Forbess 3 , Michael Weissman 3 , Jorg Goronzy 1 

and Cornelia M. Weyand 1 , 1 Stanford University School 

of Medicine, Stanford, CA, 2 Stanford University, Palo 

Alto, CA, 3 Cedars-Sinai Medical Center, Los Angeles, CA 

3:00 pm 

3142. Tocilizumab Enhances Regulatory T-Cell 

Activation and Proliferation in Giant Cell Arteritis 

Chie Miyabe, Klemen Strle, Yoshishige Miyabe, John 

H. Stone, Andrew D. Luster and Sebastian Unizony, 



3:15 pm 

3143. Mapping the Back-Door Routes into the 

Vascular Wall: 3D Microscopic Reconstruction of 

Microvasculature in the Normal Temporal Artery 

and in Giant Cell Arteritis 

Daniel Drayton 1 , Aruna Chakrabarty 2 , Ann Morgan 1 , 

Darren Treanor 2 and Sarah Mackie 1 , 1 University of 

Leeds, Leeds, United Kingdom, 2 Leeds Teaching 

Hospitals NHS Trust, Leeds, United Kingdom 

3:30 pm 

3144. Efficacy and Safety of Tocilizumab for 

Polymyalgia Rheumatica 

Lindsay Lally 1 , Lindsy J. Forbess 2 , Chris Hatzis 1 and 

Robert F. Spiera 3 , 1 Hospital for Special Surgery, New 

York, NY, 2 Cedars-Sinai Medical Center, Los Angeles, 

CA, 3 HSS, New York, NY 

3:45 pm 

3145. Efficacy and Safety of Modified-Release 

Prednisone in Patients with Polymyalgia 

Rheumatica: Results of a Multicenter, Randomized, 

Active-Controlled Phase 3 Study 

Maurizio Cutolo 1 , Michael Hopp 2 , Stefan Liebscher 2 , 

Bhaskar Dasgupta 3 and Frank Buttgereit 4 , 1 Research 

Laboratory and Academic Division of Clinical 


166 




Rheumatology, Department of Internal Medicine, 

University of Genova, Genova, Italy, 2 Mundipharma 

Research GmbH & Co. KG, Limburg, Germany, 

3 

Southend University Hospital, Essex, United Kingdom, 

4 

Charité – Universitätsmedizin Berlin, Berlin, Germany 

ACR/ARHP CONCURRENT ABSTRACT 

SESSION 

2:30 – 4:00 pm 

West – 2004 

ACR/ARHP Combined Abstract Session: Pediatric 

Rheumatology PM Ed Pd PS PrM FIT 

Moderators: Gloria C. Higgins, MD, PhD and Donald P. 

Goldsmith, MD 

2:30 pm 

3146. Health Related Quality of Life in Adults with 

JIA - a 30 Year Longitudinal Study 

Anita Tollisen 1 , Anne Marit Selvaag 2 , Hanne A. Aulie 2 , 

Anners Lerdal 3 and Berit Flato 2 , 1 Lovisenberg Diakonale 

Hospital, Oslo, Oslo, Norway, 2 Department of 

Rheumatology, Oslo University Hospital, Rikshospitalet, 

Oslo, Norway, 3 Faculty of Medicine, Institute of Health 

and Society, University of Oslo, Oslo, Norway 

2:45 pm 

3147. Inter-Provider Reliability in Scoring the 

Physician Global Assessment of Disease Activity 

Among Patients with Juvenile Idiopathic Arthritis 

Patients Who Met the ACR Provisional Criteria for 

Clinical Inactive Disease 

Janalee Taylor 1 , Edward H. Giannini 1 , Daniel J Lovell 2 

and Esi M. Morgan DeWitt 1 , 1 Cincinnati Children’s 

Hospital Medical Center, Cincinnati, OH, 2 PRCSG, 

Cincinnati Children’s Hospital Medical Center, 

Cincinnati, OH 

3:00 pm 

3148. Physical Activity in Children and Adolescents 

with Juvenile Idiopathic Arthritis and Associated 

Factors 

Sabrina Cavallo 1 , Marie-Ève Mathieu 2 , Annette 

Majnemer 3 , Désirée B. Maltais 4 , Ciarán M. Duffy 5 , 

Mélanie Henderson 6 and Debbie Ehrmann Feldman 1 , 

1 

Université de Montréal, Montreal, QC, 2 Université de 

Montréal, Montréal, QC, 3 McGill University, Montreal, 

QC, 4 Université de Laval, Québec, QC, 5 Children’s 

Hospital of Eastern Ontario and University of 

Ottawa, Ottawa, ON, 6 Centre de recherche du Centre 

Hospitalier Universitaire Sainte-Justine, Montréal, QC 

3:15 pm 

3149. Predictors of Longitudinal Quality of Life 

Impact in Pediatric Localized Scleroderma 

Kaveh Ardalan, Christina Kelsey and Kathryn S. Torok, 

Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, 

PA 

3:30 pm 

3150. Virtual Peer-to-Peer Mentoring Support for 

Adolescents with Juvenile Idiopathic Arthritis: The 

Virtual Peer-to-Peer Program 

Jennifer N. Stinson 1 , Sara Ahola Kohut 2 , Khush Amaria 3 , 

Mary J. Bell 2 , Paula Forgeron 4 , Miriam Kaufman 1 , 

Nadia Luca 5 and Lynn R. Spiegel 1 , 1 The Hospital for 

Sick Children, Toronto, ON, 2 University of Toronto, 

Toronto, ON, 3 Hospital for Sick Children, Toronto, 

ON, 4 University of Ottawa, Ottawa, ON, 5 Division of 

Rheumatology, The Hospital for Sick Children, Toronto, 

ON 

3:45 pm 

3151. Validation of Patient-Reported Outcomes 

Measurement Information System (PROMIS ® ) 

Modules for Use in Childhood-Onset Lupus 

Jordan T. Jones 1 , Janet Wootton 2 , Jun Ying 3 , Brianna 

Liberio 4 , Jiha Lee 1 , Adam Carle 1 , Laura Schanberg 2 and 

Hermine I. Brunner 1 , 1 Cincinnati Children’s Hospital 

Medical Center, Cincinnati, OH, 2 Duke Medical Center, 

Durham, NC, 3 University of Cincinnati, Cincinnati, OH, 

4 

University of Cincinnati College of Medicine, Cincinnati, 

OH 

ARHP SESSIONS 

2:30 – 4:00 pm 

West – 2007 


Moderators: Kimberly F. Kimpton, PT and Christine A. 

Stamatos, DNP, ANP-C 

PM PS E 



2 0 1 5 


tracker 

plus 

167 


2:30 pm 


Jillian A. Rose, LCSW 

3:00 pm 


Monica C. Richey, ANP, BC, BSN, MSN 

3:30 pm 


Kiana Johnson, PhD 

West – 2009 

Fall Prevention Interventions 

Moderator: Jennifer L. Trizuto, MPT 

2:30 pm 

Epidemiology of Falls 

Kamil E. Barbour, PhD 

PM PS E 

2:45 pm 

Occupational Therapy Fall Interventions 

Nancy A. Baker, ScD, MPH, OTR/L 

3:00 pm 

Physical Therapy Fall Interventions 

G. Kelley Fitzgerald, PhD, PT, FAPTA 

West – 2006 

Make Self-Management a Reality PM PS E 

Moderator: Teresa J. Brady, PhD 

2:30 pm 

The Definition of Self-management Support (SMS) 

Integration in the Clinical Setting 

Patrick McGowan, PhD and Kate Lorig, DrPH 

2:45 pm 

Small Group Process to Identify Challenges 

Participants Have Experienced Attempting to 

Integrate Self-management Support into Their Clinical 

Setting 

Patrick McGowan, PhD and Kate Lorig, DrPH 

3:00 pm 

Small Groups Report Their Identified Challenges 

Kate Lorig, DrPH 

3:15 pm 

Make Self-Management a Reality 

Patrick McGowan, PhD 

3:30 pm 

Participant Questions, General Discussion and Wrapup 

Kate Lorig, DrPH 

West – 2008 

Manage Persistent Pain: An Interprofessional 

Approach PM PS E 

Moderator: Mary E. Christenson, PhD, PT 

2:30 pm 

Physical Therapy: Management of Persistent Pain 

Wendy Anemaet, PT, DPT, PhD, GCS, GTC 

2:45 pm 

Pharmacology: Management of Persistent Pain 

James D Nash, PharmD, MPH 

3:00 pm 

Nursing: Management of Persistent Pain 

Susan Dalbey, DNP, RN 

3:15 pm 

Counseling: Management of Persistent Pain 

Camille S. Debell, DNP, RN, CNE 

ACR SESSION 

3:00 – 4:00 pm 


ILAR Global Burdens of Rheumatic and 

Musculoskeletal Diseases in Different Regions 

of the World 

Moderator: Carlos Pineda, MD, MSc 

3:00 pm 

African League of Associations for Rheumatology 

(AFLAR) 

Girish Mody, MD 

3:15 pm 

Asia Pacific League of Associations for Rheumatology 

(APLAR) 

Lyn March, MBBS, MSc, PhD 


168 




3:30 pm 

European League Against Rheumatism (EULAR) 

Gerd Burmester, MD 

3:45 pm 

Pan American League of Associations for 

Rheumatology (PANLAR) 

John D. Reveille, MD 


4:00 – 6:00 pm 











August 30. 

West – 3006 

240 – Histopathology of Rheumatic Lung 

Disease 

Speakers: Allen Burke, MD and Fabio Tavora, MD, PhD 

West – 3008 

241 – Systemic Sclerosis: How to Perform Skin 

Scores 

Speaker: Daniel E. Furst, MD 

West – 3002 

*242 – Ultrasound Injection Guidance 

Speakers: Gurjit S. Kaeley, MBBS, MRCP and Janak R. 

Goyal, MD 

ARHP SESSION 

4:30 – 5:30 pm 

West – 2007 

The Influence of Sleep on Health and Disease 

PM PS E 


Speaker: Donn Posner, PhD, CBSM 

ACR SESSIONS 

4:30 – 6:00 pm 

West – 2011 

Disease Targeted Research: A Rheumatology 

Research Foundation Special Session 

Moderator: Timothy B. Niewold, MD 

4:30 pm 

A Signature for Response to Methotrexate in Juvenile 


Mara L Becker, MD, MSCE 

5:00 pm 

DNA Methylation Profiling in Rheumatoid Arthritis 

Lindsey A. Criswell, MD, MPH 

5:30 pm 

Pathogenic Humoral Autoimmunity in the Transition 

to Clinically Apparent Rheumatoid Arthritis 

V. Michael Holers, MD 


Extra-articular Manifestations of Rheumatoid 

Arthritis 

Moderators: Shawn Slack, MD and Gregory Gardner, 

MD 

4:30 pm 

Diagnosing and Treating Pulmonary Manifestations of 


Eric L. Matteson, MD, MPH 

5:00 pm 

Diagnosing and Treating Ocular Manifestations of 


James T. Rosenbaum, MD 



2 0 1 5 


tracker 

plus 

169 


5:30 pm 

Diagnosing and Treating Cutaneous Manifestations of 


Ruth Ann Vleugels, MD, MPH 


Novel Mechanisms in Myopathy 

Moderators: Ann M. Reed, MD and Ingrid E. Lundberg, 

MD, PhD 

4:30 pm 


Wael N. Jarjour, MD 

5:00 pm 


Steven A. Greenberg, MD 

5:30 pm 


S. Russ Price, PhD 


4:30 – 6:00 pm 


ACR Late-Breaking Abstract Session 


West – 2014 

B cell Biology and Targets in Autoimmune 

Disease: Novel B Cell Roles in Rheumatoid 

Arthritis and Systemic Lupus Erythematosus 

Moderator: Anne Davidson, MBBS 

4:30 pm 

3152. The IL-21 Signaling Pathway Is Enhanced in RA 

B Cells and Has the Potential to Alter Development 

and Cytokine Production in RA B Cells 

Jane H. Buckner and Elizabeth Samuelson, Benaroya 

Research Institute at Virginia Mason, Seattle, WA 

4:45 pm 

3153. Microrna-155/PU.1 Axis As an Epigenetic 

Regulator of B-Cells in Rheumatoid Arthritis 

Stefano Alivernini 1 , Barbara Tolusso 1 , Mariola 

Kurowska-Stolarska 2 , Roberta Benvenuto 3 , Antonella 

Mangoni 3 , Silvia Canestri 1 , Luca Petricca 1 , Anna Laura 

Fedele 1 , Maria Rita Gigante 1 , Clara Di Mario 1 , Elisa 

Gremese 1 , Iain B. McInnes 2 and Gianfranco Ferraccioli 1 , 

1 

Division of Rheumatology, Institute of Rheumatology, 

Catholic University of the Sacred Heart, Rome, Italy, 

2 

Institute of Infection, Immunity and Inflammation, 

College of Medicine, Veterinary Medicine and Life 

Sciences, University of Glasgow, Glasgow, United 

Kingdom, 3 Division of Pathology - Catholic University of 

the Sacred Heart, Rome, Italy 

5:00 pm 

3154. The Importance of Somatic Hypermutation 

for the Immunoreactivity Towards Neutrophil 

Extracellular Traps (NETs)-Citrullinated 

Autoantigens of RA Synovial Monoclonal Antibodies 

Elisa Corsiero 1 , Emanuela Carlotti 2 , Costantino Pitzalis 3 

and Michele Bombardieri 4 , 1 WHRI - EMR, London, 

United Kingdom, 2 William Harvey Research Institute, 

QMUL, London, United Kingdom, 3 Queen Mary’s School 

of Medicine and Dentistry, London, United Kingdom, 

4 

Queen Mary University of London, London, United 

Kingdom 

5:15 pm 

3155. Bob1 Expression Is Elevated in Rheumatoid 

Synovium and Its Expression in B Cells Is Required 

for Development of Collagen-Induced Arthritis 

Maartje Levels 1 , Melissa van Tok 2 , Tineke Cantaert 3 , 

Frans G.M. Kroese 4 , Hergen Spits 5 , Dominique 

Baeten 2 and Nataliya Yeremenko 3 , 1 Laboratory of 

Experimental Immunology, Academic Medical Center/ 

University of Amsterdam, Amsterdam, Netherlands, 

2 

Amsterdam Rheumatology and Immunology Center, 

Amsterdam, Netherlands, 3 Clinical Immunology and 

Rheumatology, Academic Medical Center/University 

of Amsterdam, Amsterdam, Netherlands, 4 University 

Medical Center Groningen, University of Groningen, 

Groningen, Netherlands, 5 Department of Cell Biology 

and Histology, Academic Medical Center/University of 

Amsterdam, Amsterdam, Netherlands 

5:30 pm 

3156. IL17 Promotes Development of Autoreactive 

Early Stage B Cells in Distinct Regions of the Spleen 

Follicle 

Jennie Hamilton, Qi Wu, PingAr Yang, Jun Li, Yanna 

Ding, Bao Luo, John Mountz and Hui-Chen Hsu, 

University of Alabama at Birmingham, Birmingham, AL 


170 




5:45 pm 

3157. B Cell Profile As a Biomarker of Disease 

Segmentation and Flare Prognosis in SLE 

Chungwen Wei 1 , Bridget Neary 1 , Jamie Biear 2 , Jennifer 

Barnard 2 , Michelle Petri 3 , Alex Rosenberg 2 , Jennifer H. 

Anolik 4 and Ignacio Sanz 1 , 1 Emory University, Atlanta, 

GA, 2 University of Rochester, Rochester, NY, 3 Johns 

Hopkins University Hospital, Baltimore, MD, 4 University 

of Rochester Medical Center, Rochester, NY 

West – 2000 

Epidemiology and Public Health IV: Risk 

Factors and Comorbidities for Systemic Lupus 

Erythematosus and Psoriatic Arthritis 

Moderator: Julia F. Simard, ScD 

4:30 pm 

3158. Impact of Family History of Systemic Lupus 

Erythematosus on Risk of Autoimmune Diseases: 

National Cohort Study in Denmark 1977-2012 

Constance Jensina Ulff-Møller 1 , Jacob Simonsen 2 , 

Søren Jacobsen 1 and Morten Frisch 2 , 1 Department of 

Rheumatology, Rigshospitalet, Copenhagen University 

Hospital, Copenhagen, Denmark, 2 Department of 

Epidemiology Research, Statens Serum Institut, 

Copenhagen, Denmark 

4:45 pm 

3159. Systemic Lupus Erythematosus Is a Risk 

Factor for Young Stroke: A Population-Based Cohort 

Study 

Elizabeth V Arkema 1 , Elisabet Svenungsson 2 , 

Christopher Sjöwall 3 and Julia F Simard 4 , 1 Karolinska 

Institutet, Stockholm, Sweden, 2 Rheumatology Unit, 


3 

Rheumatology/AIR, Linköping, Sweden, 4 Stanford 

School of Medicine, Stanford, CA 

5:00 pm 

3160. Comparative Rates of Serious Infections 

and All-Cause Mortality Among Systemic Lupus 

Erythematosus Patients Receiving Mycophenolate 

Mofetil Versus Azathioprine 

Candace H. Feldman 1 , Francisco M. Marty 2 , Wolfgang 

C. Winkelmayer 3 , Hongshu Guan 2 , Jessica M. Franklin 4 , 

Daniel H. Solomon 5 , Seoyoung C. Kim 2 and Karen H. 

Costenbader 5 , 1 Division of Rheumatology, Immunology 


Medical School, Boston, MA, 2 Brigham and Women’s 

Hospital, Boston, MA, 3 Baylor College of Medicine, 

Houston, TX, 4 Division of Pharmacoepidemiology and 

Pharmacoeconomics, Brigham and Women’s Hospital, 

Boston, MA, 5 Brigham and Women’s Hospital, Harvard 


5:15 pm 

3161. Rates of Hospitalization for Infection and 

Related Mortality By Race/Ethnicity and Sex Among 

Patients with End-Stage Renal Disease Due to 

Systemic Lupus Erythematosus 

Candace H. Feldman 1 , Francisco M. Marty 2 , Wolfgang 

C. Winkelmayer 3 , Hongshu Guan 2 , Jessica M. Franklin 4 , 

Seoyoung C. Kim 5 , Daniel H. Solomon 6 and Karen H. 

Costenbader 5 , 1 Division of Rheumatology, Immunology 


Medical School, Boston, MA, 2 Brigham and Women’s 

Hospital, Boston, MA, 3 Baylor College of Medicine, 

Houston, TX, 4 Division of Pharmacoepidemiology and 

Pharmacoeconomics, Brigham and Women’s Hospital, 

Boston, MA, 5 Brigham & Women’s Hospital, Boston, 

MA, 6 Harvard Medical School, Brigham and Women’s 

Hospital, Division of Rheumatology, Division of 

Pharmacoepidemiology, Boston, MA 

5:30 pm 

3162. Prevalence of Chronic Comorbidities in 

Patients with Rheumatoid Arthritis, Psoriatic 

Arthritis, Ankylosing Spondylitis and Systemic 

Lupus Erythematosus: An Analysis of UK Biobank 

Data 

Eftychia Bellou 1 , Michael Cook 1 , John Bowes 1 , Jamie 

C Sergeant 2 , Anne Barton 3 , Terence W. O’Neill 1 

and Suzanne M.M. Verstappen 1 , 1 The University of 

Manchester, Centre for Musculoskeletal Research, 

Manchester, United Kingdom, 2 University of 

Manchester, Manchester, United Kingdom, 3 The 

Kellgren Centre for Rheumatology, Central Manchester 

Foundation Trust, NIHR Manchester Biomedical 

Research Centre, Manchester, United Kingdom 



2 0 1 5 


tracker 

plus 

171 


5:45 pm 

3163. The Smoking Paradox in the Development of 

Psoriatic Arthritis Among Psoriasis Patients 

Uyen-Sa Nguyen 1 , Yuqing Zhang 2 , Na Lu 3 , Qiong 

Louie-Gao 2 , Jingbo Niu 2 , David T. Felson 2 , Michael P. 

Lavalley 4 , Thorvardur Love 5 , Maureen Dubreuil 2 , Jeffrey 

A. Sparks 6 , Elizabeth W. Karlson 6 and Hyon K. Choi 3 , 

1 

Univerity of Massachusetts Medical School, Worcester, 

MA, 2 Boston University School of Medicine, Boston, 

MA, 3 Massachusetts General Hospital, Harvard Medical 

School, Boston, MA, 4 Boston University, Boston, MA, 

5 

Brigham and Women’s Hospital and Harvard Medical 

School, Boston, MA, 6 Brigham & Women’s Hospital, 

Boston, MA 

North – 130 

Metabolic and Crystal Arthropathies II: 

Mechanisms and Associations 

Moderators: Nicola Dalbeth, MBChB, MD and Angelo L. 

Gaffo, MD, MSPH 

4:30 pm 

3164. Calcium Pyrophosphate Deposition Disease 

and Associated Medical Co-Morbidities in the 

Veteran Population 

Crystal Kleiber Balderrama 1 , Daniel S. Lans 2 , Ann K. 

Rosenthal 2 and Christie M. Bartels 3 , 1 Medical College 

of Wisconsin, Milwaukee, WI, 2 Clement J. Zablocki 

Veterans Affairs Medical Center, Milwaukee, WI, 

3 

University of Wisconsin School of Medicine and Public 

Health, Madison, WI 

4:45 pm 

3165. Do Omega-3 Fatty Acids Reduce Risk of 

Recurrent Gout Attacks? 

MaryAnn Zhang 1 , Yuqing Zhang 1 , Robert Terkeltaub 2 , 

Clara Chen 3 and Tuhina Neogi 1 , 1 Boston University 

School of Medicine, Boston, MA, 2 VA Medical Ctr/ 

University of California San Diego, San Diego, CA, 

3 

Boston University School of Public Health, Boston, MA 

5:00 pm 

3166. Epistatic Interaction of Functional 

Inflammasome Genetic Variants in Determining 

the Risk of Gout 

Tony R. Merriman 1 , Lisa Stamp 2 , Nicola Dalbeth 3 , 

Ruth Topless 1 , Richard Day 4 , Diluk Kannangara 4 , 

Kenneth Williams 4 , Matthijs Janssen 5 , Tim Jansen 6 , 

Leo A. Joosten 7 , Timothy Radstake 7 , Philip L. Riches 8 , 

Anne-Kathrin Tausche 9 , Frederic Lioté 10 , Alex So 11 and 

Cushla McKinney 1 , 1 University of Otago, Dunedin, 

New Zealand, 2 University of Otago, Christchurch, 

Christchurch, New Zealand, 3 University of Auckland, 

Auckland, New Zealand, 4 University of New South 

Wales, Sydney, Australia, 5 Ziekenhuis Rijnstate, 

Arnhem, Netherlands, 6 P O Box 581, Haarlem, 

Netherlands, 7 Radboud University Nijmegen Medical 

Centre, Nijmegen, Netherlands, 8 Centre for Genomic 

and Experimental Medicine, Western General Hospital, 

Edinburgh, United Kingdom, 9 Universitätsklinikum Carl 

Gustav Carus an der Technischen Universität Dresden, 

Dresden, Germany, 10 Rheumatology Department; 

Inserm UMR-S606; Paris-Diderot University, hôpital 

Lariboisiere, Paris, France, 11 CHUV, Lausanne, 

Switzerland 

5:15 pm 

3167. Association of the Apolipoprotein A1-C3-A4 

Gene Cluster with the Risk of Gout: Evidence for a 

Causal Role in Gout 

Tony R. Merriman 1 , Amanda Phipps-Green 1 , Ruth 

Topless 1 , Malcolm D. Smith 2 , Catherine Hill 3 , Susan 

Lester 3 , Maureen Rischmueller 4 , Matthijs Janssen 5 , 

Tim Jansen 6 , Leo A. Joosten 7 , Timothy Radstake 7 , Philip 

L. Riches 8 , Anne-Kathrin Tausche 9 , Frederic Lioté 10 , 

Alex So 11 , Andre M. van Rij 1 , Gregory T. Jones 1 , Sally 

McCormick 1 , Andrew Harrison 1 , Lisa Stamp 12 , Nicola 

Dalbeth 13 and Humaira Rasheed 1 , 1 University of Otago, 

Dunedin, New Zealand, 2 Repatriation General Hospital, 

Adelaide, Australia, 3 The Queen Elizabeth Hospital, 

Woodville, Australia, 4 Queen Elizabeth Hospital, 

Adelaide, Australia, 5 Ziekenhuis Rijnstate, Arnhem, 

Netherlands, 6 P O Box 581, Haarlem, Netherlands, 

7 

Radboud University Nijmegen Medical Centre, 

Nijmegen, Netherlands, 8 Centre for Genomic and 

Experimental Medicine, Western General Hospital, 

Edinburgh, United Kingdom, 9 Universitätsklinikum Carl 

Gustav Carus an der Technischen Universität Dresden, 

Dresden, Germany, 10 Rheumatology Department; 

Inserm UMR-S606; Paris-Diderot University, hôpital 

Lariboisiere, Paris, France, 11 CHUV, Lausanne, 

Switzerland, 12 University of Otago, Christchurch, 

Christchurch, New Zealand, 13 University of Auckland, 

Auckland, New Zealand 


172 




5:30 pm 

3168. How Strong Cardiovascular Risk Factor Are 

Gouty Tophi? 

Rada Gancheva 1 , Atanas Kundurdjiev 2 , Mariana 

Ivanova 1 , Todor Kundurzhiev 3 and Zlatimir 

Kolarov 1 , 1 University Hospital “St. Iv. Rilski”, Clinic of 

Rheumatology, Sofia, Bulgaria, 2 University Hospital 

“Alexandrovska”, Clinic of Nephrology, Sofia, Bulgaria, 

3 

Medical University, Faculty of Public Health, Sofia, 

Bulgaria 

5:45 pm 

3169. Diagnostic Value of Ultrasound for the 

Diagnosis of Gout in a Prospective Cross-Sectional 

Study 

Alexis Ogdie-Beatty 1 , William J. Taylor 2 , Tuhina Neogi 3 , 

Jaap Fransen 4 , Tim Jansen 5 , H. Ralph Schumacher 

Jr. 6 and Nicola Dalbeth 7 , 1 University of Pennsylvania, 

Philadelphia, PA, 2 University of Otago Wellington, 

Wellington, New Zealand, 3 BUSM, Boston, MA, 

4 

Radboud University Medical Centre, Nijmegen, 

Netherlands, 5 P O Box 581, Haarlem, Netherlands, 6 U 

Penn & VA Med Ctr, Philadelphia, PA, 7 University of 

Auckland, Auckland, New Zealand 


Osteoporosis and Metabolic Bone Disease – 

Clinical Aspects and Pathogenesis 

Moderators: Jennifer M. Grossman, MD and Nancy E. 

Lane, MD 

4:30 pm 

3170. Peripheral Osteoblastogenesis in Rheumatoid 

Arthritis Is Enhanced after TNF Blocker Treatment, 

Irrespective of Systemic Inflammation 

Mie Jin Lim, Won Park, Seong-Ryul Kwon, Kyong-Hee 

Jung and Min Jung Son, Inha University Hospital, 

Incheon, South Korea 

4:45 pm 

3171. Combination Therapy with Denosumab and 

Biologic DMARD Associated with Higher Risk of 

Serious Infections Compared to Denosumab Alone 

and Biologic DMARD Alone 

Ivana Parody 1 , Luis Arias-Urdaneta 2 , Ricardo Garcia 

Alemany 2 and Carlos Sesin 2 , 1 Mount Sinai Medical 

Center, Miami Beach, FL, 2 Vanguard Rheumatology 

Partners, Miami Beach, FL 

5:00 pm 

3172. Effect of Anti Citrullinated Protein Antibodies 

on Periarticular and Systemic Bone Mass in Early 

Arthritis Patients 

Irene Llorente Cubas* 1 , Leticia Merino-Meléndez 2 , 

Ana M. Ortiz Garcia 2 , Eugenio Escolano 1 , Teresa 

Velasco 1 , Elena García 2 , Esther Vicente-Rabaneda 2 , 

Alberto Garcia-Vadillo 3 , Rosario Garcia-Vicuña 3 , Isidoro 

González-Alvaro* 2 and Santos Castañeda* 2 , 1 H.U La 

Princesa, Madrid, Spain, 2 H.U. La Princesa, Madrid, 

Spain, 3 Hospital Universitario de La Princesa. IIS La 

Princesa, Madrid, Spain 

5:15 pm 

3173. Premature Mortality Due to Fractures in 

a Population-Based Prospective Cohort Study of 

238,673 Older Women and Men 

Lyn March 1 , Weiwen Chen 2 , Judy M Simpson 3 , Fiona 

Blyth 4 and Jacqueline Center 2 , 1 Northern Clinical School, 

Institute of Bone and Joint Research, Kolling Institute, 

University of Sydney & Department of Rheumatology, 

Royal North Shore Hospital, St Leonards, Sydney, 

Australia, 2 Osteoporosis & Bone Biology Garvan 

Institute of Medical Research, St Vincent’s Clinical 

School, UNSW, Darlinghurst, Australia, 3 University of 

Sydney School of Public Health, Sydney, Australia, 

4 

Concord Clinical School University of Sydney and Sax 

Institute, Sydney, Australia 

5:30 pm 

3174. Vitamin D Binding Protein and Tenofovir- 

Associated Bone Loss Among Individuals with HIV 

Evelyn Hsieh 1 , Liana Fraenkel 2 , Weibo Xia 1 , Yang Han 1 , 

Michael Yin 3 , Karl Insogna 2 , Ting Zhu 1 and Taisheng Li 1 , 

1 

Peking Union Medical College Hospital, Beijing, China, 

2 

Yale School of Medicine, New Haven, CT, 3 Columbia 

University Medical Center, New York, NY 

5:45 pm 

3175. Strength at the Lumbar Spine and Hip 

Improves with Romosozumab Compared with 

Teriparatide in Postmenopausal Women with Low 

Bone Mass 

TM Keaveny 1 , DB Crittenden 2 , MA Bolognese 3 , HK 

Genant 4 , K Engelke 5 , B Oliveri 6 , JP Brown 7 , BL Langdahl 8 , 

YC Yang 2 , A Grauer 2 and C Libanati 9 , 1 UC Berkeley, 

Berkeley and O.N. Diagnostics, Berkeley, CA, 2 Amgen 

Inc., Thousand Oaks, CA, 3 The Bethesda Health 

Research Center, Bethesda, MD, 4 UCSF & Synarc 



2 0 1 5 


tracker 

plus 

173 


Inc., San Francisco, CA, 5 Synarc Germany, Hamburg, 

Germany, 6 Hospital de Clínicas, INIGEM, Buenos Aires, 

Argentina, 7 Laval University and CHU de Québec 

(CHUL) Research Centre, Québec City, QC, 8 Aarhus 

University Hospital, Aarhus, Denmark, 9 UCB Pharma, 

Brussels, Belgium 

North – 132 


Therapeutic Aspects IV: Imaging and Novel 

Clinical Interventions 

Moderator: Lisa F. Imundo, MD 

4:30 pm 

3176. New Prospects for Interpreting Bony 

Depressions in Juvenile Idiopathic Arthritis: A Novel 

MRI Computer-Assisted Technique for Detection of 

Erosive Progression 

Pieter van Dijkhuizen 1 , Carlotta Covizzi 1 , Andrea 

Schiappacasse 2 , Michela Moraldo 3 , Matteo Santoro 4 , 

Francesca Magnaguagno 5 , Gianmichele Magnano 6 , 

Alberto Martini 3 and Clara Malattia 3 , 1 Istituto G 

Gaslini, Pediatria II, Reumatologia, Genova, Italy, 

2 

DIBRIS Università degli studi di Genova, Genova, Italy, 

3 

DINOGMI Università degli studi di Genova, Genova, 

Italy, 4 Camelot Biomedical Systems, Genova, Italy, 

5 

Istituto G Gaslini, UO Radiologia Pediatrica, Genoa, 

Italy, 6 Istituto G Gaslini, UO Radiologia Pediatrica, 

Genova, Italy 

4:45 pm 

3177. Whole-Body MRI: A Valuable Diagnostic Tool 

for the Assessment of Disease Damage in Juvenile 

Dermatomyositis 

Clara Malattia 1 , Agnese Beltramo 1 , Isabella Buffoni 1 , 

Annalisa Madeo 1 , Francesca Magnaguagno 2 , Stefania 

Viola 1 and Alberto Martini 1 , 1 Istituto G Gaslini, Pediatria 

II, Reumatologia, Genova, Italy, 2 Istituto G Gaslini, UO 

Radiologia Pediatrica, Genoa, Italy 

5:00 pm 

3178. Tocilizumab in Refractory Uveitis Associated 

to Juvenile Idiopathic Arthritis. Multicenter Study 

of 13 Cases 

Montserrat Santos-Gómez 1 , Vanesa Calvo-Río 1 , Ricardo 

Blanco 1 , Inmaculada Calvo 2 , Marina Mesquida 3 , Alfredo 

Adan 3 , M. Victoria Hernández 3 , Olga Maiz Alonso 4 , 

Antonio Atanes-Sandoval 5 , Beatriz Bravo 6 , Consuelo 

Modesto 7 , Gisela Diaz Soriano 8 , Javier Loricera 1 , Leyre 

Riancho-Zarrabeitia 1 , Natalia Palmou 1 and Miguel 

Angel Gonzalez-Gay 1 , 1 Hospital Universitario Marqués 

de Valdecilla. IDIVAL, Santander, Spain, 2 Hospital 

La Fe, Valencia, Spain, 3 Hospital Clinic, Barcelona, 

Spain, 4 Donostia University Hospital, Donostia, Spain, 

5 

Complejo Hospitalario Universitario de La Coruña, La 

Coruña, Spain, 6 Hospital Universitario HUVN, Granada, 

Spain, 7 Hospital HSLL, Palma de Mallorca, Spain, 

8 

Hospital Regional Universitario de Málaga, Málaga, 

Spain 

5:15 pm 

3179. Diagnosing Childhood Small Vessel CNS 

Vasculitis 

Marinka Twilt 1 , Maryam Nabavi Nouri 2 , Pascal N. 

Tyrrell 3 , Anastasia Dropol 1 , Shehla Sheikh 4 , Cynthia 

Hawkins 4 and Susanne Benseler 5 , 1 Alberta Children’s 

Hospital, Calgary, AB, 2 The Hospital for Sick Childern, 

Toronto, ON, 3 University of Toronto, Toronto, ON, 4 The 

Hospital for Sick Children, Toronto, ON, 5 Department of 

Pediatrics/University of Calgary, Calgary, AB 

5:30 pm 

3180. Mesenchymal Stromal Cell Treatment in 

Juvenile Idiopathic Arthritis: A Pilot Study 

Joost Swart 1 , Nico Wulffraat 2 , Berent J. Prakken 3 , Ineke 

Slaper-Cortenbach 2 and Caroline Lindemans 4 , 1 UMC 

Utrecht, Utrecht, Netherlands, 2 University Medical 

Center Utrecht, Utrecht, Netherlands, 3 University 

Medical Center, Utrecht, Netherlands, 4 Wilhelmina 

Children’s Hospital/ UMC Utrecht, Utrecht, Netherlands 

5:45 pm 

3181. How Common Is Inactive Disease in a 

Prospective Cohort of Patients with Juvenile 

Idiopathic Arthritis? the Importance of Definition 

Stephanie Shoop 1 , Suzanne M. Verstappen 2 , Eileen 

Baildam 3 , Alice Chieng 4 , Joyce Davidson 5 , Helen 

Foster 6 , Yiannis Ioannou 7 , Flora McErlane 6 , Lucy R 

Wedderburn 8 , Wendy Thomson 9 and Kimme L. Hyrich 9 , 

1 

ARC Epidemiology Unit, The University of Manchester, 

M13 9PT, United Kingdom, 2 ARC Epidemiology Unit, 

the University of Manchester, Manchester, United 

Kingdom, 3 Alder Hey Children’s NHS Foundation 

Trust, Liverpool, United Kingdom, 4 Royal Manchester 

Children’s Hospital, Manchester, United Kingdom, 5 The 

Royal Hospital for Sick Children, Glasgow, Glasgow, 


174 




United Kingdom, 6 Royal Victoria Hospital, Newcastle, 

United Kingdom, 7 Rayne Institute, University College 

London, London, UK, London, United Kingdom, 

8 

Paediatric Rheumatology, London, United Kingdom, 

9 

arc Epidemiology Unit, Manchester, United Kingdom 

West – 2001 

Rheumatoid Arthritis – Clinical Aspects V: Goal 

= Remission 

Moderators: Vivian Bykerk, MD and Paul Emery, MD 

4:30 pm 

3182. High Body Mass Index Negatively Impacts 

Time to Achieving Sustained Remission in Early 

Rheumatoid Arthritis: Results from a Multicenter 

Early Arthritis Cohort Study 

Elizabeth Schulman 1 , Kathleen Andersen 2 , Meng 

Zhang 2 , Susan M. Goodman 2 , Daming Lin 3 , Gilles Boire 4 , 

Boulos Haraoui 5 , Carol Hitchon 6 , Shahin Jamal 7 , Edward 

C. Keystone 3 , Janet E. Pope 8 , Diane Tin 9 , Carter Thorne 9 , 

Vivian P. Bykerk 2 and CATCH Investigators, 1 Hospital 

for Special Surgey, New York, NY, 2 Hospital for 

Special Surgery, New York, NY, 3 Mount Sinai Hospital, 

University of Toronto, Toronto, ON, 4 Department of 

Medicine/Division of Rheumatology, University of 

Sherbrooke, Sherbrooke, QC, 5 Institut de Rhumatologie 

de Montréal, Montréal, QC, 6 University of Manitoba, 

Winnipeg, MB, 7 Vancouver Coastal Health, Vancouver, 

BC, 8 University of Western Ontario, London, ON, 

9 

Southlake Regional Health Centre, Newmarket, ON 

4:45 pm 

3183. The Clinical and Economic Costs of Not 

Achieving Remission in Rheumatoid Arthritis 

Jeffrey R. Curtis 1 , Lang Chen 1 , Meredith Kilgore 1 , 

Huifeng Yun 1 and Jeffrey D. Greenberg 2 , 1 University of 

Alabama at Birmingham, Birmingham, AL, 2 Corrona, 

LLC, Southborough, MA 

5:00 pm 

3184. Is Treat-to-Target Really Working? a 

Longitudinal Analysis in Biodam 

Sofia Ramiro 1 , Robert B.M. Landewé 2 , Désirée van 

der Heijde 1 , Oliver FitzGerald 3 , Mikkel Østergaard 4 , 

Joanne Homik 5 , Ori Elkayam 6 , J Carter Thorne 7 , 

Margaret Larche 8 , Gianfranco Ferraccioli 9 , Marina 

Backhaus 10 , Gilles Boire 11 , Bernard Combe 12 , Thierry 

Schaeverbeke 13 , Alain Saraux 14 , Maxime Dougados 15 , 

Silvano Adami 16 , Marcello Govoni 17 , Luigi Sinigaglia 18 , 

Alain G. Cantagrel 19 , Cornelia F. Allaart 1 , Cheryl 

Barnabe 20 , Clifton O. Bingham III 21 , Paul P. Tak 2 , 

Dirkjan van Schaardenburg 22 , Hilde Berner Hammer 23 , 

Rana Dadashova 24 , Edna Hutchings 24 , Joel Paschke 24 

and Walter Maksymowych 5 , 1 Leiden University 

Medical Center, Leiden, Netherlands, 2 Amsterdam 

Rheumatology Center, Amsterdam, Netherlands, 

3 

St Vincent’s University Hospital, Dublin, Ireland, 

4 

Copenhagen Center for Arthritis Research, Center 

for Rheumatology and Spine Diseases, Rigshospitalet 

- Glostrup, Glostrup, Denmark, 5 University of Alberta, 

Edmonton, AB, 6 Tel Aviv Sourasky Medical Center, 

Tel Aviv, Israel, 7 University of Toronto, Toronto, 

ON, 8 McMaster University, Hamilton, ON, 9 Catholic 

University of the Sacred Heart, Rome, Italy, 10 Charite 

University Hospital, Berlin, Germany, 11 Department 

of Medicine/Division of Rheumatology, University of 

Sherbrooke, Sherbrooke, QC, 12 Lapeyronie Hospital 

and Montpellier University, Montpellier, France, 

13 

Pellegrin University Hospital, Bordeaux, France, 14 CHU 

de la Cavale Blanche, Brest Cedex, France, 15 Paris 

Descartes University, Paris, France, 16 University of 

Verona, Verona, Italy, 17 University of Ferrara, Ferrara, 

Italy, 18 Department of Rheumatology, Gaetano Pini 

Institute, Milan, Italy, 19 Centre Hospitalier Universitaire 

de Toulouse, Toulouse, France, 20 Cumming School of 

Medicine, University of Calgary, Calgary, AB, 21 Johns 

Hopkins University, Baltimore, MD, 22 Amsterdam 

Rheumatology and immunology Center, Reade, 

Amsterdam, Netherlands, 23 Diakonhjemmet Hospital, 

Oslo, Norway, 24 CaRE Arthritis, Edmonton, AB 

5:15 pm 

3185. A Cluster-Randomized Trial of a Behavioral 

Intervention to Incorporate a Treat-to-Target 

Approach in the Clinical Care of Rheumatoid 

Arthritis Patients in the United States 

Leslie R. Harrold 1 , George W. Reed 1 , J. Timothy 

Harrington 2 , Christine J. Barr 1 , Katherine C. Saunders 1 , 

Allan Gibofsky 3 , Eric M. Ruderman 4 , Tmirah Haselkorn 5 , 

Jeffrey D. Greenberg 1 , Ani John 5 and Joel M. Kremer 6 , 

1 

Corrona, LLC, Southborough, MA, 2 Joiner Associates, 

LLC, Madison, WI, 3 Hospital for Special Surgery, New 

York, NY, 4 Northwestern University Feinberg School 



2 0 1 5 


tracker 

plus 

175 


of Medicine, Chicago, IL, 5 Genentech, Inc, South San 

Francisco, CA, 6 Albany Medical College and The Center 

for Rheumatology, Albany, NY 

5:30 pm 

3186. Foot Synovitis in Patients with Rheumatoid 

Arthritis in Apparent Remission Is Associated 

with Unstable Remission Status, Radiographic 

Progression and Worse Long-Term Functional 

Outcomes 

Mihir D. Wechalekar 1 , Susan Lester 2 , Maureen 

Rischmueller 3 , Catherine Hill 3 and Susanna Proudman 3 , 

1 

Royal Adelaide Hospital, Adelaide, Australia, 2 Basil 

Hetzel Institute, QEH, Woodville South, Australia, 

3 

University of Adelaide, Adelaide, Australia 

5:45 pm 

3187. Predictors of Disease Relapse and Recapture 

of Remission Following Relapse in an Ontario 

Rheumatoid Arthritis Population 

Bindee Kuriya 1 , Xiuying Li 2 , George A. Tomlinson 3 , 

Edward C. Keystone 1 , Claire Bombardier 2 and OBRI 

Investigators, 1 Mount Sinai Hospital, University of 

Toronto, Toronto, ON, 2 Toronto General Hospital 

Research Institute, University Health Network, Toronto, 

ON, 3 Mount Sinai Hospital, Toronto, ON 


Rheumatoid Arthritis Animal Models II 

Moderators: Miriam A. Shelef, MD, PhD and Eric 

Toussirot, MD, PhD 

4:30 pm 

3188. Inhibition of Lymphatic Muscle Contraction 

By Lymphatic Endothelial iNOS Impairs Lymph 

Drainage from Arthritic Joints in TNF-Tg Mice and Is 

Prevented By Herbal Drugs 

Qianqian Liang 1 , Yan Chen 1 , Jinlong Li 1 , Wensheng 

Wang 2 , Li Zhang 1 , Hao Xu 1 , Ronald Wood 2 , Brendan 

Boyce 2 , Edward Schwarz 2 , Yongjun Wang 1 and Lianping 

Xing 3 , 1 Longhua Hospital, Shanghai University of 

Traditional Chinese Medicine, Shanghai, China, 

2 

University of Rochester, Rochester, NY, 3 University of 

Rochester Medical Center, Rochester, NY 

4:45 pm 

3189. Enhancement of Mitochondrial Biogenesis 

Inhibits Cell Proliferation and MMP-3/RANKL 

Secretion in Rheumatoid Arthritis Fibroblast-like 

Synovial Cells and Joint Destruction in Arthritis 

Model Mice 

Takeshi Ueha 1 , Yoshitada Sakai 1 , Masayuki Morishita 1 , 

Toshihisa Maeda 1 , Koji Fukuda 1 , Miho Inoue 1 , Risa 

Harada 1 , Masaya Minoda 1 , Yasushi Miura 1 , Akira 

Hashiramoto 2 and Masahiro Kurosaka 1 , 1 Kobe 

University Graduate School of Medicine, Kobe, Japan, 

2 

Kobe University Graduate School of Health Sciences, 

Kobe, Japan 

5:00 pm 

3190. Netrin-1 and Its Receptor Unc5b Are Novel 

Targets for the Treatment of Inflammatory 

Arthritis 

Aranzazu Mediero 1 , Tuere Wilder 2 and Bruce 

Cronstein 3 , 1 NYU School of Medicine, New York City, 

NY, 2 NYU School of Medicine, New York, NY, 3 NYU 

School of Medicine, NEW YORK, NY 

5:15 pm 

3191. Siglec9 Suppresses Arthritis in Collagen- 

Induced Mice Model and Inhibits M1 Activation of 

RAW264.7 Macrophages 

Takuya Matsumoto, Nobunori Takahashi, Toshihisa 

Kojima and Naoki Ishiguro, Nagoya University Hospital, 

Nagoya, Japan 

5:30 pm 

3192. KCa3.1 Ion Channel in the Pathogenesis 

of Rheumatoid Arthritis: KCa3.1-/- Mice Do Not 

Develop CIA 

Siba Raychaudhuri 1 , Smriti K. Raychaudhuri 2 and Heike 

Wulff 3 , 1 Univ California Davis/VA Sacramento, Davis, CA, 

2 

VA Sacramento Medical Center, Davis, CA, 3 UC Davis 

School of Medicine, Davis, CA 

5:45 pm 

3193. Immunomodulatory and Antiviral Therapies 

in a Mouse Model of Chikungunya Viral Arthritis 

Jonathan Miner, Lindsey Cook, Raeann Shimak, Julie 

Fox, Alissa Young, Kristen Monte, Subhajit Poddar, 

Michael Diamond and Deborah Lenschow, Washington 

University in Saint Louis School of Medicine, Saint 

Louis, MO 


176 






Biologics and Gene Therapy VI: Strategies 


4:30 pm 

3194. Oral to Subcutaneous Methotrexate 

Dose-Conversion Strategies in the Treatment of 


Michael Schiff 1 and Peter Sadowski 2 , 1 University 

of Colorado, Denver, CO, 2 Antares Pharma Inc., 

Minneapolis, MN 

4:45 pm 

3195. Circulating Micro-RNA Profiles in Responders 

to Adalimumab Plus Methotrexate Versus 

Methotrexate Alone: A Placebo-Controlled Clinical 

Trial 

Jacob Sode 1 , Sophine B. Krintel 2 , Anting L. Carlsen 1 , 

Merete Lund Hetland 3 , Julia Johansen 4 , Kim Hørslev- 

Petersen 5 , Kristian Stengaard-Pedersen 6 , Peter Junker 7 , 

Mikkel Østergaard 8 , Niels H. H. Heegaard 1 and OPERA 

study group, 1 Statens Serum Institut, Copenhagen, 

Denmark, 2 Copenhagen University Hospital at 

Glostrup, Copenhagen, Denmark, 3 The DANBIO 

Registry, Copenhagen Center for Arthritis Research, 

Center for Rheumatology and Spine Diseases, 

Rigshospitalet, Glostrup, Denmark, 4 University of 

Copenhagen, Copenhagen, Denmark, 5 Research Unit 

at King Christian X Hospital for Rheumatic Diseases, 

Graasten, Graasten, Denmark, 6 Aarhus University 

Hospital, Aarhus, Denmark, 7 Odense University 

Hospital, Odense, Denmark, 8 Copenhagen Center for 

Arthritis Research, Center for Rheumatology and Spine 

Diseases, Rigshospitalet - Glostrup, Glostrup, Denmark 

5:00 pm 

3196. Predictive Biomarkers for Response or Non- 

Response to MTX Monotherapy in Early RA 

Karen Hambardzumyan 1 , Rebecca J. Bolce 2 , Saedis 

Saevarsdottir 3 , Kristina Forslind 4 , Johan A Karlsson 5 

and Ronald F. van Vollenhoven 1 , 1 Unit for Clinical 

Therapy Research, Inflammatory Diseases (ClinTRID), 

The Karolinska Institute, Stockholm, Sweden, 

2 

Crescendo Bioscience Inc., South San Francisco, CA, 

3 

Rheumatology Unit, The Karolinska Institute and 


4 

Section of Rheumatology, Helsingborg, Sweden, 

5 


Sciences Lund, Lund University, Lund, Sweden 

5:15 pm 

3197. Clinical Practice Experience in Rheumatoid 

Arthritis Patients Treated with Triple Therapy and 

Methotrexate-Tumor Necrosis Factor Inhibition 

Differs from That of Randomized Controlled Trials 

Daniel Erhardt 1 , Brian Sauer 1 , Chia-Chen Teng 2 , Ted 

R. Mikuls 3 , Jeffrey R. Curtis 4 , Derek Tang 5 , Bradley S. 

Stolshek 5 and Grant W. Cannon 1 , 1 Salt Lake City VA 

Medical Center and University of Utah, Salt Lake City, 

UT, 2 HSR&D SLC VA Medical Center and University 

of Utah, Salt Lake City, UT, 3 University of Nebraska 

Medical Center, Omaha, NE, 4 University of Alabama at 

Birmingham, Birmingham, AL, 5 Amgen, Inc., Thousand 

Oaks, CA 

5:30 pm 

3198. Treatment of Rheumatoid Arthritis with an 

Anti-Tumor Necrosis Factor Agent or Tocilizumab 

As First Biologic Therapy in a Global Comparative 

Observational Study 

Ernest H. Choy 1 , Corrado Bernasconi 2 , Maher Aassi 2 , 

Jose F. Molina 3 and Oscar M. Epis 4 , 1 Cardiff University, 

Institute of Infection and Immunity, Tenovus Building, 

University Hospital of Wales, Cardiff, United Kingdom, 

2 

F. Hoffmann-La Roche, Basel, Switzerland, 3 Centro 

Integral de Reumatologia Reumalab, Medellin, 

Colombia, 4 A.O. Ospedale Niguarda Ca’ Granda, Milan, 

Italy 

5:45 pm 

3199. In Rheumatoid Arthritis (RA) Patients, 

Retreatment with Rituximab (RTX) at Half Dose 

Does Not Alter Maintenance on Drug and Allows 

One Third Reduction of Cumulative Dose of Drug/ 

Year: Data from the Autoimmunity and Rituximab 

(AIR) Registry 

julien henry 1 , stéphane pavy 1 , Jacques-Eric Gottenberg 2 , 

rakiba belkhir 1 , Stéphanie Rouanet 3 , Jérémie Sellam 4 , 

Xavier Mariette 5 and raphaèle seror 1 , 1 Assistance 

Publique-Hôpitaux de Paris (APHP), Hôpitaux 

universitaires Paris Sud, Université Paris Sud, kremlin 

bicetre, France, 2 Hautepierre, Strasbourg, France, 

3 

Roche France, Boulogne-Billancourt, France, 4 AP-HP, St 

Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France, 



2 0 1 5 


tracker 

plus 

177 


5 

Université Paris-Sud, AP-HP, Hôpitaux Universitaires 

Paris-Sud, Paris, France 


Sjögren’s Syndrome II: Clinical Discoveries 

Moderators: Arthur Bookman, MD and Simon Bowman, 

PhD 

4:30 pm 

3200. Characterization of Early and Progressive 

Autoimmunity in Sjogrens Syndrome: The 

Incomplete Sjogrens Syndrome Model 

Astrid Rasmussen 1 , Christopher J Lessard 1 , Indra 

Adrianto 1 , Graham B. Wiley 1 , Donald U Stone 2 , C. Erick 

Kaufman 3 , Lida Radfar 4 , David M. Lewis 3 , Stephen 

K Young 3 , Michael H. Weisman 5 , Daniel J Wallace 5 , 

Swamy Venuturupalli 6 , Barbara M. Segal 7 , John A. 

Ice 1 , Juan-Manuel Anaya 8 , Michael D. Rohrer 9 , Raj 

Gopalakrishnan 9 , Glen D Houston 10 , James Chodosh 11 , 

Pamela J Hughes 9 , Nelson L. Rhodus 12 , Jennifer A. Kelly 1 , 

Kiely Grundahl 13 , Kimberly Hefner 14 , R. Hal Scofield 3 

and Kathy L. Sivils 1 , 1 Oklahoma Medical Research 

Foundation, Oklahoma City, OK, 2 King Khaled Eye 

Specialist Hospital, Riyadh, Saudi Arabia, 3 University 

of Oklahoma Health Sciences Center, Oklahoma City, 

OK, 4 University of Oklahoma Health Sciences Center 

College of Dentistry, Oklahoma City, OK, 5 Cedars-Sinai 

Medical Center, Los Angeles, CA, 6 Cedars-Sinai Medical 

Center, West Hollywood, CA, 7 Hennepin County Medical 

Center, Minneapolis, MN, 8 Center for Autoimmune 

Diseases Research (CREA), Universidad del Rosario., 

Bogota, Colombia, 9 University of Minnesota, 

Minneapolis, MN, 10 Heartland Pathology, Oklahoma 

City, OK, 11 Massachusetts Eye and Ear Infirmary, 

Harvard Medical School, Boston, MA, 12 University 

of Minnesota School of Dentistry, Minneapolis, MN, 

13 


CIty, OK, 14 Hefner Eye Care and Optical Center, 

Oklahoma City, OK 

4:45 pm 

3201. IL-7 Drives Cytokine Secretion of IL-7Ra bright 

CCR9-Expressing T-Follicular Helper-like Cells: 

Potential New Axis in Lymphoid Neogenesis in 

Salivary Glands of Primary Sjogren s Syndrome 

Patients 

S.L.M. Blokland 1 , M.R. Hillen 1 , A.A. Kruize 1 , A. Kislat 2 , S. 

Meller 2 , B. Homey 2 , G.M. Smithson 3 , J. Zalevsky 4 , T.R.D.J. 

Radstake 1 and J.A.G. van Roon 1 , 1 University Medical 

Center Utrecht, Utrecht, Netherlands, 2 University of 

Düsseldorf, Medical Faculty, Düsseldorf, Germany, 

3 

Takeda Pharmaceuticals International, Chicago, IL, 

4 

Takeda California, San Diego, CA 

5:00 pm 

3202. Functional Anti-Muscarinic Receptor-3 

Monoclonal Antibodies Derived from Salivary Gland 

in Patients of Sjögren’s Syndrome 

Syed M.S. Quadri 1 , Kristi A. Koelsch 2 , Valerie Harris 1 , Biji 

T Kurien 3 and R. Hal Scofield 1 , 1 University of Oklahoma 

Health Sciences Center, Oklahoma City, OK, 2 Oklahoma 

Medical Research Foundation, Okalahoma City, OK, 

3 


City, OK 

5:15 pm 

3203. The Clinical Efficacy and Safety of 

Baminercept, a Lymphotoxin-Beta Receptor 

Fusion Protein, in Primary Sjogren’s Syndrome: 

Results from a Randomized, Double-Blind, Placebo- 

Controlled Phase II Trial 

E. William St.Clair 1 , Alan N. Baer 2 , Ghaith Noaiseh 3 , 

Anne Parke 4 , Andreea Coca 5 , Tammy Utset 6 , Mark C. 

Genovese 7 , Daniel J Wallace 8 , James McNamara 9 , Karen 

Boyle 10 , Lynette Keyes-Elstein 10 , Nathalie Franchimont 11 , 

Judith A James 12 and for the Autoimmunity Centers 

of Excellence supported by a grant from NIAID 5U19- 

AI056363, 1 Duke University, Durham, NC, 2 Johns 

Hopkins University School of Medicine, Baltimore, MD, 

3 

University of Pittsburgh Medical Center, Pittsburgh, 

PA, 4 University of Connecticut, Farmington, CT, 

5 

University of Rochester Medical Center, Rochester, NY, 

6 

University of Chicago, Chicago, IL, 7 Stanford University 

Medical Center, Palo Alto, CA, 8 Cedars-Sinai Medical 

Center, West Hollywood, CA, 9 NIAID/NIH, Bethesda, 

MD, 10 Rho Federal Systems, Inc., Chapel Hill, NC, 

11 

Biogen, Cambridge, MA, 12 OMRF, OU, Oklahoma City, 

OK 

5:30 pm 

3204. Hypoechoic Lesions on Parotid Gland 

Ultrasound Are a Surrogate Marker of Focal 

Lymphocytic Sialadenitis on Minor Salivary Gland 

Biopsy in Sjogren’s Syndrome 

Thomas Grader-Beck 1 , Joel Fradin 1 , Jean Kim 2 , Esen 


178 




Akpek 1 , Brendan Antiochos 2 , Julius Birnbaum 1 and Alan 

N. Baer 1 , 1 Johns Hopkins University School of Medicine, 

Baltimore, MD, 2 Johns Hopkins University, Baltimore, 

MD 

5:45 pm 

3205. Treatment with Abatacept or Rituximab 

Targets T Follicular Helper Cells in Patients with 

Primary Sjogren s Syndrome 

Gwenny M. Verstappen 1 , Petra M. Meiners 1 , Odilia B.J. 

Corneth 2 , Rudi W. Hendriks 2 , Arjan Vissink 1 , Frans G.M. 

Kroese 1 and Hendrika Bootsma 1 , 1 University Medical 

Center Groningen, University of Groningen, Groningen, 

Netherlands, 2 Erasmus MC, Rotterdam, Netherlands 

West – 2022 

Spondylarthropathies and Psoriatic Arthritis 

– Clinical Aspects and Treatment: Clinical 

Aspects, Imaging and Biomarkers 

Moderators: Filip van Den Bosch, MD, PhD and Walter 

Maksymowych, MD 

4:30 pm 

3206. Inflammation on MRI in Sacroiliac-Joints 

and Spine Is Longitudinally Related to Disease 

Activity in Male but Not in Female Patients with 

Axial Spondyloarthritis: 2-Year Data from the DESIR 

Cohort 

Victoria Navarro-Compán 1 , Sofia Ramiro 2 , Robert B. 

M. Landewé 3 , Maxime Dougados 4 , Corinne Miceli- 

Richard 5 , Pascal Richette 6 and Désirée van der Heijde 2 , 

1 

University Hospital La Paz, Madrid, Spain, 2 Leiden 

University Medical Center, Leiden, Netherlands, 

3 

Amsterdam Rheumatology & Immunology Center, 

Academic Medical Center, Amsterdam, Netherlands, 

4 

Université Paris René Descartes and Hôpital Cochin, 

Paris, France, 5 Université Paris Sud, Le Kremlin Bicêtre, 

France, 6 Université Paris Diderot, UFR médicale, Paris, 

France; APHP Hôpital Lariboisière, Fédération de 

Rhumatologie and Inserm U1132, Hôpital Lariboisière, 

Paris, France 

4:45 pm 

3207. Axial Disease in Psoriatic Arthritis: A Clinical 

and Radiographic Comparison with Ankylosing 

Spondylitis 

Deepak R. Jadon 1 , Raj Sengupta 1 , Alison L Nightingale 2 , 

Mark Lindsay 2 , Eleanor Korendowych 1 , Graham 

Robinson 3 , Amelia Jobling 2 , Gavin Shaddick 2 , Anne 

Barton 4 and Neil J. McHugh 5 , 1 Royal National Hospital 

for Rheumatic Diseases, Bath, United Kingdom, 

2 

University of Bath, Bath, United Kingdom, 3 Royal 

United Hospital, Bath, United Kingdom, 4 Centre for 

Musculoskeletal Research, Manchester Academic 

Health Science Centre, The University Of Manchester, 

Manchester, United Kingdom, 5 Royal National Hospital 

for Rheumatic Diseases, Upper Borough Walls, United 

Kingdom 

5:00 pm 

3208. Spinal Radiographic Progression in Early Axial 

Spondyloarthritis: Data from the DESIR Cohort 

Sofia Ramiro 1 , Désirée van der Heijde 1 , Rosaline van 

den Berg 1 , Victoria Navarro-Compán 2 , Antoine Feydy 3 , 

Maria-Antonietta d’Agostino 4 , Damien Loeuille 5 , 

Maxime Dougados 6 , Monique Reijnierse 1 and Pascal 

Claudepierre 7 , 1 Leiden University Medical Center, 

Leiden, Netherlands, 2 University Hospital La Paz, 

Madrid, Spain, 3 Paris Descartes University, Radiology B 

department, Cochin Hospital, Paris, France, 4 Versailles- 

Saint Quentin en Yvelines University, Boulogne- 

Billancourt, France, 5 Nancy University Hospital, Nancy, 

France, 6 Paris-Descartes University, Paris, France, 

7 

Université Paris Est Créteil, Créteil, France 

5:15 pm 

3209. Utility of Power Doppler Ultrasound-Detected 

Synovitis for the Prediction of Short Term Flare in 

Psoriatic Arthritis Patients in Clinical Remission 

Josefina Marin 1 , M Laura Acosta-Felquer 2 , Leandro 

Ferreyra-Garrot 3 , Erika Catay 4 , Javier Rosa 4 , Santiago 

Ruta 2 , Mirtha Sabelli 2 , Ricardo Garcia-Monaco Sr. 4 and 

Enrique R. Soriano 4 , 1 Rheumatology Unit, Internal 

Medical Services, Hospital Italiano de Buenos Aires, 

Buenos Aires, Argentina, 2 Rheumatology Unit, Internal 

Medicine Service, Hospital Italiano de Buenos Aires, 

Buenos Aires, Argentina, 3 Rheumatology Section, 

Internal Medicine Service, Hospital Italiano de Buenos 

Aires, Instituto Universitario Hospital Italiano de 

Buenos Aires, and Fundacion PM Catoggio, Internal 

Medicine, Argentina, Buenos Aires, Argentina, 4 Hospital 

Italiano de Buenos Aires, Buenos Aires, Argentina 



2 0 1 5 


tracker 

plus 

179 


5:30 pm 

3210. Evaluation of Sacroiliac Joint Radiographs in 

Patients with Chronic Low Back Pain: Is Erosion the 

Main Driver of Interreader Disagreement? 

Alice Ashouri Christiansen 1 , Oliver Hendricks 1 , Dorota 

Kuettel 1 , Kim Hørslev-Petersen 1 , Anne Grethe Jurik 2 , 

Steen Nielsen 1 , Kaspar Rufibach 3 , Anne Gitte Loft 4 , 

Susanne Juhl Pedersen 5 , Louise Thuesen Hermansen 1 , 

Mikkel Østergaard 6 , Bodil Arnbak 7 , Claus Manniche 2 

and Ulrich Weber 1 , 1 King Christian 10th Hospital for 

Rheumatic Diseases, Graasten, Denmark, 2 Spine 

Centre of Southern Denmark, Middelfart, Denmark, 

3 

rePROstat, Basel, Switzerland, 4 Aarhus University 

Hospital, Aarhus, Denmark, 5 University of Copenhagen, 

Copenhagen, Denmark, 6 Copenhagen Center for 

Arthritis Research, Center for Rheumatology and Spine 

Diseases, Rigshospitalet - Glostrup, Glostrup, Denmark, 

7 

University of Southern Denmark, Odense, Denmark 

5:45 pm 

3211. Current Smoking, Its Intensity and Duration, 

Is Associated with Fat Metaplasia on MRI in 

Patients with Spondyloarthritis 

Walter Maksymowych 1 , Stephanie Wichuk 1 , Praveena 

Chiowchanwisawakit 2 , Zheng Zhao 3 , Donald Spady 1 , 

Barbara Conner-Spady 1 , Robert G Lambert 4 and 

Susanne Juhl Pedersen 5 , 1 Medicine, University of 

Alberta, Edmonton, AB, 2 Medicine, Siriraj Hospital, 

Mahidol University, Bangkok, Thailand, 3 Chinese PLA 

General Hospital, Beijing, China, 4 Radiology, University 

of Alberta, Edmonton, AB, 5 Copenhagen Center for 

Arthritis Research, Glostrup Hospital, University of 

Copenhagen, Copenhagen, Denmark 

West – 2016 

Systemic Lupus Erythematosus – Animal Models 

Moderators: Dwight H. Kono, MD and Chaim 

Putterman, MD 

4:30 pm 

3212. Characterizing the Effects of the G-CSF-R 

Coding rs13377964 SNP Located within Murine 

Lupus Susceptibility Locus Sle2c2 

Ramya Sivakumar and Laurence Morel, University of 

Florida, Gainesville, FL 

4:45 pm 

3213. WITHDRAWN 

5:00 pm 

3214. Impaired Phagocytosis of Apoptotic Cells in 

Pristane-Induced Lupus Simulates the Clearance 

Defect in Human SLE 

Shuhong Han 1 , Haoyang Zuang 1 , Ravil Khaybullin 2 , 

Stepan Shumyak 3 , Anan Afaneh 3 , Xin Qi 4 , Lijun 

yang 1 and Westley H. Reeves 1 , 1 University of Florida, 

Gainesville, FL, 2 University of Flordia, gainesville, FL, 

3 

university of florida, gainesville, FL, 4 University of 

Florida, gainesville, FL 

5:15 pm 

3215. Bim Suppresses the Development of SLE By 

Limiting Macrophage Inflammatory Responses 

Fu-Nien Tsai and Harris R. Perlman, Northwestern 

University, Chicago, IL 

5:30 pm 

3216. T Cell Restricted Deletion of Serine/Arginine- 

Rich Splicing Factor 1 (SRSF1) in Mice Causes 

Immune Cell Dysfunction and Contributes to 

Lupus-like Nephritis 

Vaishali R. Moulton, Michael W. Mosho, Hao Li, Andrew 

R. Gillooly and George C. Tsokos, Beth Israel Deaconess 

Medical Center, Harvard Medical School, Boston, MA 

5:45 pm 

3217. Macrophage Depletion Using a Specific 

CSF-1R Kinase Inhibitor Ameliorates Kidney and 

Skin Disease in a Mouse Model of Systemic Lupus 

Erythematosus 

Jessica Doerner, Samantha Chalmers and Chaim 

Putterman, Albert Einstein College of Medicine, Bronx, 

NY 



Aspects and Treatment VI: Novel Therapies 

Moderator: Ian N. Bruce, MD 

4:30 pm 

3218. A Randomized, Double-Blind, Placebo- 

Controlled, 52-Week Study of the Efficacy and 

Safety of Belimumab Administered Subcutaneously 

Plus Standard Care to Patients with Systemic Lupus 

Erythematosus (SLE) 


180 




William Stohl 1 , Andreas Schwarting 2 , Masato 

Okada 3 , Morton Scheinberg 4 , Andrea Doria 5 , Anne 

Hammer 6 , Christi Kleoudis 7 , Damon Bass 8 , James 

Groark 9 , Norma Lynn Fox 10 , David Roth 11 and David 

Gordon 11 , 1 University of Southern California Keck 

School of Medicine, Los Angeles, CA, 2 ACURA Kliniken, 

Bad Kreuznach, Germany, 3 St. Luke’s International 

Hospital, Tokyo, Japan, 4 Rheumatology Hospital 

Abreu Sodre Pesquisa Clínica, São Paulo, Brazil, 

5 

University of Padova, Padova, Italy, 6 GlaxoSmithKline, 

Research Triangle Park, NC, 7 Parexel, Durham, 

NC, 8 GlaxoSmithKline, King of Prussia, PA, 

9 

GlaxoSmithKline, Philadelphia, NC, 10 GlaxoSmithKline, 

Washington, MD, 11 GlaxoSmithKline, Philadelphia, PA 

4:45 pm 

3219. Efficacy and Safety of 4 Weeks Administration 

of Arsenic Trioxide in Moderate Active Systemic 

Lupus Erythematosus. a Phase I/II Proof-of-Concept 

Sequential Dose Escalation Multicenter Study 

Mohamed Hamidou 1 , Benjamin Gaborit 2 , Eric 

Hachulla 3 , Zahir Amoura 4 , Mikael Ebbo 5 , Emmanuel 

Chatelus 6 , Jean Sibilia 7 , Jean-Francois Viallard 8 , Julie 

Graveleau 1 , Melanie Saint Jean 9 , Sandrine Gardes 10 , 

Yohann Foucher 10 , Christelle Volteau 1 , Joel Poupon 11 , 

Antoine Neel 2 and François Rieger 12 , 1 Nantes University 

Hospital, Nantes, France, 2 Department of Internal 

Medicine, Nantes University Hospital, Nantes, France, 

3 

Department of Internal Medicine, University Lille 

Nord-de-France, Lille, France, 4 Pitié-Salpêtrière 

hospital, Paris, France, 5 Aix-Marseille Université, AP- 

HM, Marseille, France, 6 Department of Rheumatology, 

Strasbourg University Hospital, Strasbourg, France, 

7 

Department of Rheumatology, Strasbourg University 

Hospital, Strasbourg, France, 8 Haut Lévèque Hospital, 

Bordeaux, France, 9 Department of Dermatology, 

Nantes University Hospital, Nantes, France, 10 Nantes 

Universitary Hospital, Nantes, France, 11 Paris 

University, Paris, France, 12 MEDSENIC, Hôpital Cochin, 

Paris Descartes University, Paris, France 

5:00 pm 

3220. Anifrolumab Differentially Suppresses 

Peripheral Biomarkers of Systemic Lupus 

Erythematosus Compared with Placebo in a Phase 

IIb Trial 

Xiang Guo 1 , L Wang 2 , G Illei 1 , P Brohawn 1 , Brandon 

Higgs 1 and Wendy White 1 , 1 MedImmune, LLC, 

Gaithersburg, MD, 2 MedImmune, Gaithersburg, MD 

5:15 pm 

3221. Safety and Efficiency of Low-Dose 

Interleukin-2 Treatment in Systemic Lupus 

Erythematosus 

Jing He 1 , Xia Zhang 2 , Yunbo Wei 3 , Xiaolin Sun 4 , Jianping 

Guo 2 , Yuebo JIn 2 , Rulin Jia 2 , Lei Zhu 2 , Zhaohua Hou 5 , 

Yaping Chen 6 , Yuan An 2 , Yuan Jia 2 , Xu Liu 2 , Limin Ren 2 , 

Ru Li 2 , HUA YE 2 , Shi Chen 2 , Xuewu Zhang 2 , Yin Su 2 , Eric 

Morand 7 , Yu Di 6 and Zhanguo Li 2 , 1 Peking Univerisity 

People’s Hospital, Beijing, China, 2 Peking University 

People’s Hospital, Beijing, China, 3 Shandong Analysis 

and Test Center, Shandong Academy of Science, 

Shandong, China, 4 People’s hospital,Peking University, 

Beijing, China, 5 Shandong Analysis and Test Center, 

Beijing, China, 6 Monash University, Clayton, Austria, 

7 

Monash University, Clayton, Australia 

5:30 pm 

3222. Repeated Administration of Dapirolizumab 

Pegol (DZP) Appears Safe and Well Tolerated in 

Patients with Systemic Lupus Erythematosus (SLE) 

and Is Accompanied By an Improvement in Disease 

Activity: Results from a Phase 1 Study 

Chris Chamberlain 1 , Murray Urowitz 2 , Julie Soranson 1 , 

Mark Watling 1 , Peter Colman 1 , Olivier Harari 1 , Thomas 

Dorner 3 and Falk Hiepe 3 , 1 UCB Pharma, Slough, United 

Kingdom, 2 University of Toronto, Toronto, ON, 3 Charité 

– Universitätsmedizin, Berlin, Germany 

5:45 pm 

3223. Anifrolumab, an Anti-Interferon Alpha 

Receptor Monoclonal Antibody, in Moderate to 

Severe Systemic Lupus Erythematosus (SLE) 

R Furie 1 , JT Merrill 2 , VP Werth 3 , M Khamashta 4 , K 

Kalunian 5 , P Brohawn 6 , G Illei 6 , J Drappa 6 , L Wang 6 and 

S Yoo 7 , 1 North Shore-LIJ Health System, New York, NY, 

2 


City, OK, 3 Philadelphia V.A. Medical Center, Philidelphia, 

PA, 4 Graham Hughes Lupus Research Laboratory, 

The Rayne Institute, St Thomas’ Hospital, London, 

United Kingdom, 5 UCSD School of Medicine, La Jolla, 

CA, 6 MedImmune, Gaithersburg, MD, 7 Regenx Bio, 

Rockville, MD 



2 0 1 5 


tracker 

plus 

181 


West – 2018 

Vasculitis IV 

Moderators: Yusuf Yazici, MD and Paul A. Monach, MD, 

PhD 

4:30 pm 

3224. Salivary IL-1 Alpha and IL-1 Beta Levels Are 

Associated with Oral Mucosal Activity in Behcet’s 

Disease 

Nilufer Alpay Kanitez 1 , Bahtiyar Toz 1 , Feyza Berktas 1 , 

Sertan Ergun 2 , Meltem Koray 2 , Nuray Gurel Polat 1 , 

Burak Erer 1 and Ahmet Gül 1 , 1 Istanbul University, 

Istanbul Faculty of Medicine, Istanbul, Turkey, 2 Istanbul 

University, Faculty of Dentistry, Istanbul, Turkey 

4:45 pm 

3225. Whole Exome Sequencing Identifies Rare 

Protein-Coding Variants in Behcet’s Disease 

Mikhail Ognenovski 1 , Paul Renauer 1 , Ina Koetter 2 , 

Joerg C. Henes 3 , Bruno Casali 4 , Carlo Salvarani 5 , 

Haner Direskeneli 6 , Kenneth M. Kaufman 7 and Amr 

H. Sawalha 8 , 1 University of Michigan, Ann Arbor, 

MI, 2 Asklepios Klinik Altona, Hamburg, Germany, 

3 

University Hospital Tuebingen, Tuebingen, Germany, 

4 

Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, 

5 

Arcispedale S.Maria Nuova, Reggio Emilia, Italy, 

6 

Marmara University Faculty of Medicine, Istanbul, 

Turkey, 7 Cincinnati Children’s Hospital Medical Center, 

Cincinnati, OH, 8 Division of Rheumatology, University of 


5:00 pm 

3226. Increased Serum Levels of IgG Antibodies 

Against to Alpha-Enolase Are Associated with 

Severity of Oral Ulcers in Patients with Behcet’s 

Disease 

Shin Eui Kang 1 , Sang Jin Lee 2 , Jin Kyun Park 3 , Joo Youn 

Lee 4 , Eun Young Lee 2 , Eun Bong Lee 2 and Yeong 

Wook Song 5 , 1 Department of Molecular Medicine and 

Biopharmaceutical Sciences, BK 21 plus Graduate 

School of Convergence Science and Technology, and 

College of Medicine or College of Parmarcy, Seoul 

National University, Seoul, South Korea, 2 Division of 

Rheumatology, Department of Internal Medicine, 

Seoul National University College of Medicine, Seoul, 

South Korea, 3 Department of Molecular Medicine 

and Biopharmaceutical Sciences Graduate School of 

Convergence Science and Technology, and College 

of Medicine or College of Pharmacy Seoul National 

University, Seoul, South Korea, 4 Department of 

Molecular Medicine and Biopharmaceutical Sciences, 

BK21 plus Graduate School of Convergence Science 

and Technology, and College of Medicine or College 

of Pharmacy, Seoul National University, Seoul, South 

Korea, 5 Department of Molecular Medicine and 

Biopharmaceutical Sciences, Graduate School of 

Convergence Science and Technology and College of 

Medicine Seoul National University, Seoul, South Korea 

5:15 pm 

3227. Identification of Novel Protein-Coding Genetic 

Variants Associated with Takayasu Arteritis 

Paul Renauer 1 , Patrick Coit 1 , Peter A. Merkel 2 and Amr 

H. Sawalha 3 , 1 University of Michigan, Ann Arbor, MI, 

2 

University of Pennsylvania, Philadelphia, PA, 3 Division 

of Rheumatology, University of Michigan, Ann Arbor, MI 

5:30 pm 

3228. Sofosbuvir Plus Ribavirin for Hepatitis C 

Virus Associated Cryoglobulinemia Vasculitis: 

Vascuvaldic Study 

David Saadoun 1 , V Thibault 2 , L Alric 3 , C Guillaud 4 , H 

Izzedine 2 , M Costopoulos 2 , L Musset 2 , H Fontaine 5 , 

C Hezode 4 , S Pol 5 , T Poynard 2 , P Cacoub 2 and SN SI 

Ahmed 6 , 1 Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ 

Paris 06, Paris, France, 2 CHU Pitie Salpetriere, Paris, 

France, 3 CHU Toulouse, Toulouse, France, 4 CHU H 

Mondor, Creteil, France, 5 CHU Cochin, Paris, France, 

6 

CH Orleans, Orleans, France 

5:45 pm 

3229. Using Exome Sequencing to Identify Novel 

Genetic Associations with Granulomatosis with 

Polyangiitis Susceptibility 

Angel C.Y. Mak 1 , Paul L.F. Tang 2 , Gang Xie 3 , Pui-Yan 

Kwok 4 , Paul A. Monach 5 , Simon Carette 3 , David 

Cuthbertson 6 , Gary S. Hoffman 7 , Nader A. Khalidi 8 , 

Curry L. Koening 9 , Carol A. Langford 7 , Carol A. 

McAlear 10 , Larry W. Moreland 11 , Christian Pagnoux 3 , 

Philip Seo 12 , Ulrich Specks 13 , Antoine G. Sreih 14 , 

Steven R. Ytterberg 13 , Peter A. Merkel 10 , Katherine A. 

Siminovitch 3 , Sharon A. Chung 15 and Vasculitis Clinical 

Research Consortium, 1 Cardiovascular Research 

Institute, University of California, San Francisco, San 

Francisco, CA, 2 University of California, San Francisco, 


182 




San Francisco, CA, 3 Mount Sinai Hospital, Toronto, ON, 

4 

Institute for Human Genetics, University of California, 

San Francisco, San Francisco, CA, 5 Boston University 

School of Medicine, Boston, MA, 6 University of South 

Florida, Tampa, FL, 7 Cleveland Clinic, Cleveland, OH, 

8 

McMaster University, Hamilton, ON, 9 University of 

Utah, Salt Lake City, UT, 10 University of Pennsylvania, 

Philadelphia, PA, 11 University of Pittsburgh, Pittsburgh, 

PA, 12 Johns Hopkins University, Baltimore, MD, 13 Mayo 

Clinic College of Medicine, Rochester, MN, 14 Hospital 

of the University of Pennsylvania, Philadelphia, 

PA, 15 Rosalind Russell / Ephraim P. Engleman 

Rheumatology Research Center, University of 

California, San Francisco, San Francisco, CA 


4:30 – 6:00 pm 











August 30. 

West – 3003 

081 – Crystal: Diagnosis and Management of 

Gout PM PS E 

Speaker: John S. Sundy, MD, PhD 

West – 3005 

082 – Macrophage Activation Syndrome 

Speaker: Alexei A. Grom, MD 

West – 3007 


Digital Ischemia 

Speaker: Fredrick M. Wigley, MD 

West – 3009 

084 – Pediatrics: Difficult to Treat Juvenile 

Idiopathic Arthritis Pediatrics 

Speaker: Charles H. Spencer, MD 

West – 3011 

085 – Pulmonary Hypertension in the 


Speaker: Dinesh Khanna, MD, MS 

West – 3016 


Speaker: Michael Weinblatt, MD 

West – 3018 

087 – Systemic Lupus Erythematosus: Difficult 

to Treat Systemic Lupus Erythematosus 

Speaker: Eliza Chakravarty, MD, MS 

West – 3020 

088 – Temporal Arteritis 

Speaker: Robert F. Spiera, MD 

West – 3022 

089 – Vasculitis: Factors That Influence Disease 

Patterns 

Speaker: Kenneth J. Warrington, MD 

West – 3024 

090 – What is Not Central Nervous Angiitis: 

Making the Right Diagnosis 

Speaker: Leonard H. Calabrese, DO 

ARHP SESSIONS 

4:30 – 6:00 pm 

West – 2006 

Empowerment Through the Family-Centered 

Care Approach PM Ed Pd PS PrM FIT 

Moderator: Karla B. Jones, MS, RN, CNP 



2 0 1 5 


tracker 

plus 

183 


4:30 pm 

Utilizing Educational Programs for Pediatric Patients 

and Their Families 

Linda Miranda, RN, BSN, PHN, CPN 

5:00 pm 

Improving Treatment Compliance for the Pediatric 

Population 

Barbara Paliughi, BSN 

5:30 pm 

Empowerment Through the Family-Centered Care 

Approach 

Kimberlea Hamilton, PT 

West – 2008 

Lesbian, Gay, Bisexual, Transgender and Queer: 

Conversations and Care PM Ed PM Pd PS PrM PS FIT E 

Moderator: Donah Z. Crawford, BS, MA 

4:30 pm 

LGTBQ – Medical Conversations and Care 

Barbara Snyder, MD 

4:45 pm 

LGBTQ – Conversations and Care 

Caroline Hill, MSW, LCSW 

West – 2009 

Telehealth: Opportunities and Pitfalls 

Moderator: Mary E. Christenson, PhD, PT 

4:30 pm 

Tele-health: Opportunities and Pitfalls 

Daniel Albert, MD 

5:00 pm 

Tele-health: Opportunities and Pitfalls 

John Mecchella, DO, MPH 

5:30 pm 

Telehealth: Opportunities and Pitfalls 

Zsolt Kulcsar, DO 


4:30 – 6:00 pm 

West – 2004 

ARHP IV: Clinical Practice and Patient Care 

Moderator: Sara Monday 

4:30 pm 

3230. Perceived Barriers in Care for Arthritis 

Elizabeth M. Badley 1 , Lynn Moore 2 and Monique A.M. 

Gignac 3 , 1 Toronto Western Research Institute, Toronto, 

ON, 2 The Arthritis Society, Toronto, ON, 3 Instititue for 

Work and Health, Toronto, ON 

4:45 pm 

3231. A Systematic Review of the Persuasive Design 

Principles Used in Health Apps for Arthritis 

Jonas Geuens 1 , Vero Vanden Abeele 1 , Thijs Swinnen 2 , 

R Westhovens 3 , Kurt L. de Vlam 3 and Luc Geurts 1 , 1 KU 

Leuven, Leuven, Belgium, 2 UZ Leuven, Leuven, Belgium, 

3 

University Hospitals Leuven, Leuven, Belgium 

5:00 pm 

3232. The Comparative Efficacy of Kinesio Taping 

and Local Steroid Injection in Patients with 

Subacromial Impingement Syndrome 

Hamit Goksu 1 , Pinar Borman 2 , Figen Gokoglu 3 and 

Seher Kocaoglu 2 , 1 Ankara Training and Research 

Hospital, Ankara, Turkey, 2 Ministry of Health Ankara 

Education and Research Hospital, Ankara, Turkey, 3 Ahi 

Evran University, Medical Faculty, Kýrþehir, Turkey 

5:15 pm 

3233. A Comparison of Interobserver Agreement 

Between Advanced Practice Physiotherapists 

and Rheumatologists in the Detection of Axial 

Spondyloarthritis 

Laura Passalent 1 , Christopher Hawke 2 , Ahmed Omar 2 , 

Khalid Alnaqbi 3 , Dinny Wallis 4 , Nigil Haroon 2 and Robert 

D Inman 2 , 1 Toronto Western Hospital, Toronto, ON, 

2 

Toronto Western Hospital, University of Toronto, 

Toronto, ON, 3 Al Ain Hospital, Al Ain, United Arab 

Emirates, 4 University Hospital Southampton NHS 

Foundation Trust, Southampton, United Kingdom 


184 



TUESDAY & WEDNESDAY, NOVEMBER 10, 11, 2015 

5:30 pm 

3234. Roadblocks Perceived By Canadian 

Dermatologists for Referring Patients with 

Suspected Psoriatic Arthritis 

Renise Ayearst 1 , Daniel Pereira 1 , Charles Lynde 2 , 

Holly Etchegary 3 and Vinod Chandran 1 , 1 University 

of Toronto, Toronto Western Hospital, Toronto, 

ON, 2 University of Toronto, Toronto, ON, 3 Memorial 

University of Newfoundland, St.John’s, NF 

5:45 pm 

3235. Factors Associated with Nonadherence to 

Recently Initiated Disease-Modifying Antirheumatic 

Drugs 

Candace H. Feldman 1 , Elena Massarotti 2 , Alyssa 

Wohlfahrt 3 , Anarosa Campos 3 , Yuanyu Lo 3 , Zhi Zhang 3 , 

Maura D. Iversen 4 and Daniel H. Solomon 2 , 1 Division of 

Rheumatology, Immunology and Allergy, Brigham and 


MA, 2 Brigham and Women’s Hospital, Harvard Medical 

School, Boston, MA, 3 Brigham and Women’s Hospital, 

Boston, MA, 4 Northeastern University, Department of 

Physical Therapy, and Brigham & Women’s Hospital, 


INDUSTRY-SUPPORTED SYMPOSIA 

6:30 – 9:30 pm 

These symposia are both CME-accredited and non- 

CME company-directed programs. For CME-accredited 

symposia, the sponsoring organization is responsible for 

planning and providing CME credit. All non-CME programs 

are wholly sponsored and supported by commercial 

entities. Please visit the organization’s exhibit booth, the 

industry-supported symposia booth or download the 

ACR Annual Meeting App for more information on each 

symposium. 

ACR SESSIONS 

7:30 – 8:30 am 



Immunology Update on Adaptive Immunity: 

Immune Regulation and Tolerance 

Moderator: George C. Tsokos, MD 

Speaker: Mark Anderson, MD, PhD 


New Adult and Juvenile Myositis Response 

Criteria PM Ed Pd PS PrM FIT 

Moderator: Frederick W. Miller, MD, PhD 

7:30 am 

How to Measure Myositis Response in Adult 

Dermatomyositis and Polymyositis 

Rohit Aggarwal, MD, MS 

7:55 am 

How to Apply the New Response Criteria for Juvenile 

Dermatomyositis in Clinic and Research 

Lisa G. Rider, MD 


Rheumatology Roundup: Highlights from the 

2015 Annual Meeting 


Speakers: John J. Cush, MD and Arthur Kavanaugh, MD 


Use of Individual Cell and Cell Subset 

Transcriptomes as Biomarkers of 

Disease PM Ed Pd PS PM Ed PrM Pd PS PrM FIT FIT 

Moderators: Nora G. Singer, MD and Maripat Corr, MD 

Speaker: Ken Smith, MD 



2 0 1 5 


tracker 

plus 

185 


ARHP SESSIONS 

7:30 – 8:30 am 


Modeling of Categorical Data 

Moderator: Alyssa B. Dufour, PhD 

7:30 am 

Overview of Categorical Data 

Rebecca J. Cleveland, PhD 

7:55 am 

Statistical Models for Categorical Data, With Examples 

Todd Schwartz, DO 

ARHP SESSIONS 

9:00 – 10:00 am 


Biosimilars: The Road Ahead 


Speaker: Partha Roy, PhD 


Hematologic Manifestations of Rheumatologic 

Disease: Case Studies 

Moderator: Deanna Yamamoto, NP 

Speaker: Lee Levitt, MD 

ACR SESSIONS 

9:00 – 10:30 am 


Chronic Nonbacterial Osteomyelitis (CNO): 

From the Bedside to the Bench PM PS 

Moderator: Christian Hedrich, MD, PhD 

Ed Pd PrM FIT 

9:00 am 

Chronic Nonbacterial Osteomyelitis – Clinical Features 

and Approach to Management 

Ronald Laxer, MD 

9:30 am 

The Genetics of Chronic Nonbacterial Osteomyelitis 

Polly J. Ferguson, MD 

10:00 am 

Does the Microbiome Play a Role in the Clinical 

Manifestations of Chronic Nonbacterial 

Osteomyelitis? 

Thirumala-Devi Kanneganti, PhD 


Environmental Triggers of Autoantibodies and 

Autoimmunity 

Moderators: Rebecca L. Manno, MD, MHS and Luis 

Eduardo C. Andrade, MD, PhD 

9:00 am 

The Mechanisms Underlying the Triggers of Human 

Autoimmune Disease by Environmental Factors 

Kenneth Pollard, PhD 

9:30 am 

Autoimmune/Inflammatory Syndrome Induced 

by Adjuvants (ASIA) Syndrome: Adjuvant-Related 

Autoimmunity in Humans 

Yehuda Shoenfeld, MD 

10:00 am 

Genes, Environment, and Immunity in Rheumatic 

Disease 

Lars Klareskog, Prof, MD, PhD 


Racial Disparities in Rheumatic Diseases 

Moderators: C.Kent Kwoh, MD and Jasvinder A. Singh, 

MD, MPH 

9:00 am 

Racial and Ethnic Disparities in Rheumatoid Arthritis 

Jennifer Barton, MD 

9:30 am 

Impact of Race and Ethnicity on Outcomes in Systemic 

Lupus Erythematosus 

Ernest Vina, MD, MS 


186 




10:00 am 

Racial Disparities in Joint Arthroplasty 

Susan M. Goodman, MD 


T Follicular Cells and Their Mediators 

Moderators: Terri Laufer, MD and Andrew P. Cope, MD 

9:00 am 

The Function of T Follicular Helper (TFH) Cells 

Joseph E. Craft, MD 

9:30 am 

Transcriptional Profile of TFH 

Chen Dong, PhD 

10:00 am 

T Follicular Regulatory Cells 

Arlene Sharpe, MD, PhD 

ACR CONCURRENT ABSTRACT SESSION 

9:00 – 10:30 am 


Rheumatoid Arthritis – Clinical Aspects VI: 

Death Be Not Proud – Mortality and Treatment 

Outcomes in RA 

Includes 2014 Lee C. Howley, Sr. Prize for Arthitis Research 


Moderator: JoAnn Zell, MD 

9:00 am 

2014 Lee C. Howley, Dr. Prize for Arthritis Research 


James R. O’Dell, MD 

9:15 am 

3236. Circulating Cytokine/Chemokine 

Concentrations Predict Cancer Mortality in Men 

with Rheumatoid Arthritis 

Bryant R. England 1 , Jeremy Sokolove 2 , William H. 

Robinson 3 , Geoffrey M. Thiele 4 , Apar K. Ganti 1 , Harlan 

Sayles 1 , Kaleb Michaud 5 , Liron Caplan 6 , Lisa A. Davis 6 , 

Grant W. Cannon 7 , Brian Sauer 7 , E. Blair Solow 8 , 

Andreas Reimold 9 , Gail S. Kerr 10 , Pascale Schwab 11 , 

Joshua F. Baker 12 and Ted R. Mikuls 1 , 1 University of 

Nebraska Medical Center, Omaha, NE, 2 Stanford 

University Medical Center, Mountain View, CA, 

3 

Stanford University School of Medicine, Stanford, CA, 

4 

Omaha VA Medical Center, Omaha, NE, 5 University 

of Nebraska Medical Center and National Data Base 

for Rheumatic Diseases, Omaha, NE, 6 Univ of CO 

Denver School of Med, Aurora, CO, 7 Salt Lake City 

VA Medical Center and University of Utah, Salt Lake 

City, UT, 8 UT Southwestern Medical Center, Dallas, 

TX, 9 VAMC, University of Texas Southwestern Medical 

Center, Dallas, TX, 10 VAMC, Georgetown University, 

Washington, DC, 11 Oregon Health & Sci Univ OP09, 

Portland, OR, 12 University of Pennsylvania, Philadelphia, 

PA 

9:30 am 

3237. Decreased Cardiovascular Mortality in 

Patients with Incident Rheumatoid Arthritis (RA) in 

Recent Years: Dawn of a New Era in Cardiovascular 

Disease in RA? 

Elena Myasoedova 1 , Cynthia S. Crowson 1 , Eric L. 

Matteson 1 , John M. Davis III 1 , Terry M. Therneau 1 

and Sherine E. Gabriel 2 , 1 Mayo Clinic, Rochester, MN, 

2 

Rutgers Robert Wood Johnson Medical School, New 

Brunswick, NJ 

9:45 am 

3238. The Impact of Biologic DMARD Treatment on 

Sepsis and Mortality after Serious Infection 

Adrian Richter 1 , Anja Strangfeld 1 , Prof. Dr. Matthias 

Schneider 2 , Thomas Klopsch 3 , Andreas Kapelle 4 , Jörg 

Kaufmann 5 , Angela Zink 6 and Joachim Listing 7 , 1 German 

Rheumatism Research Center, Berlin, Germany, 

2 

Heinrich-Heine-University, Duesseldorf, Germany, 

3 

Rheumatologist in private practice, Neubrandenburg, 

Germany, 4 Rheumatologist, Hoyerswerda, Germany, 

5 

Medical practice specialising, Ludwigsfelde, Germany, 

6 

Deutsches Rheuma-Forschungszentrum, Berlin, 

Germany, 7 DRFZ, Berlin, Germany 

10:00 am 

3239. Response to Methotrexate Predicts Mortality 

in Rheumatoid Arthritis up to 30 Years 

Carolin Krause 1 , Siegfried Wassenberg 2 , Rolf Rau 3 , 

Gertraud Herborn 4 , Juergen Braun 5 and Dietmar 

Krause 6 , 1 University Munster, Munster, Germany, 

2 

Themistocles Gluck hospital - Rheumazentrum 



2 0 1 5 


tracker 

plus 

187 


Ratingen, Ratingen, Germany, 3 Expert in Rheumatology, 

Düsseldorf, Germany, 4 Evangelisches Fachkrankenhaus 

Ratingen, Ratingen, Greece, 5 Rheumazentrum 

Ruhrgebiet, Herne, Germany, 6 Dept. for Medical 

Informatics, Biometry and Epidemiology, Ruhr 

University, Bochum, Germany 

10:15 am 

3240. Improved Survival in Rheumatoid Arthritis: A 

General Population-Based Study 

Na Lu 1 , Hyon K. Choi 1 , Sara R. Schoenfeld 1 , Christine 

Peloquin 2 , Maureen Dubreuil 3 , Sharan K. Rai 4 , J Antonio 

Avina-Zubieta 5 and Yuqing Zhang 6 , 1 Massachusetts 

General Hospital, Harvard Medical School, Boston, MA, 

2 


3 

Boston VA HealthCare System, Boston, MA, 4 University 

of British Columbia, Vancouver, BC, 5 Arthritis Research 

Canada / University of British Columbia, Vancouver, BC, 

6 

BUSM, Boston, MA 


9:00 – 10:30 am 


ARHP V: Physical Activity 


9:00 am 

3241. Do Boosters Support Long-Term Physical 

Activity Maintenance after an Intervention? a 

Systematic Review 

Kathryn Remmes Martin 1 , Chloé Charlotte Schröder 2 

and Daniel Whibley 1 , 1 University of Aberdeen, 

Aberdeen, United Kingdom, 2 University of Bremen, 

Bremen, Germany 

9:15 am 

3242. A Comprehensive Method for Using 

Sensewear Mini TM Monitors to Explore Differences 

in Ambulatory Activities in People Living with 

and without Early Rheumatoid Arthritis: Moving 

Beyond Measuring Total Steps 

Lynne Feehan 1 , Jake McIvor 2 , Ju Young Yoo 2 and Linda 

Li 2 , 1 Fraser Health Authority, Surrey, BC, 2 Arthritis 

Research Canada, Richmond, BC 

9:30 am 

3243. A Randomized Controlled Trial for a Physical 

Activity Intervention for RA Fatigue 

Patricia P. Katz 1 , Mary Margaretten 2 , Steven Gregorich 1 , 

Sandi Kaplan 3 , Stephanie Rush 2 and Laura Trupin 1 , 

1 

University of California San Francisco, San Francisco, 

CA, 2 University of California, San Francisco, San 

Francisco, CA, 3 University of California, San Francisco, 

CA 

9:45 am 

3244. Evaluation of a Self-Directed Walking Program 

in Hispanics with Arthritis 

Leigh F. Callahan 1 , Alfredo Rivadeneira 2 , Mary Altpeter 2 , 

Rebecca J. Cleveland 2 , Betsy Hackney 1 , Leigha Vilen 2 , 

Victoria Sepulveda 2 , Daniel S Reuland 2 and Claudia 

Rojas 2 , 1 University of North Carolina, Chapel Hill, NC, 

2 

University of North Carolina at Chapel Hill, Chapel Hill, 

NC 

10:00 am 

3245. Factors Associated with Physical Activity in 

Older Children with Juvenile Idiopathic Arthritis 

Jennifer R. Horonjeff 1 , Shira Weiner 1 , Susan Klepper 2 , 

Ali Sheikhzadeh 1 , Philip Kahn 1 and Sherri Weiser 1 , 1 New 

York University, New York, NY, 2 Columbia University, 

New York, NY 

10:15 am 

3246. Does Loss of a Community Walking Speed 

Lead to More Symptoms of Depression in Knee 

OA? a Trajectory Analysis from the Osteoarthritis 

Initiative 

Daniel White 1 , Tuhina Neogi 2 , Yuqing Zhang 2 , Jingbo 

Niu 3 and Patricia P. Katz 4 , 1 University of Delaware, 

Newark, DE, 2 BUSM, Boston, MA, 3 Boston University 

School of Medicine, Boston, MA, 4 UCSF, SF, CA 

ACR SESSIONS 

11:00 am – 12:30 pm 


Issues in Ultrasound PM 2015 PS 

Moderator: P. Scott Pollock, MD 

Ed Pd PrM FIT 


188 




11:00 am 

Ultrasound and The Prognosis in Rheumatoid 

Arthritis: Is It Time to Include U.S. Criteria In the for 

Response/Remission? 

Gurjit S. Kaeley, MBBS, MRCP 

11:30 am 

Using Ultrasound in Musculoskeletal Procedures: Less 

Pain More Gain? 

Catherine Bakewell, MD 

Noon 

Current Status of Ultrasound Certification/ 

Credentialing: USSONAR, RADAR, Etc. 



Novel T cell Subsets 

Moderators: Shu Man Fu, MD, PhD and Vasileios C. 

Kyttaris, MD 

11:00 am 

Human Tissue T Cell Responses: 

Compartmentalization, Regulation, Function 

Donna Farber, PhD 

11:45 am 

Innate Lymphoid Cells in Immunity 

Marco Colonna, MD 


Reproductive Issues in Rheumatology 

Moderators: Megan E. B. Clowse, MD, MPH and Eliza 

Chakravarty, MD, MS 

11:00 am 

Update on the Use of Biologics in Pregnancy 

Christina D Chambers, PhD, MPH 

11:30 am 

Pregnancy Outcomes in Rheumatoid Arthritis 

Megan E. B. Clowse, MD, MPH 

Noon 

Fertility and Fertility Preservation in Rheumatic 

Diseases 

Wendy Marder, MD 


11:00 am – 12:30 pm 


Pain: Clinical Aspects PM PS E 

Moderators: Yvonne C. Lee, MD, MMSc and Nancy E. 

Lane, MD 

11:00 am 

3247. Dietary Intake of Omega-3 Fatty Acids and 

Vitamin C and D Associate with Decreased Pain, 

Independent of Inflammation, in MTX Treated Early 

RA Patients 

Cecilia Lourdudoss 1 , Alicja Wolk 2 , Lars Alfredsson 3 , 

Lars Klareskog 4 , Ronald F. van Vollenhoven 5 and Jon 

Lampa 6 , 1 ClinTRID, Karolinska institutet, Stockholm, 

Sweden, 2 Institute of Environmental Medicine (IMM), 

Karolinska institutet, Stockholm, Sweden, 3 The Institute 

of Environmental Medicine, Karolinska Institutet, 

Stockholm, Sweden, 4 Department of Medicine, 


5 

Unit for Clinical Therapy Research, Inflammatory 

Diseases (ClinTRID), The Karolinska Institute, 

Stockholm, Sweden, 6 Karolinska Institute, Stockholm, 

Sweden 

11:15 am 

3248. Which Factors Explain Multi-Site Pain Caused 

By Obesity: A 5-Year Follow-up Study in Older 

Adults? 

Feng Pan 1 , Laura Laslett 2 , Russell Thomson 2 , Tania 

Winzenberg 1 , Flavia Cicuttini 3 , Changhai Ding 2 and 

Graeme Jones 2 , 1 Menzies Institute for Medical 

Research, University of Tasmania, Hobart,7000, 

Australia, 2 Menzies Institute for Medical Research, 

University of Tasmania, Hobart, Australia, 3 Department 

of Epidemiology and Preventive Medicine, Monash 

University Medical School, Melbourne, Australia 

11:30 am 

3249. Pooled Efficacy and Safety from Phase 3 

Controlled Studies of Tanezumab in Patients with 


Leslie Tive 1 , David Radin 2 , Alfonso Bello 3 , Ha Nguyen 1 , 

Mark T. Brown 4 , Christine R. West 4 and Kenneth 

M. Verburg 4 , 1 Pfizer, Inc, New York, NY, 2 Stamford 

Therapeutics Consortium, Stamford, CT, 3 Illinois Bone 



2 0 1 5 


tracker 

plus 

189 


& Joint Inst, Glenview, IL, 4 Pfizer Inc., Groton, CT 

11:45 am 

3250. Systemic Inflammation and Pain Sensitization 

in Knee Osteoarthritis: The Multicenter 

Osteoarthritis Study 

Tuhina Neogi 1 , Laura Frey-Law 2 , Devyani Misra 1 , 

Michael C. Nevitt 3 , Lars Arendt-Nielsen 4 , Emily K. 

Quinn 5 and Cora E. Lewis 6 , 1 Boston University School of 

Medicine, Boston, MA, 2 UIowa, Iowa City, IA, 3 UCSF, San 

Francisco, CA, 4 Aalborg University, Aalborg, Denmark, 

5 

Boston University School of Public Health, Boston, MA, 

6 

University of Alabama at Birmingham, Birmingham, AL 

Noon 

3251. The Relation of Massive Weight Loss to 

Changes in Knee Pain and Sensitization 

Joshua Stefanik 1 , David T. Felson 2 , Jingbo Niu 2 , Anyu 

Hu 2 , Caroline Apovian 2 , Michael P. Lavalley 3 and Tuhina 

Neogi 2 , 1 Northeastern University, Boston, MA, 2 Boston 

University School of Medicine, Boston, MA, 3 Boston 

University School of Public Health, Boston, MA 

12:15 pm 

3252. Impact of Knee Pain Frequency on Physical 

Function in the Osteoarthritis Initiative 

Jin Zhou, Erin Ashbeck, Lynn Hamilton and C. Kent 

Kwoh, University of Arizona, Tucson, AZ 


Rheumatoid Arthritis – Clinical Aspects VII: 

Disease Activity and Updates in 

Measurement 

Moderator: Bindee Kuriya, MD, MS 

11:00 am 

3253. The Predictive Value of Antibodies to Cyclic 

Citrullinated Peptide in Two Prospective Early 

Rheumatoid Arthritis Cohorts 10 Years Apart 

Alf Kastbom 1 , Michael Ziegelasch 1 , Ingrid Thyberg 1 , 

Birgir Arge 2 , Klara Martinsson 1 , Olle Svernell 3 , Åsa 

Häggström 4 , Per Salomonsson 5 , Britt-Marie Nyhäll- 

Wåhlin 6 , Sören Transö 7 , Claudia Jacobs 8 and Thomas 

Skogh 1 , 1 IKE/Rheumatology, Linköping University, 

Linköping, Sweden, 2 Rheumatology clinic, Eskilstuna 

Hospital, Eskilstuna, Sweden, 3 Rheumatology Dpt, 

Västervik Hospital, Västervik, Sweden, 4 Rheumatology 

clinic, Kalmar Hospital, Kalmar, Sweden, 

5 

Rheumatology Clinic, Örebro University Hospital, 

Örebro, Sweden, 6 Falun Hospital, Falun, Sweden, 

7 

Rheumatology Clinic, Ryhov Hospital, Jönköping, 

Sweden, 8 Rheumatology Dept, Oskarshamn Hospital, 

Oskarshamn, Sweden 

11:15 am 

3254. A Clinical Risk Score to Predict Functional 

Disability at 1 Year in an Early Rheumatoid Arthritis 

Inception Cohort 

Caroline Kronisch 1 , David Mclernon 2 , James Dale 3 , 

Caron Paterson 3 , Stuart H. Ralston 4 , David M. Reid 2 , Ann 

Tierney 3 , John Harvie 5 , Neil McKay 6 , Hilary E. Wilson 7 , 

Robin Munro 8 , Sarah Saunders 9 , Ruth Richmond 10 , 

Derek Baxter 11 , Mike McMahon 12 , Vinod Kumar 13 , John 

McLaren 14 , Stefan Siebert 3 , Iain B. McInnes 3 , Duncan 

Porter 3 , Gary J. Macfarlane 2 and Neil Basu 2 , 1 Cantonal 

Hospital Fribourg, Fribourg, Switzerland, 2 University 

of Aberdeen, Aberdeen, United Kingdom, 3 University 

of Glasgow, Glasgow, United Kingdom, 4 Centre for 

Genomic and Experimental Medicine, Western General 

Hospital, Edinburgh, United Kingdom, 5 Raigmore 

Hospital, Inverness, United Kingdom, 6 Western General 

Hospital, Edinburgh, United Kingdom, 7 Stobhill General 

Hospital, Glasgow, United Kingdom, 8 Wishaw General 

Hospital, Lanarkshire, United Kingdom, 9 Glasgow Royal 

Infirmary, Glasgow, United Kingdom, 10 Borders General 

Hospital, Melrose, United Kingdom, 11 University 

Hospital Ayr, Ayr, United Kingdom, 12 Dumfries & 

Galloway Royal Infirmary, Dumfries, United Kingdom, 

13 

Ninewells Hospital, Dundee, United Kingdom, 

14 

Whyteman Brae Hospital, Fife, United Kingdom 

11:30 am 

3255. Brain White Matter Integrity: A Future 

Biomarker for Rheumatoid Arthritis Related 

Fatigue? 

Neil Basu 1 , Marayam Alsyedalhashem 1 , Mariella 

D’Allesandro 1 , Alison D. Murray 1 , Daniel J. Clauw 2 and 

Gordon D. Waiter 1 , 1 University of Aberdeen, Aberdeen, 

United Kingdom, 2 University of Michigan, Ann Arbor, MI 

11:45 am 

3256. Epigenetic Chromosome Conformations 

Predict MTX Responsiveness in Early Rheumatoid 

Arthritis Patients 

Claudio Carini 1 , Aroul Ramadass 2 , Philip Jordan 2 , Ewan 

Hunter 2 , Alexandre Akoulitchev 2 , Iain. B. McInnes 3 , Carl. 


190 




S. Goodyear 3 and Scottish Early Rheumatoid Arthritis 

Inception Cohort Investigators, 1 Pfizer, Cambridge, 

MA, 2 Oxford Biodynamics, Oxford, United Kingdom, 

3 

University of Glasgow, Glasgow, United Kingdom 

Noon 

3257. The Link Between DAS28 and the Short-Term 

Risk of Acute Coronary Syndrome in RA, and Its 

Driving Factors 

Lotta Ljung 1 , Thomas Frisell 2 and Johan Askling 2 , 

1 

Karolinska Institutet, Stockholm, Sweden, 2 Clinical 

Epidemiology Unit, Department of Medicine, Karolinska 

Institutet, Stockholm, Sweden 

12:15 pm 

3258. Different Perception of Disease Activity in 

Multimorbid Rheumatoid Arthritis Patients 

Helga Radner 1 , Kazuki Yoshida 2 , Sara K. Tedeschi 3 , M 

Frits 1 , C Iannaccone 4 , N Shadick 5 , Michael Weinblatt 1 , 

Daniel Aletaha 6 , Josef S. Smolen 7 and Daniel H. 

Solomon 1 , 1 Brigham and Women’s Hospital, Boston, 

MA, 2 Harvard School of Public Health, Boston, MA, 

3 

Brigham & Women’s Hospital, Boston, MA, 4 Brigham 

and Women’s Hospital, Boston, MA, 5 Brigham and 

Women’s Hosp, Boston, MA, 6 Medical University 

Vienna, Vienna, Austria, 7 Medical Univ Vienna, Vienna, 

Austria 




III 

Moderators: Janet E. Pope, MD, MPH and Dan Furst, MD 

11:00 am 

3259. Immunoablation Followed By Autologous 

Stem Cell Transplantation in Systemic Sclerosis 

Patients Decreases Significantly the Interferon 

Signatrue 

Shervin Assassi 1 , Maureen D Mayes 1 , Claudia Pedroza 1 , 

Jeffrey T. Chang 1 , Daniel E. Furst 2 , Leslie J. Crofford 3 , 

Richard Nash 4 , Peter McSweeney 4 , Mary Ellen Csuka 5 , 

Ellen Goldmuntz 6 , Lynette Keyes-Elstein 7 , Paul Wallace 8 

and Keith Sullivan 9 , 1 University of Texas Medical School 

at Houston, Houston, TX, 2 University of California, 

Los Angeles, David Geffen School of Medicine, Los 

Angeles, CA, 3 Vanderbilt University, Nashville, TN, 

4 

Colorado Blood Cancer Institute, Denver, CO, 5 Med 

Coll of Wisconsin, Milwaukee, WI, 6 National Institutes 

of Health, Bethesda, MD, 7 Rho Federal Systems, Inc., 

Chapel Hill, NC, 8 Roswell Park, Buffalo, NY, 9 Duke 


11:15 am 

3260. Increased Frequency of Malignancies 

Synchronous to the Onset of Systemic Sclerosis 

in Anti-RNA Polymerase III Antibodies Positive 

Patients: A Eustar Multicentre Study 

Maria Grazia Lazzaroni 1 , Enrico Colombo 2 , Ilaria 

Cavazzana 1 , Oliver Distler 3 , Rucsandra Dobrota 3 , 

Jasmin Eisenring 3 , Roger Hesselstrand 4 , Lazlo Czirjak 5 , 

Cecilia Varju 5 , Gabriella Nagy 5 , Vanessa Smith 6 , 

Paola Caramaschi 7 , Valeria Riccieri 8 , Eric Hachulla 9 , 

Katarzyna Romanowska-Próchnicka 10 , Alexandra 

Balbir-Gurman 11 , Emmanuel Chatelus 12 , Ana Carolina 

Araújo 13 , Yannick Allanore 14 , Paolo Airò 15 and 

EUSTAR , 1 Rheumatology and Clinical Immunology, 

Spedali Civili and University of Brescia, Brescia, Italy, 

2 

University and Spedali Civili of Brescia, Brescia, 

Italy, 3 Division of Rheumatology, University Hospital 

Zurich, Zurich, Switzerland, 4 Department of Clinical 

Sciences, Section of Rheumatology, Lund University, 

Lund, Sweden, 5 University of Pécs Medical Center, 

Pécs, Hungary, 6 Ghent University Hospital, Ghent, 

Belgium, 7 Rheumatology Unit, Azienda Ospedaliera 

Universitaria Integrata, Verona, Italy, 8 Department of 

Internal Medicine and Medical Specialities, University 

Sapienza, Rome, Italy, 9 Department of Internal 

Medicine, University Lille Nord-de-France, Lille, France, 

10 

Department of Pathophysiology, Medical University 

of Warsaw and Department of Connective Tissue 

Diseases, Institute of Rheumatology, Warsaw, Poland, 

11 

B. Shine Rheumatology Unit, Rambam Health Care 

Campus, Rappaport Faculty of Medicine, Technion - 

Institute of Technology, Haifa, Israel, 12 Department 

of Rheumatology, Strasbourg University Hospital, 

Strasbourg, France, 13 Hospital de Curry Cabral, 

Centro Hospitalar Lisboa Central, Lisbon, Portugal, 

14 

Department of Rheumatology, University Paris 

Descartes and Cochin Hospital, Paris, France, 15 Spedali 

Civili of Brescia, Brescia, Italy 



2 0 1 5 


tracker 

plus 

191 


11:30 am 

3261. Examining the Impact of Radiation Therapy 

on Scleroderma and Cancer Outcomes in 

Scleroderma Patients with Breast Cancer 

Dhaval Shah 1 , Ram Hirpara 1 , Laura K. Hummers 1 , 

Fredrick M. Wigley 1 , Virginia D. Steen 2 , Robyn T. 

Domsic 3 and Ami A. Shah 1 , 1 Johns Hopkins University 

School of Medicine, Baltimore, MD, 2 Georgetown 

University Medical Center, Washington, DC, 3 University 

of Pittsburgh, Pittsburgh, PA 

11:45 am 

3262. The Influence of Immunosuppressive Therapy 

on Microangiopathy in Systemic Sclerosis As 

Measured with Nailfoldcapillaroscopy 

Jessica Meijs 1 , B. de Boer 1 , Anne Schouffoer 2 , TW 

Huizinga 1 , Hein Putter 3 and Jeska K. de Vries-Bouwstra 1 , 

1 

Leiden University Medical Center, Leiden, Netherlands, 

2 

Haga Hospital, The Hague, Netherlands, 3 professor in 

medical statistics, Leiden, Netherlands 

Noon 

3263. The Promis-29 in Systemic Sclerosis: 

Associations with Clinical Characteristics in the 

Scleroderma Patient-Centered Intervention 

Network (SPIN) Cohort 

Linda Kwakkenbos 1 , Brett D. Thombs 1 , Susan J. 

Bartlett 1 , Marie-Eve Carrier 2 , Marie Hudson 1 , Luc 

Mouthon 3 , Vanessa L. Malcarne 4 , Maureen Sauvé 5 , 

Dinesh Khanna 6 and SPIN investigators, 1 McGill 

University, Montreal, QC, 2 Jewish General Hospital, 

Montreal, QC, 3 Paris Descartes University, UPRES- 

EA 4058, Department of Internal Medicine, Cochin 

Hospital, Paris, France, 4 SDSU/UC San Diego Joint 

Doctoral Program in Clinical Psychology, San Diego, 

CA, 5 Scleroderma Societies of Canada and Ontario, 

Hamilton, QC, 6 Division of Rheumatology, University of 


12:15 pm 

3264. Multiplex Serum Protein Analysis in 

Systemic Sclerosis Defines Potential Anti- 

Fibrotic Mechanisms and Markers of Response to 

Hyperimmune Caprine Serum 

Niamh Quillinan 1 , Kristina E.N. Clark 1 , Deirdre 

McIntosh 2 , Jeffrey Vernes 2 and Christopher Denton 3 , 

1 

UCL Division of Medicine, London, United Kingdom, 

2 

Daval International, London, United Kingdom, 

3 

University College London, London, United Kingdom 

ARHP SESSIONS 

11:00 am – 12:30 pm 


Bridging Research and Advocacy: The 

Osteoarthritis Action Alliance Update 

Moderator: Leigh F. Callahan, PhD 

What is the Osteoarthritis Action Alliance? 

Kirsten R. Ambrose, MS 

Osteoarthritis (OA) Action Alliance Resources and 

Efforts to Impact OA Awareness, Education and 

Management 

Julie J. Keysor, PhD, PT 

Osteoarthritis Action Alliance Mini-Grants and Other 

Opportunities for Engagement 

Yvonne M. Golightly, PT, MS, PhD 


11:00 am – 12:30 pm 


ARHP VI: Physical Function and Disability 

Moderators: Ross Wilkie, PhD and Rawan Alheresh, OT, 

MS 

11:00 am 

3265. Sustaining Employment with Arthritis: Can 

Existing Workplace Policies and Accommodations 

Make a Difference? 

Monique A.M. Gignac 1 , Elizabeth M. Badley 2 , Dorcas 

Beaton 3 , Vicki Kristman 4 , Cameron Mustard 5 , Peter 

Smith 5 and Selahadin Ibrahim 5 , 1 Instititue for Work 

and Health, Toronto, ON, 2 Toronto Western Research 

Institute, Toronto, ON, 3 St. Michael’s Hospital, Toronto, 

ON, 4 Lakehead University, Toronto, ON, 5 Institute for 


11:15 am 

3266. Keeping Baby Boomers in the Labour Force 

Longer: What Does It Mean for Workers with 

Arthritis? 

Monique A.M. Gignac 1 , Elizabeth M. Badley 2 , Dorcas 

Beaton 3 , Vicki Kristman 4 , Cameron Mustard 5 , Peter 


192 




Smith 5 and Selahadin Ibrahim 5 , 1 Instititue for Work 

and Health, Toronto, ON, 2 Toronto Western Research 

Institute, Toronto, ON, 3 St. Michael’s Hospital, Toronto, 

ON, 4 Lakehead University, Toronto, ON, 5 Institute for 


11:30 am 

3267. Functional Disability in Adolescents Is 

Predicted By Self-Report of Sleep Problems, 

Depressive Symptoms, Low Physical Activity and 

Worst Pain Intensity Levels 

Kari Firestone 1 , Kim Jones 2 and Anna Wilson 1 , 1 Oregon 

Health & Science University, Portland, OR, 2 Oregon 

Health Sciences Univ, Portland, OR 

11:45 am 

3268. Foot and Ankle Characteristics Associated 

with Falls in People with Rheumatoid Arthritis: A 

Prospective Longitudinal Study 

Angela Brenton-Rule 1 , Nicola Dalbeth 2 , Hylton B. 

Menz 3 , Sandra Bassett 1 and Keith Rome 1 , 1 AUT 

University, Auckland, New Zealand, 2 University of 

Auckland, Auckland, New Zealand, 3 La Trobe University, 

Bundoora, Australia 

Noon 

3269. Trends in Prevalence of Knee Pain Among US 

Adults, National Health Interview Survey, 2002- 

2010 

Jennifer M. Hootman 1 , Charles G. Helmick 1 and 

Yvonne M. Golightly 2 , 1 Centers for Disease Control and 

Prevention, Atlanta, GA, 2 University of North Carolina, 

Chapel Hill, NC 

12:15 pm 

3270. Correction of Limb Length Inequality in 

Adults with Knee or Hip Symptoms: A Pilot Study 

Yvonne M. Golightly, Michael T. Gross, Amanda 

Nelson, Leigh F. Callahan and Joanne M. Jordan, 

University of North Carolina, Chapel Hill, NC 

INDUSTRY-SUPPORTED POST-MEETING 

SYMPOSIA 

1:00 – 4:00 pm 

For CME-accredited symposia, the sponsoring organization 

is responsible for planning and providing CME credit. 

Please visit the organization’s exhibit booth, the industrysupported 

symposia booth or download the ACR Annual 

Meeting App for more information on each symposium. 


193 

These non-CME accredited presentations have been planned and will be implemented with the requirements of the 

FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. 


Innovation Theater A 

10:30 – 11:15 am 

The Changing Face of Spondylitis 

Presented by UCB, Inc. 

12:30 – 1:15 pm 

Bio-Logic: Designing Biosimilars for Clinical 

Success 

Presented by Amgen, Inc. 

2:30 – 3:15 pm 

Achieving Treatment Goals in Rheumatoid 

Arthritis (RA): Does One Size Fit All? 

Presented by Medac Pharma, Inc. 

Innovation Theater B 

11:30 am – 12:15 pm 

The Power of Biologic Therapy…With or 

Without Methotrexate (MTX)? 

Presented by Genentech, a Member of the Roche 

Group 

1:30 – 2:15 pm 

Inside Gout: The Journey of a Uric Acid 

Molecule From Production to Excretion and 

Beyond 

Presented by AstraZeneca 

3:30 – 4:15 pm 

The Science of Biosimilars 

Presented by Hospira 

MONDAY, NOVEMBER 9 


10:30 – 11:15 am 

Discussing a Biologic Therapy With a Unique 

Mechanism of Action: A Dermatologist’s and 

Rheumatologist’s Perspective on Active Psoriatic 

Arthritis and Medium to Severe Plaque Psoriasis 

Presented by Janssen Biotech, Inc. 

12:30 – 1:15 pm 

Clinical Impact of Rheumatoid Arthritis Pain 

Presented by Pfizer, Inc. 

2:30 – 3:15 pm 

The Role of IL-6 in Bone Metabolism and 

Assessment of Bone Destruction in RA 

Clinical Practice 

Presented by Regeneron/Sanofi 


11:30 am – 12:15 pm 

The Reality of Spondyloarthritis (SpA): Taking 

a Closer Look at Psoriatic Arthritis (PsA) and 

Ankylosing Spondylitis (AS) 

Presented by Novartis Pharmaceuticals 

1:30 – 2:15 pm 

From Prognosis to Pathogenesis: The Role of 

Autoantibodies in Rheumatoid Arthritis 

Presented by Bristol-Myers Squibb Company 

3:30 – 4:15 pm 

Clinical Considerations for Patients With Gout 

and Mild to Moderate Renal Impairment 

Presented by Takeda Pharmaceuticals

194 

These non-CME accredited presentations have been planned and will be implemented with the requirements of the 

FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. 



10:30 – 11:15 am 

The New Value Paradigm for Rheumatologists: 

Affordable Care Act (ACA), Medicare Access 

and CHIP Reauthorization Act (MACRA) and 

Beyond 

Presented by AbbVie 

12:30 – 1:15 pm 

Race to Remission in RA: The Ideal Finish Line 

for Patients 

Presented by UCB, Inc. 



11:30 – 12:15 pm 

Imaging of Rheumatic Diseases: A Review 

of Options 

Presented by Amgen, Inc. 

1:30 – 2:15 pm 

Biochemical Pathways and Mediators 

Associated With Development and Progression 

of Osteoarthritis of the Knee 

Presented by Ferring Pharmaceuticals

2 0 1 5 


tracker 

plus 

195 

INDUSTRY-SUPPORTED SYMPOSIA LISTING 


6:30 pm Non-CME Symposium 

The event listed below is a non-CME program wholly sponsored 

and supported by the commercial entities listed. By holding 

the program, the commercial entity has represented that the 

program has been developed and will be implemented in 

accordance with the requirements of the FDA and applicable 

standards of the PhRMA Code on Interactions with Healthcare 

Professionals. The commercial entity is to observe all guidelines 

established by federal and state regulatory agencies regarding 

non-CME educational or promotional presentations throughout 

the duration of the program. The content and views expressed 

during the program are those of the commercial entities and 

presenters. The ACR by making this venue available does not 

guarantee, warrant or endorse the content of the program nor 

the products discussed and reviewed during the program. 

Innovation and Biosimilarity: Points to Ponder in 

Rheumatology 

Developed and offered by AbbVie 

San Francisco Marriott Marquis, Golden Gate AB 

6:30 – 6:35 pm 

Welcome/Introduction/Objectives 

Arthur F. Kavanaugh, MD, University of California, 

San Diego, La Jolla, CA 

6:35 – 6:50 pm 

Biologics and Biosimilars: Molecular Overview 

Leonard Calabrese, DO, Cleveland Clinic, Cleveland, OH 

6:50 – 7:05 pm 

Recent FDA Scientific and Quality Guidance: New 

Considerations for Clinicians 

Arthur F. Kavanaugh, MD, University of California, 

San Diego, La Jolla, CA 

7:05 – 7:30 pm 

Insights into Manufacturing of Complex Biologics 

Michael Schiff, MD, University of Colorado, Denver, CO 

7:30 – 7:45 pm 

Reference Biologic and Biosimilars: Application and 

Issues in Rheumatology Practice 

Gregory F. Schimizzi, MD, Carolina Arthritis Associates, 

Wilmington, NC 
















Untangling Biosimilars: Practical Considerations for 

Clinicians 

Developed and offered by Amgen, Inc. 

San Francisco Marriott Marquis, Yerba Buena Salon 7 

6:30 – 7:00 pm 

Registration and Dinner 

7:00 – 7:30 pm 

What Is a Biosimilar? 

Mark Genovese, MD, Professor, Stanford University School 

of Medicine 

7:30 – 8:00 pm 

Challenges in Biosimilar Development and 

Manufacturing 

Richard Markus, MD, PhD, Vice President, Global 

Development, Amgen 

8:00 – 8:30 pm 

Clinical Considerations for Biosimilars 

Alan K. Matsumoto, MD, FACP, FACR, Clinician, Arthritis 

and Rheumatism Associates, P.C. 

8:30 – 9:00 pm 

Faculty Panel Discussion 

7:45 – 7:55 pm 

Panel Discussion and Q&A 

All Speakers 

7:55 – 8:00 pm 

Conclusion

196 


















Otezla® (apremilast): Psoriatic Arthritis and Psoriasis: 

Two Interrelated Diseases, One Treatment 

Developed and offered by Celgene Corporation 


6:30 – 7:00 pm 

Registration and Dinner 

7:00 – 7:15 pm 

Overview of Psoriatic Arthritis and Psoriasis and 

Unmet Therapeutic Needs 

Philip Mease, MD, Seattle Rheumatology Associates, 

Seattle, WA 

Jeffery J. Crowley, MD, FAAD, Bakersfield Dermatology 

& Skin Cancer Medical Group, Bakersfield, CA 

7:15 – 7:25 pm 

Review of Otezla’s Mechanism of Action 


Seattle, WA 

7:25 – 7:45 pm 

The Efficacy and Safety of Otezla for the Treatment 

of Patients with Psoriatic Arthritis 


Seattle, WA 

7:45 – 8:05 pm 

The Efficacy and Safety of Otezla for the Treatment 

of Patients with Psoriasis 

Jeffery J. Crowley, MD, FAAD, Bakersfield Dermatology & 

Skin Cancer Medical Group, Bakersfield, CA 

8:05 – 8:30 pm 

Q&A Session 


Seattle, WA 

Jeffery J. Crowley, MD, FAAD, Bakersfield Dermatology & 

Skin Cancer Medical Group, Bakersfield, CA 


6:30 pm CME-Accredited Symposium 

For CME-accredited symposia, the sponsoring organization is 

responsible for planning and providing CME credit. 

Targeting Inflammatory Cytokines and Intracellular 

Pathways to Personalize the Management of 


Supported by an educational grant from Eli Lilly 

Sponsored by Med Learning Group 


Physician (ACCME) Accreditation Statement: 

Med Learning Group is accredited by the Accreditation 

Council for Continuing Medical Education to provide 

continuing medical education for physicians. 

Credit Designation Statement: 

Med Learning Group will designate the symposium 

for a maximum of 1.5 AMA PRA Category 1 Credits. 

Speakers: 

Gregg J. Silverman, MD, Professor of Medicine and 

Pathology, NYU School of Medicine, Alexandria Center 

for Life Science, New York, NY 

William F.C. Rigby, MD, Professor of Medicine, Professor of 

Microbiology and Immunology, Geisel School of Medicine, 

Dartmouth Hitchcock Medical Center, Lebanon, NH 

Topics: 

Pathophysiology of Rheumatoid Arthritis (RA): Focus 

on the Roles of Inflammatory Cytokines in Cellular 

Responses and Tissue Injury 

Historical Perspectives on the Development of RA 

treatments. Focus on Tender and Swollen Joints and on 

Joint Destruction 

How do conventional DMARDs Work? 

Overview of Biologic Therapies: Mechanisms and Efficacy 

Cytokine Intracellular Signaling Pathways 

Optimizing Biologics and Small Molecule Inhibitors Use 

Across the RA Spectrum: Treat to Target 

Conclusions 

Questions and Answers

2 0 1 5 


tracker 

plus 

197 

















Taking a Closer Look at the Reality of Spondyloarthritis 

(SpA): Revealing the Pathophysiology of Psoriatic 

Arthritis (PsA) and Ankylosing Spondylitis (AS), 

Including the Role of IL-17A Signaling 

Developed and offered by Novartis Pharmaceuticals 

San Francisco Marriott Marquis, Golden Gate AB 

6:30 – 7:00 pm 

Registration 

7:00 – 7:05 pm 

Welcome and Introductions 

7:05 – 7:15 pm 

Overview of Symposium 

Stanley Cohen, MD, Chair 

7:15 – 7:30 pm 

Spondyloarthritis (SpA) Overview 


7:30 – 7:45 pm 

Patient Burden of Psoriatic Arthritis (PsA) 

Laura Coates, MD 

7:45 – 8:00 pm 

Patient Burden of Ankylosing Spondylitis (AS) 

Atul Deodhar, MD 

8:00 – 8:30 pm 

Pathophysiology of SpA 

Mark Genovese, MD 

8:30 – 8:55 pm 



Laura Coates, MD 

Atul Deodhar, MD 

Mark Genovese, MD 

8:55 – 9:00 pm 

Closing Remarks 





SPARTAN-GRAPPA-ASAS Educational Symposium 

on Axial Spondyloarthritis (axSpA) and Psoriatic 

Arthritis (PsA) 

Supported by an educational grant from AbbVie 

Sponsored by Oregon Health & Science University School 

of Medicine, Division of CME 

San Francisco Marriott Marquis, Nob Hill A-D 


This activity has been planned and implemented in 

accordance with the Essential Areas and policies of the 

Accreditation Council for Continuing Medical Education 

through Oregon Health & Science University School of 

Medicine. The OHSU School of Medicine is accredited 

by the ACCME to provide continuing medical education 

for physicians. 


OHSU School of Medicine, Division of CME, designates this 

live activity for a maximum of 3 AMA PRA Category 1 Credits. 

Program Chairs: Atul Dedhar, MD and Robert Landewe, MD 

1:00 – 1:05 pm 


Atul Deodhar, MD, Oregon Health & Science University 

1:05 – 1:20 pm 

Pre-Test 

Alexis Ogdie, MD, University of Pennsylvania

198 



1:20 – 1:45 pm 

IL-23 IL-17 Axis in Spondyloarthritis Pathogenesis & 

Management 

Dominique Baeten, MD, University of Amsterdam 

1:45 – 2:10 pm 

Role of MRI in the Management of Axial 

Spondyloarthritis 

Xenofon Baraliokos, MD, Rheumaxentrum Ruhrgebiet 

Herne 

2:10 – 2:35 pm 

Year-in-Review in Psoriatic Arthritis 

Vinod Chandran, MD, University of Toronto 

2:35 – 3:00 pm 

Year-in-Review in Spondyloarthritis 

Robert Inman, MD, University of Toronto 

3:00 – 3:15 pm 

Post-Test 

Alexis Ogdie, MD, University of Pennsylvania 

3:15 – 4:00 pm 

“Hands-on” Assessment of Axial SpA and PsA 




Latest Evidence on Osteoarthritis Treatment: Can 

We Turn Back the Clock? 

Supported by an educational grant from Bioiberica S.A. 

Jointly provided by Medical Education Resources and 

Incentevents, LLC. 

San Francisco Marriott Marquis, Yerba Buena Salons 1-3 



accordance with the accreditation requirements and 

policies of the Accreditation Council for Continuing Medical 

Education (ACCME) through the joint providership of 

Medical Education Resources (MER) and Incentevents, LLC. 

MER is accredited by the ACCME to provide continuing 

medical education for physicians. 


Medical Education Resources designates this live activity for 

a maximum of 1.5 AMA PRA Category 1 Credits. Physicians 

should claim only the credit commensurate with the extent 

of their participation in the activity. 

1:00 – 1:05 pm 

Welcome and Introduction- Chairman 

Marc Hochberg, MD, MPH, MACP, University of Maryland 

School of Medicine, Baltimore, MD, United States 

1:05 – 1:20 pm 

Osteoarthritis: Drug Use and Risks 

Philip Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Teaching 

Hospitals NHS Trust, NIHR Leeds Musculoskeletal 

Biomedical Research Unit, Leeds, England, United Kingdom 

1:20 – 1:35 pm 

Evidence of Chondroitin Sulfate Disease-Modifying 

Effects in Osteoarthritis and Underlying Mechanisms 

Johanne Martel-Pelletier, PhD, University of Montreal, 

University of Montreal Hospital Research Centre (CRCHUM) 

Montreal, Quebec, Canada 

1:35 – 1:55 pm 

MOSAIC: 24-Month Study on Structural Changes 

in Knee Osteoarthritis Assessed by MRI With 

Chondroitin Sulfate 

Jean-Pierre Pelletier, MD, University of Montreal School of 

Medicine, University of Montreal Hospital Centre (CHUM), 

University of Montreal Hospital Research Centre (CRCHUM), 

Montreal, Quebec, Canada 

1:55 – 2:10 pm 

Randomized Trial of Combined Glucosamine and 

Chondroitin on Inflammation and Oxidative Stress 

Sandi L. Navarro, PhD, Fred Hutchinson Cancer Research 

Center, Seattle, WA, United States 

2:10 – 2:20 pm 

Question and Answer Session 

2:20-2:30 pm 

Concluding Remarks 

Marc Hochberg, MD, MPH, MACP, University of Maryland 

School of Medicine, Baltimore, MD, United States 




The Challenge of Mycobacterial Infections in the 

Biologic Era 

Supported by an educational grant from Oxford 

Immunotec, Inc. 

Sponsored by CME Outfitters, LLC 

San Francisco Marriott Marquis, Yerba Buena Salons 4-6

2 0 1 5 


tracker 

plus 

199 




accordance with the Essential Areas and policies of the 

Accreditation Council for Continuing Medical Education 

through the joint sponsorship of CME Outfitters, LLC, and 

Jespersen & Associates. CME Outfitters, LLC is accredited 

by the ACCME to provide continuing medical education for 

physicians. 


CME Outfitters, LLC designates this live activity for a 

maximum of 2.0 AMA PRA Category 1 Credit(s). Physicians 

should claim only the credit commensurate with the extent 

of their participation in the activity. 

1:00 – 1:05 pm 


1:05 – 1:35 pm 

Clinical Manifestations/Presentations of 

Mycobacterium (Mtb and Atypical) in the 

Immunocompromised Patient 

Kevin Winthrop, MD, MPH, Oregon Health & Science 

University, Portland, OR 

1:35 – 2:05 pm 

Screening & Prevention of Mycobacteria Infection 

and Disease 

Juzar Ali, MD, FRCP(C), FCCP, LSU Health Sciences 

Center, New Orleans, LA 

2:05 – 2:35 pm 

Clinical Case Scenarios 

Leonard Calabrese, DO, Cleveland Clinic, Cleveland, OH 

2:35 – 3:00 pm 

Question & Answer Session 




Biosimilar Perspectives in RA: Deconstructing Data for 

Informed Clinical Decision Making 

Supported by an educational grant from Boehringer Ingelheim 

Sponsored by NACCME 

San Francisco Marriott Marquis, Yerba Buena 

Salons 10 – 12 


North American Center for Continuing Medical Education, 

LLC (NACCME) is accredited by the Accreditation Council for 

Continuing Medical Education (ACCME), and the American 

Nurses Credentialing Center (ANCC) to provide continuing 

education for the healthcare team. 


NACCME designates this enduring material for a maximum 

of 2 AMA PRA Category 1 Credits. Physicians should claim 

only the credit commensurate with the extent of their 

participation in the activity. 

1:00 PM CME-Accredited Symposium 



Clinical Convergence: Patient and Provider 

Perspectives in Psoriatic Arthritis (PsA) 

Supported by educational grants from AbbVie and UCB, Inc. 

Sponsored by RMEI, LLC 

San Francisco Marriott Marquis, Yerba Buena Salons 

13 - 15 

Physician (ACCME) Accreditation Statement 


accordance with the accreditation requirements and 

policies of the Accreditation Council for Continuing Medical 

Education (ACCME) through the joint providership of 

Albert Einstein College of Medicine and Robert Michael 

Educational Institute (RMEI, LLC). Albert Einstein College of 

Medicine is accredited by the ACCME to provide continuing 

medical education for physicians. 

Credit Designation Statement 

Albert Einstein College of Medicine of Yeshiva University 

designates this live activity for a maximum of 1.5 AMA PRA 

Category 1 Credit(s). Physicians should claim only the 

credit commensurate with the extent of their participation 

in the activity. 

1:00 – 1:30 pm 

Registration and Lunch 

1:30 – 1:35 pm 


1:35 – 1:55 pm 

Psoriatic Arthritis: Making the Right Diagnosis 

1:55 – 2:25 pm 

An Approach to Comprehensive Management of PsA 

2:25 – 2:50 pm 


2:50 – 3:00 pm 

Q&A Session/Conclusions

200 


ACKNOWLEDGEMENTS 

The ACR and ARHP wish to thank the following organizations for providing support for the 2015 ACR/ARHP Annual Meeting. 

AbbVie 

Annual Meeting App 

Networking Lounges 

Digital Signs 

Convention Banner Moscone West 

South Lobby Banner 

Amgen, Inc. 

North Lobby Escalator Clings and 

Risers 

Expanded Session Tracker, Back 

Cover 

ARHP Networking Forum 

Bristol-Myers Squibb Company 

Hanging Aisle Signs 

Technology Kiosks 


Celgene Corporation 

Exhibit Hall Floor Decals 


Genentech, A Member of the 

Roche Group 

Hotel Key Cards 

Pfizer, Inc. 

North Lobby Window Clings 

Recharge Cubes 

Digital Signs 

Regeneron/Sanofi 

Digital Signs

2 0 1 5 


tracker 

plus 

201 

ACKNOWLEDGEMENTS 

In addition to the support provided for the 2015 ACR/ARHP Annual Meeting, the ACR, the ARHP and the Foundation wish to 

thank the following organizations for providing support for activities and programs throughout the year. 

AbbVie 

Corporate Roundtable, Leadership 

Level 

State-of-the-Art Clinical Symposium 


FIT Scholarship 

Membership Directory 

Annual Meeting Corporate 

Roundtable Symposium 

Annual Meeting Industry-Supported 

Post-Conference Symposium 

Amgen, Inc. 


Level 

Fellows Education Fund: ACR/ARHP 

Annual Meeting FIT Scholarship, 

Distinguished Fellow Award, State-ofthe-Art 

Clinical Symposium 

FIT Scholarship, Rheumatology 

Research Workshop 

Amgen Fellowship Training Awards 

Pediatric Visiting Professorship 

Program 

Pediatric Research Award 



AstraZeneca 

Corporate Roundtable, Principal Level 

Division Directors, Program Directors, 

and Fellows-in-Training 

Pre-Meeting Networking Event 

Bioiberica, S.A. 



Boehringer Ingelheim 



Bristol-Myers Squibb Company 

Corporate Roundtable, Partner Level 

Celgene Corporation 



CARE 2015 



Genentech, a Member of the 

Roche Group 



Fellows-in-Training Potpourri Case 

Event 


Fellows-in-Training Networking Event 

ACR/ARHP Annual Meeting FIT 

Scholarship 

Janssen Biotech, Inc. 

Corporate Roundtable, Partner Level 


Fellows-in-Training Networking Event 

ACR/ARHP Annual Meeting FIT 

Scholarship 

Lilly USA, LLC 


Winter Rheumatology Symposium 

Maintenance of Certification Course 

Program Directors’ Conference 


Rheumatology Research Workshop 

CARE 2015 

Annual Meeting Rheumatoid Arthritis 

Educational Track 



Mallinckrodt Pharmaceuticals 


Novartis Pharmaceuticals 




Oxford Immunotec 



Pfizer, Inc. 


Level 


Program Directors’ Conference 


Musculoskeletal Ultrasound Course 


Questcor Pharmaceuticals 


UCB, Inc. 


Winter Rheumatology Symposium 




Post-Conference Symposium

202 


NOTES PAGE

2 0 1 5 


tracker 

plus 

203 

NOTES PAGE

Corporate Roundtable 

The Corporate Roundtable has 

made a substantial impact on the 

Foundation’s efforts to improve 

the health of people with rheumatic 

diseases. Thanks in large part due 

to the generosity of the Corporate 

Roundtable donors, the Foundation 

has increased its annual funding for 

research and training awards from 

$500,000 to $13.2 million. This 

funding helps to develop the next 

generation of rheumatology 

professionals, while accelerating 

research that leads to major 

breakthroughs for patients. 

LEADERSHIP $7,500,000+ 

PRINCIPAL $2,500,000+ 

PARTNER $1,000,000+

Enbrel ® (etanercept) Brief Summary 

SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION 

WARNINGS 

SERIOUS INFECTIONS AND MALIGNANCIES 

Patients treated with Enbrel are at increased risk for developing serious infections 

that may lead to hospitalization or death [see Warnings and Precautions and Adverse 

Reactions]. Most patients who developed these infections were taking concomitant 

immunosuppressants such as methotrexate or corticosteroids. 

Enbrel should be discontinued if a patient develops a serious infection or sepsis. 

Reported infections include: 

• Active tuberculosis, including reactivation of latent tuberculosis. Patients with 

tuberculosis have frequently presented with disseminated or extrapulmonary 

disease. Patients should be tested for latent tuberculosis before Enbrel use and 

during therapy. Treatment for latent infection should be initiated prior to Enbrel use. 

• Invasive fungal infections, including histoplasmosis, coccidioidomycosis, 

candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with 

histoplasmosis or other invasive fungal infections may present with 

disseminated, rather than localized, disease. Antigen and antibody testing for 

histoplasmosis may be negative in some patients with active infection. Empiric 

anti-fungal therapy should be considered in patients at risk for invasive fungal 

infections who develop severe systemic illness. 

• Bacterial, viral, and other infections due to opportunistic pathogens, including 

Legionella and Listeria. 

The risks and benefits of treatment with Enbrel should be carefully considered prior 

to initiating therapy in patients with chronic or recurrent infection. 

Patients should be closely monitored for the development of signs and symptoms of 

infection during and after treatment with Enbrel, including the possible 

development of tuberculosis in patients who tested negative for latent tuberculosis 

infection prior to initiating therapy. 

MALIGNANCIES 

Lymphoma and other malignancies, some fatal, have been reported in children and 

adolescent patients treated with TNF blockers, including Enbrel. 

INDICATIONS AND USAGE 


Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, 

inhibiting the progression of structural damage, and improving physical function in 

patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be 

initiated in combination with methotrexate (MTX) or used alone. 

Polyarticular Juvenile Idiopathic Arthritis 

Enbrel is indicated for reducing signs and symptoms of moderately to severely active 

polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older. 


Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of 

structural damage of active arthritis, and improving physical function in patients with 

psoriatic arthritis (PsA). Enbrel can be used with or without MTX. 


Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing 

spondylitis (AS). 

Plaque Psoriasis 

Enbrel is indicated for the treatment of adult patients (18 years or older) with chronic 

moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy 

or phototherapy. 

CONTRAINDICATIONS 

Enbrel should not be administered to patients with sepsis. 

WARNINGS AND PRECAUTIONS 

Serious Infections 

Patients treated with Enbrel are at increased risk for developing serious infections 

involving various organ systems and sites that may lead to hospitalization or death. 

Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, 

or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, 

coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and 

tuberculosis have been reported with TNF blockers. Patients have frequently presented 

with disseminated rather than localized disease. 

Treatment with Enbrel should not be initiated in patients with an active infection, 

including clinically important localized infections. Patients greater than 65 years of age, 

patients with co-morbid conditions, and/or patients taking concomitant 

immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk 

of infection. The risks and benefits of treatment should be considered prior to initiating 

therapy in patients: with chronic or recurrent infection; who have been exposed to 

tuberculosis; with a history of an opportunistic infection; who have resided or traveled 

in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, 

coccidioidomycosis, or blastomycosis; or with underlying conditions that may 

predispose them to infection, such as advanced or poorly controlled diabetes [see 

Adverse Reactions]. 

Patients should be closely monitored for the development of signs and symptoms 

of infection during and after treatment with Enbrel. 

Enbrel should be discontinued if a patient develops a serious infection or sepsis. 

A patient who develops a new infection during treatment with Enbrel should be 

closely monitored, undergo a prompt and complete diagnostic workup appropriate 

for an immunocompromised patient, and appropriate antimicrobial therapy should 

be initiated. 

Tuberculosis 

Cases of reactivation of tuberculosis or new tuberculosis infections have been observed 

in patients receiving Enbrel, including patients who have previously received treatment 

for latent or active tuberculosis. Data from clinical trials and preclinical studies suggest 

that the risk of reactivation of latent tuberculosis infection is lower with Enbrel than with 

TNF-blocking monoclonal antibodies. Nonetheless, postmarketing cases of 

tuberculosis reactivation have been reported for TNF blockers, including Enbrel. 

Tuberculosis has developed in patients who tested negative for latent tuberculosis prior 

to initiation of therapy. Patients should be evaluated for tuberculosis risk factors and 

tested for latent infection prior to initiating Enbrel and periodically during therapy. Tests 

for latent tuberculosis infection may be falsely negative while on therapy with Enbrel. 

Treatment of latent tuberculosis infection prior to therapy with TNF-blocking agents has 

been shown to reduce the risk of tuberculosis reactivation during therapy. Induration of 

5 mm or greater with tuberculin skin testing should be considered a positive test result 

when assessing if treatment for latent tuberculosis is needed prior to initiating Enbrel, 

even for patients previously vaccinated with Bacille Calmette-Guerin (BCG). 

Anti-tuberculosis therapy should also be considered prior to initiation of Enbrel in patients 

with a past history of latent or active tuberculosis in whom an adequate course of 

treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis 

but having risk factors for tuberculosis infection. Consultation with a physician with 

expertise in the treatment of tuberculosis is recommended to aid in the decision whether 

initiating anti-tuberculosis therapy is appropriate for an individual patient. 

Tuberculosis should be strongly considered in patients who develop a new infection 

during Enbrel treatment, especially in patients who have previously or recently traveled 

to countries with a high prevalence of tuberculosis, or who have had close contact with 

a person with active tuberculosis. 

Invasive Fungal Infections 

Cases of serious and sometimes fatal fungal infections, including histoplasmosis, have 

been reported with TNF blockers, including Enbrel. For patients who reside or travel in 

regions where mycoses are endemic, invasive fungal infection should be suspected if 

they develop a serious systemic illness. Appropriate empiric antifungal therapy should 

be considered while a diagnostic workup is being performed. Antigen and antibody 

testing for histoplasmosis may be negative in some patients with active infection. When 

feasible, the decision to administer empiric antifungal therapy in these patients should 

be made in consultation with a physician with expertise in the diagnosis and treatment 

of invasive fungal infections and should take into account both the risk for severe fungal 

infection and the risks of antifungal therapy. In 38 Enbrel clinical trials and 4 cohort 

studies in all approved indications representing 27,169 patient-years of exposure 

(17,696 patients) from the United States and Canada, no histoplasmosis infections were 

reported among patients treated with Enbrel. 

Neurologic Events 

Treatment with TNF-blocking agents, including Enbrel, has been associated with rare 

(< 0.1%) cases of new onset or exacerbation of central nervous system demyelinating 

disorders, some presenting with mental status changes and some associated with 

permanent disability. Cases of transverse myelitis, optic neuritis, multiple sclerosis, 

Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset 

or exacerbation of seizure disorders have been reported in postmarketing experience 

with Enbrel therapy. Prescribers should exercise caution in considering the use of Enbrel 

in patients with preexisting or recent-onset central or peripheral nervous system 

demyelinating disorders [see Adverse Reactions]. 

Malignancies 

Lymphomas 

In the controlled portions of clinical trials of TNF-blocking agents, more cases of lymphoma 

have been observed among patients receiving a TNF blocker compared to control patients. 

During the controlled portions of Enbrel trials in adult patients with RA, AS, and PsA, 

2 lymphomas were observed among 3306 Enbrel-treated patients versus 0 among 

1521 control patients (duration of controlled treatment ranged from 3 to 36 months). 

Among 6543 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled 

and uncontrolled portions of clinical trials, representing approximately 12,845 patientyears 

of therapy, the observed rate of lymphoma was 0.10 cases per 100 patient-years. 

This was 3-fold higher than the rate of lymphoma expected in the general US population 

based on the Surveillance, Epidemiology, and End Results (SEER) Database. An 

increased rate of lymphoma up to several-fold has been reported in the RA patient 

population, and may be further increased in patients with more severe disease activity. 

Among 4410 adult PsO patients treated with Enbrel in clinical trials up to 36 months, 

representing approximately 4278 patient-years of therapy, the observed rate of 

lymphoma was 0.05 cases per 100 patient-years, which is comparable to the rate in the 

general population. No cases were observed in Enbrel- or placebo-treated patients 

during the controlled portions of these trials. 

Leukemia 

Cases of acute and chronic leukemia have been reported in association with 

postmarketing TNF-blocker use in rheumatoid arthritis and other indications. Even in 

the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at higher 

risk (approximately 2-fold) than the general population for the development of leukemia. 

During the controlled portions of Enbrel trials, 2 cases of leukemia were observed among 

5445 (0.06 cases per 100 patient-years) Enbrel-treated patients versus 0 among 2890 

(0%) control patients (duration of controlled treatment ranged from 3 to 48 months). 

Among 15,401 patients treated with Enbrel in controlled and open portions of clinical 

trials representing approximately 23,325 patient-years of therapy, the observed rate of 

leukemia was 0.03 cases per 100 patient-years. 

Other Malignancies 

Information is available from 10,953 adult patients with 17,123 patient-years and 696 

pediatric patients with 1282 patient-years of experience across 45 Enbrel clinical studies. 

For malignancies other than lymphoma and non-melanoma skin cancer, there was no 

difference in exposure-adjusted rates between the Enbrel and control arms in the 

controlled portions of clinical studies for all indications. Analysis of the malignancy rate in 

combined controlled and uncontrolled portions of studies has demonstrated that types and 

rates are similar to what is expected in the general US population based on the SEER 

database and suggests no increase in rates over time. Whether treatment with Enbrel might 

influence the development and course of malignancies in adults is unknown. 

Melanoma and Non-melanoma skin cancer (NMSC) 

Melanoma and non-melanoma skin cancer has been reported in patients treated with 

TNF antagonists including etanercept. 

Among 15,401 patients treated with Enbrel in controlled and open portions of clinical 

trials representing approximately 23,325 patient-years of therapy, the observed rate of 

melanoma was 0.043 cases per 100 patient-years. 

Among 3306 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled 

clinical trials representing approximately 2669 patient-years of therapy, the observed rate of 

NMSC was 0.41 cases per 100 patient-years vs 0.37 cases per 100 patient-years among 1521 

control-treated patients representing 1077 patient-years. Among 1245 adult psoriasis patients 

treated with Enbrel in controlled clinical trials, representing approximately 283 patient-years of 

therapy, the observed rate of NMSC was 3.54 cases per 100 patient-years vs 1.28 cases per 

100 patient-years among 720 control-treated patients representing 156 patient-years. 

Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in 

patients treated with Enbrel. 

Periodic skin examinations should be considered for all patients at increased risk for 

skin cancer. 

Pediatric Patients 

Malignancies, some fatal, have been reported among children, adolescents, and young 

adults who received treatment with TNF-blocking agents (initiation of therapy at 

≤ 18 years of age), including Enbrel. Approximately half the cases were lymphomas, 

including Hodgkin’s and non-Hodgkin’s lymphoma. The other cases represented a 

variety of different malignancies and included rare malignancies usually associated 

with immunosuppression and malignancies that are not usually observed in children 

and adolescents. The malignancies occurred after a median of 30 months of therapy 

(range 1 to 84 months). Most of the patients were receiving concomitant 

immunosuppressants. These cases were reported postmarketing and are derived from 

a variety of sources, including registries and spontaneous postmarketing reports. 

In clinical trials of 1140 pediatric patients representing 1927.2 patient-years of therapy, 

no malignancies, including lymphoma or NMSC, have been reported. 

Postmarketing Use 

In global postmarketing adult and pediatric use, lymphoma and other malignancies have 

been reported. 

Patients With Heart Failure 

Two clinical trials evaluating the use of Enbrel in the treatment of heart failure were 

terminated early due to lack of efficacy. One of these studies suggested higher mortality 

in Enbrel-treated patients compared to placebo [see Adverse Reactions]. There have 

been postmarketing reports of worsening of congestive heart failure (CHF), with and 

without identifiable precipitating factors, in patients taking Enbrel. There have also been 

rare (< 0.1%) reports of new onset CHF, including CHF in patients without known 

preexisting cardiovascular disease. Some of these patients have been under 50 years of 

age. Physicians should exercise caution when using Enbrel in patients who also have 

heart failure, and monitor patients carefully. 

Hematologic Events 

Rare (< 0.1%) reports of pancytopenia, including very rare (< 0.01%) reports of aplastic 

anemia, some with a fatal outcome, have been reported in patients treated with Enbrel. 

The causal relationship to Enbrel therapy remains unclear. Although no high-risk group 

has been identified, caution should be exercised in patients being treated with Enbrel 

who have a previous history of significant hematologic abnormalities. All patients 

should be advised to seek immediate medical attention if they develop signs and 

symptoms suggestive of blood dyscrasias or infection (eg, persistent fever, bruising, 

bleeding, pallor) while on Enbrel. Discontinuation of Enbrel therapy should be 

considered in patients with confirmed significant hematologic abnormalities. 

Two percent of patients treated concurrently with Enbrel and anakinra developed 

neutropenia (ANC < 1 x 10 9 /L). While neutropenic, one patient developed cellulitis that 

resolved with antibiotic therapy. 

Hepatitis B Reactivation 

Reactivation of hepatitis B in patients who were previously infected with the hepatitis B 

virus (HBV) and had received concomitant TNF-blocking agents, including very rare 

cases (< 0.01%) with Enbrel, has been reported. In some instances, hepatitis B 

reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The 

majority of these reports have occurred in patients concomitantly receiving other 

medications that suppress the immune system, which may also contribute to hepatitis 

B reactivation. Patients at risk for HBV infection should be evaluated for prior evidence 

of HBV infection before initiating TNF-blocker therapy. Prescribers should exercise 

caution in prescribing TNF blockers in patients previously infected with HBV. Adequate 

data are not available on the safety or efficacy of treating patients who are carriers of 

HBV with anti-viral therapy in conjunction with TNF-blocker therapy to prevent HBV 

reactivation. Patients previously infected with HBV and require treatment with Enbrel 

should be closely monitored for clinical and laboratory signs of active HBV infection 

throughout therapy and for several months following termination of therapy. In patients 

who develop HBV reactivation, consideration should be given to stopping Enbrel and 

initiating anti-viral therapy with appropriate supportive treatment. The safety of 

resuming Enbrel therapy after HBV reactivation is controlled is not known. Therefore, 

prescribers should weigh the risks and benefits when considering resumption of 

therapy in this situation. 

Allergic Reactions 

Allergic reactions associated with administration of Enbrel during clinical trials have 

been reported in < 2% of patients. If an anaphylactic reaction or other serious allergic 

reaction occurs, administration of Enbrel should be discontinued immediately and 

appropriate therapy initiated. 

Caution: The following components contain dry natural rubber (a derivative of latex), 

which may cause allergic reactions in individuals sensitive to latex: the needle cover of 

the prefilled syringe and the needle cover within the needle cap of the SureClick ® 

autoinjector. 

Immunizations 

Live vaccines should not be given concurrently with Enbrel. It is recommended that 

pediatric patients, if possible, be brought up-to-date with all immunizations in 

agreement with current immunization guidelines prior to initiating Enbrel therapy [see 

Drug Interactions]. 

Autoimmunity 

Treatment with Enbrel may result in the formation of autoantibodies [see Adverse 

Reactions] and, rarely (< 0.1%), in the development of a lupus-like syndrome or 

autoimmune hepatitis [see Adverse Reactions], which may resolve following withdrawal 

of Enbrel. If a patient develops symptoms and findings suggestive of a lupus-like 

syndrome or autoimmune hepatitis following treatment with Enbrel, treatment should 

be discontinued and the patient should be carefully evaluated. 

Immunosuppression 

TNF mediates inflammation and modulates cellular immune responses. TNF-blocking 

agents, including Enbrel, affect host defenses against infections. The effect of TNF 

inhibition on the development and course of malignancies is not fully understood. In a 

study of 49 patients with RA treated with Enbrel, there was no evidence of depression 

of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in 

enumeration of effector cell populations [see Adverse Reactions]. 

Use in Wegener’s Granulomatosis Patients 

The use of Enbrel in patients with Wegener’s granulomatosis receiving 

immunosuppressive agents is not recommended. In a study of patients with Wegener’s 

granulomatosis, the addition of Enbrel to standard therapy (including cyclophosphamide) 

was associated with a higher incidence of non cutaneous solid malignancies and was 

not associated with improved clinical outcomes when compared with standard therapy 

alone [see Drug Interactions].

Use with Anakinra or Abatacept 

Use of Enbrel with anakinra or abatacept is not recommended [see Drug Interactions]. 

Use in Patients with Moderate to Severe Alcoholic Hepatitis 

In a study of 48 hospitalized patients treated with Enbrel or placebo for moderate to 

severe alcoholic hepatitis, the mortality rate in patients treated with Enbrel was similar 

to patients treated with placebo at 1 month but significantly higher after 6 months. 

Physicians should use caution when using Enbrel in patients with moderate to severe 

alcoholic hepatitis. 

ADVERSE REACTIONS 

Across clinical studies and postmarketing experience, the most serious adverse 

reactions with Enbrel were infections, neurologic events, CHF, and hematologic events 

[see Warnings and Precautions]. The most common adverse reactions with Enbrel were 

infections and injection site reactions. 

Clinical Studies Experience 

Adverse Reactions in Adult Patients With Rheumatoid Arthritis, Psoriatic Arthritis, 

Ankylosing Spondylitis, or Plaque Psoriasis 

The data described below reflect exposure to Enbrel in 2219 adult patients with RA 

followed for up to 80 months, in 182 patients with PsA for up to 24 months, in 138 patients 

with AS for up to 6 months, and in 1204 adult patients with PsO for up to 18 months. 

In controlled trials, the proportion of Enbrel-treated patients who discontinued 

treatment due to adverse events was approximately 4% in the indications studied. 

Because clinical trials are conducted under widely varying conditions, adverse 

reactions rates observed in the clinical trials of a drug cannot be directly compared to 

rates in the clinical trials of another drug and may not predict the rates observed in 

clinical practice. 

Infections 

Infections, including viral, bacterial, and fungal infections, have been observed in 

adult and pediatric patients. Infections have been noted in all body systems and have 

been reported in patients receiving Enbrel alone or in combination with other 

immunosuppressive agents. 

In controlled portions of trials, the types and severity of infection were similar between 

Enbrel and the respective control group (placebo or MTX for RA and PsA patients) in RA, 

PsA, AS and PsO patients. Rates of infections in RA and PsO patients are provided in 

Table 3 and Table 4, respectively. Infections consisted primarily of upper respiratory 

tract infection, sinusitis and influenza. 

In controlled portions of trials in RA, PsA, AS and PsO, the rates of serious infection 

were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in Enbrel/Enbrel + MTX-treated 

groups). In clinical trials in rheumatologic indications, serious infections experienced by 

patients have included, but are not limited to, pneumonia, cellulitis, septic arthritis, 

bronchitis, gastroenteritis, pyelonephritis, sepsis, abscess and osteomyelitis. In clinical 

trials in PsO, serious infections experienced by patients have included, but are not 

limited to, pneumonia, cellulitis, gastroenteritis, abscess and osteomyelitis. The rate of 

serious infections was not increased in open-label extension trials and was similar to 

that observed in Enbrel- and placebo-treated patients from controlled trials. 

In 66 global clinical trials of 17,505 patients (21,015 patient-years of therapy), 

tuberculosis was observed in approximately 0.02% of patients. In 17,696 patients 

(27,169 patient-years of therapy) from 38 clinical trials and 4 cohort studies in the US 

and Canada, tuberculosis was observed in approximately 0.006% of patients. These 

studies include reports of pulmonary and extrapulmonary tuberculosis [see Warnings 

and Precautions]. 

Injection Site Reactions 

In placebo-controlled trials in rheumatologic indications, approximately 37% of patients 

treated with Enbrel developed injection site reactions. In controlled trials in patients 

with PsO, 15% of patients treated with Enbrel developed injection site reactions during 

the first 3 months of treatment. All injection site reactions were described as mild to 

moderate (erythema, itching, pain, swelling, bleeding, bruising) and generally did not 

necessitate drug discontinuation. Injection site reactions generally occurred in the first 

month and subsequently decreased in frequency. The mean duration of injection site 

reactions was 3 to 5 days. Seven percent of patients experienced redness at a previous 

injection site when subsequent injections were given. 

Immunogenicity 

Patients with RA, PsA, AS or PsO were tested at multiple time points for antibodies to 

etanercept. Antibodies to the TNF receptor portion or other protein components of the 

Enbrel drug product were detected at least once in sera of approximately 6% of adult 

patients with RA, PsA, AS or PsO. These antibodies were all non-neutralizing. Results 

from JIA patients were similar to those seen in adult RA patients treated with Enbrel. 

In PsO studies that evaluated the exposure of etanercept for up to 120 weeks, the 

percentage of patients testing positive at the assessed time points of 24, 48, 72 and 96 

weeks ranged from 3.6%–8.7% and were all non-neutralizing. The percentage of 

patients testing positive increased with an increase in the duration of study; however, 

the clinical significance of this finding is unknown. No apparent correlation of antibody 

development to clinical response or adverse events was observed. The immunogenicity 

data of Enbrel beyond 120 weeks of exposure are unknown. 

The data reflect the percentage of patients whose test results were considered positive 

for antibodies to etanercept in an ELISA assay, and are highly dependent on the 

sensitivity and specificity of the assay. Additionally, the observed incidence of any 

antibody positivity in an assay is highly dependent on several factors, including assay 

sensitivity and specificity, assay methodology, sample handling, timing of sample 

collection, concomitant medications, and underlying disease. For these reasons, 

comparison of the incidence of antibodies to etanercept with the incidence of antibodies 

to other products may be misleading. 

Autoantibodies 

Patients with RA had serum samples tested for autoantibodies at multiple time points. In 

RA Studies I and II, the percentage of patients evaluated for antinuclear antibodies (ANA) 

who developed new positive ANA (titer ≥ 1:40) was higher in patients treated with Enbrel 

(11%) than in placebo-treated patients (5%). The percentage of patients who developed 

new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay 

(15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by 

Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebotreated 

patients). The proportion of patients treated with Enbrel who developed 

anticardiolipin antibodies was similarly increased compared to placebo-treated patients. 

In RA Study III, no pattern of increased autoantibody development was seen in Enbrel 

patients compared to MTX patients [see Warnings and Precautions]. 

Other Adverse Reactions 

Table 3 summarizes adverse reactions reported in adult RA patients. The types of 

adverse reactions seen in patients with PsA or AS were similar to the types of adverse 

reactions seen in patients with RA. 

Table 3. Percent of Adult RA Patients Experiencing Adverse Reactions in 

Controlled Clinical Trials 

Placebo Controlled a 

(Studies I, II, and a Phase 

2 Study) 

Placebo 

(N = 152) 

Enbrel c 

(N = 349) 

Active Controlled b 

(Study III) 

MTX 

(N = 217) 

Enbrel c 

(N = 415) 

Reaction Percent of Patients Percent of Patients 

Infection d (total) 

Upper Respiratory 

Infections e 

Non-upper Respiratory 

Infections 

Injection Site 

Reactions 

Diarrhea 

Rash 

Pruritus 

Pyrexia 

Urticaria 

Hypersensitivity 

39 

30 

15 

11 

9 

2 

1 

– 

1 

– 

50 

38 

21 

37 

8 

3 

2 

3 

– 

– 

86 

70 

59 

18 

16 

19 

5 

4 

4 

1 

81 

65 

54 

43 

16 

13 

5 

2 

2 

1 

a Includes data from the 6-month study in which patients received concurrent MTX 

therapy in both arms. 

b Study duration of 2 years. 

c Any dose. 

d Includes bacterial, viral, and fungal infections. 

e Most frequent Upper Respiratory Infections were upper respiratory tract infection, 

sinusitis, and influenza. 

In placebo-controlled PsO trials, the percentages of patients reporting adverse 

reactions in the 50 mg twice a week dose group were similar to those observed in the 

25 mg twice a week dose group or placebo group. 

Table 4 summarizes adverse reactions reported in adult PsO patients from Studies I and II. 

Table 4. Percent of Adult PsO Patients Experiencing Adverse Reactions in 

Placebo-Controlled Portions of Clinical Trials (Studies I & II) 

Reaction 

Infection b (total) 

Non-upper Respiratory 

Infections 

Upper Respiratory 

Infections c 

Injection Site 

Reactions 

Diarrhea 

Rash 

Pruritus 

Urticaria 

Hypersensitivity 

Pyrexia 

Placebo 

(N = 359) 

28 

14 

17 

6 

2 

1 

2 

– 

– 

1 

Percent of Patients 

Enbrel a 

(N = 876) 

27 

12 

a Includes 25 mg SC QW, 25 mg SC BIW, 50 mg SC QW, and 50 mg SC BIW doses. 

b Includes bacterial, viral and fungal infections. 

c Most frequent Upper Respiratory Infections were upper respiratory tract infection, 

nasopharyngitis and sinusitis. 

Adverse Reactions in Pediatric Patients 

In general, the adverse reactions in pediatric patients were similar in frequency and type 

as those seen in adult patients [see Warnings and Precautions]. The types of infections 

reported in pediatric patients were generally mild and consistent with those commonly 

seen in the general pediatric population. Two JIA patients developed varicella infection 

and signs and symptoms of aseptic meningitis, which resolved without sequelae. 

In open-label clinical studies of children with JIA, adverse reactions reported in those 

ages 2 to 4 years were similar to adverse reactions reported in older children. 

Postmarketing Experience 

Adverse reactions have been reported during post approval use of Enbrel in adults and 

pediatric patients. Because these reactions are reported voluntarily from a population of 

uncertain size, it is not always possible to reliably estimate their frequency or establish 

a causal relationship to Enbrel exposure. 

Adverse reactions are listed by body system below: 

Blood and lymphatic 

pancytopenia, anemia, leukopenia, neutropenia, 

system disorders: 

thrombocytopenia, lymphadenopathy, aplastic 

anemia [see Warnings and Precautions] 

Cardiac disorders: 

Gastrointestinal disorders: 

General disorders: 

Hepatobiliary disorders: 

Immune disorders: 

Musculoskeletal and 

connective tissue disorders: 

Neoplasms benign, 

malignant, and unspecified: 

Nervous system disorders: 

Ocular disorders: 

Respiratory, thoracic 

and mediastinal disorders: 

17 

15 

3 

1 

1 

1 

1 

– 

congestive heart failure [see Warnings 

and Precautions] 

inflammatory bowel disease (IBD) 

angioedema, chest pain 

autoimmune hepatitis, elevated transaminases, 

hepatitis B reactivation 

macrophage activation syndrome, 

systemic vasculitis 

lupus-like syndrome 

melanoma and non-melanoma skin cancers, 

merkel cell carcinoma [see Warnings and Precautions] 

convulsions, multiple sclerosis, demyelination, 

optic neuritis, transverse myelitis, paresthesias 

[see Warnings and Precautions] 

uveitis, scleritis 

interstitial lung disease 

Skin and subcutaneous 

tissue disorders: 

cutaneous lupus erythematous, cutaneous 

vasculitis (including leukocytoclastic vasculitis), erythema 

multiforme, Stevens-Johnson syndrome, toxic epidermal 

necrolysis, subcutaneous nodule, new or worsening psoriasis 

(all sub-types including pustular and palmoplantar) 

Opportunistic infections, including atypical mycobacterial infection, herpes zoster, 

aspergillosis and Pneumocystis jiroveci pneumonia, and protozoal infections have also 

been reported in postmarketing use. 

DRUG INTERACTIONS 

Specific drug interaction studies have not been conducted with Enbrel. 

Vaccines 

Most PsA patients receiving Enbrel were able to mount effective B-cell immune 

responses to pneumococcal polysaccharide vaccine, but titers in aggregate were 

moderately lower and fewer patients had 2-fold rises in titers compared to patients not 

receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel 

may receive concurrent vaccinations, except for live vaccines. No data are available on 

the secondary transmission of infection by live vaccines in patients receiving Enbrel. 

Patients with a significant exposure to varicella virus should temporarily discontinue 

Enbrel therapy and be considered for prophylactic treatment with varicella zoster 

immune globulin [see Warnings and Precautions]. 

Immune-Modulating Biologic Products 

In a study in which patients with active RA were treated for up to 24 weeks with 

concurrent Enbrel and anakinra therapy, a 7% rate of serious infections was observed, 

which was higher than that observed with Enbrel alone (0%) [see Warnings and 

Precautions] and did not result in higher ACR response rates compared to Enbrel alone. 

The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 

cases). One patient with pulmonary fibrosis and pneumonia died due to respiratory 

failure. Two percent of patients treated concurrently with Enbrel and anakinra 

developed neutropenia (ANC < 1 x 10 9 /L). 

In clinical studies, concurrent administration of abatacept and Enbrel resulted in 

increased incidences of serious adverse events, including infections, and did not 

demonstrate increased clinical benefit [see Warnings and Precautions]. 

Cyclophosphamide 

The use of Enbrel in patients receiving concurrent cyclophosphamide therapy is not 

recommended [see Warnings and Precautions]. 

Sulfasalazine 

Patients in a clinical study who were on established therapy with sulfasalazine, to which 

Enbrel was added, were noted to develop a mild decrease in mean neutrophil counts in 

comparison to groups treated with either Enbrel or sulfasalazine alone. The clinical 

significance of this observation is unknown. 

USE IN SPECIFIC POPULATIONS 

Pregnancy 

Pregnancy Category B 

Pregnancy Surveillance Program 

There is a Pregnancy Surveillance Program that monitors outcomes in women exposed 

to Enbrel during pregnancy. Women who become pregnant during Enbrel treatment are 

encouraged to enroll. Patients or their physicians should call 1-800-77-AMGEN (1-800- 

772-6436) to enroll. 

Risk Summary 

There are no adequate and well controlled studies in pregnant women. Based on 

limited data, etanercept concentration in cord blood at the time of delivery showed 

that etanercept crossed the placenta in small amounts. 

Developmental toxicity studies have been performed in rats and rabbits at doses 

ranging from 60- to 100-fold higher than the human dose and have revealed no 

evidence of harm to the fetus due to Enbrel. Because animal reproduction studies are 

not always predictive of human response, this drug should be used during pregnancy 

only if clearly needed. 

Human Data 

Three case reports showed that cord blood levels of etanercept at delivery in infants, 

born to mothers administered etanercept during pregnancy, were between 3 and 32% 

of the maternal serum level. 

Nursing Mothers 

Limited data from published literature show that etanercept is present in low levels in 

human milk and minimally absorbed by a breastfed infant. Caution should be exercised 

when Enbrel is administered to a nursing woman. The development and health benefits 

of breastfeeding should be considered along with the mother’s clinical need for Enbrel 

and any potential adverse effects on the breastfed child from the drug or from the 

underlying maternal condition. 

Women who choose to continue Enbrel treatment while nursing are encouraged to enroll 

in Amgen’s Lactation Surveillance Program. Patients or their physicians should call 

1-800-77-AMGEN (1-800-772-6436) to enroll. 

Pediatric Use 

Enbrel has not been studied in children < 2 years of age with JIA. The safety and 

efficacy of Enbrel in pediatric patients with PsO have not been studied. 

Rare (< 0.1%) cases of IBD have been reported in JIA patients receiving Enbrel, which is 

not effective for the treatment of IBD [see Adverse Reactions (6.2)]. 

The clinical significance of infant exposure to Enbrel in utero is unknown. The safety of 

administering live or live-attenuated vaccines in exposed infants is unknown. Risks and 

benefits should be considered prior to administering live or live-attenuated vaccines to 

exposed infants. 

Geriatric Use 

A total of 480 RA patients ages 65 years or older have been studied in clinical trials. In 

PsO randomized clinical trials, a total of 138 out of 1965 subjects treated with Enbrel or 

placebo were age 65 or older. No overall differences in safety or effectiveness were 

observed between these patients and younger patients, but the number of geriatric PsO 

subjects is too small to determine whether they respond differently from younger 

subjects. Because there is a higher incidence of infections in the elderly population in 

general, caution should be used in treating the elderly. 

Use in Diabetics 

There have been reports of hypoglycemia following initiation of Enbrel therapy in 

patients receiving medication for diabetes, necessitating a reduction in anti-diabetic 

medication in some of these patients. 

Rx Only. 

This brief summary is based on ENBREL prescribing information. v.55 3/2015 

© 2015 Amgen Inc., Thousand Oaks, CA 91320 

All rights reserved. 

US License Number 1132 

© 1998 – 2015 Immunex Corporation. 

All rights reserved. 

US Patent Nos. 7,915,225; 5,605,690; Re. 36,755. 

For more information please call 

1-888-436-2735 or visit www.enbrel.com 

PIV55

IMPORTANT SAFETY INFORMATION 

SERIOUS INFECTIONS 

Patients treated with ENBREL (etanercept) are at increased risk for developing 

serious infections that may lead to hospitalization or death. Most patients who 

developed these infections were taking concomitant immunosuppressants such as 

methotrexate or corticosteroids or were predisposed to infection because of their 

underlying disease. ENBREL should not be initiated in the presence of sepsis, active 

infections, or allergy to ENBREL or its components. ENBREL should be discontinued 

if a patient develops a serious infection or sepsis. Reported infections include: 

1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have 

frequently presented with disseminated or extrapulmonary disease. Patients should 

be tested for latent TB before ENBREL use and periodically during therapy. 

Treatment for latent infection should be initiated prior to ENBREL use, 2) Invasive 

fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, 

aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or 

other invasive fungal infections may present with disseminated, rather than localized, 

disease. Antigen and antibody testing for histoplasmosis may be negative in some 

patients with active infection. Empiric antifungal therapy should be considered in 

patients at risk for invasive fungal infections who develop severe systemic illness, 

and 3) Bacterial, viral, and other infections due to opportunistic pathogens, 

including Legionella and Listeria. 

The risks and benefi ts of treatment with ENBREL should be carefully considered 

prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who 

have been exposed to TB, 3) who have resided or traveled in areas of endemic TB 

or endemic mycoses, or 4) with underlying conditions that may predispose them 

to infections such as advanced or poorly controlled diabetes. Patients should be 

closely monitored for the development of signs and symptoms of infection during and 

after treatment with ENBREL, including the possible development of TB in patients 

who tested negative for latent TB prior to initiating therapy. 

MALIGNANCIES 

Lymphoma and other malignancies, some fatal, have been reported in children 

and adolescent patients treated with tumor necrosis factor (TNF) blockers, 

including ENBREL. 

In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to 

control patients. The risk of lymphoma may be up to several-fold higher in RA and psoriasis 

patients. The role of TNF blocker therapy in the development of malignancies is unknown. 

Cases of acute and chronic leukemia have been reported in association with postmarketing 

TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients 

with RA (approximately 2-fold) than the general population. 

Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with 

TNF blockers, including ENBREL. Periodic skin examinations should be considered for all 

patients at increased risk for skin cancer. 

Pediatric Patients 

In patients who initiated therapy at ≤18 years of age, approximately half of the reported 

malignancies were lymphomas (Hodgkin’s and non-Hodgkin’s lymphoma). Other cases 

included rare malignancies usually associated with immunosuppression and malignancies 

that are not usually observed in children and adolescents. Most of the patients were 

receiving concomitant immunosuppressants. 

NEUROLOGIC EVENTS 

Treatment with TNF-blocking agents, including ENBREL, has been associated with rare 

(

In moderately to severely active rheumatoid arthritis (RA) 

ENBREL gives you options down the road 

START WITH IF NEEDED, CONTINUE WITH 

ENBREL is proven in combination with MTX. 

ENBREL is also effective as a monotherapy when needed. 

• In open-label extension trials with ENBREL, a substantial number of patients who initially received concomitant MTX 

were able to reduce their doses or discontinue MTX while maintaining their clinical responses 1 

An estimated 30% of all patients on biologic therapy are on biologic monotherapy 2-6 

• Real-world data from national registries suggest that approximately 30% of patients on biologics are taking them without 

a DMARD 2-6 

• These patients may either have been initiated on biologic monotherapy or started on combination therapy, but ended up 

on biologic monotherapy 2-6 

Prescription ENBREL is administered by injection. 

INDICATION 

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting 

the progression of structural damage, and improving physical function in patients with moderately to 

severely active rheumatoid arthritis (RA). ENBREL can be initiated in combination with methotrexate (MTX) 

or used alone. 

VISIT 

BOOTH 

#601 

SELECTED SAFETY INFORMATION 

ENBREL has been shown to increase the risk of serious infections leading to hospitalization or death, including tuberculosis 

(TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic 

pathogens, and should be discontinued if a patient develops a serious infection or sepsis. Test for latent TB (if positive, 

start treatment for TB prior to starting ENBREL) and monitor for active TB during treatment. Lymphoma and other 

malignancies, some fatal, have been reported in children and adolescents treated with tumor necrosis factor (TNF) 

blockers, including ENBREL. 

Please see additional Important Safety Information and 

Brief Summary on preceding pages. 

Enbrel ® and the Enbrel ® logo are registered trademarks of Immunex Corporation.

session

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?